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ABSTRACT 
Genetic Mechanisms Controlling Human Hair Growth 
Gina M. DeStefano 
The genetic underpinnings of human hair growth are complex, relying upon 
several mechanisms to regulate gene expression. As such, inherited skin and hair 
disorders can arise from a variety of mutational events in the genome, from changes in 
single nucleotides to structural rearrangements of chromosomes. Importantly, inherited 
conditions affecting hair growth can be used as models to interrogate the molecular 
basis of the disease, and obtain novel insight into mechanisms and pathways required 
for normal hair growth. The approaches used to identify pathogenic mutations in a given 
disorder will depend on the inheritance pattern and disease prevalence in the 
population. In rare, Mendelian disorders of the skin and hair, the genetic architecture is 
often composed of rare variants with large effects, detected by linkage or whole-
exome/genome sequencing. In contrast, polygenic disorders are composed of common 
and rare variants that contribute small to moderate effects and can be detected using 
Genome-Wide Association Studies (GWAS). 
The primary goal of my thesis research is to identify and characterize genetic 
mechanisms controlling human hair growth. To accomplish this, I have studied three 
inherited conditions affecting human hair growth as genetic models in which I performed 
detailed functional and molecular analyses of the causal genetic lesions and their 
downstream effects on gene expression in the hair follicle. My thesis work revolved 
around the use of three major approaches to identify and characterize genetic 
mechanisms underlying human hair growth: 1. Identifying genomic effects on human 
hair growth in a rare, sporadic Mendelian disorder (Chapter II), 2. Characterizing single-
gene effects on human hair growth in a rare, familial condition (Chapter III), and 3. 
Functional analysis of rare, non-coding variants in a complex polygenic autoimmune 
disease, alopecia areata (Chapter IV). 
In the first part of my thesis work, I investigated the genetic mechanism 
associated with X-linked hypertrichosis (XLH), a very rare condition of excessive hair 
overgrowth. We identified a large interchromosomal insertion at chrXq27.1 that 
completely cosegregated with the phenotype, and was consistent with findings of 
interchromosomal insertions in two previously reported XLH families. Remarkably, the 
insertions in all three families occur at the exact same palindromic sequence, and 
because the sequences contained within each insertion are distinct, we hypothesized 
that the presence of the insertion (rather than its content) may be responsible for the 
excessive hair overgrowth phenotype. I then tested the impact of the insertion on the 
expression of the surrounding genes and found that FGF13 levels were selectively and 
dramatically reduced in patient hair follicles, suggesting a position effect as a result of 
the interchromosomal insertion. We postulate that the presence of this insertion disrupts 
key inter- and intrachromosomal interactions required for normal hair growth. 
In the second part of my thesis, I identified single-gene mutations that affect 
human hair growth by investigating the genetic basis of autosomal recessive congenital 
generalized hypertrichosis terminalis (CGHT) in a consanguineous family. We 
performed whole-exome sequencing and identified a novel, rare splice variant in ABCA5 
that cosegregates with the phenotype in a homozygous recessive manner. I found that 
 
 
ABCA5 is highly expressed in human skin and hair follicles, and its expression pattern is 
conserved in mouse tissues as well. The ABCA5 mutation in CGHT leads to a complete 
loss-of-function in patient hair follicles, as well as reduced lysosome function and 
cholesterol transport, a finding consistent with defects in Abca5-/- mice. Moreover, we 
identified a deletion spanning ABCA5 in an unrelated sporadic CGHT case and found 
that ABCA5 levels were dramatically reduced in patient hair follicles. Collectively, our 
findings point to a novel role for ABCA5 in regulating hair growth. 
In the third part of my thesis, I characterized the genetic architecture of a 
complex, polygenic disease affecting hair growth by studying rare, non-coding variants 
in alopecia areata. The Christiano lab previously performed the first GWAS, identifying 
the ULBP3/6 locus on chr.6q25.1 encoding NKG2D T cell receptor ligands as the most 
significant association outside the HLA region. A strong upregulation of these ligands 
was observed on both human and mouse hair follicles, and we recently showed that T 
cells bearing the NKG2D receptor are both necessary and sufficient to induce disease 
in the mouse model. To identify the susceptibility variants at ULBP3/6 in human AA, we 
performed targeted deep resequencing and functional genomics studies and identified 
three rare, novel variants that reside within ULBP6 regulatory elements and CTCF 
binding sites. I found that these variants disrupt CTCF binding and regulatory activity in 
vitro, and CTCF binding is enriched at ULBP6 in vivo. Future studies examining long-
range reporter activity and CTCF-mediated interactions will define the role of CTCF in 
the repression of the ULBP3/6 genes in the human hair follicle. 
Collectively, I used a variety of genetic approaches to identify novel genes and 
mechanisms controlling human hair growth. 
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Chapter I. General Introduction 
 
Chapter I.1. Patterns of Inheritance 
In humans, genetic disorders can arise from a variety of mechanisms and mutational 
events in the genome, ranging from changes in single nucleotides to structural 
rearrangements of chromosomes. Beyond mutations, epigenetic or heritable changes in 
gene expression and phenotype can also play a key role in disease pathogenesis. 
Thus, we can use inherited conditions as models to identify novel genes and 
mechanisms controlling a particular trait of interest (i.e. hair growth). However, the 
approaches used to identify pathogenic mutations in a given disorder depend on the 
inheritance pattern and disease prevalence in the population (Figure 1). To date, there 
are approximately 7,000 rare monogenic diseases reported in Online Mendelian 
Inheritance of Man (OMIM) (defined as affecting fewer than 1 in 200,000 individuals in 
the United States or fewer than 1 in 2,000 in Europe), yet the molecular underpinnings 
of nearly half of these diseases has been identified. While the genetic architecture of 
some Mendelian diseases may have been more readily detectable, the pathogenic 
variants underlying several rare genetic disorders have been difficult to identify using 
the traditional approaches, due to limited availability of affected families, decreased 
reproductive fitness, and locus heterogeneity. Similarly, complex (polygenic) disorders 
have not been amenable to the conventional methods and approaches. Importantly, the 
completion of the Human Genome Project in 2003 greatly facilitated the development of 
advanced technologies for genome sequencing and mutational discovery in both 
monogenic and polygenic conditions.  
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Based on the inheritance pattern and disease prevalence in the population, 
human genetic disorders can primarily be classified as: 1. Rare, sporadic, 2. Rare, 
familial Mendelian, and 3. Complex, polygenic (non-Mendelian). In the rare, sporadic 
Mendelian traits, the genetic architecture is usually characterized by large genomic 
rearrangements or copy number variants (CNVs) that are private, or restricted to the 
proband and immediate relatives (GILISSEN et al. 2012), whereas in rare, familial 
conditions, the genetic architecture is composed of intragenic (i.e. exonic, splice site) 
mutations that are not private but rather, tend to be present at a very low frequency 
(~0.1-0.5%). Both of these diseases are characterized by rare variants contributing 
large effect sizes. In contrast, in common, polygenic conditions, many common and low 
frequency variants (1-5%) contribute small effects and interact with the environment to 
produce the phenotype (CIRULLI AND GOLDSTEIN 2010). The detailed approaches and 
methods to identify pathogenic mutations are discussed in Chapter I.1.3. 
I have used several methods and approaches to interrogate the genetic and 
molecular basis of three inherited conditions affecting hair growth, and obtain novel 
insight into mechanisms and pathways required for normal hair growth. The three 
approaches to study rare, Mendelian (sporadic, familial) and non-Mendelian disorders 
comprise the basis of my thesis and are discussed in Chapters II-IV. 
1.A Mendelian (Monogenic) Inheritance Patterns 
A Mendelian-inherited trait is one controlled by a single gene or locus and transmitted to 
offspring in a consistent pattern and frequency based on the laws of segregation and 
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independent assortment of chromosomes. 
 
The genetic variants underlying monogenic (single-gene) traits can be located either on 
autosomes, producing an autosomal inheritance pattern, or on the X chromosome 
producing an X-linked inheritance pattern. When a mutation in one of two alleles is 
sufficient to produce a phenotype, the trait is considered dominant, whereas a condition 
is recessive when both alleles of a gene must be altered in order to produce a 
phenotype. Thus, a Mendelian-inherited trait can be classified into four groups: 1. 
Autosomal dominant, 2. Autosomal recessive, 3. X-linked recessive, and 4. X-linked 
dominant.  





COSEGREGATES WITH DISEASE IN FAMILY 
DE NOVO, PRIVATE VARIANTS  





ENRICHED, SHARED VARIANTS LIKELY CAUSAL 
RARE, BUT NOT PRIVATE VARIANTS 
COMMON + LOW FREQUENCY VARIANTS 
(MAF 0.01, MAF > 0.05) 













    STRUCTURAL VARIANTS, CNVS         INTRAGENIC VARIANTS        MOSTLY INTERGENIC VARIANTS 
Figure 1. The genetic architecture of Mendelian and non-Mendelian disorders. Rare, sporadic conditions (red) 
are characterized by de novo, private variants (structural variants, CNVs) with large effect sizes. Rare, familial 
disorders (purple) are most often composed of rare, intragenic variants with large effect sizes, and non-Mendelian, 
polygenic conditions (blue) are characterized by many common and low-frequency variants with small effects, plus 
environmental interactions.  
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An autosomal dominant trait can be transmitted from either parent to the 
offspring with the same frequency, but not from an unaffected individual.  The 
mechanisms whereby dominant mutations can give rise to a phenotype are 
haploinsufficiency, where one gene product is not enough to sustain function, and a 
dominant negative effect, where the mutated protein interacts with and prevents the 
wild-type protein from functioning. In a pedigree of an autosomal recessive disease, 
affected individuals have clinically unaffected parents, and there is no sex bias or 
vertical transmission. The mechanisms whereby recessive mutations can give rise to a 
phenotype include familial consanguinity that leads to homozygosity (identical by 
descent) for the mutant allele, and compound heterozygosity for two distinct mutations 
in the same gene. Both phenomena have been observed in several skin and hair 
disorders, yet familial consanguinity is the more common mechanism underlying rare 
traits aggregated in certain geographic populations. In Chapter II, I investigated the 
genetic basis of an autosomal recessive condition of excessive hair overgrowth in a 
consanguineous family. 
In X-linked dominant traits, affected individuals have at least one affected parent, 
the disorder can occur in both males and females, and there is no male-to-male 
transmission. Some X-linked dominant diseases are lethal in males during early 
intrauterine development but occasional male patients can be explained by functional or 
genomic mosaicism arising from an extra X chromosome or a de novo half-
chromatid/postzygotic mutation, respectively. Females with X-linked conditions are 
considered hetero- or hemizygous (for dominant and recessive traits, respectively) and 
generally have a milder or mosaic phenotype. Lyonization, or random epigenetic 
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inactivation of one of the two X chromosomes in each female cell produces this mosaic 
pattern, which can be directly visualized in skin diseases. This phenomenon has been 
observed in females with focal dermal hypoplasia (Goltz syndrome), characterized by 
mutations in the PORCN gene (GOLTZ 1992) and incontinentia pigmenti, caused by 
mutations in the NEMO gene (SMAHI et al. 2000). In Chapter II, I examined the genetic 
basis of an X-linked condition of excessive hair overgrowth using the approaches and 
methods discussed in the following section (Chapter I.2.A). 
1.B Exceptions to Basic Mendelian Inheritance 
Mendelian diseases are often caused by mutations in a single gene or locus, however, 
there are several mechanisms by which this gene can modify/be modified by others and 
by epigenetic/environmental factors, creating a more complex and variable phenotype. 
As such, there are several monogenic conditions that appear to defy the basic 
Mendelian patterns of inheritance due to variation in gene expression, the location of 
the mutant gene, as well as other factors, and thus have major impacts on risk 
assessment for disease transmission and genetic counseling. These deviations from the 
basic Mendelian patterns are considered exceptions, and include incomplete or reduced 
penetrance and late-onset diseases, variable expression, X inactivation, de novo 
mutations, genomic and gonadal, revertant mosaicism, inbreeding, quasidominant 
inheritance, uniparental disomy, mitochondrial inheritance, epigenetics and imprinting. A 
thorough explanation of these exceptions to basic Mendelian patterns and examples in 
monogenic disease is described in detail elsewhere (DESTEFANO AND CHRISTIANO (In 
press)) (DESTEFANO AND CHRISTIANO 2014). 
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Throughout the work described in my thesis, the approaches and methods I have 
utilized to identify the underlying pathogenic mutations in conditions affecting human 
hair growth have been guided by the inheritance pattern and knowledge of any 
exception(s) to basic Mendelian patterns. Chapters II and III discuss de novo mutations 
and consanguinity in two inherited forms of excessive hair growth. 
1.C Chromosomal Anomalies, Structural Variants, and Position Effects 
In many human disorders, the underlying genetic defect is not contained within a single 
gene but rather involving a large genomic region or even entire chromosomes. 
Historically, researchers detected numerical and structural chromosomal anomalies 
using karyotypes, which are chromosome “profiles” that allow for visualization of 
chromosome banding patterns via a chemical stain that detects densely packed DNA 
(heterochromatin) and loosely packed DNA (euchromatin) in metaphase chromosomes. 
The current methods of detection for chromosomal abnormalities are discussed in 
Chapter I.2.A.  
Chromosomal anomalies are defined as changes in the number and/or structure 
of genomic DNA fragments.  Chromosomal numerical abnormalities can involve the 
whole genome (polyploidy) or just one pair of homologues (aneuploidy). Chromosomal 
structural anomalies involve chromosome breakage and create a net gain/loss 
(unbalanced) or no change (balanced) in genetic information, where the latter can 
include translocations and inversions. In a reciprocal translocation, two breaks in two 
non-homologous chromosomes occur and the chromosomal segments distal to the 
breaks are exchanged, and the total number of chromosomes remains the same. If the 
translocation breakpoint affects a gene/regulatory sequence or places it under the 
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control of novel regulatory elements (i.e. in the case of the MYC gene in Burkitt’s 
lymphoma) (BERNHEIM 2010), it can create a position effect (discussed below) on nearby 
genes and cause an observable phenotype. In contrast to translocations, inversions are 
balanced rearrangements in which two breaks occur in the same chromosome and the 
intervening segment is inverted before the chromosome is reconstituted. In a pericentric 
inversion, the inverted segment includes the centromere, whereas in a paracentric 
inversion, the two breaks occur in the same chromosome arm, without involvement of 
the centromere. 
 A classic example of chromosomal anomalies associated with human genetic 
disease is hypohidrotic ectodermal dysplasia (HED), characterized by a decreased 
ability to sweat, where patients have been reported to possess rearranged X 
chromosomes, including X;autosome translocations or genomic deletions involving the 
EDA gene (THOMAS et al. 1993). Similarly, CNVs on chromosome 4q26-q27 have been 
reported in patients with Cantú Syndrome, a rare disorder of congenital hypertrichosis, 
cardiomegaly, macrosomia, and osteochondrodysplasia (KURBAN et al. 2011). 
Cytogenetic abnormalities have also been reported on chromosome 8q22 in several 
cases of Ambras syndrome (BAUMEISTER et al. 1993) (BALDUCCI et al. 1998) (TADIN et al. 
2001; FANTAUZZO et al. 2008), a form of congenital universal hypertrichosis, which the 
Christiano lab has previously studied (discussed in Chapter I.5 and I.6) 
Interestingly, changes in copy number and/or location of chromosomal segments 
can disrupt the expression of the neighboring genes, leading to position effects.  A 
position effect is defined as a change in gene expression as a result of altering the 
location of the gene relative to its chromosomal surroundings (KLEINJAN AND VAN 
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HEYNINGEN 1998).  Several genetic mechanisms, including chromosomal 
rearrangements, insertions, deletions, and copy number variants, can lead to the 
separation of the gene from a tissue- or temporal-specific modifier element (KLEINJAN 
AND VAN HEYNINGEN 1998). This definition of position effect is distinct from the classical 
phenomenon of position effect variegation, first reported in Drosophila at the white+ 
locus, which describes the heritably stable inhibition of gene expression as a result of 
juxtaposition with heterochromatin (WEILER AND WAKIMOTO 1995). 
Paradoxically, a position effect on a gene may cause a different phenotype from 
that produced by loss of function mutations in the coding region of the gene. This, in 
conjunction with the fact that most diseases are relatively rare make it more difficult to 
identify and directly implicate position effects in human genetic disease. Despite these 
obstacles, position effects on single genes have been reported as a result of large 
chromosomal rearrangements or copy number variants in several human genetic 
diseases.  Some examples include SHH in Holoprosencephaly (a cephalic disorder in 
which the forebrain fails to develop into two hemispheres), SHH in Preaxial polydactyl II 
(a congenital physical anomaly resulting in extra digits), and SOX9 in Campomelic 
dysplasia (a genetic disorder of the femur and tibia) (ROESSLER et al. 1997; LETTICE et 
al. 2003; VELAGALETI et al. 2003; FERNANDEZ et al. 2005; LEIPOLDT et al. 2007). 
The Christiano lab has previously reported position effects on genes regulating 
hair follicle development, which will be discussed in Chapter I.5. Throughout the work 
described in Chapters II-IV, chromosomal anomalies, structural variants, and position 
effects are discussed in the context of genetic mechanisms regulating human hair 
growth, which is the subject of my thesis.  
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1.D Polygenic Disorders  
Human genetic disorders that are caused by mutations in a single gene are quite rare 
within the general population, representing only a small proportion of genetic diseases. 
In contrast, the majority of inherited conditions are more common, genetically complex, 
and do not follow the basic Mendelian inheritance patterns despite their high prevalence 
within families; these are referred to as polygenic disorders or multifactorial traits. In 
addition to multiple genetic factors underlying the pathology, genetic interactions with 
the environment can significantly impact the disease prevalence amongst related 
individuals and in the general population, as well as phenotypic severity (i.e. 
expressivity). Thus, the risks for multifactorial traits have been estimated based largely 
on epidemiologic data. It is currently thought that the genetic basis of complex human 
disorders is composed of many common variants with small to moderate effects, rare 
variants with moderate to large effects, structural variations (i.e. CNVs), genetic 
interactions, and gene-environment interactions (MANOLIO et al. 2009)	  (MACARTHUR et 
al. 2014). Although the classical genetic approach (discussed in Chapter 1.2.A) has 
been widely successful in identifying the pathogenic genes underlying diseases 
inherited in a Mendelian fashion, these methods have not been as effective in dissecting 
the genetic architecture of polygenic diseases. However, powerful tools have been 
developed over the past decade that circumvent the limitations of preexisting methods 
and have aided in uncovering the genetic complexity of many of these diseases 
(discussed in Chapter I.2.B).  
In common, complex diseases, the degree of inheritance was usually inferred by 
studying the trait in monozygotic (identical) and dizygotic (fraternal) twins, where a high 
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discordance rate between monozygotic twins strongly suggests environmental and/or 
epigenetic factors that contribute to the variability in inheritance and expressivity of the 
trait (ZWIJNENBURG et al. 2010). For example, in alopecia areata, an autoimmune 
disease of hair loss, the concordance rate among monozygotic twins is 55%, whereas 
that in dizygotic twins is 0%, strongly suggesting a genetic basis (RODRIGUEZ et al. 
2010). In addition to twin studies, genetic association studies and parametric linkage 
analyses using epidemiological data identified regions of the genome significantly 
associated with the trait (PETUKHOVA AND CHRISTIANO 2013). Collectively, twin studies, 
family-based linkage analyses, as well as observed heritability among relatives were 
used to provide evidence for a genetic basis in common, complex diseases.  
Nearly a decade ago, the Genome-Wide Association Study (GWAS) became the 
gold standard technique for identifying common SNPs shared among unrelated 
individuals with a given complex trait. This method assays several thousand to more 
than a million SNPs in the genome, requiring a large sample size to produce a high 
resolution and power for detection of differences in allele frequencies between control 
and affected individuals. Several GWAS studies have been performed on at least 
eleven polygenic skin and hair related diseases within the last six years (Petukhova et 
al. 2010; Sarig et al. 2012; Zhang 2012; Luo et al. 2013), confirming previous findings 
from parametric linkage analysis and genome-wide scans as well as identifying new risk 




Chapter I.2. Approaches to Identifying Pathogenic Mutations 
2.A Approaches and Methods to Identify Disease-Causing Mutations in Rare 
Mendelian Diseases 
One overarching goal in the study of inherited diseases is to find the causative gene(s) 
responsible for the phenotype manifested in a given disorder and define its function. 
The classical genetic approaches used to map, sequence, and characterize mutations 
(discussed below) have proven to be the most fruitful in identifying hundreds of genetic 
mutations in dozens of monogenic Mendelian diseases (Figure 2). However, for rare 
Mendelian conditions that are sporadic and in complex traits (discussed in Chapter 
I.2.B), the underlying genetic lesions were difficult to identify using the conventional 
methods (Figure 2). Importantly, next-generation sequencing technologies, in 
conjunction with CNV analysis (discussed below) have been instrumental in identifying 
de novo chromosomal structural defects in single affected individuals as well as within 
families.  
In rare, Mendelian extreme traits that are sporadic, the genetic architecture is 
usually characterized by large genomic rearrangements or copy number variants 
(CNVs) that are private, or restricted to the proband and immediate relatives, producing 
large effects (i.e. disrupting multiple genes) (Figure 1). In the cases where linkage and 
cytogenetic methods to detect chromosomal abnormalities provided an incomplete 
picture of the genetic architecture, Next-Generation Sequencing (NGS) methods 
including whole-exome and whole-genome sequencing have been successful in 
uncovering novel and rare variants (Figure 2). Since the mutational event is sporadic 
and private, determining causality is limited to performing a cosegregation analysis, 
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whereby all affected family members are genotyped for the candidate variant(s) to 
determine whether it fully cosegregates with the disease phenotype. 
 
In the rare, Mendelian traits that are familial, the genetic architecture is 
composed of intragenic (i.e. exonic, splice site) mutations that are not private but rather, 
are present at a very low frequency (~0.1-0.5%) in the population, exerting large effects 
(Figure 1). These variants are detectable by the conventional methods of linkage and 
Sanger sequencing for gene mapping (discussed below), and family cohorts are used to 
determine cosegregation of the variant(s) with the disease phenotype (Figure 2). While 













































Figure 2. Approaches and Methods to Identify Disease-Causing Mutations. In rare, Mendelian disorders of 
the skin and hair, the genetic architecture is often composed of rare variants with large effects, detected by 
linkage, CNV analysis and/or whole-exome and genome sequencing. In contrast, polygenic disorders are 
composed of common and rare variants that contribute small to moderate effects and can be detected using 
Genome-Wide Association Studies (GWAS), followed by functional genomics studies. 
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family cohorts manifesting the same phenotype, in addition to functional studies (i.e. 
mouse models and/or cell culture based systems) provide the strongest evidence for 
their causality in disease pathogenesis.    
Upon the identification of candidate variants in rare Mendelian disorders using 
the approaches discussed below, cosegregation analysis using Sanger sequencing will 
establish whether the variant is present in the DNA of all affected family members, 
thereby cosegregating with the disease. Once cosegregation is established, 
downstream functional analyses should be performed to determine the involvement of 
the variants identified in disease pathogenesis.  
Functional and Positional Cloning Strategies in Mendelian Disorders 
Two major approaches have been used to isolate the gene responsible for a given 
phenotype: functional and positional cloning (Figure 3) (YAMANISHI 1996; DESTEFANO 
AND CHRISTIANO 2014). The suitability of each approach for a given disease depended 
on what prior biochemical information was known about the defective gene product, as 
well as whether the inherited disease was sufficiently prevalent to study multiple 
affected individuals within a kindred. Functional cloning (reverse genetics), or the 
candidate gene approach, does not require positional information but rather exploits 





To select and clone a candidate gene, knowledge of the defective protein 
product/biochemical pathway and homology to mutated genes responsible for closely 
related phenotypes are important criteria. Animal models have also proved useful 
resources in elucidating the candidate gene, an approach that relies on the existence of 
a syntenic chromosomal region, where the spatial arrangement of encompassing genes 
is evolutionarily conserved. Once the genetic interval in humans is determined, the 
syntenic interval in mice can be analyzed to identify additional candidate genes. If a 
similar phenotype in the mouse has been mapped to this region and the mutated gene 
is known, this becomes an excellent candidate for the human disease counterpart, and 
vice versa. This comparative genomic approach was used to identify mutations in the 
Hairless gene underlying atrichia with papular lesions (AHMAD et al. 1998) and 
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mutations in the DSG4 gene in patients with localized autosomal recessive 
hypotrichosis (KLJUIC et al. 2003), where Hairless and DSG4 mutations in mouse 
models phenocopied the human diseases. Although functional cloning has been useful 
for elucidating the pathological and genetic basis of several monogenic diseases, its 
application is limited to the few disorders that feature an obvious biochemical defect.  
In contrast, positional cloning (forward genetics) relies only on the inheritance of 
the disease among related individuals to identify the common, shared region that 
completely cosegregates with the disease phenotype (gene mapping) (Figure 3). Once 
the candidate region has been narrowed, the gene can be isolated and cloned, and 
further studies can be performed to determine its function. One of the most widely used 
methods to accomplish this is linkage analysis, a tool that enables the mapping of a 
gene or locus by analyzing its segregation with genetic markers (microsatellite markers, 
SNPs) of known chromosomal position. These methods will be discussed in greater 
detail in the following section. 
The approach that has been most fruitful in identifying candidate disease genes 
is a combination of both functional and positional information. In the positional candidate 
approach, once the chromosomal location of the disease locus is known, functional 
information is utilized to directly analyze the candidate genes contained in that particular 
chromosomal region. Among many human genetic disorders, the positional candidate 
approach was successfully employed to investigate the genetic basis of hypertrichosis. 
The Christiano lab recently reported homozygous recessive mutations in the FGF5 
gene, a known regulator of hair length, in large consanguineous families from Pakistan 
with trichomegaly (long eyelashes) and hypertrichosis (HIGGINS et al. 2014). Linkage 
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and homozygosity mapping (discussed below) were conducted using SNP-genotyping 
to identify shared regions of the genome for which affected individuals were 
homozygous, and whole-exome sequencing identified intragenic mutations in FGF5, 
defining the candidate region (HIGGINS et al. 2014).   
Importantly, the human genome sequence as a resource has made the positional 
candidate approach the most powerful disease-gene cloning strategy because it 
provided a detailed map of polymorphic markers and positional information on 
characterized (known) as well as predicted genes. Publically available Internet 
resources include the National Center for Biotechnology Information (NCBI; 
www.ncbi.nlm.nih.gov), Ensembl Genome Browser (www.ensembl.org/), and the UCSC 
Genome Browser (http://genome.ucsc.edu/index.html). 
 
Linkage and Haplotype Analysis  
The power of linkage is based on the genetic principles of segregation and independent 
assortment, such that two traits located on separate chromosomes (or very far apart on 
the same chromosome) segregate independently, and thus have a recombination 
fraction of 50%. The closer the traits are, the less frequent recombinants are found; a 
recombination fraction (RF) of 0 implies the traits are tightly linked. In pedigree analysis, 
LOD (logarithm of the odds) scores are generated to calculate the likelihood that two 
loci are linked (MORTON 1955); positive scores indicate linkage (≥ 3.0) and negative 
scores indicate that linkage is less likely (≤ -2.0). To conduct linkage analysis, a 
thorough definition of the phenotype, availability of pedigrees with sufficient power for 
linkage, as well as map of polymorphic SNP markers are required.  
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Once the linkage interval has been defined, an additional step of narrowing the 
locus is often required since these intervals often span tens-to-hundreds of kilobases 
encompassing hundreds of genes. In some cases, information on a candidate gene 
and/or chromosomal abnormalities associated with the disorder is available and can aid 
in refining the interval. In the absence of this information, the number of individuals and 
recombination events/markers analyzed should be increased to define the shared 
haplotype. Importantly, recombination events can ‘break’ the shared haplotype in 
different members/generations of the pedigree, so identifying an individual in whom 
recombination has occurred inside the disease-associated haplotype (the key 
recombination event), further reduces the region where the disease gene is presumed 
to be located.  
The linkage interval that cannot be further reduced is considered the candidate 
region that cosegregates with the disease phenotype and harbors the disease gene. 
Sequencing and genotyping-based methods can then be used in conjunction with 
haplotype analysis to analyze the candidate regions and identify genetic variants. In the 
case of autosomal recessive traits driven by rare alleles with large effects, regions of 
homozygosity can be mapped using SNPs as markers for homozygosity, or 
autozygosity mapping. Moreover, overlaying identical-by-descent regions of the genome 
with linkage peaks is a robust approach and has been fruitful in the identification of 
candidate genes for several conditions (GILISSEN et al. 2012) (PETUKHOVA et al. 2009). 
Identifying Structural Variants by CNV Analysis 
The genetic architecture of rare, sporadic conditions is usually characterized by large 
genomic rearrangements or copy number variants (CNVs). Historically, researchers 
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have used karyotyping to detect numerical and structural chromosomal anomalies, 
however, fluorescence in situ hybridization (FISH) has gradually become a preferable 
choice, as it detects DNA sequences as short as 1 Kb (MILLER 2001) and allows for the 
resolution of very small changes in the chromosomal constitution that are not visible by 
the use of conventional banding techniques. To detect multiple chromosomal regions 
simultaneously, multicolor FISH (mFISH) allows for combinatorial labeling using 
fluorophore-conjugated probe sets, and for whole-genome analysis, Comparative 
Genomic Hybridization (CGH), enables the identification of all CNVs in a single 
hybridization procedure, and maps these changes onto normal chromosomes (PINKEL 
AND ALBERTSON 2005). While this method has an improved resolution (5-10 Mb) 
compare to chromosomal banding, it still requires metaphase chromosomal 
preparations and is unable to identify balanced chromosomal rearrangements. More 
recently, advances in microarray technology have enabled the use of DNA microarray-
based CGH (aCGH) for detection of copy number variations (CNVs) at a considerably 
higher level of resolution (~100 Kb) than chromosome-based methods, making it more 
suitable for diagnostic applications (GAO et al. 2012).  
Currently, SNP oligonucleotide microarray analysis (SOMA) yields the highest 
resolution (5.8 Kb), combining SNP data with the detection of CNVs (TORGYEKES et al. 
2011). SOMA is widely used for clinical cytogenetic analysis because both visible and 
submicroscopic cytogenetic imbalances are detectable, which has allowed for the 
detection of cryptic insertions/deletions on apparently balanced chromosomes. 
Additionally, genotype information obtained from mapping SNP positions to the genome 
browser is available for further DNA-based studies including uniparental disomy and 
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zygosity. Moreover, this method can identify all previously characterized cytogenetic 
aberrations (TORGYEKES et al. 2011).  
In the work described in Chapters II and III, these cytogenetic methods in 
conjunction with next-generation sequencing methods (discussed below), were used to 
identify the underlying genetic lesions in human conditions characterized by excessive 
hair growth.  
Whole-Exome and Whole-Genome sequencing 
When studying Mendelian traits, including those not amenable to conventional genetic 
approaches, it is of critical value to identify the rare variants that cosegregate with the 
disease phenotype. In such cases where linkage is not applicable or was not 
informative, whole-genome and whole-exome sequencing methods have proven very 
useful in identifying pathogenic variants that were otherwise missed. Next-generation 
sequencing in probands of large families with linkage evidence has also proven a useful 
strategy to narrow the list of candidate genes and identify pathogenic mutations, similar 
to the approach of overlaying information on identical-by-descent with linkage peaks 
described in the previous section. 
The coding fraction, or exome, comprises only 1-2% of the genome, however, its 
contribution to biological function is profound, evidenced by the large number of genetic 
diseases caused by mutations in single genes (GILISSEN et al. 2012). In Mendelian traits 
for which there is known linkage information and/or a candidate gene, whole-exome 
sequencing can be used to identify variants in coding regions, an approach that has 
been highly fruitful in identifying rare variants with large effects (CIRULLI AND GOLDSTEIN 
2010; LAI-CHEONG AND MCGRATH 2010). For both recessive and dominant traits, whole-
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exome sequencing followed by bioinformatics analysis has recently emerged as an 
efficient, more cost-effective approach to identifying mutations compared to whole-
genome sequencing. This method is especially useful for studying monogenic 
conditions caused by intragenic (exonic, intronic, etc) mutations that produce large 
phenotypic effects.  
In monogenic skin and hair disorders, massive parallel whole-exome sequencing 
has successfully identified many novel genes in both dominant and recessive 
conditions, including hypotrichosis simplex (RPL21 gene, autosomal dominant), terminal 
osseous dysplasia (FLNA gene, X-linked dominant), Adams-Oliver syndrome 
(ARHGAP31 gene, autosomal dominant), Clericuzio-type piokiloderma with neutropenia 
(c16orf57 gene, autosomal recessive), and Sensenbrenner syndrome (FLNA gene, X-
linked dominant) (LAI-CHEONG AND MCGRATH 2010). Importantly, whole-exome 
sequencing in conjunction with homozygosity mapping has been shown to be key for 
studying autosomal recessive conditions for which there is known consanguinity and the 
potential involvement of multiple genes. This strategy was recently demonstrated in a 
case of oculocutaneous albinism and neutropenia, an atypical disease phenotype 
comprised of two separate disorders, where pathogenic homozygous recessive 
mutations were identified in both the SLC45A2 and G6PC3 genes that explained the 
oculocutaneous albinism and neutropenia phenotypes, respectively (CULLINANE et al. 
2011). If the candidate approach alone had been used to screen for all the known genes 
associated with either of these conditions, the genotype-phenotype correlation would 
have been incorrect and the patient may have been misclassified. More recently, whole-
exome sequencing and homozygosity mapping identified a novel homozygous 
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missense mutation in the CHST8 gene (encoding the GalNAc4-ST1 transferase) in a 
large consanguineous family with generalized peeling skin syndrome (PSS) (CABRAL et 
al. 2012). CHST8 is normally expressed in the epidermis and functional in vitro studies 
revealed that this mutation leads to a significant reduction in protein levels as well as 
total sulfated glycosaminoglycan levels in the cell, suggesting a complete loss-of-
function	  (CABRAL et al. 2012). 
In addition to inherited monogenic conditions, whole-exome sequencing has also 
been successfully used for the identification of de novo mutations that are not inherited, 
but rather acquired in somatic cells. In individuals with Proteus syndrome, postzygotic, 
somatic mutations were identified in the AKT1 oncogene, where sequencing reads from 
the whole-exome study revealed the presence of mosaicism for the mutation with levels 
varying from 1-50% in affected vs. normal tissues from patients (LINDHURST et al. 2011). 
Importantly, this was the first application of whole-exome sequencing to identifying de 
novo somatic mutations underlying a human genetic disorder. 
As a tool to systematically identify genomic aberrations in the context of 
tumorigenesis, whole-exome sequencing revealed a novel de novo mutation in the 
GRIN2A gene (encoding a glutamate receptor) that was frequently observed in 
melanoma patient samples, and downstream bioinformatics analysis identified the 
glutamate signaling pathway as significantly enriched in melanoma	  (WEI et al. 2011). 
Moreover, this approach has successfully identified novel mutations in genes for chronic 
lymphocytic leukemia, B cell lymphoma, as well as carcinomas of the lung, brain, 
kidney, and pancreas (LOHR et al. 2012) (PUGH et al. 2012) (XU et al. 2012) (LIU et al. 
2013) (QUESADA et al. 2012). Concurrent with the identification of such pathogenic 
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variants was the development of analytical tools designed to systematically decode and 
integrate this information with copy number variation and loss-of-heterozygosity, 
enabling a robust survey of the genetic landscape of various pathologies (PABINGER et 
al. 2014). Importantly, the availability of these new sequencing technologies and 
analytic tools has facilitated the discovery of novel, deleterious mutations associated 
with cancers and other diseases, and in many cases, provided a comprehensive catalog 
of clinically relevant genes and pathways involved in disease pathogenesis.   
Whole-genome sequencing as a tool for disease gene discovery has been used 
to elucidate the underlying pathogenic variants in human genetic diseases, particularly 
those with an extreme phenotype and a rare variant enriched in the affected population 
(CIRULLI AND GOLDSTEIN 2010). This method is especially useful for cases in which these 
data are not available or uninformative, but used in conjunction with linkage or 
haplotype analysis, can be helpful in focusing the search for the pathogenic variant. For 
example, in the rare, dominant Mendelian disease, metachondromatosis, whole-
genome sequencing was performed on a patient with partial linkage data, and identified 
a deletion in the PTPN11 gene that cosegregates with the disease phenotype 
(SOBREIRA et al. 2010). Moreover, the clinical relevance of PTPN11 to disease 
pathogenesis was further validated through the identification of a second mutation in an 
independent family (SOBREIRA et al. 2010). In the context of genetic diagnosis, whole-
genome sequencing has been tested in a patient with a recessive form of Charcot-
Marie-Tooth disease, and revealed clinically relevant, compound heterozygous variants 
in the SH3TC2 gene (LUPSKI et al. 2010). Importantly, next-generation sequencing 
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methods, in conjunction with classical linkage and haplotype analysis provide a robust 
and powerful approach to identifying pathogenic mutations in rare, Mendelian disorders.  
In the work described in Chapters II and III, the next-generation sequencing 
methods described above were instrumental in the identification of pathogenic variants 
in rare human conditions of excessive hair growth whose genetic basis had previously 
remained elusive for decades.  
2.B Approaches to Identifying Disease-Causing Mutations in Common, Polygenic 
Conditions 
The candidate gene approach has been successful in identifying pathogenic mutations 
in Mendelian diseases, however, the more common, polygenic conditions have not 
historically lent themselves to the conventional genetic approach. Unlike Mendelian 
disease, their underlying genetic architecture is composed of many common and low 
frequency variants (1-5%) that contribute small effects and interact with the environment 
for the full manifestation of the trait (i.e. hair loss). Whereas in Mendelian conditions, 
family cohorts are used to identify shared variants that are likely causal, population-
based cohorts of affected and unaffected individuals are used to identify susceptibility 
loci in polygenic diseases whose association can be detected by Genome-Wide 
Association Studies (GWAS) (Figure 2). While most (if not all) of the mutations identified 
in monogenic (single-gene) diseases reside within protein-coding genes, recent 
evidence from GWAS, next-generation sequencing and functional genomic studies 
(discussed in the following sections) have revealed that the majority of significant 
associations reside within non-coding, intergenic DNA, thus requiring an integrative, 
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robust analytic approach to determine their contribution to disease pathogenesis 
(MAURANO et al. 2012; GUSEV et al. 2014). 
Genome-Wide Association Studies (GWAS) and meta-GWAS 
For complex disorders in which the trait does not follow a Mendelian inheritance pattern, 
Genome-Wide Association Studies (GWAS) have been used to identify single 
nucleotide variants enriched in cases compared to controls. The goal is to identify 
susceptibility loci and variants that are significantly associated with the trait compared to 
the general population, and confer a degree of genetic risk. Until recently, this process 
was challenging, dependent on candidate-based approaches and limiting in its 
informative value. However, the development of newer technologies (i.e. SNP 
genotyping platforms) with improved genome-wide coverage has enabled the unbiased, 
systematic identification of pathogenic variants. Currently, large-scale and genome-wide 
technologies utilize microarray-based chips containing hundreds and thousands of 
oligonucleotide SNP probes. The Illumina OmniExpress GWAS array is applicable for 
genotyping genome-wide variants implicated in GWAS experiments, and specifically for 
autoimmune diseases, the Immunochip is commonly used to test associations with 
known disease-associated variants (MOROZOVA AND MARRA 2008). 
The success of a GWA study is highly dependent on the nature of the disease 
being studied (i.e. the characteristics of the phenotype, variation, sensitivity and 
specificity in the diagnosis, etc), and extremely large cohorts of individuals are required 
to identify a statistically significant association between a tag SNP (representative of a 
haplotype) and the disease. Because of this methodology, the associated SNPs only 
capture of snapshot of the genetic variation across a region thus, requiring follow-up 
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studies of targeted deep resequencing (discussed below) in candidate GWAS regions to 
identify the susceptibility variants in association with the disease. It is important to note 
that some variants, particularly missense and silent substitutions, can be non-
pathogenic (present in the general population as polymorphisms), therefore, they need 
to be crosschecked with publically available databases (1000 genomes, dbSNP, NCBI, 
UCSC, etc.) containing information on natural genomic variation. 
Following GWAS, the next step is to determine the validity of the associations 
identified by analyzing an independent cohort (i.e. geographic region, ancestry) in a 
replication study, and then perform a meta-GWAS analysis. A meta-analysis entails 
combining the data generated from the initial GWAS with that of the replication study, 
and using statistical methods (i.e. logistic regression) to calculate the odds ratio and 
standard error per allele. The goal is to replicate the previous findings as well as identify 
novel loci associated with the trait that surpass genome-wide significance (p ≤ 10-8). 
While a replication study is not always available may not have been performed, the 
meta-GWAS has become the standard approach to validating the association of a 
genomic region with the disease prior (or in parallel) to embarking upon functional 
genomics or deep sequencing studies.  
The application of GWAS and meta-GWAS to study common diseases is based 
on the premise that common allelic variants are present in greater than ~5% of the 
general population, yet the proportion of heritability accounted for by the identified 
variants is relatively small (~20%) (MANOLIO et al. 2009). The “missing heritability” is 
said to be explained by a large number of variants with small effects, rare variants with 
moderate effects, structural variants (i.e. CNVs), genetic and gene-environment 
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interactions (MANOLIO et al. 2009). This observation further highlights the need for a 
robust and powerful strategy to detect pathogenic variants not identified in GWAS, and 
determine the biological/clinical relevance of disease-associated mutations. Importantly, 
a comprehensive picture of the genetic architecture in complex disorders can be 
obtained using a functional genomics approach (discussed in the following section), 
integrating genome-wide datasets on genetic variation and mutations at the DNA level, 
with gene expression and functional information at the RNA and protein levels.  
In the work described in Chapter IV, these methods were used to characterize 
the complex genetic architecture of alopecia areata, and were instrumental in the 
identification of a novel gene cluster that plays a crucial role in disease pathogenesis. 
Targeted Deep Sequencing 
GWAS test for association with tag SNPs, meant to capture the variation in a particular 
region, but are only representative of a small subset of the variation in that region. The 
next step after demonstrating an association is to determine what variants are in linkage 
disequilibrium with the tagged SNP and could be driving association. To focus in on a 
particular region of genetic association or inheritance (i.e. based on linkage 
disequilibrium peaks), targeted deep resequencing is a suitable approach to identify 
both rare and common variants that exist within a selected genomic region. However, in 
cases where deep sequencing is not feasible, genotype-based methodologies (i.e. 
Sequenom genotyping, Agilent and HiSeq targeted sequencing) are used to test for 
known causal or associated variants.  
Allelic frequencies for genetic variants can be determined through comparing 
their prevalence in affected to healthy cohorts as well as to the general population using 
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public genome database information (1000 genomes, dbSNP, NCBI, UCSC, etc.). To 
prioritize the biologically interesting loci for targeted deep resequencing, data obtained 
from other studies can provide useful information for narrowing the list of candidate 
regions contributing to disease pathogenesis. These sources include family-based 
studies (linkage, whole-exome, CNV analysis) for some complex diseases, gene 
expression studies (i.e. microarrays, RNA-seq), and mouse models that recapitulate the 
disease phenotype. More recently, these approaches have successfully identified both 
non-coding and coding variants in polygenic traits including various autoimmune 
disorders (VERLAAN et al. 2009; HUTCHINSON et al. 2014) (RIVAS et al. 2011; BEAUDOIN et 
al. 2013). 
Whole-genome and targeted resequencing approaches provide comprehensive 
polymorphism and mutation discovery in human genomes. Unlike Mendelian disorders, 
the large majority of genomic regions in strong association with complex, polygenic 
traits (i.e. autoimmune diseases) lie outside of genes (intergenic) and within 
presumptive regulatory regions (HINDORFF et al. 2009; XU AND TAYLOR 2009). Functional 
genomics studies can be used to test the consequence of both coding and non-coding 
variants on gene networks by integrating data on DNA sequence, expression and 
genetic/protein interactions. As in rare Mendelian disorders, further functional studies (in 
vitro and in vivo) should be performed to test the effects of the variants and their 
potential contribution to disease pathogenesis.  
Functional Genomic Studies 
To determine the biological involvement of disease variants and their interactions at the 
molecular, genetic and epigenetic levels, researchers have recently begun to use 
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functional genomics to gain a clear and comprehensive picture of the relationship 
between genotype and phenotype. The Human Genome Project as well as the next-
generation sequencing methods developed thereafter (discussed above) have been 
instrumental in the implementation of this approach to studying complex human 
diseases, where the ultimate goal is to validate the biological and clinical relevance of 
disease-associated mutations. As a follow-up to the Human Genome Project, the 
ENCODE (Encyclopedia of DNA Elements) Project was developed to identify all the 
functional regulatory elements in the human genome and currently serves as a 
comprehensive and indispensible resource for the scientific community (ENCODE 
2004). The ENCODE and Roadmap Epigenomics Projects, as well as FANTOM5 
(functional annotation of the mammalian genome 5) have facilitated the identification of 
novel DNA regulatory elements including gene promoters, enhancers, transcription 
factor binding sites, and regions of the genome subject to chromatin and histone 
modifications. In the context of both natural human variation and genetic disease, these 
data are of tremendous value in propelling the field of functional genomics, revealing 
how non-coding DNA can influence gene transcription and regulation, and the 
downstream consequences of non-coding pathogenic variants in human disease. 
The functional genomics approach integrates genetic/mutational analyses with 
functional and regulatory information on gene transcription, translation, and protein-
protein interactions in a high-throughput manner rather than a candidate-by-candidate 
approach. At the mRNA level, transcriptome sequencing (i.e. RNA-seq) provides 
information on gene expression, splicing, and discovery of transcribed SNPs or somatic 
mutations (MOROZOVA AND MARRA 2008). At the chromatin level, genome-wide mapping 
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of protein-DNA interactions can be achieved using chromatin immunoprecipitation 
sequencing (ChIP-seq) (RIVERA AND REN 2013).  Bioinformatics analysis, coupled 
together with computational biology tools can be used to functionally integrate this 
information and provide a clear and potentially meaningful representation of the data for 
further interpretation and downstream analyses.  
Following the identification of variants, the next step is often testing their 
downstream consequences on gene expression. This can be accomplished using 
various methods and approaches, including microarray analysis, quantitative RT-PCR 
(qRT-PCR) and/or RNA-sequencing. Additionally, this information can be correlated 
with histological/immunohistochemistry analysis of patient samples, followed by 
functional studies employing cell culture systems (in vitro) and mouse models (in vivo) 
to test a how a given coding or non-coding variant behaves and its overall contribution 
to disease pathogenesis. 
In the work described in Chapter IV, targeted deep resequencing of a disease-
associated locus, followed by functional genomics studies enabled the identification and 




Chapter I.3. The Biology of the Skin and Hair Follicle  
3.A Mammalian skin and hair follicle development 
The skin is the largest organ in the body, and serves as a protective barrier against 
injury, possessing both flexible and rigid properties governed by the types of molecules 
expressed in each cell that permit proper association and communication between 
individual cells (DESTEFANO AND CHRISTIANO 2014)	  (FUCHS 2007). Several different cell 
types of both mesenchymal and epithelial origin make up the skin: the ectodermally 
derived epidermis is composed of keratinocytes, and the underlying dermis consists of a 
heterogeneous population of mesenchymal cells that includes fibroblasts that secrete 
the connective tissue matrix. In the epidermis, as in all stratified squamous epithelia (i.e. 
esophagus and cornea), there are undifferentiated and differentiated keratinocytes 
expressing specific type-I (acidic) and type-II (basic) keratin intermediate filaments, as 
well as structural proteins required for intercellular adhesion.  
Among the ectodermal appendages of the skin, the hair follicle is a miniorgan of 
a highly complex and dynamic structure, providing physical protection, 
thermoregulation, sensory perception, and cues in psychosocial and sexual 
communication. In mammals, hair follicle development arises through a series of 
reciprocal signaling events that occur between the undifferentiated epithelium and 
underlying mesenchyme, where gradients of activators/inhibitors regulate the patterning 
of hair follicles across the body. During morphogenesis, a signal emanating from the 
dermis instructs the epidermis to thicken and form a placode (Figure 4).  At around 
E14.0 in the mouse, a signal from the epidermis then instructs these underlying 
mesodermal cells that will become the dermal papilla to condense at the site of the 
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newly-forming follicle (MILLAR 2002). As the epidermis proliferates, it envelops the 
dermal condensate, which leads to the formation and down growth of the developing 
hair follicle. The developing outer root sheath (ORS) (the outer most epithelial layer in 
the hair follicle) is continuous with the epidermis, and residing at the base of the hair 
follicle are matrix cells (also called transit amplifying cells), which are in direct contact 
with the dermal papilla (Figures 4 and 5).  
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During hair follicle growth, matrix cells proliferate and differentiate upwards to 
give rise to the three cylinders of the inner root sheath (IRS) and the hair shaft within the 
center of the follicle, but they have a limited proliferative capacity (Figure 5). Following 
exhaustion, they are replenished from a reservoir of epithelial stem cells located in the 
bulge, which serves a primary stem cell niche for the hair follicle and mediates the self-
renewal and continuous cycling through the active growth (anagen), regression 
(catagen), and resting (telogen) phases (OHYAMA 2007) (FUCHS 2007) (Figure 4). 
Importantly, the hair follicle is an excellent system in which to study genetics due to its 
readily accessible nature, cycling properties, developmental pathways, diverse range of 
cell types (Figure 5), and widely studied spatiotemporal regulation of gene expression. 
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3.B Hair patterning  
Hair types in humans can be grouped into three categories based on size, cellular 
composition, pigmentation and androgen responsiveness (GARN 1951). Lanugo hairs 
are the first to form during development (appearing on the scalp by the 10th gestational 
week) and are uniformly long, fine and unpigmented. These hairs are shed in utero in a 
synchronized manner and are predominantly replaced by vellus hairs, which are fine 
and unpigmented, but shorter than lanugo hairs. Unlike the vellus hairs that cover the 
majority of the body, terminal hairs are the course, pigmented, and medullated hair 
follicles that penetrate into the fatty layer of the dermis. Terminal hair follicles first 
develop on the scalp, replacing the vellus intermediate-like hairs from 3-7 months of age 
and display characteristic features of terminal hairs by age 2, later appearing on 
additional sites of the body subject to androgen stimulation (i.e. sites of secondary sex 
characteristics) during puberty (GARN 1951).  
Compared to other mammals, humans have lost most of their body hair over the 
course of the 90 million years of evolution. However, regional differences in hair 
patterning across the body found on other mammals are conserved. In both humans 
and lower-level mammals (i.e. Mus musculus), the cellular origin of the ectodermal 
compartment of the skin and hair follicle is non-neural and relatively uniform across the 
body, whereas the mesenchyme is spatially derived from distinct cellular lineages 
during development: the somites (dorsal dermis), lateral plate mesoderm (ventral 
dermis), and the neural crest and paraxial mesoderm (craniofacial dermis) (TRAN et al. 
2010). Tissue recombination experiments performed several decades ago have 
revealed that during hair follicle development, the dermal mesenchyme possesses the 
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inductive factors responsible for initiating hair follicle growth, specifying location, size, 
and proper distribution pattern of the developing hair follicles (SENNETT AND RENDL 
2012). Interestingly, studies in humans and mice have demonstrated that dermal 
fibroblasts derived from different anatomic positions possess strikingly distinct gene 
expression profiles that are correlated with the anterior-posterior, proximal-distal, and 
dermal-nondermal axes (RINN et al. 2006; RINN et al. 2008).  
As the human hair follicle cycles through anagen, catagen, and telogen, it is not 
synchronized with its neighboring follicles or with those at different body sites (in 
contrast to the synchronization in mouse hair follicles). Thus, depending on the location 
and type of hair produced, the hair cycle can last from months up to several years. On 
the scalp, hairs remain in anagen for 2-6 years, in catagen for 2-3 weeks, and telogen 
for ~3 months, whereas the vellus hairs covering the body are primarily in telogen, only 
spending 6-12 weeks in anagen. It is likely that differences in mesenchymal cell origin 
and initial cell fate specification contribute to the visible patterning and regionalization 
differences of hair follicles found on the scalp, face, and body surface. 
Following hair patterning, hair follicles can retain the identity and characteristics 
of the donor site when transplanted to a recipient site, a phenomenon called donor 
dominance, is observed in hair transplantation on the scalp (back of the head to the 
front), as well as scalp or facial hairs (eyebrows) transplanted to other sites of the body 
(i.e. the leg) (ORENTREICH 1959). Importantly, this remarkable property forms the basis 
for hair transplantation in individuals with androgenetic alopecia (male-pattern 
baldness), where hairs relocated from the back of the scalp to the front survive for 
decades (ORENTREICH 1959; BARRETO 1998; LEE et al. 1999; GANDELMAN AND EPSTEIN 
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2004). While it is known that certain regions of the scalp (such as the occipital fringe) 
remain refractive to the effects of androgens while others are susceptible (front and 
top), the molecular mechanisms governing this phenomenon have not been studied.  
3.C Mouse Models for Hair Follicle Morphogenesis and Cycling 
While there are several notable differences between human and mouse hair follicles 
(i.e. hair types, cycling properties, etc), the mouse as a model has proven useful in 
identifying the genes and pathways that control hair follicle morphogenesis and cycling 
(NAKAMURA et al. 2013). Since the molecular and biological pathways underlying hair 
follicle growth have been well characterized in mice, most of what we know about the 
controls of hair growth, size, patterning has been determined by the use of spontaneous 
and genetically-engineered mouse models exhibiting hair follicle defects (NAKAMURA et 
al. 2013). For example, angora mice null for the Fgf5 gene have abnormally long hair, 
due to a prolonged anagen phase (HEBERT et al. 1994). Interestingly, mutations in the 
FGF5 gene have also been identified in angora rabbits, sheep, cats, goats and most 
recently, the Christiano lab reported FGF5 mutations in humans with trichomegaly (long 
eyelashes) (HIGGINS et al. 2014), highlighting the critical and conserved role for this 
growth factor in regulating hair length. 
Over the past few decades, studies in mouse models have revealed that a wide 
variety of well-conserved growth factors and molecules involved in cell signaling, 
adhesion and communication are crucial for the development and dynamic maintenance 
of the skin and hair follicle. The genes regulating the development of hair follicles are 
very similar (and in some cases, identical) to those regulating the formation of other 
ectodermal appendages (i.e. teeth, mammary gland), such that mutations in these 
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genes produce pleiotropic effects (SCHMIDT-ULLRICH AND PAUS 2005; NAKAMURA et al. 
2013). Many studies have demonstrated a key role for the Wnt/β-catenin signaling 
pathway during hair follicle patterning and morphogenesis, where forced expression of 
β-catenin in the mouse epithelium leads to an overall increase in the number in hair 
follicles, an acceleration in morphogenesis and growth, and the production of hair-
derived tumors (GAT et al. 1998). Conversely, ectopic expression of the Wnt inhibitor, 
Dickkopf (Dkk1) in epidermal keratinocytes abrogates placode formation and patterning 
(ANDL et al. 2002). 
In addition to the Wnt/β-catenin signaling pathway, components of the Bmp, Shh, 
Eda/EdaR, Fgf, and Pdgf signaling pathways, as well as several transcription factors 
(Sox9, Hoxc13, Msx1/2, Lef1, Gata3, etc.) possess essentials roles in morphogenesis 
and hair growth (SCHMIDT-ULLRICH AND PAUS 2005; NAKAMURA et al. 2013). These 
pathways are known to converge, since mouse models with targeted or spontaneous 
mutations in these genes, depending on the developmental time point, can act both 
upstream and downstream of one another (i.e. Wnt signaling controls and is controlled 
by the Eda/EdaR/NF-KB signaling pathway during hair follicle induction). Importantly, 
positive and negative feedback regulatory loops are required for augmenting or 
attenuating gene expression levels, and this spatiotemporal regulation is required for 
proper development of the skin and hair follicle. 
3.D Genetic Mutations in Human Hereditary Hair Disorders 
In humans, mutations in key signaling molecules, transcription factors, structural 
proteins, and transporters have been identified in several Mendelian ectodermal 
dysplasias, or abnormal development of the hair, skin, nails, teeth and/or eccrine glands 
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(SHIMOMURA AND CHRISTIANO 2010). Notably, the phenotypes in human genetic skin and 
hair disorders are often recapitulated in the mouse models harboring mutations in these 
same genes (SCHMIDT-ULLRICH AND PAUS 2005; NAKAMURA et al. 2013). Humans with 
autosomal recessive odonto-onycho-dermal dysplasia, characterized by hypotrichosis, 
hypodontia, nail dystrophy and keratoderma, possess loss-of-function mutations in the 
WNT10A gene (ADAIMY et al. 2007). Similarly, in hereditary hypotrichosis simplex, an 
autosomal dominant nonsyndromic disorder of hair loss, the Christiano lab previously 
reported heterozygous mutations in the APCDD1 gene, encoding a membrane-bound 
repressor of the WNT/β-catenin signaling pathway, in large families from Pakistan 
(SHIMOMURA et al. 2010a). In addition to WNT signaling, proteins of the TNF pathway, 
EDA, EDAR, and EDARADD regulate hair follicle patterning and morphogenesis, where 
mutations in these proteins cause both autosomal and X-linked forms of hypohidrotic 
ectodermal dysplasia (HED), characterized by abnormal development of the hair, skin, 
nails, teeth and eccrine glands (CLUZEAU et al. 2011). Moreover, the human HED 
phenotype recapitulates that observed in four spontaneous mouse models that harbor 
mutations in the homologous genes (Tabby/Sleek/downless/crinkled, named after the 
phenotypes) (SHIMOMURA AND CHRISTIANO 2010).  
Signaling pathways that regulate lipid metabolism (i.e. biosynthetic enzymes) and 
ion transport also play an important role in regulating hair growth and the overall 
structural integrity of the hair follicle and shaft. Mutations have been identified in the 
LPAR6 (also known as P2RY5, encoding an orphan G-protein coupled receptor for 
LPA), and LIPH (lipase H) genes in humans with LAH and autosomal recessive woolly 
hair syndromes (KAZANTSEVA et al. 2006; SHIMOMURA et al. 2008; SHIMOMURA et al. 
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2009), where the Liph knockout mouse phenotype recapitulates the human condition 
(INOUE et al. 2011). Interestingly, these genes are all expressed in the IRS of human 
hair follicles and perfectly overlap with the expression of the KRT71 and KRT74 genes 
that underlie autosomal dominant forms of woolly hair/hypotrichosis (SHIMOMURA et al. 
2008; FUJIMOTO et al. 2012).  Furthermore, it is known that LIPH encodes a membrane-
associated phosphatidic acid-selective phospholipase that produces 2–acyl 
lysophosphatidic acid (LPA) from phosphatidic acid, and that phosphatidic acid 
promotes hair growth, highlighting the critical role for these lipid mediators in the overall 
integrity of the hair follicle (SONODA et al. 2002; PASTERNACK et al. 2008). 
Several genes encoding transcription factors required for patterning and 
differentiation of hair follicle cells are also mutated in hereditary hair disorders. Classic 
examples include p63 in several autosomal dominant diseases (i.e. ectodermal 
dysplasia) (CELLI et al. 1999), the zinc-finger transcription factor/histone demethylase 
Hairless (HR) that regulates catagen and is mutated in atrichia with papular lesions 
(AHMAD et al. 1998; PANTELEYEV et al. 1999), and FOXN1, a forkhead box transcription 
factor expressed in the matrix and hair shaft whose loss-of-function causes T cell 
immunodeficiency, congenital alopecia (hair loss), and nail dystrophy (FRANK et al. 
1999; SCHLAKE et al. 2000).  
In addition to transcription factors, a great number of mutations have been 
identified in genes encoding structural proteins and cellular adhesion molecules (i.e. 
components of the desmosome) in hereditary hair disorders, where mutations in the 
KRT81, KRT83, and KRT86 genes underlie monilethrix (fragility of scalp hairs), and 
KRT74 and KRT71 mutations cause autosomal dominant woolly hair syndrome and 
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hypotrichosis (WINTER et al. 1997; CHIEN et al. 2006; SHIMOMURA et al. 2010b). Similarly, 
we previously identified mutations in the DSG4 gene in patients with localized 
autosomal recessive hypotrichosis (LAH), and in conjunction with comparative 
genomics studies in the lanceolate hair mouse, defined the critical role for DSG4, a 
suprabasally expressed desmoglein, in the skin and hair follicle (KLJUIC et al. 2003). 
Importantly, this was one of the first reports of positional cloning that was accelerated by 
the Human Genome Project (2003) because DSG4 had not been identified by previous 
cloning or sequencing methods. 
Whereas genetic mutations in structural and signaling proteins result in hair 
anomalies, other factors including hormones, nutrients, and environmental stress can 
perturb hair growth and in some cases, phenocopy a hereditary disorder. Human 
patients with hypo- and hyperthyroidism experience hair loss, and mice deficient for 
thyroid hormone receptors TRα1 and TRβ have impaired epidermal proliferation, hair 
growth and wound healing as a result of defective mobilization of stem cells out of the 
niche (CONTRERAS-JURADO et al. 2015). Additionally, neurotransmitters, growth factors, 
cytokines and steroids are all molecules delivered to the hair follicle via vasculature 
and/or neighboring cell types and are reported to influence the dynamics of hair growth.  
Hair follicle morphogenesis and growth are tightly regulated processes, where 
even minor perturbations lead to abnormalities in size, pattern, structure and the 
number of hair follicles.  Importantly, the many genetic studies performed over the past 
several decades have taught us a great deal about the complexity of the skin and hair 
follicle, and the various classes of molecules that are responsible for maintaining their 
overall structural integrity.  
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Chapter I.4. Inherited Hypertrichosis 
Inherited hypertrichoses are very rare human disorders characterized by excessive hair 
growth that does not depend on androgen stimulation and is independent of age, 
gender, and ethnicity (BEIGHTON 1970). Hypertrichosis syndromes fall under the larger 
umbrella of ectodermal dysplasias, or abnormal development of the hair, skin, nails, 
teeth and/or eccrine glands, and are often associated with additional anomalies 
including gingival hyperplasia, deafness, cardiomegaly, and bone abnormalities 
(GARCIA-CRUZ et al. 2002). Dating back to the Middle Ages, individuals with 
hypertrichosis became exhibitionists for the purposes of entertainment and art, as the 
striking image of an individual completely covered in hair has long fascinated humans, 
particularly evolutionary geneticists (Figure 6). These conditions are extremely rare, with 
only approximately 60 reported cases to date, and it has been suggested that inherited 
hypertrichoses represent examples of atavisms, or the recurrence of an ancestral 
phenotype, where the genes that promote a full coat of hair in other mammals and were 
silenced throughout evolution have become reactivated in human hypertrichosis, 
invoking unusual genetic mechanisms to explain their occurrence (HALL 1984; CANTU 
AND RUIZ 1985). 
The excessive hair overgrowth phenotype of hypertrichosis can be produced 
from drug reactions, hormone imbalances and toxic environmental effects. Similarly, 
there are several syndromes with congenital localized hypertrichosis as an associated 
feature, including Cantú syndrome (OMIM 239850)	  (CANTU et al. 1982a; CANTU et al. 
1982b), a condition first described in 1982 that is characterized by hypertrichosis, 
coarse facial features, cardiac hypertrophy and osteochondrodysplasia, and Coffin-Siris 
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syndrome	  (OMIM 135900) (QAZI et al. 1990), a rare autosomal dominant condition of 
mental retardation, craniofacial anomalies, hypertrichosis and other ectodermal 
dysplasias. Importantly, several forms of hypertrichosis as an inherited, isolated 
disorder have been described, where the excessive hair overgrowth phenotype is the 
primary clinical feature and is most often generalized rather than localized. These 
include hypertrichosis universalis congenita, Ambras type (OMIM 145701), 
hypertrichosis lanuginosa congenita (OMIM 145700), X-linked hypertrichosis (OMIM 
307150), and congenital generalized hypertrichosis terminalis with or without gingival 




4.A Structural and Copy Number Variants Associated with Hypertrichosis 
Up until the past decade, the underlying genetic basis of these syndromes remained 
elusive, but recent studies from the Christiano lab and others have identified structural 
defects, copy number variants, and position effects associated with the autosomal 
dominant, sporadic and X-linked forms (discussed in Chapter 1.5). In hypertrichosis 
congenita, Ambras type (a form of hypertrichosis that affects the shoulders, forehead, 
nose, cheeks, eyelids, and ears), the Christiano lab defined a candidate interval on 
chromosome 8q containing the TRPS1 gene based on the cytogenetic breakpoints in 
three patients (TADIN et al. 2001; FANTAUZZO et al. 2008). TRPS1 was deleted in a 
patient with an 8q23 chromosomal rearrangement, and its expression was significantly 
downregulated in another patient with an inversion breakpoint 7.3Mb downstream of 
TRPS1 (FANTAUZZO et al. 2008).  
 In the autosomal dominant form of congenital generalized hypertrichosis 
terminalis (CGHT), the Christiano lab identified a series of microduplications within a 2.4 
Mb region on chromosome 17q24.2-24.3 ~1 Mb upstream of the SOX9 gene 
(FANTAUZZO et al. 2012). In an independent report, CNVs were identified in three CGHT 
families and one sporadic case, where the underlying genetic lesions were three distinct 
microdeletions in the familial cases, as well as one inverted duplication in the sporadic 
case (SUN et al. 2009). Taken together, these results strongly implicate the chr17q24.2-
24.3 region in CGHT pathogenesis, providing an allelic series of five reported CNVs. 
 In Chapter III, I further studied the chr17q24.2-24.3 region to identify genetic 
mechanisms underlying human hair growth in two independent CGHT cases (one 
sporadic, one familial).  
 
44 
4.B Position Effects on Genes Regulating Hair Follicle Development 
Position effects on single genes as a result of large chromosomal rearrangements or 
copy number variants have been reported in several ectodermal dysplasias, including 
hypertrichosis syndromes. Despite the pleiotrophic phenotypes of these syndromes and 
their reported association with large chromosomal rearrangements and copy number 
variants, the causative genetic mechanism underlying human hypertrichoses remained 
elusive. 
Within the past five years, position effects as the underlying genetic basis of 
these syndromes have been reported on the TRPS1 and SOX9 genes that reside ~1 
Mb to as distant as 7.3 Mb from these chromosomal rearrangements in hypertrichosis 
congenita, Ambras type and congenital generalized hypertrichosis terminalis (CGHT), 
respectively (FANTAUZZO et al. 2008; FANTAUZZO et al. 2012). In humans with autosomal 
dominant and sporadic forms of hypertrichosis, the Christiano lab identified position 
effects on SOX9 as a result of a 1.2 Mb deletion upstream of the gene, and observed 
reduced SOX9 expression at the mRNA and protein levels throughout patient hair 
follicles (FANTAUZZO et al. 2012). Several reports have demonstrated a crucial role for 
SOX9 in specifying hair follicle stem cells, where the conditional ablation of Sox9 in 
mice results in depletion of the stem cell niche and progressive hair loss (VIDAL et al. 
2005; NOWAK et al. 2008; KADAJA et al. 2014). This finding, though seemingly 
contradictory to the human phenotype of excessive hair growth from decreased SOX9 
expression, highlights the paradoxical nature of position effects in generating distinct 
phenotypes from that produced by intragenic loss-of-function mutations.  
In the X-linked forms of hypertrichosis, the Christiano lab and other groups have 
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reported linkage to chromosome Xq24-27 in two independent Mexican families 
(FIGUERA et al. 1995; TADIN-STRAPPS et al. 2003). More recently, large 
interchromosomal insertions were been reported in one of these Mexican families and a 
Chinese family containing linkage to chromosome Xq24-27, where the insertions in both 
families occurred at the exact same Xq27.1 extragenic palindrome site (ZHU et al. 
2011). Importantly, the sequences contained within each insertion differed between the 
families, suggesting that the presence rather than the content was responsible for 
mediating the excessive hair overgrowth phenotype.  
In Chapter II, I investigated the underlying genetic mechanism in the Mexican 
family with X-linked congenital generalized hypertrichosis in which the Christiano lab 
previously identified linkage to chr24-27 over a decade ago. 
4.C Intragenic mutations 
The genetic basis of hypertrichosis syndromes is largely composed of structural 
anomalies and CNVs. Prior to the work described in Chapter III, there were no reported 
intragenic mutations underlying CGHT cases. However, intragenic mutations have been 
reported in rare genetic conditions manifesting hypertrichosis as an associated (but not 
primary) clinical feature, including Coffin-Siris syndrome, Cantú syndrome, Schinzel- 
Giedion syndrome, and Cornelia de Lange syndrome. In patients with Coffin-Siris 
syndrome, a rare autosomal dominant condition of mental retardation, craniofacial 
anomalies and ectodermal dysplasias (including hypertrichosis), whole-exome 
sequencing identified fifteen mutations in genes encoding subunits of the SWI/SNF 
chromatin remodeling complex (TSURUSAKI et al. 2012). Over the past few years, 
several independent groups have studied the genetic basis of Cantú syndrome, and 
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whole-exome sequencing in families and unrelated cases identified intragenic, dominant 
gain-of-function mutations in the ABCC9 gene (HARAKALOVA et al. 2012; VAN BON et al. 
2012).  ABCC9 encodes the SUR2 protein component of the ATP-sensitive potassium 
channel complex. Minoxidil (Rogaine) is an agonist of this potassium channel and 
directly binds the SUR2 subunit (SCHWANSTECHER et al. 1998). Interestingly, the 
phenotypic similarities between Cantú syndrome patients and individuals with side 
effects from Minoxidil suggest that the dominant mutations in ABCC9 cause constitutive 
channel opening (VAN BON et al. 2012). Importantly, this observation further supports a 
role for ABCC9 in regulating human hair growth, highlighting the significance of ion 
transport in the hair follicle.   
 In patients with Schinzel-Giedion midface retraction syndrome, characterized by 
mental retardation, multiple congenital skeletal anomies, hypertrichosis and distinctive 
facial features, heterozygous de novo mutations in the SETBP1 gene were identified by 
whole-exome sequencing	  (HOISCHEN et al. 2010). Similarly, mutations in the NIPBL 
gene have been identified in the autosomal cases of Cornelia de Lange syndrome type 
I, where patients possess facial dysmorphism, hypertrichosis, mental retardation and 
several craniofacial anomalies	  (PIE	  et	  al.	  2010). In the X-linked forms, mutations have 
been identified in other components of the cohesin complex (SMC1A, SMC3, and 
RAD21) and in the HDAC8 gene	  (ROHATGI et al. 2010)	  (MUSIO et al. 2006). 
In Chapter III, I studied the genetic basis of autosomal recessive CGHT using 
whole-exome sequencing and characterized a novel transporter in human hair growth. 
4.D Mouse models 
Although little is known about the genes and mechanisms perturbed in hereditary 
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hypertrichosis syndromes, mouse models have proved useful for recapitulating the 
phenotype and identifying genetic pathways that regulate hair growth. As mentioned in 
Chapter I.3, the angora mouse harboring a mutation in Fgf5 has a prolonged anagen 
phase, leading to a striking increase in length of the pelage hairs (HEBERT et al. 1994). 
Similarly, forced expression of Noggin, a BMP antagonist, leads to the production of 
enlarged anagen hair follicles (SHAROV et al. 2006), and targeted overexpression of β-
catenin in the epidermis during morphogenesis leads to an overall increase in the 
number of hairs induced, and accelerated morphogenesis and growth (GAT et al. 1998). 
The Koala mutant mouse is a model for hypertrichosis, containing a 
chromosomal inversion whose proximal breakpoint maps 791 bp upstream of Trps1 
(Fantauzzo et al. 2008). Remarkably, the position effect the Christiano lab identified on 
Trps1 associated with Ambras syndrome was recapitulated in the Koala mouse, which 
demonstrated a marked decrease in Trps1 expression at the sites of pathology for the 
phenotype (Fantauzzo et al. 2008). Further functional studies performed in the lab 
demonstrated a role for TRPS1 as a novel regulator of the Wnt signaling pathway. 
SOX9 was identified as a direct transcriptional target gene of TRPS1, where these 
genes form an important feedback loop with SHH to regulate epithelial proliferation in 
the hair follicle (FANTAUZZO AND CHRISTIANO 2012; FANTAUZZO et al. 2012). 
Importantly, functional studies performed in mouse models, in conjunction with a 
thorough analysis of human patient samples suggests three mechanisms by which the 
excessive hair overgrowth phenotype may arise: an increased duration of anagen, an 
overall increase in the number of hair follicles during induction, and a vellus-to-terminal 
transformation, where fine, unpigmented hairs are stimulated to grow larger and extend 
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deep into the dermis, become pigmented and form a medulla. In the context of 
hypertrichosis, it is likely that human patients possess a combination of these three 
defects to produce the excessive hair overgrowth phenotype. 
In Chapter II, I investigated genomic effects involving structural variants and 
position effects on human hair growth, and in both Chapters II and III, discuss these 
genetic mechanisms underlying both X-linked and autosomal forms of hypertrichosis. 
5. The Genetic Basis of Alopecia Areata 
5.A Epidemiology and Immunopathology 
The human hair follicle is considered an immune privileged site, tolerating antigen 
production without inducing an inflammatory response (ITO et al. 2008b). Hair follicle 
immune privilege is accomplished through the downregulation of MHC class I molecules 
that are involved in antigen presentation, active repression of ligands that stimulate 
natural killer (NK) cell activation, and the secretion of immunosuppressive molecules 
(i.e. TGFβ1 and β2, and macrophage migration inhibitory factor, MIF) that allow the hair 
follicle to evade immunosurveillance (GILHAR et al. 2012).  
Alopecia areata (AA) is a complex autoimmune disease characterized by 
disfiguring hair loss due to the collapse of immune privilege in the hair follicle. Among all 
autoimmune diseases, AA is one of the most common (lifetime risk of 1.7%), affecting 
approximately 5.3 million people of both genders and of varying age and race 
(PETUKHOVA AND CHRISTIANO 2013). Moreover, AA is one of the most burdensome 
chronic skin diseases with an unpredictable onset and relapse period, producing 
psychologically devastating effects on an individual’s self-image and self-esteem. The 
 
49 
onset of AA has been described as the sudden whitening of hair, as the target of 
autoimmune attack is the growing (anagen), pigmented follicle, resulting in the loss of 
patches of hair (patchy AA), all scalp hair (alopecia totalis), or complete body hair 
(alopecia universalis) (GILHAR AND KALISH 2006) (Figure 7, A-D). 
 
During active disease, the hair cycle is disrupted by the early onset into catagen, 
leading to a shift in the ratio of anagen to telogen and catagen hair follicles. The 
immunopathology of human AA is characterized by the infiltration of CD3+ and CD8+ T 
lymphocytes at the base of the hair follicle (resembling a ‘swarm of bees’) (Figure 7, E-
H), where the immune infiltrate is composed of cytotoxic T cells, natural killer (NK) cells 
as well as activated T-helper cells (GILHAR AND KALISH 2006). The triggering event in 
active disease is thought to be due in part to the loss of immune privilege, and the 
pathogenicity of this immune infiltrate has been demonstrated in human xenograft 
models, where lesional human lymphocytes transferred to immunocompromised SCID 
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mice bearing a human scalp skin graft were able to induce disease (GILHAR et al. 1998). 
Although T lymphocyte-mediated autoimmune attack causes destruction of the AA hair 
follicle, there is no permanent organ damage as the stem cell compartment is spared 
(similar to the destruction in catagen), thus making hair regrowth possible. 
5.B Genetic studies in family-based cohorts 
Evidence supporting a genetic basis for AA includes the observed heritability in first-
degree relatives (10-fold increased risk) (VAN DER STEEN et al. 1992; MCDONAGH AND 
TAZI-AHNINI 2002), concordance rates in twin studies (55% concordance in monozygotic 
(MZ) twins; 0% in dizygotic (DZ) twins) (JACKOW et al. 1998) and family-based linkage 
studies (MARTINEZ-MIR et al. 2003). While the majority of the genetic studies in AA were 
conducted using candidate association analysis, the Christiano lab conducted the first 
genome-wide scan for linkage with AA, and identified evidence for linkage on 
chromosomes 6, 10, 16 and 18 that have been replicated in subsequent studies 
(MARTINEZ-MIR et al. 2007). The HLA region on chromosome 6p possessed the 
strongest signal in both association studies and linkage analysis, pointing to specific 
HLA-DQB and HLA-DR alleles that conferred risk. Outside the HLA region, a significant 
peak on chromosome 6q25.1 was present in a region not previously associated with an 
autoimmune disease, and this association is discussed in following section. 
In a subsequent study, the MICA locus was subsequently identified in an 
extended haplotype of the HLA region in strong association with AA, where the MICA 
(MHC class I chain-related gene A) gene encodes a ligand for the cytotoxic T cell 
receptor, NKG2D (BARAHMANI et al. 2006). NKG2D is activated in the presence of a 
stressed cell emitting a “danger signal” upregulating ligand expression, and this 
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ultimately leads to cellular destruction (CAILLAT-ZUCMAN 2006). The NKG2D signaling 
pathway in cytotoxicity has been well described in the context of viral infection, 
autoimmunity as well as cancer (GONZALEZ et al. 2006). The association of 
MICA/NKG2D signaling with autoimmune disease was previously known, implicated in 
the pathology of type I diabetes and rheumatoid arthritis. In the context of AA, MICA 
expression is upregulated in AA lesional hair follicles, a finding that together with the 
strong genetic association provides evidence for the NKG2D signaling pathway in AA 
disease pathogenesis (BARAHMANI et al. 2006; ITO et al. 2008a). 
5.C GWAS 
Several family-based studies have been conducted to identify susceptibility loci 
associated or in LD with AA, however, small sample sizes and candidate-based 
approaches limited their informative value. Thus, a more robust and unbiased approach 
using population-based studies was required to elucidate the key pathogenic risk 
variants underlying this complex disease. The Christiano lab conducted the first GWAS 
for AA using 1,054 cases and 3,278 controls, and identified eight regions of the genome 
significantly associated with AA that clustered into discrete LD blocks. Among the 
associated regions were the HLA, ULBP3/6, CTLA4, IL-2/IL-21, IL-2RA, IKZF4, PRDX5, 
and STX17 loci, many of which have been previously implicated in other autoimmune 
diseases (including T1D, RA, celiac disease) (PETUKHOVA 2010) and were recently 
replicated in our meta-GWAS analysis (BETZ et al. 2015). In Chapter IV.2, I performed 
functional studies on novel genes associated with AA that were identified in our recent 




Remarkably, the ULBP3/6 locus on chromosome 6q25.1 possessed the highest 
association signal (P = 4.49 x 10-19) with AA outside the HLA, and the significance of 
this association increased in our replication study (P = 5.9 x 10-24) (BETZ et al. 2015). 
The ULBP (cytomegalovirus UL16-binding protein) genes 1-6 reside in a 180-kilobase 
MHC class I-related cluster (Figure 8A) and encode ligands for the activating cytotoxic T 
cell receptor, NKG2D (CAO AND HE 2004). While allelic variants and polymorphisms in 
other NKG2D ligands (i.e. MICA/MICB) have been previously associated with AA 
(BARAHMANI et al. 2006; ITO et al. 2008a), the GWAS study conducted in the Christiano 
lab is the first to implicate the ULBP gene cluster in any human disease. The statistical 
association of ULBP3/6 with AA was biologically validated by immunofluorescence 
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staining, whereby ULBP3 expression was strongly upregulated in lesional hair follicles, 
and the T cell infiltrate at the base of the hair follicle was found to contain NKG2D+ 
CD8+ T cells (PETUKHOVA et al. 2010) (Figure 8B). Importantly, subsequent studies in 
mouse models have demonstrated that inducible overexpression of Rae1 (ULBP 
homologue) in the mouse epidermis, pulmonary epithelium, and β-islet cells causes 
infiltration of cytotoxic T cells similar to what is observed in autoimmune disease 
(MARKIEWICZ et al. 2012) (STRID et al. 2008; BORCHERS et al. 2009). 
These immunological findings and the strong genetic association of ULBP3/6 
with human AA provide evidence for a role for the ULBP-NKG2D signaling axis, yet the 
precise mechanism(s) by which pathogenic NKG2D ligand variants contribute to 
autoimmunity in the hair follicle remained unknown. Interestingly, the majority of 
susceptibility variants associated with complex genetic disorders identified by GWAS 
are intergenic, residing within non-coding DNA and presumptive regulatory regions 
(MANOLIO et al. 2009; WANG et al. 2010). Moreover, the emerging picture of the genetic 
architecture underlying complex disease supports a role for both common and rare 
variants that drive associations and contribute to the “missing heritability” (MANOLIO et 
al. 2009). Considering the loss of immune privilege in the AA hair follicle and ectopic 
expression of key immune-related genes, I postulated that non-coding variants at the 
ULBP3/6 locus contribute to the marked upregulation of these ligands in AA. 
5.D C3H/HeJ mouse model for alopecia areata 
An additional line of evidence in support of a genetic basis for AA comes from the study 
of animal models. The C3H/HeJ inbred strain spontaneously develops AA (~20% rate), 
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however, the disease can be induced using a well-established efficient skin grafting 
model (95-100% reliable), allowing us to study interventions in the context of both 
disease prevention and reversal (SUNDBERG et al. 2004) (MCELWEE et al. 1998). Genetic 
linkage studies in the C3H/HeJ strain have identified four susceptibility loci on 
chromosomes 8 (Alaa3), 9 (Alaa2), 15 (Alaa4), and 17 (Alaa1), where Alaa1 
corresponds to the human HLA region (SUNDBERG et al. 2004). Although the regions of 
genetic association differ between the human and mouse disease (excluding the HLA 
locus), the C3H/HeJ mouse model recapitulates many pathological features of adult AA, 
including the infiltration of T lymphocytes at the base of the growing hair follicle. 
 Whereas in other autoimmune diseases the end organ tends to be irreparably 
destroyed, the skin and hair follicles remain accessible and amenable for histological 
and molecular studies in AA. Thus, in human AA patients and the mouse model, we can 
isolate the affected target tissue to interrogate the molecular pathology both prior to and 
during disease pathogenesis. This feature provides us with a tremendous advantage, 
allowing us to dissect the transcriptional network and crosstalk between the target hair 
follicle and effector T cells. The trajectory and approaches we used to accomplish this 
ultimately led to the development of therapeutic interventions in the mouse model and 
now in human AA patients (Chapter IV.3). 
 In Chapter IV.3, I aimed to identify and characterize genes whose mRNA levels 
were dysregulated in the mouse model using microarray expression profiling and 
immunohistological analysis.  In Chapter IV.4, I focused my studies on the ULBP3/6 
locus given its strong genetic association with AA and role of NKG2D signaling in 
disease pathogenesis. In this work, I investigated the mechanisms regulating ULBP3/6 
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expression and characterized novel susceptibility variants using functional genomics. 
6. Long-Range Interactions Controlling Gene Expression
In addition to position effects (discussed in Chapter I.5), changes in the local chromatin 
structure and long-range interactions between enhancer elements and gene promoters 
play a critical role in orchestrating the spatiotemporal expression and repression of 
genes. These changes are accompanied by a reorganization of the nuclear architecture 
and the formation of active chromatin hubs engaged in both intra- and 
interchromosomal looping interactions. Over the past few years, several methods have 
been developed to detect and capture long-range interactions, including the 
Chromosome Conformation Capture technologies (3C, 4C, 5C, Hi-C) (DOSTIE et al. 
2006; SIMONIS et al. 2006; ZHAO et al. 2006), ChIA-PET (Chromatin Interactions 
Analysis with Paired-End Tag Sequencing) (LI et al. 2010) for interactions bound by a 
protein of interest, ChIP-loop (HORIKE et al. 2005), a method that combines ChIP and 
3C, as well as the protein-tethered Dam methylase technique, where methylated 
regions can be attributed to chromatin looping (VAN STEENSEL AND HENIKOFF 2000). In 
conjunction with these approaches, FISH at a high resolution (3D FISH) can be used to 
detect and validate the juxtaposition of distinct genomic regions (OSBORNE et al. 2004).  
Long-range interactions have been observed in several cell types and biological 
processes requiring spatiotemporal control of gene expression. Depending on the 
context, cis acting regulatory elements (i.e. enhancers and repressors/insulators) can 
be located and act in close proximity to the gene (i.e. intronic region) or exert effects 
over very large distances (several Mb). Allele-specific long-range interactions have 
been described at the H19/IGF2 imprinting control region (ICR) during imprinting, where 
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parental-specific expression of the H19 and IGF2 alleles is required for normal 
development. The CCCTC-binding factor, CTCF, has been reported to act as an 
insulator in preventing interactions between the H19 enhancers and IGF2 promoter on 
the maternal allele, (LI et al. 2008; PHILLIPS AND CORCES 2009; CUNNINGHAM et al. 2010; 
GUIBERT et al. 2012), where its occupancy at the ICR is inversely correlated with 
methylation status. Importantly, disrupted transcriptional regulation of imprinted genes 
can lead to severe defects, and has often been reported to cause human imprinting 
disorders (i.e. Beckwith-Wiedemann syndrome and chr11p15.5) (NATIVIO et al. 2011).  
Long-range interactions in the immune system 
Beyond imprinting, long-range interactions and a role for CTCF have been described in 
the immune system during lineage commitment, the generation of antigen diversity, as 
well during an immune response (JHUNJHUNWALA et al. 2009; SEKIMATA et al. 2009; 
MAJUMDER AND BOSS 2010; WILLIAMS et al. 2013; SHARAF et al. 2014). Several immune-
related genes are exclusively expressed from one allele (monoallelic expression) to 
ensure uniformity in the recognition of molecules in the context of an immune response 
(i.e. antigen recognition). Over the past decade, studies have begun to uncover the 
complex transcriptional regulation of the highly polymorphic MHC Class I and II genes 
at the HLA locus, where the binding of CTCF to conserved insulator elements in 
between the HLA-DR and HLA-DQ gene clusters physically links the MHC promoters to 
distal enhancer elements, promoting an active configuration of transcription (MAJUMDER 
et al. 2008; MAJUMDER AND BOSS 2010; GILLEN AND HARRIS 2011). Similarly, CTCF-
mediated chromatin remodeling and long-range interactions have been reported at the 
IFNG and Th2 IL4 loci during T cell differentiation/maturation, as well as at the IL-1/IL-
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36/IL-37 gene cluster during the activation of monocytes (LEE et al. 2005; SHARAF et al. 
2014). Recent studies have demonstrated the presence of lineage-specific super 
enhancers (SEs) at well-characterized immune loci that engage in long-range 
interactions, where these SE boundaries are demarcated by CTCF binding (HNISZ et al. 
2013; FARH et al. 2015; VAHEDI et al. 2015). Importantly, functional studies abrogating 
these long-range interactions and the trans binding factors involved have provided 
evidence for spatiotemporal coordination of chromatin remodeling during these 
processes (AGARWAL et al. 1999). 
Long-range interactions during skin development 
More recently, long-range interactions have also been identified in several lineages of 
the skin, the most well characterized example being the Epidermal Differentiation 
Complex (EDC) located on human chromosome 1q21 that encompasses genes 
regulating cornified envelope formation. This locus is coordinated spatially and 
temporally, utilizing a conserved enhancer that establishes spatial interactions with 
these gene promoters to ensure exclusive expression within the differentiating 
keratinocytes of the stratifying epidermis (OH et al. 2014). Moreover, p63 is a 
transcriptional master regulator of epidermal differentiation that binds to a conserved 
enhancer to engage in looping interactions, and directly controls the expression of 
trans-binding factors (i.e. Satb1, Brg1) that are required for such higher-order chromatin 
configurations (ANTONINI et al. 2006; MARDARYEV et al. 2014). Recently, long-range 
interactions were reported at the PPARγ2 and IRF4 loci during adipocyte and 
melanocyte differentation, respectively (LEBLANC et al. 2014; VISSER et al. 2015). 
Collectively, these findings highlight the critical role of long-range interactions in the 
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spatiotemporal expression of key genes regulating skin development. 
7. Work Described in This Thesis 
The primary goal of my thesis research is to identify and characterize genetic 
mechanisms controlling human hair growth. To accomplish this, I have studied three 
inherited conditions affecting human hair growth as genetic models in which I performed 
detailed functional and molecular analyses of the causal genetic lesions and their 
downstream effects on gene expression in the hair follicle. The three major approaches 
to identify and characterize genetic mechanisms underlying human hair growth include: 
1. Identifying genomic effects on human hair growth in rare, sporadic conditions 
(Chapter II), 2. Characterizing single-gene effects on human hair growth in rare, familial 
conditions (Chapter III), and 3. Functional analysis of rare, non-coding variants in a 
complex polygenic autoimmune disease, alopecia areata (Chapter IV). 
The genetic architecture of rare, sporadic Mendelian disorders is usually 
characterized by large genomic rearrangements and copy number variants (CNVs) with 
large effect sizes. The Christiano lab and other groups have previously studied the 
genetic basis of inherited hypertrichoses, an extremely rare condition of excessive hair 
overgrowth that is often associated with additional congenital abnormalities (i.e. 
craniofacial, bone, and heart defects), identifying copy number variants and 
chromosomal rearrangements in autosomal and sporadic forms of the disease. In 
Chapter II of my thesis, I investigated the genetic mechanism associated with X-linked 
hypertrichosis (XLH) in a family in which the Christiano lab previously reported linkage 
to chromosome Xq24-27.  
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In collaboration with Drs. Brynn Levy and Dorothy Warburton, we performed 
cytogenetic analysis to detect structural variants underlying XLH. Using SOMA and 
FISH, we identified a 386 Kb duplication of chromosome 6 that had inserted onto the X 
chromosome. To identify the breakpoints and sequence through the insertion, we 
performed whole-genome sequencing and in collaboration with Dr. David Goldstein’s 
laboratory whose members provided analytic tools and expertise, we identified a large 
interchromosomal insertion at chrXq27.1 that completely cosegregates with the 
phenotype. Our finding was consistent with previous reports of interchromosomal 
insertions in two other unrelated XLH families (ZHU et al. 2011). Remarkably, all three 
insertion events occurred at the same palindromic sequence at Xq27.1, yet the 
sequences contained within the insertions in each family are distinct. We then 
postulated that the presence of the insertion (rather than its content) may be 
responsible for the excessive hair overgrowth phenotype.  
To determine the impact of the interchromosomal insertion on the expression 
levels of the surrounding genes, I performed RNA-seq and qRT-PCR that revealed a 
dramatic reduction in FGF13 levels in affected individuals. Using several methods of 
detection, I found that FGF13 is highly expressed in human hair follicles, and this 
expression is markedly reduced in XLH hair follicles. While we reported FGF13 as the 
target of a position effect, it is highly likely that the interchromosomal insertion separates 
several genes from distal regulatory elements (i.e. enhancers) that are active in the hair 
follicle, and disrupts key intra- and/or interchromosomal interactions required for normal 
hair growth. Future studies using Chromosome Conformation Capture technologies will 
provide insight into perturbed or ectopic interactions in XLH. 
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In Chapter III, I studied a rare, familial condition of excessive hair overgrowth in a 
consanguineous family with autosomal recessive congenital generalized hypertrichosis 
terminalis (CGHT). The genetic architecture of rare, familial Mendelian disorders is 
usually composed of intragenic (exonic and splice site) mutations with large effect sizes. 
To identify rare, coding mutations in autosomal recessive CGHT, we performed whole-
exome sequencing and using a standard filtering approach, identified a novel, rare 
splice variant in ABCA5 that cosegregates with the phenotype in a homozygous 
recessive manner. Using immunohistochemistry and immunofluorescence staining, I 
found that ABCA5 is highly expressed within the epithelial and mesenchymal 
compartments of both human and mouse skin and hair follicles. To determine the 
overall consequences of the mutation associated with CGHT, I then analyzed and 
quantified ABCA5 mRNA and protein levels in CGHT patient cells, and visualized its 
localization pattern in affected skin and hair follicle tissues. Importantly, I found using 
several methods of detection that the ABCA5 mutation not only leads to decreased 
protein levels in CGHT hair follicles, but also to a complete loss-of-function.  
Since independent reports of Abca5 function in mouse tissues demonstrated a 
role for this ABC transporter in lysosome function and cholesterol efflux, I next tested 
whether CGHT patient cells possessed such defects at the cytological level. In 
collaboration with the Di Paolo laboratory at Columbia University, I analyzed and 
quantified lysosome function in the context of autophagy, and observed the free 
cholesterol distribution in patient keratinocytes. Importantly, cytological analyses in 
CGHT cells revealed defective autophagosome clearance and an overall accumulation 
of endolysosomal cholesterol, further supporting a loss-of-function mutation in ABCA5.  
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In parallel to these studies, we analyzed an unrelated sporadic case of CGHT 
using several cytogenetic techniques in collaboration with Drs. Brynn Levy, Dorothy 
Warburton, and Vaidehi Jobanputra. We identified a t3;17 translocation and cryptic 1.3 
Mb deletion spanning ABCA5, creating an allelic series of six total CNVs at chr17q24.2-
24.3 associated with CGHT. I hypothesized that ABCA5 levels were disrupted in 
sporadic CGHT and although I did not identify an intragenic mutation on the opposite 
allele, I found using several methods of detection that both mRNA and protein levels 
were dramatically reduced in patient cells and hair follicles, suggesting 
haploinsufficiency of ABCA5. Importantly, these findings suggest a novel role for this 
transporter in regulating hair growth, and future functional studies using Abca5 deficient 
mice will elucidate the precise mechanism(s) by which Abca5 regulates hair growth. 
In Chapter IV, I investigated the genetic architecture of a complex, polygenic 
disease affecting hair growth by studying the role of rare, non-coding variants in 
alopecia areata (AA). AA is an autoimmune disease of hair loss resulting from the 
collapse of immune privilege in the hair follicle, and the Christiano lab previously 
performed the first Genome-Wide Association Study (GWAS) to determine the genetic 
architecture of AA, and identified the ULBP3/6 locus on chr.6q25.1 (p = 5.9 x 10-24) as 
the most significantly associated locus outside the HLA region. More recently, we 
conducted a meta-GWAS to expand gene discovery and identify true positive 
associations. We validated our previous findings and identified novel susceptibility loci 
(ACOXL/BCL2L11(BIM) on chr2q13 and GARP (LRRC32) on chr11q13.5) (Betz, 
Petukhova et al. 2015).  
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In Chapter IV.2, I characterized the expression of BIM, a gene that possesses 
known functions in apoptosis in melanocytes and the immune system (O'REILLY et al. 
2000; LUO AND RUBINSZTEIN 2013). Moreover, I examined its expression pattern in 
mouse skin harvested in the growth (anagen), destructive (catagen), and resting 
(telogen) stages of the hair cycle. Interestingly, I observed BIM expression exclusively in 
catagen hair follicles, which are characterized by massive apoptosis. Using a mouse 
model that recapitulates the genetic and pathological basis of human AA, I found that 
BIM expression was no longer restricted to catagen hair follicles in lesional skin, but 
rather widespread and dramatically increased (Betz, Petukhova et al. 2015). Given the 
known role of BIM as a pro-apoptotic factor in the immune system, we postulate that its 
dysregulation contributes to the early entry of hair follicles into dystrophic catagen in 
active disease. 
In Chapter IV.3, I investigated the molecular profiles of human and mouse AA. To 
identify dysregulated genes in AA, we performed transcriptional profiling using 
Affymetrix microarrays. I analyzed the expression data from the mouse model and 
identified key immune-related genes with dysregulated expression, which I validated 
using qRT-PCR and immunofluorescence staining in AA samples (XING et al. 2014). 
Using bioinformatics tools and unsupervised hierarchical clustering, we identified 
discrete gene expression signatures defined by key drivers of cytotoxicity, including 
IL15 and interferon gamma (IFNG), and observed a striking upregulation of these 
inflammatory cytokines and NKG2D ligands in both human and mouse lesional hair 
follicles. Using lymph node subcutaneous injections, we demonstrated that 
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CD8+NKG2D+ T cells are necessary and sufficient to induce disease in the mouse 
model, defining a role for the ULBP-NKG2D pathway in AA (XING et al. 2014).  
In Chapter IV.4, I focused my studies on the ULBP3/6 locus on chr.6q25 given 
the strong genetic association with AA (P = 4.49 x 10-19). Interestingly, this was the most 
significant region of association outside the HLA, and was not previously associated 
with any human disease. The ULBP genes encode ligands for the NKG2D cytotoxic T 
cell receptor, and we found in both human and mouse AA lesional hair follicles that 
NKG2D ligands are strongly upregulated (PETUKHOVA 2010; XING et al. 2014), further 
elucidating the involvement of the NKG2D/ULBP signaling axis in disease 
pathogenesis.  
To identify human genetic variants at ULBP3/6, we performed targeted deep 
resequencing with Raindance technology and identified common and rare variants 
enriched on GWAS risk haplotypes. Using functional genomics, we uncovered a small 
number of rare, non-coding variants, three of which are novel and reside within ULBP6 
regulatory elements as well as CTCF binding sites. Since CTCF is an insulator protein 
involved in chromatin remodeling and gene repression, and ULBP3/6 genes are not 
normally expressed in healthy hair follicles, I postulated that ULBP6 non-coding variants 
disrupt transcription factor binding site motifs (i.e. CTCF) and/or regulatory elements 
required for ULBP3/6 repression. 
Using ChIP-PCR, I found that endogenous CTCF binding is enriched at the 
ULBP6 candidate region in human scalp fibroblasts. Moreover, I demonstrated using in 
vitro reporter assays that the ULBP6 region possesses regulatory activity that is 
reduced in the presence of AA rare variants, and that these variants abrogate CTCF-
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mediated repression of the ULBP6 sequence in vitro. Future studies examining this 
candidate region in long-range reporter assays and the long-range chromatin 
interactions in vivo will elucidate the mechanisms by which ULBP3/6 gene expression is 
repressed in the healthy hair follicle, and whether CTCF-mediated interactions are 
disrupted in AA patient hair follicles.  
Collectively, throughout my thesis, I used a wide range of methods and 
approaches to study three inherited conditions affecting hair growth, from rare, sporadic 
conditions to complex, polygenic diseases. Based on the inheritance pattern and 
disease prevalence of each condition, I employed different strategies to identify the 
underlying genetic variants, and these strategies were instrumental in my success 
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Chapter II.1 Preface 
 The genetic basis underlying rare, sporadic conditions is frequently characterized 
by structural rearrangements and/or copy number variants involving a locus or entire 
chromosome, rather than a single gene. While in some cases, the pathogenic variants 
can be detected using CNV analysis (i.e. by karyotyping), identifying complex 
rearrangements, microdeletions/duplications, and interchromosomal insertions has 
historically posed challenges, as these lesions were not as readily detectable using the 
conventional methods and approaches. In larger families with several affected members 
where the inheritance pattern is clear, positional information from linkage analysis has 
aided in narrowing the search. However, because these rare variants are sporadic and 
restricted to only the proband and affected family members, the power of the candidate 
approach is diminished and will most likely not detect the pathogenic defect. 
 Over the past decade, novel and more sophisticated technologies have been 
developed for genome sequencing, CNV analysis and SNP-based genotyping, and 
have proved useful in identifying the classes of mutations that were previously 
undetectable. Importantly, the completion of the Human Genome Project (2003) 
accelerated the development of these advanced technologies, thus facilitating 
mutational discovery. Importantly, an approach combining current methods for CNV 
analysis (i.e. SOMA), linkage (if applicable), and next-generation sequencing (i.e. 
whole-exome and whole-genome sequencing) is an optimal, robust and well-powered 
strategy to detect the rare and sporadic mutations in human disease. Upon the 
identification of candidate variants, a cosegregation analysis must be performed for 
families with more than one affected individual to establish whether there is a correlation 
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between the genotype and disease phenotype. To determine the involvement and 
mechanism(s) by which the candidate variants are causal to the pathology, further 
functional studies should be performed using in vitro (i.e. cell culture) and in vivo (i.e. 
mouse model) approaches.  
 In Chapter II.2, I investigated the genetic mechanism associated with X-linked 
hypertrichosis (XLH), a very rare condition of excessive hair overgrowth that the 
Christiano lab had previously studied over a decade ago. Linkage with microsatellite 
markers and haplotype analysis was performed in a large Mexican family with XLH 
segregating with deafness, palate and dental anomalies, which defined a 19 Mb minimal 
region on chrXq24-27 encompassing 82 genes. In collaboration with Dr. Conrad Gilliam, 
all 82 genes were sequenced using the Sanger method, but no mutations were found. 
Whole-exome sequencing was also performed, but this approach also failed to identify 
mutations in the candidate region. Several years following and in collaboration with Drs. 
Brynn Levy and Dorothy Warburton, we revisited this case to test our hypothesis that 
the underlying genetic lesion could be characterized by a structural/ numerical 
chromosomal abnormality rather than an intragenic mutation.  
 In Chapter II.2, we used SOMA to first detect CNVs or changes in dosage (such 
as insertions), followed by FISH to determine the location of the CNV or fragment. This 
approach was fruitful in identifying a copy number variant that created a structural 
variant via an interchromosomal insertion on the X chromosome (consistent with the 
inheritance pattern). Drs. Brynn Levy and Dorothy Warburton performed SOMA and 
analyzed the data.  In order to identify the breakpoints as well as the content of the 
insertion, we performed whole-genome sequencing (WGS). We collaborated with Drs. 
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David Goldstein, Elizabeth Cirulli, and Yujun Han, who analyzed our WGS data using 
an in-house software program (SV-Finder) to sequence through the entire insertion. To 
determine whether all affected and carrier individuals contained this insertion, I then 
performed cosegregation analysis using a PCR-based approach to screen for the 
insertion breakpoints. Because skewed X-inactivation in female carriers is a hallmark 
feature of X-linked disorders, we tested X chromosome inactivation in XLH females. 
Drs. Maryam Shirazi and Vaidehi Jobanputra performed the X-chromosome inactivation 
assay and analyzed the data. 
 Interestingly, at the time we identified the genetic defect in this family, two other 
XLH families with linkage to chrXq24-27 were reported, where both families contained 
interchromosomal insertions on chrX. Remarkably, all three insertion events occurred at 
the same palindromic sequence at Xq27.1, however, the sequences contained within 
the insertions in each family are distinct. Therefore, we postulated that the presence of 
the insertion (rather than its content) might be responsible for the excessive hair 
overgrowth phenotype by disruption of the chromosomal architecture in the region. 
Consistent with our hypothesis, the sizes of the insertions (Kb) in each family and the 
severity of the phenotype with respect to the manifestation of additional congenital 
anomalies (i.e. deafness and craniofacial defects) greatly differs, inviting us to further 
investigate the downstream effects of the interchromosomal insertions.  
 In Chapter II.2, I investigated the mechanism(s) by which the interchromosomal 
insertion exerts pathogenic effects in XLH.  Considering previous studies from the 
Christiano lab in another form of hypertrichosis (Ambras syndrome) that identified a 
position effect on the zinc-finger transcription factor, TRPS1 as a result of CNVs and 
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chromosomal rearrangements, I hypothesized that the interchromosomal insertion in 
XLH might disrupt the expression levels of the neighboring genes. I then tested the 
expression levels of the neighboring genes on both sides of the insertion using qRT-
PCR and RNA-seq on RNA isolated from whole skin, and Drs. Xiaoyun Sun and Yufeng 
Shen provided me with assistance in the RNA-seq data analysis. Drs. Julio Cesar 
Salas-Alanis and Rodrigo Cepeda obtained patient skin biopsies and clinical photos. 
Transcriptome sequencing revealed that among the genes surrounding the insertion, 
FGF13 levels were significantly decreased in XLH.  
 FGF13 is an interesting candidate gene given the known role of FGFs in 
regulating hair growth (i.e. FGF5 and the angora phenotype). I then determined whether 
FGF13 was expressed in the human hair follicle, and using qRT-PCR, in situ 
hybridization, and immunofluorescence staining, I characterized its expression in both 
human scalp hair follicles and mouse hair follicles during morphogenesis and hair 
cycling. In the context of XLH, I tested FGF13 levels using qRT-PCR and 
immunofluorescence analysis on keratinocytes and dermal fibroblasts, and patient hair 
follicles, respectively. Although in this study, we identified decreased levels of FGF13 
associated with XLH, it is more likely that larger effects involving other genes (including 
disrupted inter- and intrachromosomal interactions as a result of the insertion), may also 
contribute to the excessive hair overgrowth phenotype. 
 In Chapter II.3, I discuss these findings in a broader context and describe 
ongoing and future experiments to address the role of the interchromosomal insertion in 
the XLH pathogenesis. 
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X-linked congenital generalized hypertrichosis (Online Mendelian
Inheritance in Man 307150) is an extremely rare condition of hair
overgrowth on different body sites. We previously reported link-
age in a large Mexican family with X-linked congenital generalized
hypertrichosis cosegregating with deafness and with dental and
palate anomalies to Xq24-27. Using SNP oligonucleotide microar-
ray analysis and whole-genome sequencing, we identified a 389-
kb interchromosomal insertion at an extragenic palindrome site at
Xq27.1 that completely cosegregates with the disease. Among the
genes surrounding the insertion, we found that Fibroblast Growth
Factor 13 (FGF13) mRNA levels were significantly reduced in af-
fected individuals, and immunofluorescence staining revealed
a striking decrease in FGF13 localization throughout the outer root
sheath of affected hair follicles. Taken together, our findings sug-
gest a role for FGF13 in hair follicle growth and in the hair cycle.
congenital hypertrichosis | excessive hair growth
Inherited hypertrichoses are rare human disorders character-ized by excessive hair growth that does not depend on andro-
gen stimulation and is independent of age, sex, and ethnicity (1).
Hypertrichosis syndromes fall under the larger umbrella of ec-
todermal dysplasias, or abnormal development of the hair, skin,
nails, teeth, and/or eccrine glands, and are often associated with
additional anomalies including gingival hyperplasia, deafness,
cardiomegaly, and bone abnormalities (2). It has been suggested
that inherited hypertrichoses represent examples of atavisms, or
the recurrence of an ancestral phenotype, where the genes that
promote a full coat of hair in other mammals and were silenced
throughout evolution have become “reactivated” in human hy-
pertrichosis, invoking unusual genetic mechanisms to explain their
occurrence (3, 4).
We and others have identified genetic defects in two forms of
autosomal dominant congenital generalized hypertrichosis (CGH)
associated with copy number variants on chromosome 17q24 and
with rearrangements on chromosomes 3, 7, and 8 (5–7). We pre-
viously reported a position effect on the zinc-finger transcription
factor Trichorhinophalangeal syndrome 1 (TRPS1) associated
with Ambras syndrome congenital hypertrichosis, which was
recapitulated in the koala (Koa) mouse hypertrichosis model (8).
Likewise, we recently demonstrated a position effect on SRY-
related HMG box gene 9 (SOX9) associated with CGH termi-
nalis (9). Importantly, our findings provided evidence for position
effects—instances in which a change in gene expression results
from altering the location of a gene relative to its native chro-
mosomal position (10)—as mechanisms contributing to inherited
hypertrichoses (8).
In this work, we sought to identify the genetic mechanism
associated with X-linked CGH in a family in which we pre-
viously reported linkage to chromosome Xq24-27 (11). We
identified a large interchromosomal insertion that leads to
decreased expression of a distant gene, Fibroblast Growth
Factor 13 (FGF13), which is expressed in the hair follicle,
providing evidence to support a position effect as the un-
derlying genetic basis of X-linked hypertrichosis.
Results and Discussion
We ascertained a large kindred from Mexico with X-linked CGH
(Online Mendelian Inheritance in Man 307150) cosegregating
with deafness and with dental and palate anomalies (Fig. 1 A–E)
(11). Affected males have approximately three times the number
of normal hairs on the scalp and exhibit excessive growth
of highly pigmented terminal hairs (medullated) on the scalp,
back, shoulders, chest, arms, legs as well as on the face (Fig. 1 A–
D), whereas hemizygous carrier females have mild hypertrichosis
uniformly distributed across the body (Fig. 1E).
Histological analysis of affected hair follicles using hematoxylin
and eosin staining confirmed that the hairs are of the terminal
type because they are medullated, pigmented, and penetrate deep
within the dermis (Fig. 1 H and J). Affected individuals have an
increased density in the number of hair follicles and a trans-
formation from vellus (fine, nonmedullated, unpigmented) to
terminal hair follicles on multiple body sites, which cause an
excessive hair overgrowth phenotype. Morphometric analysis
of affected hair follicles revealed a widened dermal papilla
(threefold increase; P = 0.0000343), matrix (1.9-fold increase;
P = 0.0000642), and hair shaft (1.25-fold increase; P = 0.036) in
hair follicles from three affected individuals compared with
controls (Fig. 1 G–J and Fig. S1).
In our previous work on this family, we performed linkage
analysis, which defined a 19-Mb region on Xq24-27 that spans ∼82
genes and completely cosegregates with the disease (11). Se-
quencing the coding exons of every gene in the interval proved
unsuccessful in identifying the mutation. To identify the genetic
defect, we next performed SNP oligonucleotide microarray anal-
ysis (SOMA) using the Affymetrix Cytogenetics Whole-Genome
2.7M array, which revealed a 386-kb duplication of chromosome
6p21.2 (Fig. 2A). We then visualized the duplication at the cyto-
genetic level using fluorescence in situ hybridization (FISH) with
two nonoverlapping BAC probes spanning the chromosome 6p21.2
duplication, which revealed a third signal for chromosome 6 present
on the X chromosome (Fig. 2 B and C). To identify the insertion
breakpoints as well as their content, we performed whole-genome
sequencing (WGS), which revealed a large interchromosomal
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insertion at an extragenic palindromic sequence on chromosome
Xq27.1, consisting of a 386-kb duplication of chromosome 6p21.2
and 56 bp of chromosome 3q21.1 in the reverse orientation,
separated by 14 bp of unknown origin (Fig. 3 A and B). This
complex insertion leads to a 2-bp deletion within the Xq27.1 pal-
indromic site and contains sequences from two genes on chromo-
some 6p21.2 [Dishevelled associated activator of morphogenesis 2
(DAAM2) and Kinesin family member 6 (KIF6)] and one gene
from chromosome 3q21.2 [Family with sequence similarity 162,
member A (FAM162A)], none of which have reported functions
in the skin or hair follicle. To confirm that the insertion cose-
gregated with the disease phenotype, we used PCR amplification
of the centromeric and telomeric breakpoint junctions on genomic
DNA from control, carrier, and affected individuals, which
revealed junction bands present only in affected and carrier indi-
viduals, whereas DNA from controls produced an amplicon rep-
resentative of an unaffected X chromosome (Fig. 3 C and D).
To gain insight into whether the insertion at Xq27.1 affects
X-chromosome inactivation in female carriers, because skewed
X inactivation is a phenomenon reported in several X-linked
disorders (12, 13), we performed the X-chromosome inactivation
(XCI) assay and did not observe significant skewing (≥80%) in
four of five carriers (Table S1 and SI Materials and Methods).
Importantly, two other recently reported families with X-linked
CGH contain linkage to chromosome Xq24-27, consistent with
our findings in which one family contains a 300-kb interchromo-
somal insertion from chromosome 4q31.2 and the other family
contains a 125-kb interchromosomal insertion from chromosome
5q35.3 (14) (Fig. S2). Interestingly, the insertion events in all
three families occur at the same human-specific extragenic pal-
indrome sequence at Xq27.1, suggesting that the presence of the
insertion (rather than its content) may be responsible for the
excessive hair overgrowth phenotype by disruption of the chro-
mosomal architecture in the region.
Despite the identification of different insertions in these three
cases, their impact on the expressionof the surrounding genes has not
been thoroughly investigated. Therefore, we analyzed the expression
of several neighboring genes using quantitativeRT-PCR(qRT-PCR)
on RNA isolated from control, carrier, and affected skin biopsies.
Unexpectedly, we found thatFGF13 levels were significantly reduced
in affected individuals by approximately fourfold (P=0.0007) relative
to controls and observed a clear dosage effect when comparing levels
between carrier and affected individuals (Fig. 4 A and B). To verify
that the change in FGF13 expression observed in affected skin
biopsies was not due to differences in the number of hair follicle
cells present, we normalized FGF13 expression to that of Keratin 14
(KRT14), which marks the outer root sheath and basal layer of the
epidermis, and found that FGF13 levels were dramatically reduced
(18.1-fold; P = 0.00006) in affected hair follicle cells (Fig. 4C).
Importantly, the mRNA levels of additional neighboring genes
were not significantly changed, and SOX3 and Chromosome X
open reading frame 66 (Cxorf66) expression levels were un-
detectable in control and affected individuals (Fig. 4A). To fur-
ther examine the expression levels of the genes surrounding the
389-kb insertion, we performed RNA sequencing (RNA-seq) on
RNA from the skin of one control and one affected individual,
which verified the decrease in FGF13 expression (eightfold; P =
0.012) and revealed that the expression levels of most of the genes
in the surrounding region over a distance of ∼3 Mb on either side
of the insertion were not significantly changed (Table S2 and SI
Materials and Methods). The expression of the microRNA, miR-
504, intronic to FGF13, was reduced by approximately 1.5-fold in
the carrier and affected individuals by qRT-PCR (P = 0.00831)
(Fig. 4A). FGF13 is not a predicted target gene of miR-504, yet
there are several predicted targets with known roles in hair fol-
licle development and cycling whose expression levels were al-
tered in X-linked hypertrichosis, detected by RNA-seq (Table S3
and SI Materials and Methods). Although these changes in gene
expression may simply reflect a difference in the number of hair
follicle cells present, it remains possible that the reduction of
FGF13–miR-504 transcripts either directly or indirectly leads to
increased expression of some of these downstream genes.
FGF13 is a plausible candidate gene to be the target of the
position effect because its expression was previously detected in
the hair follicle bulge, which is the stem cell compartment of the
hair follicle (15, 16). However, it was unclear whether these were
the only FGF13-expressing cells in the human hair follicle or
whether expression was more widespread. Using in situ hybrid-
ization and immunofluorescence staining on hair follicles in the
growth stage of the hair cycle, anagen, we detected expression of
FGF13 in the outer root sheath within the middle and upper
portions of the human hair follicle (Fig. 4 D and E). We also
observed FGF13 expression in the trichilemma, or outer root
sheath compartment of the club hair, during the resting stage of
the hair cycle, telogen, by immunofluorescence staining (Fig. 4F).
In anagen hairs, FGF13 localizes to the outer root sheath (ORS)
where KRT14 is expressed and also localizes to the companion
layer that separates the outer from the inner root sheath, as evi-
denced by overlapping expression with KRT75 (companion layer
marker) (Fig. S3 A and B). However, we did not observe FGF13
Fig. 1. Clinical features, pedigree, and histology of
hair follicles in a Mexican family with X-linked CGH,
deafness, and palate and dental anomalies. (A–D)
Clinical photos of affected males with excessive hair
growth on the back, shoulders, arms (A and B),
chest (C), and (D) face. (D) Dental anomalies and
a bulbous nose are also evident on patients. (E)
Moderate hair growth is observed on the back of
a female carrier. (Inset) A close-up image of a cow-
lick on the back of another carrier. (F) Pedigree of
a four-generation family, three of whom are obli-
gate carriers and eight of whom are affected. (G–J)
Histology of a normal hair follicle and affected hair
follicle, both from males, revealed that the hairs are
of the terminal type, as they are medullated and
highly pigmented. Affected hair follicles have a
widened dermal papilla (white arrows), matrix (Mx),
and hair shaft (HS) compared to control hair fol-
licles. (Scale bars, 100 μm.)






localization to the bulge region of the anagen human hair follicle,
through costaining with CD200, a well-characterized bulge marker
(Fig. S3C).
To gain insight into which cells exhibited decreased FGF13
levels, we performed FGF13 immunofluorescence staining on
control, carrier, and affected hair follicles and observed a de-
crease in the intensity of expression and the number of FGF13-
positive cells throughout the outer root sheath of affected ana-
gen follicles compared with controls and carriers (Fig. 5 A and
C). Moreover, a comparison of affected and carrier telogen
follicles revealed a decrease in expression throughout the af-
fected hair follicle, recapitulating the dosage effect observed at
the mRNA level (Fig. 5B).
To further investigate the selective decrease of FGF13 ex-
pression in affected keratinocytes, we performed qRT-PCR on
keratinocytes and fibroblasts cultured from control, carrier, and
affected skin biopsies and observed a significant decrease in
FGF13 expression in affected keratinocytes of 6.7-fold (P =
0.00193) (Fig. 5D), but not in the fibroblasts. Consistent with our
previous observations, our findings localize the defect to the
keratinocyte compartment.
To determine Fgf13 expression during murine hair follicle mor-
phogenesis, we performed whole-mount and section in situ hy-
bridization on embryonic day 12.5 (E12.5)–E16.5 embryos and
observed strong expression in placodes (the sites of newly forming
follicles), as well as in the dermal condensate beneath the plac-
odes that becomes the dermal papilla of the hair follicle at E14.5
within the developing whisker pad and guard hair pelage follicles
(Fig. S4A). Immunofluorescence staining of vibrissae follicles
during morphogenesis at E16.5 revealed that Fgf13 localizes to
the outer root sheath, similar to the postnatal localization pat-
tern of the human FGF13 protein in anagen follicles (Fig. S4B).
Moreover, immunofluorescence staining on postnatal skin re-
vealed that Fgf13 localizes to the bulge, isthmus region, and outer
root sheath of the hair follicle (Fig. S4 C and D). Taken together,
our results suggest a potential role for Fgf13 in regulating hair
follicle growth and cycling.
In mice and in humans, five-prime alternative splicing of FGF13
and use of different transcription start sites generates transcripts
with distinct 5′ exons referred to as 1S, 1U, 1V, 1Y, and 1V+1Y,
where exons 2–5, encoding the conserved core region of the pro-
tein, are common to all transcripts. Isoform-specific PCR revealed
that isoforms 1S, 1V, 1Y, and 1V+1Y are expressed in human scalp
skin (Fig. S5). To gain insight into the mechanism by which the
interchromosomal insertion alters FGF13 transcript levels in X-
linked hypertrichosis, we used the RNA-seq data to test for dif-
ferentially expressed isoforms using Cuffdiff (SI Materials and
Methods), but did not observe differential expression between the
FGF13 isoforms, suggesting that the interchromosomal insertion
disrupts the transcription of all isoforms rather than altering the use
of a particular transcription start site.
Position effects on single genes have been reported in several other
human genetic diseases associated with large chromosomal rear-
rangements where the distances of the farthest breakpoints from the
target genes were as large as 1.0 Mb [sonic hedgehog (SHH) in
preaxial polydactylyl II] (17, 18), 1.3 Mb (SOX9 in camptomelic
dysplasia) (19, 20), and 7.3 Mb (TRPS1 in Ambras syndrome) (8).
Because FGF13 lies 1.2 Mb away from the insertion and its expres-
sionwas selectively reduced, we postulate that the interchromosomal
insertion at Xq27.1 separates the gene from a tissue- or temporal-
specific modifier element (such as an enhancer) required for proper
FGF13 expression during hair follicle morphogenesis and cycling.
Consistent with this notion, we found that FGF13 expression was
selectively reduced in a tissue-specific manner, as transcript levels
were decreased in affected keratinocytes, but not in fibroblasts.
Our data indicate that FGF13 is primarily expressed throughout
the outer root sheath of human hair follicles, and findings from
the clinical, histological, and morphometric analyses revealed
increased width of hair follicles in X-linked hypertrichosis (Fig.
1 H and J and Fig. S1). Several genes expressed in the outer root
Fig. 2. SOMA identified a 386-kb duplication of chromosome 6, and FISH revealed its insertion on the X chromosome. (A) SOMA performed on an affected
individual using the Affymetrix Cytogenetics Whole-Genome 2.7M array revealed a 386-kb duplication of chromosome 6p21.2 encompassing the KIF6 and
DAAM2 genes (as shown in C). (B) FISH on control and carrier metaphase chromosomes revealed the insertion of the chromosome 6 duplication onto the
X chromosome at the cytogenetic level. Boxes indicate X chromosomes, white arrows indicate chromosome 6, and the red arrow indicates the X chromosome
containing the insertion. Insets are magnified images of the unaffected and affected X chromosome from control and carrier individuals, respectively. (C)
Nonoverlapping BAC clones used to span the chromosome 6 duplication include the KIF6 and DAAM2 genes (drawn to scale). Genomic coordinates reference
the UCSC Genome Browser human reference genome build hg19.
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sheath of hair follicles have been reported to have noncell au-
tonomous effects on other compartments, indirectly or directly
leading to changes in hair follicle width and/or length. In the case
of Dishevelled 2 (Dvl2), an effector of wingless-type MMTV in-
tegration site family, member 3 (Wnt3) signaling normally ex-
pressed in the outer root sheath and the precortical and precuticle
cells of the hair shaft, its overexpression in the outer root sheath
induces a short-hair phenotype by altering the differentiation of hair
shaft precursor cells (21). Similarly, overexpression of Vegf in the
outer root sheath, where it is normally expressed, induces peri-
follicular vascularization of the hair follicle, resulting in accelerated
hair regrowth and in increased size of hair shafts (22).
In our mouse expression studies, we found that Fgf13 is
expressed during hair follicle induction and morphogenesis,
suggesting that it may play an important role in these processes.
Affected individuals in the X-linked hypertrichosis family pos-
sess an increased density of hairs; thus, it is possible that dys-
regulation of FGF13 levels in X-linked hypertrichosis leads to
the formation of extra hairs, but further studies using Fgf13-
deficient mice would be needed to directly implicate a role for
Fgf13 in hair follicle morphogenesis and cycling. Interestingly,
Fgf13 expression has been demonstrated in the dental mesen-
chyme and developing tooth bud (23), an additional site of
pathology for X-linked hypertrichosis patients who have dental
and palate anomalies, suggesting a potential role for this gene
in odontogenesis.
Several FGFs and their receptors are known to play impor-
tant roles in hair regrowth. Although canonical FGFs are
known to signal through their respective receptors to control
hair growth via stem cell activation and quiescence, FGF13 is
the first noncanonical FGF to be implicated in hair follicle
morphogenesis and cycling. As FGF13 has been reported to
bind the MAPK scaffolding protein islet brain 2 (IB2) (24),
leading to activation of a stress-induced MAPK that lies
downstream of the canonical FGF-signaling pathway (24), one
possibility is that FGF13 internally modulates the transcrip-
tional output of canonical FGF signaling to control hair growth.
Consistent with this notion, we found the expression levels of
several FGFs to be dysregulated in X-linked hypertrichosis
(Table S4). Among these was FGF5, a known regulator of the
anagen-to-catagen transition and responsible for the excessive
hair overgrowth phenotype in angora mice, dogs, goats, and
rabbits (25–28). A second possibility is that FGF13 acts as a
microtubule-stabilizing protein in the hair follicle, similar to its
role in neurons (29), to regulate additional signaling molecules
active in the developing follicle. Further functional studies on
FGF13 will reveal the mechanism by which it regulates hair fol-
licle growth and distribution.
In this study, we identified a 389-kb interchromosomal inser-
tion at Xq27.1 that completely cosegregates with the X-linked
CGH phenotype and found that, among the genes surrounding
the insertion, FGF13 expression was selectively and profoundly
reduced. FGF13 lies 1.2 Mb away from the insertion, revealing a
position effect on a distant gene as a result of the chromosomal
insertion at Xq27.1. Although it has been suggested that these
large interchromosomal insertions may mediate pathogenic ef-
fects by introducing novel regulatory elements, it is more likely
that the presence of the insertions (rather than their content) is
responsible for the hair overgrowth phenotype because the se-
quences contained within each insertion are different among the
families (14). Moreover, these insertions occur at an extragenic
palindrome sequence and do not disrupt the coding region of a
gene in the surrounding region (Fig. S2).
The density of hair follicles covering the human body is
markedly reduced compared with other primates, and as such,
the excessive hair phenotype observed in hereditary hyper-
trichosis has been suggested to be reminiscent of an atavism
(3). Various examples of atavisms involving several body parts
Fig. 3. Whole-genome sequencing revealed a 389-kb interchromosomal insertion at Xq27.1 that cosegregates with the X-linked hypertrichosis phenotype.
(A) Chromosome Xq27.1 in X-linked hypertrichosis. The genes and microRNAs encoded in the surrounding region are shown as black boxes with arrows
indicating the direction of transcription. (B) WGS was used to determine the breakpoints and content of the interchromosomal insertion (shown in blue),
including the 386-kb duplication from chromosome 6p21.2, 14 bp of unknown origin, and 56 bp of chromosome 3q21.2. (C) PCR amplification of the cen-
tromeric and telomeric junctions of the insertion on DNA from control, carrier, and affected individuals demonstrated segregation of the X-linked phenotype
in the family at the genomic level. CB, TB, and C represent centromeric breakpoint, telomeric breakpoint, and controls, respectively. M, marker (1 kb +
ladder). (D) Primer design of the centromeric and telomeric junctions; colored arrows correspond to the amplicons produced as shown in C. All images are
drawn to scale. Genomic coordinates reference the UCSC Genome Browser human reference genome build hg19.






have been reported in mammals, including the occurrence of
complete ulnas and fibulas in miniature horses, reptile-like
coronary circulation and myocardial architecture in humans, and
the development of the ancestral tooth primordia in retinoic acid
receptor-deficient mice (30–32). Importantly, the occurrence
and prevalence of these ancestral features is highly suggestive
of a genetic basis, one involving unusual mechanisms. Here, we
report a position effect on FGF13 in X-linked hypertrichosis that
alters the spatiotemporal expression of the gene in the hair fol-
licle. In light of our findings, we suggest that the altered FGF13
expression in affected hair follicles influences important down-
stream signaling pathways, ultimately leading to the terminal hair
overgrowth phenotype of X-linked hypertrichosis.
Materials and Methods
Ethics Statement. Informed consent was obtained from all subjects and ap-
proval for this study was provided by the Institutional Review Board of
Columbia University in accordance with the Declaration of Helsinki Principles.
Patient Materials, Histological Analysis, and RNA Extraction. DNA was pre-
viously collected from 26 members of a family, 3 of whom are obligate carriers
and 8 ofwhom are affected (11).Whole-skin biopsies taken from the backwere
then obtained from three female carriers and three affected male individuals.
Biopsies were divided into three separate pieces for RNA extraction, cell culture
[see SI Materials and Methods for details), and optimal cutting temperature
compound (OCT) embedding for histological andmorphometric analysis (see SI
Materials and Methods for details]. We obtained control hair follicles from
occipital scalp biopsies fromdiscarded tissue followinghair transplant surgeries.
Samples were designated as non-human subject research under 45 Code of
Federal Regulations (CFR) Part 46, and we therefore received an institutional
review board exemption to use these materials. RNA extraction was performed
using the Qiagen RNeasy Mini Kit following the manufacturer’s instructions.
Total RNA was used for first-strand cDNA synthesis, as previously described (8).
SOMA and WGS. DNA from an affected individual was prepared and hybridized
as per the manufacturer’s instructions on the Affymetrix Cytogenetics Whole-
Genome 2.7Marray, and datawere analyzedwith the Affymetrix Chromosome
Analysis Suite.WGSwas performedonone affectedmale of thisMexican family
using the methods described in SI Materials and Methods. All coordinates ref-
erence the UCSC Genome Browser human reference genome build hg19.
Cytogenetic Analysis, Amplification of Genomic DNA, and qRT-PCR. FISH anal-
ysis was performed on metaphase chromosome spreads prepared from phy-
tohemagglutinin (PHA)-stimulated cultured peripheral blood cells using
standard techniques. The RPCI-11 clone 505E17 [labeled with Orange 5-TAMRA
(carboxytetramethylrhodamine) dUTP] and RPCI-11 clone 150F10 (labeled
with green 5-fluorescein dUTP) from Empire Genomics were used as FISH
probes. Hybridization and posthybridization washing were performed as per
the manufacturer’s instructions. To test cosegregation of the insertion with
Fig. 4. FGF13 levels are reduced in X-linked hypertrichosis, and FGF13 is expressed in the human hair follicle. (A) qRT-PCR of candidate genes surrounding the
insertion on control, carrier, and affected skin biopsies reveals that FGF13 levels are reduced by approximately fourfold in affected individuals relative to
controls. (B) FGF13 qRT-PCR in control, carrier, and affected individuals reveals a dosage effect. (C) FGF13 expression normalized to K14 reveals that FGF13
levels are dramatically reduced by eighteen fold in affected cells relative to that of controls. qRT-PCR results are representative of the averaged values of
three independent experiments on three controls, three carriers, and three affected individuals. Values are relative to the unaffected samples and stan-
dardized to the housekeeping gene GAPDH (in A and B). A Student t test was performed comparing each value to control 1 with a cutoff P value of 0.05 for
statistical significance; **P < 0.01; ***P < 0.001. Error bars represent the SEM. (D) In situ hybridization of FGF13 in anagen hair follicles reveals expression in
the outer root sheath (ORS) within the middle and upper portions of the hair follicle, where the sense probe produced no signal. (E) Immunofluorescence
staining reveals that FGF13 localizes to the outer root sheath (magnified image) within the middle and upper portions of the human anagen hair follicle (n =
5). ORS, outer root sheath; IRS, inner root sheath; HS, hair shaft. (F) FGF13 expression is detected in the trichilemma (ORS) of telogen club-hair follicles by
immunofluorescence staining. (Scale bar, 100 μm.)
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the disease phenotype, 100 ng of DNA was used for PCR amplification of the
centromeric and telomeric breakpoints as well as of the control region of the
unaffected X chromosome (details listed in the SI Materials and Methods).
qRT-PCR was performed as previously described (8) using the Delta-Delta-Ct
(ddCt) method, and primers are listed in the SI Materials and Methods.
In Situ Hybridization and Immunofluorescence Staining. Whole-mount in situ
hybridization was performed as previously described (8) (see SI Materials and
Methods for details). Immunofluorescence staining was performed on human
control, carrier, and affected 12-μm hair follicle sections as well as on Swiss
Webster dorsal skin sections (10 μm) from postnatal day 30 (anagen) and 50
(telogen) mice using the conditions described in the SI Materials andMethods.
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Fig. 5. Immunofluorescence staining reveals that FGF13
expression is dramatically reduced in affected hair follicles
compared with control. (A) Immunofluorescence staining
in control and affected anagen hair follicles reveals a de-
crease in FGF13 localization throughout the outer root
sheath (ORS) in the mid and upper portions of the hair
follicle. (B) Immunofluorescence staining in carrier and af-
fected telogen hair follicles reveals decreased FGF13 ex-
pression in the affected hair follicle, recapitulating the
dosage effect seen at the mRNA level. Z-stack images were
taken using identical settings and a consistent Z-stack in-
terval between control, carrier, and affected samples. CH,
club hair of a telogen follicle. (C) Quantification of the
percentage of FGF13-expressing ORS cells in control and
affected hair follicles reveals a decrease in the number of
FGF13-expressing cells within the upper and midfollicle
regions of the ORS (P < 0.05). Data represent the averaged
value of three independent experiments, where images
taken at a 40× magnification were used to quantify the
number of FGF13-positive cells relative to the total number
of ORS cells. For immunofluorescence studies, hair follicles
were stained from three control and two affected skin biopsies. (D) qRT-PCR revealed that FGF13 expression is reduced in keratinocytes but not in fibroblasts
grown from skin biopsies. A Student t test was performed with a cutoff P value of 0.05 for statistical significance; *P < 0.05, **P < 0.01. Error bars represent
the SEM. (Scale bar, 100 μm.)
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SI Materials and Methods
Histological and Morphometric Analysis of X-linked hypertrichosis
(XLH) Skin Biopsies. Whole-skin biopsies from the affected, car-
rier, and control individuals were embedded in optimal cutting
temperature (OCT) compound, and a microtome cryostat was
used to create 12-μm-thick hair follicle sections. Sections were
stained with hematoxylin and eosin, permanently mounted with
Permount (Thermo Fischer Scientific), and imaged using an
HRc AxioCam fitted onto an Axioplan2 fluorescence microscope
(Carl Zeiss). For morphometric analysis, the length-measuring
tool in the AxioVision (release 4.8.2) program was used to cal-
culate the distance between two points for each of the indicated
hair follicle components; the widest distance for each structure
was used, and the average value was taken using two to four
measurements per section (with three to six sections per slide).
Hair follicles were analyzed from one control and two affected
individuals, where each skin biopsy contained two hair follicles,
both of which were analyzed.
Isolation and Culture of Human Keratinocytes and Fibroblasts from
Whole-Skin Biopsies. Keratinocytes and fibroblasts were grown
from control, carrier, and affected skin biopsies using the fol-
lowing protocol: skin biopsies were collected in 10% (vol/vol) FBS
in Dulbecco’s Modified Eagle Medium (DMEM), washed with
5 mL PBS, and then chopped into small pieces that were trans-
ferred to 5 mL Dispase (5 mg/mL) overnight at 4 °C. Epidermis
and dermis were separated with a scalpel, and the epidermis was
placed into 5 mL 0.25% trypsin–EDTA at 37 °C for 30 min and
then into 20 mL 10% (vol/vol) FBS in DMEM. Cells were
collected by centrifugation at 1,000 × g for 7 min and re-
suspended in epidermal keratinocyte growth media, defined
with supplements (CnT-07; CELLnTECH). Fibroblasts were
isolated by digesting the dermis in 10 mL 0.3% collagenase for
4 h at 37 °C. Cells were collected by centrifugation at 1,200 × g for
10 min, washed in 30 mL fibroblast culture medium [10% (vol/vol)
FBS in DMEM] twice, and then resuspended in fibroblast cul-
ture medium.
Whole-Genome Sequencing. DNA was prepared for sequencing
according to the Illumina DNA sample preparation kit protocol.
Initially, the DNA was randomly fragmented by nebulization fol-
lowed by end repair, addition of a single A base, adaptor ligation,
and gel electrophoresis to isolate 300-bp fragments followed by
PCR amplification. Next, the size-selected libraries were used for
cluster generation on the flow cell. All prepared flow cells were run
on the IlluminaHiSeq using the paired-endmodule: the paired-end
reads were each 100 bp long. DNA was aligned to the reference
genome (National Center for Biotechnology Information Build
36 Ensembl release 50) using the BWA software (version 0.4.9)
(1). Picard was used to remove potential PCR duplicates via the
rmdup command. SAMtools (version 0.1.5c) was used for variant
identification, using the pileup command with the –c option and
default settings (2). The variants were then filtered using a
SAMtools variation filter with the default settings but removing
the filter for a maximum allowed coverage per variant by setting
it to 10 million. All variants were screened for quality by keeping
only those with a consensus score and quality score of at least 20
[50 for insertions/deletions (INDELs)] and that had at least
three reads supporting the variant. Heterozygous INDELs were
also excluded if the ratio of variant reads to reference reads was
less than 0.2. The average coverage for this sample was 44.4×.
Large deletions and duplications were identified with the Esti-
mation by Read Depth with SNVs software. Structural variants
including insertions and translocations were identified using
SV-Finder, software developed in the Duke Center for Human
Genome Variation that uses multiple alignment-based approaches
with an emphasis on split-read and pair-end.
The genomewide identification of functional gene variants was
facilitated by SequenceVariantAnalyzer (3).
Amplification of Genomic DNA. The reaction conditions were as
follows: 95 °C for 5 min, 94 °C for 30 s, 55 °C for 40 s, and 68 °C
for 1.5 min, where 35 cycles were run with a final extension time
of 10 min at 68 °C. The primers used for the control reaction
were (F) TGGCATTACAAGAGTTAGCTTCTGA and (R) AA-
TGCTTTGTAGTGGCTTTGTTTCC, producing an amplicon of
1,911 bp (4); the primers used for the centromeric breakpoint
were (F) TGGCATTACAAGAGTTAGCTTCTGA and (R) CC-
TCCAGGGTGACTAAATTTG, producing an amplicon of 1,813
bp; and the primers used for the telomeric breakpoint were (F)
AACTAGAAGGCCATTGGCTG and (R) AATGCTTTGTA-
GTGGCTTTGTTTCC, producing an amplicon of 609 bp.
Quantitative RT-PCR Analysis. The primers used in these assays
were as follows: human Fibroblast Growth Factor 13 (hFGF13)
(core)—(F) CAGCCGACAAGGCTACCAC and (R) GTTCC-
GAGGTGTACAAGTATCC; human MCF2 cell line derived
transforming sequence (hMCF2)—(F) GCAGCAGGAACTT-
TTGACAG and (R) GCTGGTGTGTTCCAATTCAG; human
SRY related HMG box 3 gene (hSOX3)—(F) GTTGGGACGC-
CTTGTTTAGC and (R) TAGCGCGAAGAAATATCAAAC-
AG (4): human Coagulation Factor IX (hF9)—(F) GCATTCT-
GTGGAGGCTCTATC and (R) GCTGCATTGTAGTTGT-
GGTG; human ATPase, class VI, type IIC (hATP11C)—(F)
GGACATTTCTGGCTGCCTTTG and (R) CCAGAATC-
GGGTATCCAAG; hK14—(F) GGGATCTTCCAGTGGG-
ATCT and (R) GCAGTCATCCAGAGATGTGACC; and
hGAPDH—(F) ATGGACACGCTCCCCTGACT and (R) GA-
AAGGTGGGAGCCTCAGTC. hFGF13 isoform-specific PCR
was performed using the following primers: FGF13-001 (1S)—
(F) CGAGAAATCCAACGCCTGC (5) and (R) CACCACTC-
GCAGACCCACAG; FGF13-002 (1U)—(F) GTTAAGGAAG-
TCGTATTCAGAGC (5) and (R) CACCACTCGCAGACCC-
ACAG; FGF13-203 (1V)—(F) GATGCTTCTAAGGAGCCT-
CAG and (R) CACCACTCGCAGACCCACAG; FGF13-202
(1Y)—(F) ACAGAGCCGGAAGAGCCTCAG and (R) CAC-
CACTCGCAGACCCACAG; and FGF13-201, -3 (1V+1Y)—(F)
GATGCTTCTAAGGTTCTGGAT and (R) CACCACTCGCA-
GACCCACAG.
Expression was normalized to the GAPDH housekeeping gene
and compared with the control samples. For each assay, cDNA
was used from three controls, three carriers, and three affected
individuals unless indicated otherwise. For expression analysis of
microRNAs, human–miR-504 and human–miR-505, the follow-
ing miScript primer assays (Qiagen) were used: Hs_miR-504_1,
Hs_miR-505_1, and Hs_RNU6-2_1 miScript (miScript PCR
Control). Images were generated using GraphPad Prism.
Whole-Mount and Section in Situ Hybridization. For mouse section in
situ hybridization, dorsal skin isolated from Swiss Webster mice
at indicated time points was harvested and embedded in OCT,
where a microtome cryostat was used to generate 10-μm sections.
For human studies, 12-μm hair follicle sections were used. The
sense and antisense riboprobes were constructed using in vitro
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transcription and the Digoxigenin (DIG)-labeling system (Ro-
che). The following primers were used and recognize the core
region of the FGF13 sequence: mouse Fgf13 (mFgf13)—(F)
TCAAACCAAGCTGTATTTGGC and (R) CTTTCAGTGGT-
TTGGGCAGAA; and hFGF13—(F) AGCCTCAGCTTAAG-
GGTATAG and (R) CAAGAACACTGTTACCTTGAGC.
Immunofluorescence Staining on Skin Biopsies. Sections were fixed
with acetone at −20 °C for 10 min, washed three times in 1× PBS,
and then blocked in 1.5% (vol/vol) fish gelatin/1% (vol/vol) BSA
in 1× PBS at room temperature for 1 h. The rabbit anti-FGF13
antibody recognizing the C terminus of the protein was gener-
ously provided by Geoffrey Pitt (Duke University, Durham, NC)
and was used at a concentration of 1:400 in 1.5% (vol/vol) fish
gelatin/1% (vol/vol) BSA in 1× PBS. The rat anti-mouse CD200
antibody (1:100) (BD Pharmingen), guinea pig anti-human K75
(1:1,000) (a gift from Lutz Langbein, German Cancer Research
Center, Heidelberg) and rabbit anti-human K14 (1:1,000) (Co-
vance) were diluted in 1.5% (vol/vol) fish gelatin/1% (vol/vol)
BSA in 1× PBS. The anti-rabbit, -rat, and -guinea pig IgG isotype
(Santa Cruz Biotechnologies) antibodies were used as primary
controls at the same concentrations as the respective primary
antibodies listed above. Following PBS washes, the Alexa Fluor
488 donkey anti-rabbit IgG (Molecular Probes, Invitrogen), Alexa
Fluor 594 donkey anti-rat IgG (Molecular Probes, Invitrogen),
and Alexa Fluor 594 goat anti-guinea pig IgG (Molecular Probes,
Invitrogen) secondary antibodies were added to the cryosections
at a concentration of 1:800 in 1× PBS. Sections were mounted in
VECTASHIELD mounting medium with DAPI (Vector Labo-
ratories) and imaged using a LSM 5 laser-scanning Axio Observer
Z1 confocal microscope (Carl Zeiss). For human studies, Z-
stack images were taken at 10× and 20× magnifications using
identical settings and consistent Z-stack intervals between slides.
For mouse studies, images were taken at a 20× magnification.
Statistical Analysis. A Student t test (two-tailed) was used to de-
termine statistical significance in quantitative RT-PCR assays
with a significance level (α) of 0.05. Three biological replicates
were used in each analysis (unless indicated otherwise), and
values represent the average of three independent experiments
for the three biological replicates. Error bars represent the SEM.
Assessment of X-Inactivation Skewing in Female Carriers.The human
androgen receptor assay (HUMARA) was performed to de-
termine skewing of X inactivation as previously described (6).
Genomic DNA from five female carriers was used for ampli-
fication of a differentially methylated CpG dinucleotide site
near a polymorphic region in exon 1 of the Androgen Receptor
(AR) gene, and PCR products were digested with the HpaII
(methylation-sensitive) and RsaI (cocutter, methylation-insensitive)
restriction enzymes to distinguish between methylated and non-
methylated alleles. X-chromosome-inactivation skewing percent-
age was determined using the method described in ref. 6.
RNA Sequencing in Whole Skin. RNA sequencing (RNA-seq) was
performed on whole skin from one control and one affected
individual. Preparation of the cDNA library for sequencing was
performed using the TruSeq kit (Illumina). In brief, 100 ng total
RNA extracted from affected and control skin biopsies was pu-
rified (using polyA capture to select for mRNAs), fragmented,
and converted into single-stranded cDNA using random hexamer
priming. Next, the second strand was generated and double-
stranded cDNA was purified using bead capture. End repair was
then performed to create blunt ends, followed by adenylation of
the 3′ ends (to prevent intramolecular ligation), ligation of in-
dexing adaptors to the ends of the double-stranded cDNA, and
enrichment of DNA fragments containing adaptor molecules
using PCR. The resulting cDNA library was then sent to the
genomics core facility at The Rockefeller University to be se-
quenced on the Illumina HiSeq. 2000 machine using single-end
reads of ∼50 bp, with an overall sequencing depth of ∼15 million
reads per sample. Reads were mapped to the human reference
genome (National Center for Biotechnology Information build
37.2) using TopHat, an algorithm designed to align reads from
an RNA-Seq to a reference genome based on existing transcript
annotation and inferred new splice sites (7). To estimate the
relative abundance of genes and splice isoforms, the data were
then analyzed using Cufflinks, a program that contains algo-
rithms that estimate transcript abundance while accounting for
alternative splicing (8). Fragments per kilobase of exon per
million fragments mapped were normalized to the upper quar-
tile. Differential expression of isoforms was tested using Cuffdiff,
a program that uses the Cufflinks transcript quantification engine
to determine transcript levels in more than one condition.
In Silico Prediction Analysis of miR-504 Target Genes.miR-504 target
genes were determined using a comprehensive database, miR-
Walk (9), which provides information on predicted, validated,
and published microRNA target genes. We applied filters to
select target genes with a minimum seed sequence of seven nu-
cleotides, the longest transcript of a given gene, and a P value of
0.05 or less, which represents the strength of the prediction
through a Poisson distribution. Furthermore, target genes that
appeared in three or more of the following prediction programs
were selected: TargetScan, miRanda, miRDB, PICTAR5, miR-
Walk, RNA22, and DIANA-mT.
1. Li H, Durbin R (2009) Fast and accurate short read alignment with Burrows-Wheeler
transform. Bioinformatics 25(14):1754–1760.
2. Li H, et al.; 1000 Genome Project Data Processing Subgroup (2009) The Sequence
Alignment/Map format and SAMtools. Bioinformatics 25(16):2078–2079.
3. Ge D, et al. (2011) SVA: Software for annotating and visualizing sequenced human
genomes. Bioinformatics 27(14):1998–2000.
4. Zhu H, et al. (2011) X-linked congenital hypertrichosis syndrome is associated with
interchromosomal insertions mediated by a human-specific palindrome near SOX3. Am
J Hum Genet 88(6):819–826.
5. Wang C, et al. (2011) Fibroblast growth factor homologous factor 13 regulates Na+
channels and conduction velocity in murine hearts. Circ Res 109(7):775–782.
6. Warburton D, et al. (2009) Skewed X chromosome inactivation and trisomic
spontaneous abortion: No association. Am J Hum Genet 85(2):179–193.
7. Trapnell C, Pachter L, Salzberg SL (2009) TopHat: Discovering splice junctions with RNA-
Seq. Bioinformatics 25(9):1105–1111.
8. Trapnell C, et al. (2010) Transcript assembly and quantification by RNA-Seq reveals
unannotated transcripts and isoform switching during cell differentiation. Nat
Biotechnol 28(5):511–515.
9. Dweep H, Sticht C, Pandey P, Gretz N (2011) miRWalk–database: Prediction of possible
miRNA binding sites by “walking” the genes of three genomes. J Biomed Inform
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Fig. S1. Morphometric analysis of patient hair follicles reveals matrix, dermal papilla, and hair shaft defects. Quantification of hair follicle components using
the length-measuring tool in the AxioVision program revealed a widened dermal papilla (threefold increase; P = 0.0000343), matrix (1.9-fold increase; P =
0.0000642), and hair shaft (1.25-fold increase; P = 0.036). Inner root sheath (IRS) differences in the lower and upper outer root sheath were not statistically
significant. Hair follicles were analyzed from one control and two affected individuals, where the average widest distance was calculated for each hair follicle
structure. A Student t test was performed comparing the affected to the control value with a cutoff P value of 0.05 for statistical significance; *P < 0.05; ***P <
0.001. Error bars represent the SD.
Fig. S2. Summary of interchromosomal insertion events in all three X-linked congenital generalized hypertrichosis families. Zoomed-out view of chromosome
Xq27.1 region in X-linked hypertrichosis, where boxes indicate the insertion events and sizes of each from chromosomes 4, 5, and 6. Colored lines connected to
the inverted triangle indicate orientation of the insertion events, where all three occur at the same palindromic sequence at Xq27.1. *, corresponds to ref. 1.
1. Zhu H, et al. (2011) X-linked congenital hypertrichosis syndrome is associated with interchromosomal insertions mediated by a human-specific palindrome near SOX3. Am J Hum Genet
88(6):819–826.
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Fig. S3. FGF13 localizes to all layers of the outer root sheath (ORS) and the companion layer but not the human hair follicle bulge. (A) Immunofluorescence
staining of FGF13 juxtaposed with Keratin 14 (KRT14) (which marks all layers of the ORS) demonstrates that FGF13 is broadly expressed throughout the ORS.
The far right image is a hematoxylin-and-eosin staining of an anagen hair follicle for reference of morphology. (B) Costaining of FGF13 with KRT75, a marker of
the companion layer between the ORS and inner root sheath (IRS), demonstrates that FGF13 localizes to the companion layer (arrows). (C) Costaining of FGF13
and CD200 (a marker of the bulge region of the hair follicle) demonstrates that FGF13 does not localize to the human hair follicle bulge. BL, basal layer. (Scale
bar, 100 μm.)
Fig. S4. Fgf13 is expressed in the developing and cycling mouse hair follicle. (A) Whole-mount and section in situ hybridization of Fgf13 on embryonic day 14.5
(E14.5) embryos reveals expression in the developing whisker pad (WP), guard hair follicle placodes, and dermal condensates at E14.5 (n = 3; AS, antisense;
S, sense). Arrows indicate vibrissa and guard hair follicles. (B) Immunofluorescence staining on E16.5 vibrissae follicles demonstrates that Fgf13 localizes to the
outer root sheath (ORS) (n = 3). (C) Immunofluorescence staining of Fgf13 in anagen (day 30) hair follicles reveals that Fgf13 localizes to the bulge (B), isthmus
(I), and ORS. (D) Costaining of Fgf13 and CD200 in telogen (day 50) hair follicles reveals that Fgf13 localizes to the bulge. (Scale bar, 100 μm.)
DeStefano et al. www.pnas.org/cgi/content/short/1216412110 4 of 8
Fig. S5. Isoform-specific PCR of FGF13 in whole skin. (A) Schematic of the FGF13 locus at chromosome Xq26.3–27.1 (chr. Xq26.3–27.1). Alternating 5′ exons
(termed 1S, 1U, 1V, 1Y, and 1V+1Y) are represented as boxes with distinct colors, whereas exons 2–5, common to all transcripts, are shown as blue boxes. The
dark box at the 5′ end of the 1S isoform represents a nuclear localization signal. (Scale bar at top right, 100 kb.) (B) Amplification of FGF13 transcripts using
cDNA from whole skin demonstrates that the 1S, 1Y, and 1V+1Y isoforms are strongly expressed, and the V isoform is faintly expressed. “Core” represents the
3′ region common to all these isoforms. The Ensembl transcripts corresponding to these splice variants are FGF13-001 (1S), FGF13-002 (1U), FGF13-203 (1V),
FGF13-202 (1Y), and FGF13-201, -3 (1V+Y).
Table S1. X chromosome inactivation experiment in XLH female
carriers
Sample ID Description % skewing
II-2 Female carrier 43
II-9 Female carrier 81
II-1 Female carrier 67
II-6 Female carrier 62
III-11 Female carrier 74
II-8 Female nonaffected Noninformative
III-8 Female nonaffected Noninformative
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Table S2. Differential expression of FGF13 (bolded) and other genes ∼3 Mb on either side of the 389-kb insertion (underlined and







(affected vs. unaffected) P value
ZIC3 Chr:136476011–136481925 No N.D. N.D. 0.213
LOC158696 Chr:137524557–137527465 No N.D. N.D. 0.159
FGF13 Chr:137541399–138114851 Yes 2.076 −7.976 0.012
MIR504 Chr:137541399–138114851 No N.D. N.D. 1.000
LOC100129662 Chr:137541399–138114851 No N.D. N.D. 1.87E-05
Pseudogene (SRD5A1P1) Chr:138356643–138358798 Yes 1.562 −4.770 0.005
F9 Chr:138440560–138473283 No N.D. N.D. 0.023
MCF2 Chr:138491595–138618047 Yes 0.320 −1.376 0.501
ATP11C Chr:138636170–138742113 Yes 0.184 −1.201 0.663
MIR505 Chr:138833972–138834056 No N.D. N.D. 1.000
CXorf66 Chr:138865549–138875343 No N.D. N.D. 1.000
Insertion at chrX:139,330,620
SOX3 Chr:139412817–139414891 No N.D. N.D. 1.000
RP1-177G6.2 Chr:139619589–139624662 No N.D. N.D. 0.677
CDR1 Chr:139693090–139694389 Yes 0.567 −1.763 0.387
MIR320D2 Chr:139836002–139836050 No N.D. N.D. 1.000
SPANXB1 Chr:139924426–139925542 No N.D. N.D. 1.000
LDOC1 Chr:140097596–140098976 Yes 0.382 −1.465 0.484
SPANXC Chr:140163261–140164312 No N.D. N.D. 1.000
SPANXA1 Chr:140418508–140565735 No N.D. N.D. 1.000
SPANXA2 Chr:140418508–140565735 No N.D. N.D. 1.000
SPANXA2-OT1 Chr:140418508–140565735 No N.D. N.D. 0.079
SPANXD Chr:140613233–140614321 No N.D. N.D. 1.000
SPANXE Chr:140613233–140614321 No N.D. N.D. 1.000
MAGEC3 Chr:140753767–140813284 No N.D. N.D. 0.159
MAGEC1 Chr:140819307–140824853 No N.D. N.D. 1.000
MAGEC2 Chr:141117793–141120742 No N.D. N.D. 1.000
SPANXN4 Chr:141941369–141949732 No N.D. N.D. 1.000
Genomic coordinates reference UCSC Genome Browser human reference hg18. ln, natural logarithm; N.D., not detectable.
Table S3. miR-504 predicted target genes differentially expressed in XLH by RNA-seq
Gene name Locus
Fold change
(affected vs. unaffected) ln(fold change) P value Q value
BATF2 Chr11:64511992–64521093 40.711 −3.707 0.001 0.008
FZD9 Chr7:72486044–72488386 34.025 −3.527 1.80E-05 0.000
TGM4 Chr3:44891101–44931092 31.450 −3.448 0.002 0.015
NPTX1 Chr17:76055227–76064999 30.048 −3.403 3.92E-09 2.91E-07
CRTAM Chr11:122214464–122248557 26.236 −3.267 0.003 0.022
HTR7 Chr10:92490555–92607651 22.499 −3.113 0.000 0.002
UBASH3B Chr11:122031607–122190397 21.982 −3.090 2.47E-08 1.49E-06
FUT5 Chr19:5816836–5821551 19.225 −2.956 2.66E-05 0.001
ATP8B3 Chr19:1733073–1763270 18.705 −2.929 2.83E-08 1.67E-06
MDGA1 Chr6:37708261–37773744 16.793 −2.821 6.99E-07 2.79E-05
FJX1 Chr11:35596310–35598997 11.675 −2.457 5.67E-06 0.000
KIF21B Chr1:199205136–199259451 11.648 −2.455 6.60E-13 9.76E-11
MET Chr7:116099694–116225676 10.666 −2.367 1.44E-06 5.17E-05
TP53RK Chr20:44619868–44751683 10.417 −2.343 4.26E-05 0.001
MALL Chr2:110198735–110231432 10.377 −2.340 1.09E-05 0.000
IL6R Chr1:152644292–152708550 10.361 −2.338 1.09E-08 7.38E-07
STC1 Chr8:23755378–23768265 10.269 −2.329 1.39E-05 0.000
HAS3 Chr16:67696967–67723994 9.828 −2.285 1.78E-08 1.13E-06
S100A7A Chr1:151655623–151662325 8.701 −2.163 3.66E-05 0.001
MTHFD2 Chr2:74279197–74295932 8.430 −2.132 2.00E-06 6.96E-05
CDCP1 Chr3:45098772–45162918 8.277 −2.113 5.62E-05 0.001
EXOSC6 Chr16:68841634–68843334 8.037 −2.084 0.000 0.002
TNFRSF9 Chr1:7898517–7925812 8.020 −2.082 0.004 0.030
P2RY11 Chr19:10077898–10091599 7.800 −2.054 0.000 0.002
LPCAT1 Chr5:1514541–1577076 7.264 −1.983 0.000 0.003




(affected vs. unaffected) ln(fold change) P value Q value
LIF Chr22:28966441–28972796 6.932 −1.936 0.000 0.003
PNO1 Chr2:68238508–68256595 6.650 −1.895 0.000 0.005
BYSL Chr6:41996942–42008762 5.907 −1.776 0.001 0.009
TRIB3 Chr20:309307–326203 5.706 −1.742 0.001 0.010
PCDH10 Chr4:134289919–134332182 5.591 −1.721 0.005 0.033
BCAT1 Chr12:24854224–24993660 5.357 −1.678 0.001 0.010
CNO Chr4:6768742–6770288 5.247 −1.658 0.003 0.023
CYGB Chr17:72035024–72053053 5.226 −1.654 0.005 0.035
ZFAT Chr8:135559212–135794474 5.216 −1.652 8.57E-08 4.52E-06
STK40 Chr1:36577811–36624072 5.210 −1.651 0.002 0.016
SPRED2 Chr2:65391488–65513160 5.123 −1.634 9.36E-05 0.002
FUT2 Chr19:53891039–53901003 5.119 −1.633 0.000 0.005
IPPK Chr9:94099460–94472368 5.105 −1.630 0.002 0.015
PXN Chr12:119123476–119187957 5.053 −1.620 5.16E-08 2.90E-06
CD86 Chr3:123256898–123322678 5.052 −1.620 0.001 0.007
ABL2 Chr1:177335084–177465442 5.027 −1.615 9.74E-13 1.43E-10
KLHL21 Chr1:6573370–6585516 4.985 −1.606 0.007 0.044
FSCN1 Chr7:5598961–5612813 4.963 −1.602 0.004 0.031
RUNX1 Chr21:35081967–35343465 4.835 −1.576 2.14E-05 0.001
RRAGC Chr1:39077605–39097927 4.730 −1.554 0.002 0.020
SERTAD1 Chr19:45620248–45623772 4.697 −1.547 0.003 0.022
OSBP2 Chr22:29420792–29633811 4.695 −1.547 0.005 0.033
ZNF264 Chr19:62394679–62426026 4.653 −1.538 0.004 0.028
DNMBP Chr10:101625323–101759666 4.581 −1.522 0.003 0.023
PLEKHM1 Chr17:40869048–40923929 4.558 −1.517 2.80E-05 0.001
PDRG1 Chr20:29996418–30003544 4.414 −1.485 0.007 0.042
MBP Chr18:72819776–72973762 4.300 −1.459 3.75E-05 0.001
PLCD3 Chr17:40544533–40565417 4.266 −1.451 0.005 0.033
SLC7A1 Chr13:28981550–29067825 4.162 −1.426 0.007 0.043
GMEB2 Chr20:61689398–61728825 4.160 −1.425 0.007 0.041
LRRC8A Chr9:130684211–130720138 4.158 −1.425 0.000 0.006
KCNK1 Chr1:231816372–231874881 4.037 −1.396 0.006 0.039
NUDT15 Chr13:47509703–47519283 4.004 −1.387 0.008 0.046
LY6K Chr8:143778530–143805393 3.958 −1.376 0.001 0.006
SMURF1 Chr7:98462993–98579679 3.939 −1.371 0.002 0.016
GPER Chr7:1003148–1144419 3.871 −1.354 0.008 0.047
RRAS2 Chr11:14256041–14342628 3.637 −1.291 0.000 0.002
CRTC3 Chr15:88874201–88989581 3.559 −1.270 0.001 0.010
MAPKAPK2 Chr1:204924987–204974253 3.464 −1.242 0.005 0.035
ZBTB24 Chr6:109890411–109911133 3.342 −1.207 0.008 0.047
NRF1 Chr7:129038790–129184158 3.334 −1.204 0.006 0.038
DIAPH1 Chr5:140874771–140978806 3.312 −1.197 0.001 0.011
PAPD5 Chr16:48744329–48826720 3.160 −1.151 0.008 0.045
DHX33 Chr17:5284955–5313104 3.083 −1.126 0.003 0.022
PVR Chr19:49838937–49861268 2.872 −1.055 0.001 0.009
TGFBR1 Chr9:100907232–100956294 2.854 −1.049 0.008 0.046
GAS7 Chr17:9754650–10042593 2.703 −0.994 0.006 0.036
IL1RAP Chr3:191714533–191857680 2.632 −0.968 0.002 0.015
CTDP1 Chr18:75540788–75615498 2.594 −0.953 0.007 0.044
VEGFA Chr6:43845923–43862201 2.490 −0.912 0.000 0.005
CNOT4 Chr7:134697086–134845415 2.220 −0.798 0.004 0.026
Genomic coordinates reference UCSC Genome Browser human reference hg18. ln, natural logarithm.
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Table S4. FGFs with dysregulated expression levels in XLH by RNA-seq in whole skin
Gene name Locus
Fold change
(patient vs. control) P value
FGF5 Chr4:81406765–81431195 −56.33 2.53E-09
FGF18 Chr5:170779271–170817235 −11.22 3.00E-05
FGF14 Chr13:101171205–101852125 −9.13 0.0004
FGF13 Chr:137541399–138114851 −7.98 0.012
FGF12 Chr3:193339875–193928082 −6.09 0.006
FGFR1OP Chr6:167332805–167374056 −3.37 0.007
FGFR3 Chr4:1764836–1780397 −3.21 0.001
FGFR2 Chr10:123227833–123347962 −2.32 0.0008
FGFBP1 Chr4:15546289–15549461 13.58 3.70E-06
Genomic coordinates reference UCSC Genome Browser human reference hg18.













Chapter II.3 Discussion 
The density of hair follicles across the human body is regionally decreased on 
different body sites compared to other mammals. Thus, the extreme excessive hair 
overgrowth phenotype observed in inherited hypertrichosis has long fascinated 
evolutionary geneticists. Historically, it has been considered an atavism, or recurrence 
of an ancestral phenotype (HALL 1984; CANTU AND RUIZ 1985). The estimated incidence 
of these syndromes in the general population is extremely low, with approximately 60 
reported cases to date, suggesting an unusual underlying genetic mechanism whose 
observed frequency is just as rare, and likely characterized by unusual, sporadic 
mutations with pleiotropic effects.   
Characterizing the genetic basis of X-linked hypertrichosis 
In Chapter II.2 of my thesis, I investigated the genetic basis of the X-linked form of 
hypertrichosis in a family in which the Christiano lab previously reported linkage to 
chromosome xq24-27 over a decade ago (TADIN-STRAPPS et al. 2003). The initial 
approach searching for intragenic mutations using conventional sequencing strategies 
did not provide insight into the underlying genetic defect. With the advent of new 
technologies, we used a comprehensive approach combining high-resolution CNV 
analysis, FISH, and next-generation whole-genome sequencing technologies to detect 
the rare, pathogenic variant residing within the candidate linkage interval for this 
disease. Remarkably, this strategy enabled us to detect a large interchromosomal 
insertion with a complex sequence origin and inverted orientation that otherwise failed 
to detect using the conventional methods. We defined the precise location of this 
insertion at an extragenic palindromic site using whole-genome sequencing, and then 
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demonstrated complete cosegregation with the disease phenotype using a PCR-based 
screening approach, providing strong causal evidence for this insertion in XLH 
pathology (DESTEFANO et al. 2013). Importantly, our collaborations and access to 
several newer and more sophisticated methods (i.e. SOMA and whole-genome 
sequencing) empowered us with the tools to identify the critical insight in understanding 
the genetic architecture underlying XLH.  
Three interchromosomal insertions occured at the same palindrome site  
Considering the extremely rare occurrence of this condition in the general population, as 
well as the complex nature of the interchromosomal insertion resulting from eight 
double-strand breaks, the probability of identifying an independent, unrelated case 
characterized by the same unusual genetic mechanism is extremely low. Curiously, 
there are two additional XLH families of different ethnic backgrounds with linkage to the 
same genomic region (chrXq24-27), and recently, interchromosomal insertions were 
identified in both families (ZHU et al. 2011). Remarkably, all three insertions occurred at 
the exact same palindromic sequence on chrXq27.1. In all cases, at least one 
breakpoint resides within the palindrome site, and the insertion sequences are 
composed of autosomal CNV gains not present in control individuals or any public 
database. However, the sequence content and sizes of the insertions are distinct 
between the three families, verifying that they arose independently. Based on the nature 
of the genetic lesions identified in XLH, it was suggested that XLH is a genomic 
disorder, or one that is characterized by structural and numerical chromosome 
anomalies, though the precise mechanisms underlying the pathology remain unclear.  
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The identification of three distinct interchromosomal insertions at the exact same 
palindrome site raises intriguing questions, such as how do these interchromosomal 
insertions exert their pathogenic effects and cause excessive hair overgrowth? And 
what is the significance of their identical locations at the same palindromic site? To 
address the first question, I discuss several plausible mechanisms by which the 
insertions can act, including: 1. The disruption of a gene in the region; 2. The 
introduction of novel regulatory elements; 3. The presence of dosage-sensitive genes 
within the insertion; 4. The physical separation of neighboring genes from their 
regulatory elements, altering spatiotemporal expression; and 5. Disrupted chromosomal 
architecture and/or perturbed intra- and interchromosomal interactions required for 
normal development.  
In all three families, the insertions are located at an extragenic palindromic site 
situated within a 485 Kb gene desert. In two families, both breakpoints reside within the 
center of the palindrome, and in the third family, the distal breakpoint resides within the 
palindrome, where the proximal is located 1.3 Kb from the palindrome (ZHU et al. 2011). 
Since all insertion events are contained within the 485 Kb gene desert, this provides 
evidence against the intragenic disruption hypothesis. Regarding the insertion content, 
the sequences are different among the three families (125 Kb from chr5q35.3, 300 Kb 
from chr4q31.2, and 389 Kb from chr6p21.2 (our study)), where each segment 
possesses different regulatory characteristics (based on ENCODE data). Furthermore, 
the genomic segments in two of the insertions (chr4 and 6) do not contain full genes, 
but rather fragments and/or introns, and none of these sequences have known roles in 
skin or hair follicle development. These observations highlight the unlikelihood of novel 
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regulatory elements and/or dosage-sensitive genes causing the XLH phenotype, and 
suggest that the presence of the insertion (rather than its content) mediates pathogenic 
effects.  
In my thesis work described in Chapter II.2, I tested whether the 
interchromosomal insertion disrupted the expression levels of the genes in the 
surrounding region. In the following sections, I address the significance of the three 
insertions at the same palindromic sequence and overall incidence of interchromosomal 
insertions in sporadic conditions. Moreover, I discuss the rationale behind the 
approaches I used, the current questions that remain unanswered, as well as ongoing 
and future studies to elucidate the mechanisms by which the insertions act in XLH.  
Palindromic sequences are identical in the 5’-3’ orientation on one strand as they 
are on the other strand, thus, they are capable of forming hairpin structures that contain 
stem-loops (SMITH 2008). Interestingly, the cell recognizes these stem-loop structures in 
the same way (i.e. using the same machinery) as it does a Holliday junction (a branched 
structure of four double-stranded DNA molecules), and initiates a double-strand break. 
Studies in yeast have demonstrated that palindromic sequences as short as 140 bp can 
undergo conformational changes to form cruciform structures (substrates for the 
Holliday-junction resolvases to initiate double-strand breaks)	  (NAG AND KURST 1997). 
Thus, palindromic sequences are inherently unstable, and act as hotspots for meiotic 
recombination events in the genome (SMITH 2008). In the three XLH families, the 
insertion events occurred at a 180 bp palindromic site on chrXq27.1. Notably, deletions 
of varying sizes (both within and encompassing the palindrome) were found in several 
healthy individuals from PCR analysis and whole-genome sequencing studies, 
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highlighting the unstable nature of this sequence and its propensity for genomic 
rearrangement, insertions and deletions (ZHU et al. 2011).   
The 180 bp palindrome on Xq27.1 is flanked on one side by a long-terminal 
repeat (LTR), as well as a long interspersed element (LINE). Comparative genomic 
studies of the orthologous genomic region in several non-human primates demonstrated 
that chimpanzee genome contains both halves of the palindrome, but they are in direct 
orientation and separated by the LTR, whereas the orangutan, rhesus and marmoset 
genomes only possess one half of the palindrome (ZHU et al. 2011). Therefore, the 
palindrome is considered evolutionarily recent since it is only found in humans. 
Importantly, while deletions involving the palindrome were detected in control 
individuals, interchromosomal insertions at this site were neither reported in healthy nor 
affected individuals with sporadic conditions, thus highlighting the rare and deleterious 
nature of the three insertions underlying XLH. 
Interchromosomal insertions represent a distinct class of insertional 
translocations (ITs) that are rare events and require at least three independent 
chromosome breaks (KANG et al. 2010). Their estimated incidence in human 
pathologies was reported between 1:10,000-1:80,000 live births (FRYNS et al. 1984) 
(VAN HEMEL AND EUSSEN 2000). Subsequent studies using array CGH and confirmatory 
FISH in 18,000 clinical samples detected submicroscopic Its, increasing the overall 
incidence of ITs to 1:500, suggesting they may not be as rare as previously thought 
(KANG et al. 2010). Moreover, the identification of previously undetected ITs in reported 
CNV cases highlights the need for FISH to detect genomic location of CNVs identified. 




Based on the observation that the insertion content differs across the three XLH 
families, I postulated that the insertion may exert its pathogenic effects through the 
physical separation of neighboring genes from their regulatory elements (creating 
position effects), and/or disrupting chromosomal architecture and/or intra- and 
interchromosomal interactions required for normal development. In other forms of 
hypertrichosis our lab has studied, including Ambras syndrome and autosomal forms of 
CGHT, position effects on the TRPS1 and SOX9 genes were identified as a result of 
large chromosomal rearrangements, insertions and deletions as far as 7.3 Mb away 
(FANTAUZZO et al. 2008; FANTAUZZO et al. 2012). The Christiano lab and other groups 
have demonstrated that both of these genes play important roles in hair follicle 
morphogenesis, evidence by phenotypes in knockout mice (VIDAL et al. 2005; NOWAK et 
al. 2008; FANTAUZZO AND CHRISTIANO 2012; FANTAUZZO et al. 2012). Moreover, the 
position effect on Trps1 is recapitulated in the Koala mouse model for hypertrichosis, 
where a chromosomal rearrangement upstream of Trps1 led to decreased expression at 
the sites of pathology (FANTAUZZO et al. 2008), providing strong evidence for a position 
effect as the underlying genetic mechanism in Ambras syndrome (discussed in Chapter 
I.5).  
In the context of XLH, it was suggested that the candidate gene affected by the 
interchromosomal insertions could be SOX3, a neural gene expressed in otic pladoes 
that lies 82 Kb telomeric to the insertion, given the known roles of SOX2 and SOX9 in 
regulating hair growth (VIDAL et al. 2005; NOWAK et al. 2008; CLAVEL et al. 2012). 
However, several human syndromes associated with SOX3 mutations (i.e. X-linked 
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hypopituitarism, XX male sex reversal, X-linked recessive hypoparathyroidism, and 
premature ovary failure 1) do not manifest with hair phenotypes (BOWL et al. 2005; 
WOODS et al. 2005; FERREIRA et al. 2010; SUTTON et al. 2011). The expression of SOX3 
or any others in the surrounding region had not previously been tested in XLH, only in 
normal subjects, and SOX3 is not expressed in the skin or hair follicle (ZHU et al. 2011). 
Interestingly, SOX3 is expressed in the otic placodes that give rise to ears during 
development, and the XLH affected family members are deaf, suggesting that potential 
dysregulation of SOX3 expression during morphogenesis may contribute to this 
pathological feature.  
In my work, I examined the expression levels of the neighboring genes 
surrounding the 389 Kb insertion by qRT-PCR and RNA-seq on XLH patient and control 
samples. Where many of these genes, including SOX3 were not expressed at 
detectable levels in the skin or hair follicle, FGF13 was significantly decreased in XLH 
patients. FGF13 is an interesting candidate gene because of the known role of FGFs in 
regulating hair growth, specifically FGF5, where mutations cause the angora excessive 
hair overgrowth phenotype through an increased duration of anagen (HEBERT et al. 
1994).  Moreover, a previous report had demonstrated mouse Fgf13 expression in the 
hair follicle bulge during all stages of the hair cycle (KAWANO et al. 2004), making this a 
plausible candidate gene for further investigation.  
In both healthy and XLH hair follicles, I characterized the expression pattern of 
FGF13 using several methods of detection at both the mRNA and protein levels. 
Moreover, I analyzed Fgf13 localization in mouse tissues during morphogenesis and 
postnatal hair follicle growth and found that the same expression pattern is reflected in 
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human anagen hair follicles. We identified decreased levels of FGF13 in human XLH 
and suggested this gene as one target of a position effect resulting from the 
interchromosomal insertion. This conclusion does not distinguish a direct from indirect 
interaction between the insertion and decreased FGF13 levels, and does not eliminate 
the possible involvement of other gene(s) in the region. Recently, conditional deletion of 
Fgf13 in mice demonstrated a role for Fgf13 as a microtubule-stabilizing protein 
required for neuronal polarization and migration (WU et al. 2012). However, global Fgf13 
loss-of-function and its consequence on the hair follicle remain unknown, since this 
gene was specifically ablated in neurons and hair growth was not examined in this 
model.  
In humans, FGF13 has been associated with X-linked mental retardation (XLMR) 
in patients with Borjeson-Forssman-Lehmann Syndrome, where it lies within the 
breakpoint of a duplication (GECZ et al. 1999). The behavioral abnormalities observed in 
Fgf13 deficient mice recapitulate the developmental delay observed in humans with 
XLMR, suggesting that the Fgf13 knockout mouse may be a suitable model for human 
XLMR. Interestingly, human patients with XLMR do not have reported hair or skin 
phenotypes, and the XLH patients reported in our study do not exhibit signs of XLMR. 
While it has been reported that position effects on genes can produce distinct 
phenotypes from the intragenic loss-of-function mutations, it is likely that reduced 
FGF13 levels do not solely (if at all) contribute to the XLH pathology. In fact, our RNA-
seq analysis revealed several genes required for normal hair growth (i.e. FGF5, 
HOXC13) whose expression levels were dysregulated in XLH, highlighting the complex 
downstream effects of the insertion on the expression of autosomal genes.  
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Considering the complex and rare nature of the interchromosomal insertion in 
XLH, the rarest of rare conditions, it is likely that the insertion mediates its pathogenic 
effects through a variety of mechanisms, including the disruption of important inter- and 
intrachromosomal interactions.  This hypothesis has not yet been tested in XLH or any 
other forms of inherited hypertrichosis, since beyond functional studies in mouse 
models, no direct evidence for perturbed chromosomal interactions has been 
demonstrated. In my work, I performed an in silico analysis of regulatory elements at the 
Xq27.1 locus and observed several enhancer elements both telomeric and centromeric 
to the insertion, many of which were human-specific and several that demonstrated 
strong lacZ reporter activity in the developing mouse ectoderm (VISEL et al. 2007). 
To clearly elucidate the chromosome interactome signature in the healthy hair 
follicle and in the context of hypertrichosis, a genome-wide chromosome conformation 
capture analysis using Hi-C (3C with high-throughput sequencing) could be performed 
in the future.  This unbiased approach will reveal both inter- and intra-chromosomal 
interactions at the Xq27.1 locus that are normally active in hair follicle cells and 
potentially reveal novel interactions as a result of the interchromosomal insertion. 
Ideally, this experiment would be performed on cells from all three XLH families and in 
conjunction with transcriptome sequencing to more accurately define the global 
dysregulation of chromosome interactions in XLH. This analysis, combined with further 
functional studies employing cell culture assays and mouse models will shed 
mechanistic insight into the dysregulation of key regulators of hair follicle 
morphogenesis in XLH.  
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In summary, the goal of my work in Chapter II.2 was to uncover novel genetic 
mechanisms associated with a rare, sporadic condition affecting hair growth. Given the 
rare incidence of these syndromes within the general population, we used a 
comprehensive approach encompassing a wide range of methods to detect complex, 
sporadic lesions. Importantly, utilizing next-generation sequencing techniques provided 
us with innovative tools that proved essential to identify the pathogenic lesion. These 
and other newer technologies have profoundly improved and accelerated our ability to 
identify genetic mechanisms underlying human hair growth. Our downstream analyses 
uncovered a position effect on a distant gene, FGF13, whose expression levels were 
markedly reduced in patient hair follicles. Future functional studies at the genome-wide 
level will be instrumental in defining the precise mechanisms by which these 








Characterizing single-gene effects on human hair growth 





Chapter III.1 Preface 
 The genetic architecture of rare, Mendelian disorders is generally composed of 
rare variants with large effects, and in familial cases where the underlying genetic 
lesions are enriched within a pedigree, the best approach to identify the candidate gene 
has been to perform linkage and haplotype analysis using genetic markers (i.e. 
microsatellites or SNPs). However, small families with one or few affected individuals 
are not well powered for linkage. Assuming the effect size is large (i.e. disrupting gene 
function), and the genetic lesion is identical by descent (IBD) in related affected or 
carrier individuals, the most effective strategy to identify the causal variants is to 
perform whole exome sequencing. In Mendelian disorders, studying consanguineous 
families has greatly facilitated gene discovery because rare, recessive variants with 
large effects are overrepresented in the gene pool relative to the general population, 
and thus, are readily detectable.  
 In recent years, whole-exome sequencing has emerged as the gold-standard for 
the study of rare, Mendelian disorders, both recessive and dominant, and has proven 
very useful for identifying novel mutations that cosegregate with the disease phenotype 
in familial cases. A candidate-based filtering approach is often used to identify the 
causal variant, followed by genotyping the related affected and unaffected individuals to 
test for cosegregation of the mutation. However, when there is no candidate gene 
available based alone on function or previous genetic association, identifying copy 
number variants (CNVs) that encompass the same genomic region in other patients and 
assessing gene expression in the relevant tissue for the pathology can be very useful 
tools in narrowing the list of potentially causal variants. 
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 In Chapter III.2, I characterized single-gene effects on human hair growth by 
investigating the underlying genetic basis of autosomal recessive congenital 
generalized hypertrichosis terminalis (CGHT) (OMIM #135400). We ascertained a small 
consanguineous family from Yemen that was not sufficiently well powered for linkage 
analysis, however, given the consanguineous union between the parents of the 
proband, we assumed an autosomal recessive mode of inheritance. Drs. Kwame 
Anyane-Yeboa, Heather Feenstra, and Nanette Silverberg (St. Luke’s-Roosevelt 
Hospital Center) performed clinical evaluations of the proband (discussed in Chapter II 
Materials and Methods) and obtained clinical photos as well as blood and punch biopsy 
samples for the subsequent molecular analysis and functional studies that I performed. 
Drs. Karl Gledhill and Zongyou Guo provided me with assistance in the initial isolation 
and culturing of primary keratinocytes and fibroblasts from patient skin biopsies.  
 Given the autosomal recessive mode of inheritance as a result of consanguinity, 
we postulated that underlying mutation resided within the exome. To identify rare, 
homozygous recessive variants with large effects, we performed whole-exome 
sequencing on the proband as well as on both parents through Ambry Genetics (Allso 
Viejo, CA) and applied a standard filtering approach using bioinformatics tools 
(discussed in Chapter III.2 Materials and Methods) to identify pathogenic variants. This 
revealed three candidate genes with homozygous mutations, all of which cosegregated 
with the disease phenotype but none were associated with a Mendelian disease. I next 
tested their gene expression levels in healthy human skin and hair follicle samples using 
RT-PCR, and analyzed their genomic positions to determine overlap with known CNVs. 
This approach successfully identified ABCA5 as the candidate gene, as ABCA5 
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possesses the highest level of expression in human skin and hair follicles and most 
importantly, resides within the minimal common region (chr.17q23-24) to six reported 
CGHT cases (one of which is reported in Chapter III.2). Despite the identification of 
these CNVs, no intragenic mutations have previously been identified in CGHT cases. 
For these reasons, I selected ABCA5 for further investigation, performing detailed 
molecular analyses and functional studies to characterize the novel homozygous 
recessive mutation in human CGHT. 
 Using PCR and Sanger sequencing, I performed cosegregation analysis and 
tested the overall consequence of the mutation on mRNA splicing. I next performed 
qRT-PCR and immunoblotting to determine mRNA and protein levels, respectively, in 
both keratinocytes and fibroblasts. To gain insight as to the specific cell type(s) 
synthesizing ABCA5 in the human hair follicle, I performed immunohistochemistry, 
immunofluorescence staining, in situ hybridization, as well as RT-PCR on 
microdissected tissues of the skin and hair follicle (discussed in detail in Chapter III.2 
Results and Materials and Methods). I next characterized the expression pattern of 
Abca5 in mouse skin and hair follicles using immunohistochemistry and 
immunofluorescence analysis to determine whether it is conserved, and used the adult 
testis as a positive control for Abca5 expression. 
 To evaluate the consequence of the ABCA5 mutation in CGHT patient tissues, I 
performed immunoblotting on CGHT keratinocytes and fibroblasts as well as 
immunofluorescence staining on cryosectioned human hair follicles. Since ABCA5 is a 
reported glycosylated protein, I analyzed its glycosylated and unmodified forms in both 
healthy and affected tissues using PNGase, an enzyme that removes N-glycosyl 
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groups, followed by immunoblotting. I next sought to determine the functional 
consequence of ABCA5 loss-of-function in CGHT at the subcellular level. Since 
previous studies using mouse models have demonstrated a role for Abca5 in lysosome 
function and cholesterol transport, I hypothesized that CGHT cells may possess 
lysosomal defects and/or perturbed distribution of free cholesterol. To directly test this 
hypothesis, I collaborated with Drs. Claudia Dall’Armi and Gil Di Paolo, who provided 
me with expertise, reagents and assistance with these experiments and analyses.  
 To address lysosome function in CGHT, I tested its role in autophagy by 
measuring autophagosome clearance. I performed immunofluorescence staining on 
control and CGHT patient keratinocytes for Lamp1 (lysosome marker), p62 (marker of 
autophagic cargo), and LC3 (an autophagosome marker) following treatment with 
Bafilmoycin A1, a proton pump inhibitor that blocks the acidification and clearance of 
autophagosomes. Dr. Dall’Armi performed confocal microscopy and all quantifications. 
To visualize free cholesterol in CGHT cells, we stained for filipin, a polyene macrolide 
antibiotic and antifungal that fluoresces in the presence of unesterified cholesterol, and 
Lamp1 to detect lysosomes. Dr. Dall’Armi performed confocal microscopy analysis on 
the patient and control keratinocytes. 
 In conjunction with these studies, we reported an independent, sporadic case of 
CGHT, where only the proband was affected. Using the approach and methods outlined 
in Chapter II to study rare, sporadic conditions, we sought to identify chromosomal 
defects (CNVs and/or structural variants). Drs. Mazen Kurban, Vaidehi Jobanputra, 
Dorothy Warburton, Brynn Levy, and Antonio Sobrino performed the cytogenetic 
analyses, including G-banding of chromosomes, FISH using BAC clones, sub-telomeric 
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FISH, and CNV analysis using whole-genome mapping (Affymetrix 500k and 2.7M 
arrays). Drs. Katherine Fantauzzo, Maija Kiuru, Marija Tadin-Strapps, and Anna 
Vitebsky were involved in the downstream cytogenetic analyses and functional studies, 
and patient materials and clinical photos from this case were obtained from Drs. Julio C. 
Salas-Alanis and Larissa Lopez-Cepeda. These cytogenetic analyses revealed a t3;17 
translocation and cryptic 1.3 Mb deletion encompassing ABCA5 on one allele. Given the 
similar phentoypes between sporadic and autosomal recessive CGHT, and the 
pathogenic association with ABCA5, I hypothesized that the second allele may harbor 
an intragenic mutation and performed Sanger sequencing to directly test this. I then 
sought to determine whether ABCA5 levels were reduced in sporadic CGHT and used 
the same methods and approaches in my analysis of the autosomal recessive CGHT 
case to test ABCA5 mRNA and protein levels.  
 Using a comprehensive and robust approach that spans multiple methods of 
detection has enabled the identification of a rare, novel splice site mutation that results 
in the loss-of-function of a gene not previously associated with a human disease. In 
Chapter III.3, I discuss the known functions of ABCA5, as well as future experiments to 
test the mechanism(s) by which it may regulate human hair growth. 
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Inherited hypertrichoses are rare syndromes characterized by excessive hair growth that does not result from androgen
stimulation, and are often associated with additional congenital abnormalities. In this study, we investigated the genetic
defect in a case of autosomal recessive congenital generalized hypertrichosis terminalis (CGHT) (OMIM135400) using whole-
exome sequencing. We identified a single base pair substitution in the 59 donor splice site of intron 32 in the ABC lipid
transporter gene ABCA5 that leads to aberrant splicing of the transcript and a decrease in protein levels throughout patient
hair follicles. The homozygous recessive disruption of ABCA5 leads to reduced lysosome function, which results in an
accumulation of autophagosomes, autophagosomal cargos as well as increased endolysosomal cholesterol in CGHT
keratinocytes. In an unrelated sporadic case of CGHT, we identified a 1.3 Mb cryptic deletion of chr17q24.2-q24.3
encompassing ABCA5 and found that ABCA5 levels are dramatically reduced throughout patient hair follicles. Collectively,
our findings support ABCA5 as a gene underlying the CGHT phenotype and suggest a novel, previously unrecognized role
for this gene in regulating hair growth.
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Introduction
Inherited hypertrichosis, first described in the sixteenth century, is
characterized by hair growth that is excessive for the body site and
age of an individual and is independent of androgen stimulation [1],
[2]. These syndromes are categorized as ectodermal dysplasias and
are often associated with additional congenital defects, including
cardiomyopathy, gingival hyperplasia, and craniofacial malforma-
tions [3]. The genetic basis of these syndromes remained largely
elusive until recently, when our group and others reported several
chromosomal rearrangements, copy number variants (CNVs) and
position effects involving genes associated with autosomal dominant,
recessive, sporadic, and X-linked forms of hypertrichosis [4–10].
We previously reported a position effect on the zinc finger
transcription factor TRPS1 in Ambras syndrome hypertrichosis in
humans and the Koala hypertrichosis phenotype in mice, where
Trps1 expression was decreased at the sites of pathology for the
phenotype [5]. More recently, we and others elucidated the
genetic basis of X-linked hypertrichosis [9],[10], resulting from
large interchromosomal insertions on the X chromosome. We
found that a position effect occurs on a distant gene, FGF13,
whose expression was markedly and selectively reduced in patient
hair follicles, suggesting a novel role for this growth factor in hair
follicle growth and cycling [10].
In the autosomal dominant form of CGHT, we identified a
series of duplications of chromosome 17q24.2-q24.3 and reported
a position effect on the SOX9 gene, situated ,1 Mb downstream
of these variants, and found SOX9 expression was markedly
reduced throughout the follicular epithelium of patient hair
follicles [4]. In a separate report of CNVs in the same region of
chromosome 17q24.2-q24.3, four CNVs were identified in several
cases of CGHT [6], with an overlapping minimal region of 555 kb
encompassing four genes: ABCA6, ABCA10, ABCA5, and MAP2K6,
suggesting that disruption of one of these genes may contribute to
the CGHT phenotype. Despite the identification of CNVs and/or
position effects in this region of chromosome 17q24.2-q24.3, no
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point mutations in these or any other single genes have been
described to underlie the CGHT phenotype.
In this study, we investigated the genetic basis of autosomal
recessive CGHT (OMIM135400) in a consanguineous family.
Whole-exome sequencing revealed a novel, rare variant in the 59
donor splice site of intron 32 of ABCA5 that segregates with the
phenotype in a homozygous recessive manner. ABCA5 is highly
expressed in human skin and hair follicles, and its expression
pattern is conserved in mouse tissues as well. Importantly, the
ABCA5 loss-of-function mutation not only leads to a decrease in
protein levels in both mesenchymal and epithelial compartments
of CGHT patient hair follicles, but also to lysosomal dysfunction,
which results in a defective clearance of autophagosomes under
basal conditions and an overall accumulation of endolysosomal
cholesterol in patient keratinocytes. We also identified an
unrelated case of sporadic CGHT with a t3;17 translocation and
cryptic 1.3 Mb deletion spanning ABCA5, and found that ABCA5
levels were dramatically reduced in patient cells as well as
throughout the hair follicle epithelium. Our findings implicate
ABCA5 as a gene with an essential role in hair growth.
Results
Clinical features, histology, and quantification of hair
follicle length in congenital generalized hypertrichosis
terminalis (CGHT)
We ascertained a proband from Yemen with CGHT segregat-
ing with gingival hyperplasia as well as epilepsy. Excessive hair
growth was observed on the face, including the forehead, cheeks,
and upper cutaneous lip, arms, upper and lower back and legs
(Figure 1A). No other members of the patient’s family are affected,
however, the parents of the proband were consanguineous,
suggesting an autosomal recessive mode of inheritance (Figure 1B).
Analysis of patient hair follicles obtained from a whole skin
biopsy of the forearm by hematoxylin and eosin staining
demonstrated that the hairs are of the terminal type since they
were medullated, pigmented and penetrated deep into the dermis
(Figure S1). Patient hair follicles were thicker than those of
controls, and anagen hairs were present in the skin biopsy,
whereas no anagen hairs were detected in control skin biopsies.
We measured the length of the hair shafts from plucked patient
and control forearm hair follicles and found that the patient hair
follicles were significantly longer (87%), with an average length of
29.6 mm (60.9 mm) compared to 15.9 mm (60.6 mm) for
control follicles (P,0.0001) (Figure 1C).
Whole-exome sequencing in CGHT identified a splice site
mutation in ABCA5
To investigate the genetic basis of CGHT in this family, whole-
exome sequencing was performed (Ambry Genetics) on genomic
DNA obtained from the patient as well as both parents. Following
sequencing, bioinformatics analysis (see Materials and Methods)
and filtering on mode of inheritance ultimately lead to the
identification of variants in 26 candidate genes (33 alterations) that
were homozygous in the proband and heterozygous in both
parents (Figure 1D). Further interpretative filtering based on
literature searches focused on genotype-phenotype correlation
revealed three candidate genes with homozygous mutations,
ABCA5, DGKZ, and ZNF253, all of which are not currently
associated with a Mendelian disease, and thus are considered
novel. The nature of the homozygous mutations identified in these
genes includes one splice site mutation (in ABCA5: c.4320+1G.C),
one missense mutation (in DGKZ: c.1678C.T(p.P560S)), and one
deletion (in ZNF253: c.429delA). Segregation analysis of these
mutations revealed that both parents are heterozygous for all three
mutations, whereas neither unaffected sister carries the ABCA5
c.4320+1G.C and DGKZ c.1678C.T(p.P560S) mutations, and
only one unaffected sister carries the ZNF253 c.429delA mutation.
To determine whether these candidate genes are expressed in
the skin and hair follicle, RT-PCR analysis was performed on
RNA isolated from whole skin, which revealed that the ABCA5 and
DGKZ genes are abundantly expressed, suggesting a potential role
for these two genes in the pathogenesis of the CGHT phenotype,
whereas ZNF253 is expressed at lower levels. The function of the
ZNF253 gene is unknown. The DGKZ gene encodes diacylglycerol
(DAG) kinase zeta, a member of the DAG kinase family which
phosphorylates DAG to phosphatidic acid and plays important
roles in lipid signaling implicated in neurological diseases,
including epilepsy, depression and Alzheimer’s disease [11] –
[13]. Moreover, mice deficient in the gene encoding DAG kinase,
epsilon (Dgke) a member of the same gene family, exhibit features
associated with epilepsy [14], suggesting the DGKZ substitution
mutation may contribute to the pathogenesis of the patient’s
seizures. ABCA5, an ATP-binding cassette (ABC) protein, is a
lipid transporter involved in the efflux of cellular cholesterol levels,
and Abca5-deficient mice develop symptoms similar to several
lysosomal diseases of the heart [15], [16]. Interestingly, ABCA5 lies
in the minimal common region to four reported familial cases and
one sporadic case of autosomal dominant CGHT, both with and
without gingival hyperplasia [4] – [6], suggesting that mutations in
this gene may be associated with CGHT.
The ABCA5 mutation results from a G-to-C substitution in the
first nucleotide of intron 32 (Figure 1E). Sanger sequencing was
performed on genomic DNA from the proband as well as the
unaffected father, which confirmed homozygosity in the proband
(II-2) and heterozygosity in the father (I-2) for the c.4320+1G.C
mutation (Figure 1 E, F). Importantly, this mutation was not
present in control individuals, determined by searching various
genome databases and sequencing the genomic DNA of 10 control
individuals. Moreover, a query for genetic variants that lie within
Author Summary
Inherited hypertrichoses represent a group of hair over-
growth syndromes that are extremely rare in humans and
have remained an area of great interest to evolutionary
geneticists since they are considered to be recurrences of
an ancestral phenotype. These syndromes often present
with additional congenital abnormalities including bone,
heart and dental defects; thus, it is crucial to identify the
mechanisms and genes underlying the pathology. Copy
number variants (CNVs) have previously been reported in
several cases of congenital generalized hypertrichosis
terminalis (CGHT) with a minimal overlapping region of
555 kb encompassing four genes. However, no point
mutations in these or any other single genes have been
described to underlie the CGHT phenotype. In this study,
we report the first loss-of-function mutation in an ABC
transporter, ABCA5 and identified an additional copy
number variant in a separate case that lies within the
minimal common region. We found high levels of ABCA5
expression in both epithelial and mesenchymal compart-
ments of human and mouse hair follicles, and in CGHT
patients, this expression is significantly reduced or
completely lost. ABCA5 is a lysosomal protein, and its
loss-of-function compromises the integrity of lysosomes
and leads to an intra-endolysosomal accumulation of
cholesterol. Importantly, our findings support a novel role
for ABCA5 in regulating hair growth.
ABCA5 Cholesterol Transporter in Hair Growth
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the ABCA5 locus using the UCSC Human Genome (hg19) and
Ensemble Genome Browsers verified that this variant is not a SNP
or common variant associated with any human genetic disease.
Thus, the c.4320+1G.C mutation in ABCA5 is novel.
In light of the cosegregation of the mutation with the disease
phenotype in the family, association with the CGHT phenotype in
previously reported cases, and reported expression in the human
hair follicle with ABCA5 mRNA levels being the highest out of the
four genes within the minimal common region [6], we further
investigated the consequence of this mutation on ABCA5 mRNA
splicing and the potential role for this protein in hair follicle
growth.
Sequencing of the mutant ABCA5 transcript revealed
aberrant splicing
In silico analysis of splicing events using the computational
algorithms Berkley Drosophila Genome Project (BDGP) [17] and
ESEfinder [18], [19] predicted that the c.4320+1G.C mutation
results in complete loss of the donor splice site. To determine the
consequence of the mutation at the transcript level, we amplified
by RT-PCR the ,200 bp region flanking the mutation from
patient, carrier, and control mRNA. Sanger sequencing revealed
that the mutation leads to aberrant skipping of exon 32 in the
proband (Figure 2A). As a result of joining exon 31 to exon 33, the
remainder of the transcript downstream of the mutation is out-of-
frame, leading to a premature termination 14 bp downstream of
the mutation (Figure 2A). RT-PCR analysis of the exon 31–33
amplicon using RNA isolated from whole skin revealed the
complete absence of the wild-type transcript in the proband. In
contrast, we found the presence of the wild-type transcript at high
levels and the mutant transcript at very low levels in the father
(Figure 2A). The mutant mRNA most likely undergoes nonsense-
mediated decay, since the mutation resides near the 39 end of the
transcript and the aberrant splicing event is predicted to affect the
overall stability of the mRNA.
To investigate this possibility, we compared the relative ABCA5
mRNA levels between the proband and unaffected carrier father
by qRT-PCR using primers located at the 59 end of the mRNA,
and found that transcript levels were significantly reduced in
patient whole skin (2.7-fold; p,0.0001), cultured keratinocytes
(2.8-fold; p = 0.0016), as well as fibroblasts (4.9-fold; p,0.0001),
demonstrating that the mutant mRNA is unstable and undergoes
nonsense-mediated decay (Figure 2B).
ABCA5 is abundantly expressed in the epithelial and
mesenchymal lineages of human and mouse hair follicles
While ABCA5 expression was previously identified in plucked
human hair follicles by RT-PCR analysis [6], the specific cell
type(s) synthesizing ABCA5 in the hair follicle and potential
expression in the surrounding dermal tissue remained unknown.
Using in situ hybridization on human hair follicles in the growth
phase of the hair cycle (anagen), we observed ABCA5 transcript
expression in both the epithelial and mesenchymal compartments,
present within the outer root sheath (ORS) of the hair follicle as
Figure 1. Whole-exome sequencing in a case of congenital generalized hypertrichosis terminalis (CGHT) revealed a splice site
mutation in ABCA5. (A) Clinical photos of proband that illustrate the excessive hair overgrowth on the back (upper photo) and leg (lower photo).
The proband is two years of age in this photo. (B) Pedigree of the family from a consanguineous union (indicated by double lines), where the
proband (arrow) is the only affected member. Asterisks indicate the individuals on whom whole-exome sequencing was performed. (C) Quantification
of the length (mm) of patient versus control hair follicles derived from the forearm revealed that patient hair follicles are 87% longer, with an average
length of 29.6 mm (60.9 mm) compared to 15.9 mm (60.6 mm) for control follicles (***P,0.0001). (D) Whole-exome sequencing filtering strategy,
including the number of alterations and genes obtained at each level. One alteration (c.4320+1G.C) was identified in the ABCA5 gene, and
cosegregation analysis in the family members revealed that both parents are carriers of this mutation, whereas the two unaffected sisters do not carry
this mutation. (E) View of ABCA5 (red) and the surrounding genes (black boxes) on chr17q24.2-q24.3, where arrows indicate direction of transcription.
A magnified view of the c.4320+1G.C mutation in exon 32 of ABCA5 with the exon 32-intron 32 boundary reference sequence annotated in colors
corresponding to sequencing peaks. The G.C substitution is indicated below the control sequence. (F) Sequencing of control, carrier, and affected
genomic DNA confirmed heterozygosity for the c.4320+1G.C mutation (boxed) in the father (I-1) and homozygosity in the proband (II-1). All
coordinates reference the UCSC Genome Browser human reference genome hg19.
doi:10.1371/journal.pgen.1004333.g001
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well as dermal sheath (Figure 2C). To determine the localization
pattern of ABCA5 protein in human skin and hair follicles,
immunohistochemistry (IHC) was performed on paraffin-embed-
ded skin sections and expression was most evident in the dermal
sheath, perifollicular dermis, ORS, and IRS of hair follicles
(Figure 2 D–F). Since the ABCA5 antibody is polyclonal, we
validated endogenous ABCA5 expression in the hair follicle as well
as in the surrounding perifollicular dermis using RT-PCR on these
tissues and observed strong ABCA5 expression in plucked hair
follicles (HF), microdissected ORS, as well as perifollicular dermis
(FD) including the dermal sheath (Figure 2G).
To assess whether the human ABCA5 expression pattern was
conserved in mouse skin and hair follicles, we first determined
whether we could detect Abca5 immunoreactivity in a site of
known Abca5 expression using the same polyclonal antibody. In
mice and rats, Abca5 mRNA levels are abundant in the testis by
Northern blotting and in situ hybridization [20], [21]. Using
immunohistochemistry and immunofluorescence staining on adult
mouse testis sections, we observed strong localization of Abca5 to
the basal cells of the seminiferous tubules, interstitial cells
consisting of Leydig cells (as previously reported in [21]), as well
as the tunica albuginea (Figure S2 A–B, G). In the epididymis, we
found very strong and specific localization of Abca5 to the
connective tissue outlining the cylindrical epithelium in the corpus
and cauda regions, including fibrocytes and smooth muscle cells,
as well as within the basal and tall columnar cells of the corpus
cylindrical epithelium (Figure S2 D–E, H–I). The control testis
and epididymis sections (no primary antibody) yielded no signal
(Figure S2 C, F). Importantly, we observed the same localization
pattern of Abca5 in these tissues using two different fixatives; an
organic solvent (methanol/acetone) and cross-linking agent
(formalin), and our data are consistent with previous reports on
Abca5 mRNA expression [20], [21].
We next investigated the localization pattern of Abca5 in the
mouse anagen hair follicle using immunofluorescence staining and
immunohistochemistry, and observed high levels of Abca5
localization to the ORS and IRS of hair follicles (Figure S3).
Expression was also observed in the dermal sheath and
perifollicular dermis by the immunohistochemistry method (Figure
S3 E–F), similar to what we observed in human hair follicles
Figure 2. The ABCA5 c.4320+1G.C mutation leads to aberrant splicing and nonsense mediated decay, and ABCA5 is abundantly
expressed in the skin and hair follicle. (A) Depiction of normal splicing between exons 31 and 32 (black lines) and aberrant skipping of exon 32
as a result of the c.4320+1G.C mutation (red lines), where the adjoining of exon 31 to 33 leads to premature termination during translation. The out-
of-frame exon 33 sequence (red box) is indicated by the hatched lines, followed by a stop codon. Sequencing of the mutant transcript (MT) confirmed
the aberrant splicing event, where the amino acid sequence is listed above and the stop codon is indicated by an asterisk. RT-PCR on RNA from whole
skin followed by gel electrophoresis of the exon 31–33 amplicon demonstrates complete loss of the wild-type (WT) transcript in the patient (P), and
very low levels of the mutant (MT) transcript in the carrier (C). (B) qRT-PCR of ABCA5 transcript levels in the carrier and patient revealed a significant
reduction of levels in patient whole skin, keratinocytes and fibroblasts. A Student unpaired t test was performed with a cutoff P value of 0.05 for
statistical significance. (C) ABCA5 is expressed at strong levels throughout the outer root sheath (ORS) and dermal sheath (arrow) of the human hair
follicle by in situ hybridization using an antisense probe, whereas the sense probe produced minimal background signal. (D) ABCA5 localizes to the
perifollicular dermis, dermal sheath, as well as the hair follicle ORS and inner root sheath (IRS) by immunohistochemistry on paraffin-embedded
sections. (E) The anti-rabbit IgG primary antibody control produced no signal. (F) Immunohistochemistry of ABCA5 on hair follicle end bulbs revealed
strong expression in the dermal sheath and perifolliclar dermis but no expression was observed in the dermal papilla. (G) ABCA5 is endogenously
expressed in plucked scalp hair follicles, microdissected ORS, as well as perifollicular dermis (including dermal sheath), determined by RT-PCR.
Expression was normalized to GAPDH levels. M = marker.
doi:10.1371/journal.pgen.1004333.g002
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(Figure 2D). Importantly, ABCA5 localization in the skin and hair
follicle appears to be conserved between human and mouse, and
its broad expression pattern spans multiple cell lineages, both
within and surrounding the hair follicle. Collectively, these data
suggest a prominent, evolutionarily conserved role for this
transporter in regulating hair growth.
Homozygous loss-of-function of ABCA5, an N-
glycosylated protein
To determine the consequence of the ABCA5 c.4320+1G.C
mutation at the protein level, we performed immunofluorescence
staining on control and CGHT keratinocytes cultured from whole
skin biopsies, and observed a striking reduction in ABCA5
localization (Figure 3A). Immunoblotting revealed the loss of a
215 kDa band corresponding to the full-length transporter in its
glycosylated form, as well as a 187 kDa band, representing the
unglycosylated form [15] (Figure 3B). While the full-length
transporter was predominantly detected in keratinocytes, in
fibroblasts, we observed the expression of a previously reported
truncated variant [20] that produces a half-transporter and a
,100 kDa band. Importantly, the band representing this trun-
cated variant was not detectable in CGHT patient fibroblasts
(Figure S4). Since ABCA5 is a reported glycoprotein possessing
multiple sites for N-glycosylation, we investigated whether the
c.4320+1G.C mutation abolished the glycosylated form of the
protein in patient fibroblasts by incubating total protein in the
presence or absence of the PNGaseF enzyme that removes all N-
glycosyl modifications. Following immunoblotting, we observed
that the band corresponding to the ,100 kDa isoform that is
absent in the proband represents the glycosylated form of the
protein (Figure S4). Since glycosylation is an important post-
translational modification crucial to the proper folding, stability,
subcellular localization and/or even function of many lysosomal
proteins, including ABC transporters [22], this finding suggests a
loss-of-function of both the full- and half-transporters encoded by
ABCA5 in CGHT.
Lastly, to evaluate the consequence of the c.4320+1G.C
mutation on ABCA5 protein localization at the tissue level, we
performed immunofluorescence staining on patient and control
hair follicles and observed a striking reduction of ABCA5 protein
throughout the outer and inner root sheaths of patient hair follicles
in catagen and anagen (Figure 3C). Importantly, loss of ABCA5
expression at the site of pathology for the phenotype further
demonstrates that the c.4320+1G.C mutation results in a
complete loss-of-function allele.
ABCA5 loss-of-function in CGHT keratinocytes perturbs
endolysosomal function
Lysosomes have been reported to play a role in hair cycling,
where mice deficient for lysosomal proteases, cathepsin L (Ctsl)
and lysosomal acid phosphatase 2 (Acp2), have delayed progres-
sion through the hair cycle resulting in periodic hair loss that is
characterized by hyperproliferation of epithelial cells in the hair
follicle and basal layer of the epidermis [23] – [26]. In mice,
Abca5-deficient cells have aberrant processing of autolysosomes
and autophagosomes [15], suggesting a role in lysosome integrity
and/or autophagy, a catabolic process of intracellular digestion
and recycling of organelles [27]. To gain insight into whether
CGHT patient cells possessed intrinsic autolysosomal and/or
autophagic defects, we visualized key markers of these organelles
at the cytological level. LC3, a well-established marker for
autophagosomes, is converted from its cytosolic form (LC3-I) to
a lipidated form (LC3-II) which is able to re-localize and bind
specifically to autophagosomal membranes [27]. A large pool of
LC3-II is degraded upon lysosome-autophagosome fusion, when
the internal content of autophagosomes is destroyed by lysosomal
hydrolases. Immunofluorescence staining against endogenous LC3
revealed an increased number of LC3-positive particles (i.e.,
autophagosome-like structures) in the affected keratinocytes
compared with control, suggesting defects in the autophagy
pathway (Figure 4A).
In order to discriminate between higher levels of basal
autophagy and a defective clearance of autophagosomes, bafilo-
mycin A1 (BAF), a proton pump inhibitor that blocks the
acidification of lysosomes and thus the clearance of autophago-
somes, was added to growing cells 2 hours prior to fixation. BAF
treatment caused a 2-fold increase in the number of LC3-positive
puncta representing autophagosomes and autophagolysosomes in
control keratinocytes, compared to untreated keratinocytes
(Figure 4A, Figure S5A). In contrast, BAF treatment failed to
significantly increase the number of LC3-positive particles in the
patient keratinocytes compared to untreated cells (Figure 4A,
Figure S5A). Furthermore, immunofluorescence staining against
p62, a polyubiquitin binding protein as well as an autophagic
cargo, revealed a strong accumulation of puncta in patient
keratinocytes, further suggesting autophagy defects (Figure 4A,
Figure S5B). Overall, these results indicate that ABCA5 loss-of-
function in CGHT causes defects in the autophagy pathway, and
more specifically, point to an impairment in the clearance of
autophagosomes and autophagic flux under basal conditions.
These results also suggest that the mechanism underlying the
autophagy defects caused by the ABCA5 mutation is a decrease in
lysosomal function.
Because a previous report has shown a role for ABCA5 in the
efflux of cholesterol in macrophages [16], we next tested whether
patient cells exhibit defects in the metabolism and/or transport of
free cholesterol. Additionally, because ABCA5 is localized to the
lysosomal compartment, its mutation may affect the handling of
lipoprotein-derived cholesterol in the endolysosomal system,
perhaps contributing to the dysfunction of these organelles in
patient cells. In order to visualize cholesterol, cells were stained
with filipin, a polyene macrolide antibiotic and antifungal that
fluoresces and detects unesterified free cholesterol [28]. Remark-
ably, the mutation in ABCA5 produced an increase in intracellular
filipin staining compared to controls (Figure 4B, top panel). More
specifically, filipin-positive puncta were observed mostly inside
Lamp1-positive structures (Figure 4B, lower panel) suggesting an
accumulation of free cholesterol in the lumen of endolysosomal
organelles, likely in their intraluminal vesicles. These data suggest
that ABCA5 controls the fate of lipoprotein-derived cholesterol
and that its mutation alters the intracellular traffic of free
cholesterol, somewhat reminiscent of phenotypes observed in
lysosome storage disorders, such as Niemann Pick disease Type C
[29].
Cytogenetic analyses and breakpoint mapping in a
sporadic CGHT case revealed a t3;17 translocation and
cryptic 1.3 Mb deletion encompassing ABCA5
At around the same time we identified the ABCA5 c.4320+1G.
C mutation in homozygous recessive CGHT, we independently
studied this candidate region of chromosome 17 in a sporadic case
of hypertrichosis. We ascertained a patient from Mexico with
hypertrichosis universalis congenita (OMIM145700), whose par-
ents (nonconsanguineous union) and siblings were unaffected. The
patient exhibited excessive overgrowth of terminal hairs on the
extremities, back, chest, and the face. Moreover, histological
analysis of patient hair follicles obtained from a skin biopsy of the
ABCA5 Cholesterol Transporter in Hair Growth
PLOS Genetics | www.plosgenetics.org 5 May 2014 | Volume 10 | Issue 5 | e1004333
lower back revealed the presence of large anagen hair follicles that
penetrate deep within the dermis (Figure S6).
We initially performed karyotype analysis using G-banding of
metaphase chromosomes that revealed a translocation between
chromosomes 3q12 and 17q25, while the other chromosomes
appeared cytogenetically normal. Chromosomal paint with two
FISH probes against chromosomes 3 and 17 verified that no
other chromosomes were involved in this rearrangement
(Figure 5A), and telomere FISH (Figure S7A) confirmed that
no subtelomeric sequences were lost as a result of the
chromosome 17 breakpoint near the q telomere, suggesting an
apparently balanced translocation event. To test whether this
rearrangement segregated in the family, karyotype analysis was
performed on both parents and siblings of the patient, but no
abnormalities were detected, suggesting a de novo chromosomal
rearrangement.
We next performed FISH analysis using BAC clones, which
revealed a cryptic deletion at the breakpoint of chromosome 17,
spanning BAC clones RP11-387O17 (chr17:66,354,485-
66,568,819) and RP11-293K20 (chr17:67,076,187-67,261,438)
(Figure S7B, C). To fine-map the deleted region, we utilized the
Affymetrix 2.7M SNP array, which defined an 849.4 kb cryptic
breakpoint deletion on chromosome 3p12.2 which did not contain
any annotated genes, as well as a 1.3 Mb deletion on chromosome
17q24.2-q24.3 (Figure 5B) that encompassed 7 Ref Seq genes:
members of the superfamily of ATP-binding cassette (ABC)
transporters (ABCA8, ABCA9, ABCA6, ABCA10, ABCA5), mito-
gen-activated protein kinase kinase 6 (MAP2K6) and potassium
Figure 3. ABCA5 protein levels are significantly reduced in CGHT patient keratinocytes and hair follicles. (A) Immunofluorescence
staining on cultured keratinocytes revealed a dramatic decrease in ABCA5 localization in CGHT keratinocytes compared to control (B)
Immunoblotting on protein extracted from control and patient keratinocytes demonstrated loss of a 215 kDa band, which corresponds to the
glycosylated form of the full-length ABCA5 protein, as well as a 187 kDa band, which is the unmodified protein in the patient compared to control.
(C) Loss of ABCA5 localization to the outer root sheath (ORS) and inner root sheath (IRS) within patient hair follicles by immunofluorescence staining.
Affected hair follicles in anagen and catagen were obtained from forearm skin biopsies, and control catagen hairs were obtained from forearm skin
and anagen hairs from the occipital scalp. The anti-rabbit IgG primary antibody control produced no signal. HS = hair shaft; DP = dermal papilla; DS
= dermal sheath.
doi:10.1371/journal.pgen.1004333.g003
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inwardly-rectifying channel J16 (KCNJ16). We confirmed the
1.3 Mb deletion with quantitative PCR (qPCR) on patient and
control genomic DNA using primers specifically designed to
amplify sequences flanking and within the deleted region
(Figure 5C). To determine whether the translocation event
resulted in the disruption of a gene, we searched for transcripts
that mapped to the vicinity of the breakpoints using the Genome
Browser available at the UCSC database (hg19) and subsequently
cloned the breakpoints, which did not reveal any evidence for gene
disruption.
The cryptic 1.3 Mb deletion at chr17q24.2-24.3 leads to a
position effect on the downstream gene, SOX9
Several cases of CGHT have been reported in which CNVs on
chr17q24.2-24.3 that lie within a 2.4 Mb region (Figure S8) have
been identified and hypothesized to cause a position effect on the
SOX9 gene, a well-defined regulator of hair follicle stem cells [30],
[31], which resides 1-2 Mb downstream of these variants. In our
previous report of an autosomal dominant CGHT case, we found
SOX9 expression was dramatically reduced throughout the hair
follicles of patients who possess duplications within the
chr17q24.2-24.3 region [4]. To investigate the possibility that
the 1.3 Mb deletion identified in the present study led to altered
SOX9 expression, we performed qRT-PCR on RNA isolated from
patient and control keratinocytes and observed decreased SOX9
expression in the patient keratinocytes by approximately 2.5-fold
(P.0.001) (Figure 5D). This result is consistent with our previous
findings, suggesting a contribution of decreased SOX9 expression
levels to the excessive hair overgrowth phenotype of CGHT.
Given the association of SOX9 with CGHT and its known role
in regulating hair follicle stem cells and outer root sheath
differentiation [30], [31], we investigated the consequence of
ABCA5 loss-of-function on SOX9 transcripts in the autosomal
recessive CGHT case. Using qRT-PCR on patient and control
keratinocytes, we did not detect a significant difference in SOX9
gene expression (data not shown). While it remains possible that
SOX9 acts upstream of ABCA5, these genes may reside in separate
pathways and utilize distinct mechanisms to contribute to the
CGHT pathology.
ABCA5 mRNA and protein levels are dramatically reduced
in both epithelial and mesenchymal compartments of
the skin and hair follicle in sporadic CGHT
Since the 1.3 Mb deletion we identified encompasses the
ABCA5 locus, and both sporadic and autosomal recessive CGHT
patients possess excessive overgrowth of terminal hairs, we next
investigated the possibility that the second allele in the sporadic
CGHT case may harbor a mutation in the ABCA5 gene.
Therefore, we sequenced all the exons of ABCA5 and ,2 kb
upstream of the gene, but did not find any mutations (data not
shown). To test ABCA5 mRNA expression levels in the sporadic
CGHT case, we performed qRT-PCR in keratinocytes and
fibroblasts cultured from a patient skin biopsy compared to
control, and observed a 3.7-fold decrease in ABCA5 transcript
levels in patient keratinocytes (p,0.0001), and a 2.4-fold decrease
in patient fibroblasts (p,0.0001) (Figure 6A). Immunoblotting in
fibroblasts cultured from patient and control skin biopsies
revealed a striking decrease in ABCA5 protein levels, and
treatment with the N-glycosylase PNGaseF revealed loss of the
glycosylated form of the protein (Figure 6B). Moreover, we found
using immunofluorescence staining on patient and control hair
follicles in catagen and anagen that ABCA5 protein levels were
Figure 4. Homozygous loss-of-function of ABCA5 perturbs lysosome function, resulting in an overall accumulation of
autophagosomes and intracellular cholesterol levels in CGHT keratinocytes. (A) Control and CGHT keratinocytes were cultured in normal
media in the presence or absence of 50 nM bafilomycin, fixed and immunostained. Confocal analysis of LC3 (green), Lamp1 (red) and p62 (blue)
revealed an increased number of LC3-positive particles as well strong accumulation of p62 particles in affected keratinocytes. BAF-treated control
cells possessed a two-fold increase in the number of LC3 puncta, whereas no significant difference was observed in BAF-treated affected cells
(quantified in Figure S5). (B) Control and CGHT keratinocytes were fixed and immunostained for Filipin and Lamp1 (red), which revealed an
accumulation and redistribution of free cholesterol to Lamp1-positive organelles in affected keratinocytes.
doi:10.1371/journal.pgen.1004333.g004
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dramatically reduced throughout the outer and inner root sheath
of the patient hair follicles (Figure 6C). Collectively, these results
suggest that loss of one genomic copy of ABCA5 and its
surrounding regulatory elements severely disrupts expression
from the other allele, and significantly reduces expression levels,
suggesting haploinsufficiency of ABCA5 in the sporadic case of
CGHT.
Discussion
In this study, we investigated the genetic basis of a case of
CGHT using whole-exome sequencing and identified a homozy-
gous recessive loss-of-function mutation in a donor splice site of
ABCA5 that cosegregates with the phenotype. The c.4320+1G.C
mutation leads to loss of ABCA5 expression and localization within
patient keratinocytes, fibroblasts and hair follicles compared to
controls. We found that endogenous ABCA5 is highly expressed in
both epithelial and mesenchymal compartments of the hair follicle,
and that its homozygous recessive loss-of-function is associated
with defective lysosomes, as well as an overall accumulation of
autophagosomes and endolysosomal cholesterol. In a case of
sporadic CGHT, we performed detailed cytogenetic analyses,
breakpoint mapping, CNV analysis and expression studies, which
revealed a 1.3 Mb deletion encompassing the ABCA5 locus and
markedly reduced ABCA5 levels in patient cells and hair follicles.
In inherited hypertrichoses, the mechanism(s) that lead to an
excessive hair overgrowth phenotype observed include an
increased anagen duration, increased hair follicle density, as well
as a vellus-to-terminal transformation, where fine, unpigmented
and unmedullated hairs are stimulated to grow deeper into the
dermis, widen, and become medullated as well as pigmented [1],
[2]. In the case of CGHT, a condition that is present at birth,
Figure 5. Cytogenetic analyses, breakpoint mapping, and copy number variant analysis in a sporadic case of CGH revealed a t3;17
translocation that leads to a cryptic 1.3 Mb deletion of chr17q24.2-24.3, and SOX9 expression is reduced in patient keratinocytes.
(A) Chromosomal paint was performed in a sporadic case of CGHT with commercially available whole chromosome probes for both chromosomes 3
and 17. Note: the probes do not bind to any of the other chromosomes except 3 and 17, and the derivative chromosomes suggesting that this is an
isolated rearrangement between these two chromosomes. DAPI staining was used to visualize the entire chromosomal set (blue). (B) Copy number
variant analysis using the Affymetrix Cytogenetics Whole Genome 2.7M array validated the cryptic deletion that spans 1.3 Mb (red box). RefSeq genes
are depicted as black boxes. (C) Region of chr17q24.2-q24.3, including the genes and 1.3 Mb deletion identified by FISH and CNV analysis. The
quantitative PCR (qPCR) amplicons are indicated as vertical lines, with three amplicons residing within and two flanking the deletion. qPCR was
performed to confirm the deletion on control (C) and affected (A) genomic DNA using relative quantification and the primers listed in the Materials
and Methods. (D) qRT-PCR of SOX9 on RNA from control and affected keratinocytes revealed a 2.5-fold decrease (P.0.001) in expression in patient
keratinocytes. A Student t test (unpaired) was performed with a cutoff P value of 0.05 for statistical significance. All coordinates reference the UCSC
Genome Browser human reference genome hg19.
doi:10.1371/journal.pgen.1004333.g005
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terminal hairs develop at sites of the body where vellus hairs
should be, a developmental event that most likely occurs during
late hair follicle morphogenesis or immediately following. Lanugo
hairs shed in utero and then replaced by vellus hairs are instead
replaced with terminal hairs. In addition to a vellus-to-terminal
transformation, it is likely that the excessive hair overgrowth
phenotype in CGHT is also contributed by an increased duration
of anagen, as the hairs produced across the body are longer than
what is considered normal for the age, race, and gender of the
individual. In the autosomal recessive CGHT case in this study,
we found that the length of hair follicles plucked from the forearm
was significantly greater than that of control hair follicles.
Moreover, histological analysis of patient skin biopsies from
extensor skin of the extremities revealed the presence of large
anagen hair follicles situated deep in the dermis, whereas hair
follicles in anagen were not present in control skin biopsies.
Using several methods of detection, we found that ABCA5 is
strongly expressed in both mesenchymal and epithelial lineages of
the human hair follicle. In mouse hair follicles, we observed the
same expression pattern as in human follicles, and using
immunostaining with a polyclonal ABCA5 antibody, detected
Abca5 localization in the testis and epididymis—positive sites of
Abca5 mRNA expression. In the skin, the mesenchymal expres-
sion (perifollicular dermis, dermal sheath) appears more intense
using formalin-fixed paraffin embedded (FFPE) samples, and the
epithelial outer and inner root sheath expression is more intense
using frozen sections. These differences are most likely artifacts of
antigen accessibility and tissue preservation (organic solvent vs.
cross-linking agent) between the two methods (i.e. dermal and
subcutaneous tissue is better preserved in the FFPE sections).
However, RT-PCR analysis and in situ hybridization demonstrated
strong ABCA5 expression in both epithelial and mesenchymal
lineages, and negative controls for both mRNA and protein studies
yielded no signal.
High levels of ABCA5 localization to the hair follicle IRS is
intriguing, as several genes involving lipid metabolism or transport
possess strong inner root sheath expression and have been
described to underlie human genetic conditions with sparse hair.
P2RY5, encoding an orphan G protein-coupled receptor, is
mutated in patients with autosomal recessive wooly hair syndrome
Figure 6. ABCA5 levels are markedly reduced in patient hair follicles of the sporadic CGHT case. (A) qRT-PCR for ABCA5 on control and
affected keratinocytes and fibroblasts cultured from whole skin biopsies revealed a significant reduction in the patient cells compared to controls. A
Student unpaired t test was performed with a cutoff P value of 0.05 for statistical significance. (B) Immunoblotting on protein extracted from carrier
and patient fibroblasts in the presence or absence of the enzyme, PNGaseF revealed loss of a ,100 kDa band that is the glycosylated form of the
protein in patient fibroblasts relative to controls. (C) Immunofluorescence staining on control and patient hair follicles in the catagen and anagen
stages demonstrated reduced ABCA5 localization throughout the outer root sheath (ORS) and inner root sheath (IRS) of patient hair follicles (compare
to control catagen hair follicle in Figure 3C). HS = hair shaft; HC = hair canal.
doi:10.1371/journal.pgen.1004333.g006
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[32], [33]. Likewise, LIPH encodes the phospholipase A1 family
member that converts phosphatidic acid into lysophosphatidic
acid, and is mutated in patients with autosomal recessive wooly
hair and hypotrichosis [32] – [34]. While the precise mechanism
by which these genes control hair growth remains elusive, we
postulate that the loss of a functional ABCA5 transporter in the
IRS of patient hair follicles may contribute to excessive hair
overgrowth through blocking cholesterol efflux.
Human ABCA5 is also highly expressed in perifollicular dermal
tissue, including the dermal sheath of the hair follicle, and the
number of dermal papilla cells has been shown to be important in
determining hair follicle size in mice [35]. Since patient hair
follicles are larger and longer, we postulate that they may contain
an increased number of dermal papilla cells, but were unable to
directly test this using the skin biopsies we received. Additionally,
the control of hair follicle size is linked to BMP levels in the skin,
where mice overexpressing the BMP antagonist, Noggin, have
enlarged anagen hair follicles [36]. Therefore, ABCA5 transport of
cholesterol may normally limit hair growth and intersect with the
BMP signaling pathway, such that in ABCA5-deficient hair
follicles, the excess buildup of intra-endolysosomal cholesterol
attenuates BMP signaling and recapitulates the enlarged hair
follicle phenotype of the Noggin overexpression mouse model.
Functional studies using Abca5-/- mice would be required to
directly address this.
ABCA5 has not previously been described to be associated with a
human condition, particularly one manifesting a hair or skin
phenotype. In humans, ABCA5 is a reported biomarker for tumor
stem cells in osteosarcoma based on its overexpression, where it is
also highly expressed in melanoma and undifferentiated colon and
ovarian carcinomas [37] – [39]. Consistent with the reported role
of ABC transporters in tumor biology conferring resistance to
drugs and chemotherapy/cancer-related substrates (i.e. phospho-
lipids and cholesterol) [40], ABCA5 upregulation may protect
undifferentiated tumor cells from an intracellular accumulation of
cholesterol and other sterols.
Mutations in ABC transporters have been reported in several
other genetic skin diseases, including ABCA12 in lamellar
ichthyosis type 2 as well as the severe and lethal ichthyosis,
Harlequin ichthyosis, ABCC9 in Cantú syndrome, and ABCC6 in
the connective tissue disorder pseudoxanthoma elasticum (PXE)
[41] – [46]. ABCA12 is expressed in the skin and its deficiency
leads to abnormal lipid transport in keratinocytes, effectively
compromising the skin barrier in a cell-autonomous manner [46].
Recently, dominant missense mutations have been reported in the
ABC transporter gene, ABCC9 in several cases of Cantú syndrome,
a form of congenital hypertrichosis segregating with osteochon-
drodysplasia, distinctive facial features, as well as cardiac defects
[44], [45]. The ABCC9 gene encodes a transmembrane protein
that is a constituent of a potassium channel complex, and
electrophysiology experiments revealed that the missense muta-
tions have gain-of-function or activating effects on the protein, as
they reduce ATP-dependent inhibition of the channel [44].
Interestingly, the ABCC6 gene encodes the multidrug resistance
associated protein 6 (MRP6), and is exclusively expressed in the
liver and kidney, suggesting that mutations lead to ectopic
mineralization within the skin of PXE patients via a non cell-
autonomous mechanism [47]. Importantly, this suggests that
blocking the allocrite, or transported substrate, is the key
determinant of the phenotype, because ABCC6 itself is not
expressed in the skin, yet its loss-of-function manifests with a
cutaneous phenotype.
The allocrite of ABCA5 has remained unknown, however, we
have observed a cholesterol transport defect in human CGHT
keratinocytes and mouse Abca5 has previously been reported to
play a role in cholesterol efflux in macrophages [16]. In rats and
now mice, Abca5 localizes to the Leydig cells of the testis, a
primary site for cholesterol processing and sterol hormone
synthesis [21], suggesting cholesterol is a potential allocrite for
this transporter. Importantly, these reports as well as the
subcellular localization pattern of Abca5 are consistent with our
observation that ABCA5 deficiency in CGHT patient cells causes a
redistribution of free cholesterol and accumulation of this sterol in
the endolysosomal compartment. The resulting sequestration of
cholesterol within these organelles may prevent the delivery of this
essential lipid to other cellular compartments, such as the plasma
membrane, altering their physical and signaling properties.
Alternatively, accumulation of endolysosomal cholesterol may
decrease the overall fitness of these organelles, leading to a
decrease in the degradative capacity of lysosomes and causing
secondary defects in autophagy.
Cholesterol as a covalent modification is required for the
biological activity of several signaling proteins in the Wnt and Shh
pathways that regulate hair follicle morphogenesis and cycling
[48]. Overexpression and knockout mouse models for such
molecules have demonstrated critical roles in hair follicle
patterning and possess phenotypes reminiscent of hypertrichosis.
For example, mice deficient for the Smoothened (Smo) gene in Keratin-
14-expressing epithelia develop de novo and abnormally large hair
follicles from increased mesenchymal SHH signaling [49], and the
overexpression of a stabilized beta-catenin (Ctnnb1) induces early
placode formation as well as an increased density of hair follicles
[50]. We postulate that decreased free cholesterol in ABCA5
deficient CGHT cells may modulate the range and/or morpho-
genetic activity of such proteins either in the epithelium or
mesenchyme during hair follicle patterning. Future experiments
employing lineage-specific deletions of ABCA transporters (i.e.
Abca1, Abca5) will be useful in testing this, where free cholesterol
levels can be measured biochemically and by filipin immunostain-
ing, followed by a thorough analysis of hair follicle morphology
and density. Similarly, a pharmacological approach to deplete
sterols (i.e. cyclodextrin treatment) or block ABCA transporter
activity (i.e. glyburide treatment) in pregnant dams during hair
follicle morphogenesis may provide insight into the role of
cholesterol transport in hair patterning and growth.
In mice, the biogenesis of cholesterol and other lipids has been
shown to play a role in regulating hair growth, as mice deficient for
Stearyl-CoA Desaturase I (SCD1), the enzyme required for the
biosynthesis of monounsaturated fatty acids that compose choles-
terol esters as well as membrane phospholipids and triglycerides,
develop alopecia and possess a sparse hair coat with dry, scaly skin
[51] – [53]. Furthermore, topical treatment of mouse skin with a
cholesterol biosynthesis inhibitor of a sterol precursor leads to hair
loss through the induction of catagen [54]. It remains to be
determined whether Abca5-/- mice possess a hair phenotype, since
this has not been directly examined and hair phenotypes in mutant
mice deficient for several factors can be subtle in the absence of
detailed histological analysis [55]. If hair patterning is aberrant in
Abca5-/- mice, lineage-specific deletions of Abca5 followed by
morphometric and densitometric analysis of hair follicles may
provide insight into the target cell type underlying the pathology in
CGHT.
In the sporadic CGHT case, we found that ABCA5 transcripts
were significantly reduced. One possible explanation for this is that
a trans mechanism for regulating ABCA5 gene expression via an
enhancer or some other regulatory element is in place, such that
deletion of one copy of ABCA5 and its regulatory elements
abrogates gene expression on the other allele. Conversely, ABCA5
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may be imprinted or expressed preferentially from one allele, in
which case, deleting the transcriptionally-active allele would result
in loss of gene expression, thereby recapitulating the phenotype of
the loss-of-function mutation. Alternatively, ABCA5 may be a
dosage-sensitive gene, where altering the copy number is sufficient
to produce a phenotype, but perhaps in a distinct manner from the
loss-of-function mutation identified in the present study, since
carriers are unaffected. Since we observed a decrease in SOX9
expression in sporadic CGHT patient keratinocytes, consistent
with our previous findings in an autosomal dominant CGHT case
[4] and considering the known role of SOX9 in hair follicle stem
cells [30], [31], it is likely that the excessive hair overgrowth
phenotype observed in sporadic CGHT may be the result of
reduced levels of both ABCA5 and SOX9 transcripts. We did not
detect altered SOX9 expression in the autosomal recessive CGHT
case, suggesting either that SOX9 acts upstream of ABCA5 or that
the two genes reside in separate pathways, employing distinct
mechanisms to contribute to the CGHT pathology.
Importantly, this is the first report of the ABCA5 gene to be
associated with a human genetic condition, and the first reported
case of CGHT in which a point mutation in a single gene
contributes to the excessive hair overgrowth phenotype. Collec-
tively, our findings provide insight into the mechanisms by which
ABCA5 may directly or indirectly act to control hair growth at the
subcellular level. While there is evidence to support a role for
ABCA5 in both epithelial and mesenchymal compartments of the
hair follicle, the precise cell type(s) deficient for ABCA5 that is
associated with excessive hair overgrowth remains unclear. In light
of our findings, we postulate that the loss-of-function of ABCA5
during morphogenesis abrogates lysosome function and cholesterol
efflux in hair follicle cells, leading to the aberrant activity of one or
more downstream signaling pathways with crucial, defined roles in
hair follicle induction, development and cycling.
Materials and Methods
Ethics statement
Informed consent was obtained from all subjects and approval
for this study was provided by the Institutional Review Board of
Columbia University in accordance with the Declaration of
Helsinki Principles.
Patient information and materials
In the autosomal recessive CGHT case, the proband is an
eleven-year-old girl with congenital generalized hypertrichosis
segregating with gingival hyperplasia and epilepsy. She was the
product of a full-term uncomplicated pregnancy to a then 18-year
old Yemeni mother whose husband is her first cousin. The
patient’s initial genetic evaluation was at 6 months of age;
chromosome analysis revealed 46, XX normal complement and
SNP arrays revealed multiple regions of homozygosity consistent
with parental consanguinity. Severe hypertrichosis and a low
anterior hairline that merged with the eyebrows were observed,
and excessive body hair was present on the patient’s back and
extremities, as well as on the upper lip, genitalia, and axillary
regions. Hair overgrowth progressed on her face trunk, eyebrows
and eyelashes, and scalp as well as body hair is long and coarse.
The gingival hyperplasia became evident at 18 months of age and
progressed to the extent that it interfered with tooth eruption and
feeding. Partial gum surgical resection was initially performed at 3
years of age and has been performed several additional times over
the past eight years due to excessive gum overgrowth. Extensive
endocrine and metabolic workups have been performed over the
years and all results have been normal.
In the sporadic CGHT case, the patient initially presented to
the clinic at the age of three months. On physical exam, she had
universal hypertrichosis that was accentuated on the extremities,
the back, chest, and the face. As expected, regions that are devoid
of hair follicles including the palms, soles and distal phalanges were
spared. In addition, the patient had unusual facial features,
including a broad base of the nose, widely set eyes, and bulbous tip
of the nose. The parents reported that the excessive body hair was
shed during the first month of life, but then grew back with
increased length. The mother did not report any drug intake,
major illness or trauma during pregnancy, and the girl was born at
full term. There is no history of hypertrichosis in the family.
Extensive physical examination, radiological studies including X-
rays (skull, long bones and hands), laboratory evaluations
(complete blood count, blood chemistry, general urine examina-
tions) and abdominal ultrasonography did not reveal any
abnormalities.
In the autosomal recessive CGHT case, two small punch
biopsies from extensor skin of the extremities, 3–5 cc of blood, in
addition to plucked hairs from the forearm were received from the
proband (II-1) and the unaffected father (I-1). For each individual,
one biopsy was divided into two pieces: one flash frozen for RNA
extraction and the other embedded in OCT for histological and
immunological analyses. The other piece of whole skin was used
for the culturing of keratinocytes and fibroblasts. In the sporadic
CGHT case, a skin biopsy from the back of the affected individual
was obtained; 3–5 cc of blood for DNA and RNA extraction was
also obtained from the patient and her unaffected parents. Control
hair follicles used in expression studies were obtained either from
forearm skin biopsies or from occipital scalp biopsies, designated as
non-human subject research under 45 CFR Part 46 and therefore
IRB exempted for research.
Whole-exome sequencing
Full exome sequencing, bioinformatics analysis (consisting of
initial data processing, base calls, alignments, variant calls,
nucleotide and amino acid conservation, biochemical nature of
amino acid substitution, population frequency, and predicted
functional impact), and filtering based on autosomal and X-linked
dominant and recessive inheritance models was performed on the
autosomal recessive CGHT case using genomic DNA from the
proband (II-1), the unaffected mother (I-2), and the unaffected
father (I-1) through Ambry Genetics (Allso Viejo, CA). Evaluation
of relationships between the proband and unaffected parents was
performed using Short Tandem Repeat markers and samples were
prepared using the SureSelect Target Enrichment System (Agilent
Technologies). In brief, genomic DNA was sheared, adaptor
ligated, and PCR amplified, followed by incubation with the
exome baits, elution, and then PCR amplification. Libraries were
generated, quantified, and hybridized to the Illumina HiSeq 2000
flow cell for paired-end sequencing. Bioinformatics analysis was
used for initial data processing, base calls, alignments as well as
variant calls, and the Ambry Genetics Variant Analyzer tool
(AVA) was used to determine conservation of nucleotide and
amino acids as well as biochemical nature of substitutions,
population frequency, and predicted functional impact. Various
genome databases (Human Genome Mutation Database
(HGMD), HapMap data, Single Nucleotide Polymorphism
database (dbSNP), 1000 genomes) were used to search for
previously described mutations and/or polymorphisms, and co-
segregation studies were performed for candidate gene mutations.
Full-exome sequencing revealed a total of 53 genes (85 alterations),
and filtering based on the following criteria was used: deleterious
nature of the alteration (34 genes, 5 unique alterations), removal of
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alterations clearly unrelated to patient’s phenotype (26 genes, 33
alterations), and further interpretive analysis based on literature
searches for genotype-phenotype correlation resulted in the
selection of 3 genes (3 alterations) for further investigation.
Nucleic acid extraction and sequencing
Genomic DNA was isolated from whole blood of the proband (I-
1) and father (II-1) from the autosomal recessive CGHT case as well
as from the patient with sporadic CGHT. Total RNA was extracted
from forearm skin biopsies as well as from cultured keratinocytes
and fibroblasts from family members I-1 and II-1 using the Qiagen
RNeasy RNA extraction kit and standard methods.
PCR amplification of the exon 32-intron 32 boundary was
performed in the autosomal recessive CGHT case using standard
conditions and the following primers: F: 59-GAACATCTTCA-
GAAGACTGTAAAG-39 and R: 59- GTAATCTGAGGATTC-
CCTAGCATAC -39. To amplify and sequence the mutant ABCA5
transcript, the following primers were used: F (in Exon 28): 59-
GCTGATGGGTTGCCAGTGTTGTGAAG-39, and R (in Exon
33): 59-CACATGTGCTGTTTGGCTTTGGGATC-39. For se-
quencing of ABCA5 in the sporadic CGHT case, 100–200 ng
gDNA was used and primers were designed to flank the intron-
exon boundaries 100–150 bp from each exon.
Quantitative PCR on genomic DNA and quantitative RT-
PCR on RNA
Quantitative PCR was performed on genomic DNA from the
sporadic CGHT case to confirm the 1.3 Mb deletion identified; three
amplicons on chromosome 17 were tested using Relative Quantifi-
cation and the following primers: Amplicon 1 (chr17: 66639201-
66639359, 159 bp): F: 59-TAGATCATTCTCCTAAATGCTCT-
TCC -39, R: 59-GATGCAGCAAAGTTCTCAGGTG -39; Ampli-
con 2 (chr17: 66958719- 66958932, 214 bp): F: 59- GCTGAGCC-
TCTCCTGAAAACTGGACAAC -39, R: 59- GACTCAACTGA-
CATAGGCCATGACAG -39; Amplicon 3 (chr17: 67249799-
67249985, 213 bp): F: 59- GAACATCTTCAGAAGACTGTAA-
AG -39, R: 59- CTGAGGATTCCCTAGCATACTTAGAGC -39.
Amplicon 4 (chr17: 67716661- 67716904, 244 bp): F: 59- AC-
CATGTAAACAAGGAAAACAAC -39, R: 59- CTGAGGATT-
CCCTAGCATACTTAGAGC -39. Amplicon 5 (chr17: 68403395-
68403416, 244 bp): F: 59- CATTTATCCATATGGGAGGTAG -
39, R: 59- AACAGATGTCCAAGAGAGTCAAATC -39. Values
were normalized to the b2M amplicon (161 bp) using the following
primers: F: 59- CACCTATCCCTGTTGTATTTTATCG -39, R:
59-CTCTTTATTTCTGCTGAGGTTTT-39. All coordinates ref-
erence UCSC human reference genome build hg19.
Quantitative RT-PCR was performed on RNA isolated from
whole skin, cultured keratinocytes and fibroblasts as previously
described [5], [10] and as per the manufacturer’s instructions.
Relative quantification using the ddCT method [56] was
performed with the b2M gene as the housekeeping control. The
following primers were used for qRT-PCR assays: ABCA5: F: 59-
GAACCAACTTCAGGCCAGGTATT-39, R: 59-CACATGTG-
CTGTTTGGCTTTGGGATC -39; b2M: F: 59-GAGGCTATC-
CAGCGTACTCCA -39, R: 59- CGGCAGGCATACTCATCT-
TTT-39; SOX9: F: 59- AGTACCCGCACTTGCACAA-39, R: 59-
CCGTTCTTCACCGACTTCCT-39. GAPDH: F: 59-GGAGC-
GAGATCCCTCCAAAAT -39, R: 59- GGCTGTTGTCATA-
CTTCTCATGG-39
Statistical analysis
All experiments were performed in triplicates using materials
from affected, carrier and control individuals. Experiments were
repeated in triplicates, and a Student unpaired t-test was used to
determine statistical significance in qPCR and qRT-PCR exper-
iments with a p value of 0.05 as the cutoff value for significance.
For autophagy experiments, quantification statistical analysis was
performed using a two-tailed, equal variance Student’s t-test. P-
values of ,0.05 (*), ,0.01 (**), ,0.001 (***) were determined to
be statistically significant. The number of cells analyzed per
condition is as follows: control, no bafilomycin: 61 cells; control,
bafilomycin: 63 cells; affected, no bafilomycin: 37 cells; control,
bafilomycin: 43 cells.
Isolation and culturing of human keratinocytes and
fibroblasts from whole-skin biopsies
Keratinocytes and fibroblasts were isolated and cultured from
whole skin biopsies for the proband (I-1) and unaffected father (II-
1) from the first case, and the patient from the second sporadic
CGHT case using the method described in [10].
In situ hybridization and immunohistochemical staining
on whole skin
The DIG labeling system (Roche) was used to construct the
sense and antisense riboprobes for hABCA5 sequences, amplified
using the following primers: hABCA5 (Exon 13–19, 812 bp): F: 59-
GTGCAGAAGGTTTTACTAGATTTAGACA-39, R: 59- GTC-
TGGAACAAGTTTGATGGGAACCAC-39; hABCA5 (Exon 28–
33, 550 bp): F: 59-GCTGATGGGTTGCCAGTGTTGTGAAG-
39, R: 59-CACATGTGCTGTTTGGCTTTGGGATC -39. For
human expression studies, in situ hybridization was performed on
10 mM skin and hair follicle sections from control, carrier and
affected individuals using the methods described in [10].
Immunohistochemistry was performed on formalin-fixed par-
affin-embedded (FFPE) sections of whole skin and hair follicles. In
brief, slides were deparaffinized and rehydrated with a series of
ethanol washes and then with 1X TBS. Antigen retrieval was
performed for 10 minutes in a 1M sodium citrate, pH 6.0
solution heated to 95uC, and then slides were cooled and washed
three times in 1X TBS. Tissues were blocked in either 10%
normal donkey serum (Jackson ImmunoResearch, PA, USA) or
2% fish skin gelatin (Sigma Aldrich, MO, USA) and incubated
with primary antibody in 1X TBS at 4uC overnight. The anti -
rabbit ABCA5 antibody (ab99953, Abcam) was used at a
concentration of 1:200 and the anti -rabbit IgG isotype primary
antibody (Santa Cruz Biotechnologies, CA, USA) control was
used at the same concentration. Slides were then washed with 1X
TBS, incubated with the goat anti -rabbit biotin-conjugated
antibody (1:800 in 1X TBS) for an hour at room temperature,
washed again with 1X TBS and then incubated with the
streptavidin-alkaline phosphatase (AP) tertiary antibody (Invitro-
gen; 1:300 in 1X TBS) for 30 minutes at room temperature. The
SIGMA FAST Fast Red TR/Naphthol AS-MX Tablets (Sigma
Aldrich, MO, USA) were used to develop the slides, which were
then mounted with Dako Glycergel Mounting Medium (Dako,
CA, USA).
Immunofluorescence staining and immunoblotting
Immunofluorescence staining was performed on whole skin
10 mm sections from both human and mouse embedded in
Optimal Cutting Temperature (O.C.T.). Slides were fixed with
50% MeOH/50% Acetone for 10 minutes at 220uC, washed with
1X PBS, and then blocked with 2% fish skin gelatin (Sigma
Aldrich, MO, USA). The ABCA5 (Abcam, ab99953) and anti-
rabbit IgG (Santa Cruz Biotechnologies) primary antibodies were
used at a concentration of 1:200. Slides were then washed,
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incubated with the Alexa Fluor 488 donkey anti-rabbit IgG
(Molecular Probes, Invitrogen) secondary antibody (1:800 in 1X
PBS), mounted with VECTASHIELD mounting medium with
DAPI (Vector Laboratories, Burlingame, CA, USA), and imaged
using a LSM 5 laser-scanning Axio Observer Z1 confocal
microscope (Carl Zeiss).
For autophagy analysis, human keratinocytes were grown to
confluence, seeded on 12 mm coverslips, and then fixed with 4%
paraformaldehyde for 20 min at room temperature. After
permeabilization with 200 mg/ml digitonin (Invitrogen) in PBS
for 10 min, cells were incubated with the specified primary
antibodies for 1 hr at room temperature. Subsequently, cells were
incubated with the appropriate Alexa-Fluor-conjugated secondary
antibodies for 1 hr at room temperature, for cholesterol staining
cells were additionally incubated with Filipin complex (Sigma) for
1 hr at room temperature. Images were acquired by confocal laser
scanning microscopy (Zeiss LSM-700) and analyzed with Zeiss
Zen and ImageJ Software (NIH). The number of LC3-positive
compartments and their surface areas (expressed as number of
pixels per field) were normalized to the number of cells in each
field. The average size was obtained by dividing the surface area of
the LC3-positive compartment (in pixel2) by the number of LC3
puncta. Similar measurements were made for Lamp1 and p62
compartments. Primary antibodies used for immunofluorescence:
mouse anti-LC3 (MBL), guinea pig anti-p62 (Progen), rabbit anti-
Lamp1 (Abcam) mouse anti-Lamp2 (Santa Cruz). Bafilomycin A1
(50 nM, Wako) was added to the media 2 hours prior to cell
fixation.
Immunoblotting was performed using 10 mg total protein
extracted with RIPA buffer/proteinase inhibitor cocktail from
cultured keratinocytes and fibroblasts and SDS-PAGE was used to
separate proteins, followed by a wet transfer to a hybond ECL
nitrocellulose (Amersham, NJ, USA) or PVDF membrane
(BioRad, CA, USA) membrane. All membranes were blocked
with 5% milk for one hour at room temperature and then
incubated with the primary antibodies, ABCA5 (1:500) and beta-
actin (1:1000; Santa Cruz Biotechnologies, CA, USA) diluted in
Washing Buffer (1X PBS 0.1% Tween-20). Membranes were then
washed several times in 15-minute intervals with 1X PBST,
incubated with goat anti-rabbit or mouse- HRP conjugated
secondary antibody (Invitrogen; 1:1000), and then developed with
the SuperSignal West Dura Extended Duration Substrate
(Thermo Scientific, IL, USA).
Cytogenetic analyses
G-banding analysis was performed using standard techniques,
and FISH using chromosomal paint was performed on metaphase
chromosomes obtained from peripheral blood leukocytes (PBLs),
as per the manufacturer’s directions (VYSIS). Sub-telomeric FISH
was performed using a mixture of probes for chromosomes 17q,
17centromere, 9p, and 9q obtained from VYSIS in accordance
with the manufacturer’s instructions. Chromosomes were coun-
terstained with DAPI (VYSIS) and hybridized metaphase chro-
mosomes were viewed using a Nikon microscope fitted with a filter
wheel and Cytovision Applied Imaging software.
Breakpoint mapping and copy number variant (CNV)
analysis
Breakpoint mapping was performed using FISH with BAC
clones in the chromosome 17q24 region. To fine map the deleted
region on chromosome 17q, genome scanning was initially
performed using the Affymetrix 500k whole-genome mapping
array, and then the 2.7M array (Affymetrix) to further examine
CNVs in the region of the breakpoint.
Supporting Information
Figure S1 Histological analysis of CGHT and control hair
follicles by hematoxylin and eosin staining. (A–C) Hematoxylin
and eosin staining of a patient skin biopsy from the forearm
demonstrated that hair follicles are of the terminal type, as they are
medullated, pigmented, and penetrate deep in the dermis. (B)
Enlarged image of a late catagen hair follicle. (C) Magnified image
of an anagen hair follicle situated deep in the dermis (A). Note the
thickness of the outer root sheath compared to control hair follicles
(D–F). (D) Hematoxylin and eosin staining of a control skin biopsy
from the forearm. (E) Magnified image of a hair in catagen. (F)
Enlarged image of the apoptosing strand of the catagen hair
follicle. Note the size of the control hair follicle compared to
patient hair follicles. No anagen hair follicles were present in the
control skin biopsy. DS = dermal sheath; PFD = perifollicular
dermis; IRS = inner root sheath; ORS = outer root sheath; HS
= hair shaft; SG = sebaceous gland; DP = dermal papilla.
(TIF)
Figure S2 Mouse Abca5 localization pattern in the adult testis
and epididymis by immunohistochemistry and immunofluores-
cence staining. (A, B) Immunohistochemistry on formalin-fixed
paraffin-embedded (FFPE) adult mouse testis demonstrated strong
localization of Abca5 to the basal cells of the seminiferous tubules
(arrows in (A)), interstitial space consisting of Leydig cells, and
tunica albuginea (arrow in (B)). (D, E) Abca5 immunohistochem-
istry on formalin-fixed paraffin-embedded adult mouse epididymis
revealed strong localization to the connective tissue, smooth
muscle cells and fibrocytes surrounding the cylindrical epithelium
within the corpus and cauda regions, as well as within the basal
and tall columnar cells of the cauda cylindrical epithelium (E). (C,
F) Testis and epididymis sections incubated without primary
antibody produced no signal. (G–I) Immunofluorescence staining
of Abca5 in the testis and epididymis demonstrated Abca5
localization to the same structures within the testis and epididymis
as did the immunohistochemical staining method.
(TIF)
Figure S3 Mouse Abca5 localizes to the outer and inner root
sheath of anagen hair follicles. (A, B) Immunofluorescence staining
of Abca5 on frozen mouse anagen skin (day 30) sections
demonstrated a signal only within hair follicles (A), specifically
within the outer and inner root sheath (B, C). (E–F) Immunohis-
tochemical staining on formalin-fixed paraffin-embedded (FFPE)
anagen skin sections revealed Abca5 localization to the outer and
inner root sheath, and some signal present in the follicular dermis
including the dermal sheath. No signal was observed on sections
incubated without primary antibody (D, G).
(TIF)
Figure S4 Immunoblotting on protein extracted from carrier
and patient fibroblasts in the presence of absence of the enzyme,
PNGaseF that removes all N-glycosyl modifications revealed loss of
a ,100 kDa band that is the glycosylated form of the protein in
the patient relative to the carrier. b-actin was used as a loading
control.
(TIF)
Figure S5 Quantification of immunofluorescence staining for
LC3 and p62 reveals defective autophagic clearance in CGHT. (A)
The formation of LC3 puncta was significantly increased in
affected vs. control keratinocytes (p,0.05, – Bafilomycin; p,0.01,
+ Bafilomycin) as well as within control keratinocytes +
Bafilomycin vs. – Bafilomycin treatment (p,0.01), but no
significant difference was observed between affected keratinocytes
+ Bafilomycin vs. – Bafilomycin treatment. (B) The formation of
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p62 puncta was significantly increased in affected vs. control
keratinocytes (p,0.01) as well as within control keratinocytes +
Bafilomycin vs. – Bafilomycin treatment (p,0.01), but no
significant difference was observed between affected keratinocytes
+ Bafilomycin vs. – Bafilomycin treatment. A Student t test
(unpaired) was performed with a cutoff P value of 0.05 for
statistical significance and error bars represent the standard
deviation. ImageJ was used for image quantification.
(TIF)
Figure S6 Histological analysis of hair follicles from the sporadic
CGHT case. Hematoxylin and eosin staining of a patient skin
biopsy from the lower back reveals the presence of terminal hair
follicles in the anagen stage. DS = dermal sheath; PFD =
perifollicular dermis; IRS = inner root sheath; ORS = outer root
sheath; HC = hair canal; SG = sebaceous gland.
(TIF)
Figure S7 Telomere FISH and FISH using BAC clones
spanning chromosome 17q24.2-24.3 to detect the 1.3 Mb cryptic
deletion in sporadic CGHT. (A) Telomere FISH was performed to
test possible deletions at the end of chromosome 17q using a
commercially available probe mix for 17q (green), 17 centromere
(green), 9p (green), and 9q (red). Note the presence of the green
signal on the derived chromosome 3 indicating that the telomere
of chromosome 17 was not deleted in the t3;17 rearrangement. (B–
C) FISH using BAC clones on chromosome 17q24.2-q24.3
revealed a cryptic deletion at the breakpoint of chromosome 17.
Metaphase spreads and interphase nuclei show only one signal for
clones RP11-387O17 (green) (B) and RP11-293K20 (green) (C),
which hybridize to the deleted 1.3 Mb portion of chromosome
17q24.2-24.3.
(TIF)
Figure S8 Summary of CNVs within the chr17q24.2-24.3
region identified in autosomal dominant and sporadic cases of
CGHT illustrates that ABCA5 is located in the minimal common
region. ABCA5 (red box) and the other genes in the surrounding
region (black boxes) as well as direction of transcription (arrows)
are indicated. Nature of the variants (duplications, deletions)
previously reported as well as identified in this study is indicated as
well as the sizes and corresponding references. qPCR amplicons
are represented by vertical lines, where two amplicons flank the
1.3 Mb deleted region (red box) and three amplicons lie within it.
Database of Genomic Variants (DGV) alterations are indicated as
gray boxes. All variants lie 1–2 Mb upstream of the SOX9 gene.
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Chapter III.3 Discussion 
In rare, familial conditions, the genetic architecture is often composed of 
one or a few mutations that produce large effects at a high penetrance. The 
majority of such variants can be found in the exome, which represents ~1% of 
the genome (~30 Mb), and mutations affecting protein coding sequence and 
splicing are more likely to produce deleterious effects compared to common and 
non-coding variants. Families containing multiple affected members for a given 
rare trait with a clear Mendelian inheritance pattern may be sufficiently well- 
powered for linkage analysis. This method, combined with sequencing (targeted 
or whole-exome) and genotyping-based studies (i.e. homozygosity mapping) is 
optimal for narrowing the search for shared pathogenic variants with large 
effects. However, this approach is not applicable when only a single or a few 
individuals are affected. Thus, in the absence of positional information and/or a 
known candidate gene, the ability to sequence the exome is a robust and 
unbiased approach that has proven highly fruitful for gene discovery in Mendelian 
disease.  
Characterizing the genetic basis of autosomal recessive and sporadic CGHT 
In Chapter III.1, I characterized the genetic defect underlying a rare, familial 
condition affecting hair growth. The approach I used in this study included whole-
exome sequencing and filtering for rare variants with large effect sizes, taking 
into account the autosomal recessive mode of inheritance resulting from 
consanguinity. To narrow the list of candidate genes, I performed expression 
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analysis in human skin and hair follicle tissues based on the assumption that the 
candidate gene would be expressed at the site of pathology for the phenotype, 
although this does not necessarily hold true for genes that act in a non-cell 
autonomous manner. Importantly, the key factor in this filtering approach was 
genomic position and association with reported CNVs associated with CGHT. 
The identification of a homozygous recessive mutation in a gene previously 
associated with the disease pathogenesis based on genomic position provided 
strong evidence for the ABCA5 gene as a candidate. In the context of function, 
mutations in the family of ABC transporters have been reported in several 
inherited conditions manifesting dermatological phenotypes (described in 
Chapter III.2 and the following section) (QUAZI AND MOLDAY 2011), which provided 
an even stronger case for the involvement of this gene in CGHT pathogenesis.  
To definitively implicate ABCA5 in CGHT pathogenesis, I tested the 
cosegregation of the splice variant with the disease phenotype and found indeed 
that both unaffected parents were heterozygous for this alteration. I characterized 
the effects of the substitution mutation on mRNA splicing by sequencing the 
transcripts and performing qRT-PCR on RNA from both affected and unaffected 
individuals, which revealed aberrant splicing activity that leads to nonsense-
mediated decay and premature translational termination. I validated this finding 
at the protein level using immunoblotting in patient keratinocytes and fibroblasts, 
which revealed a marked decrease in both unmodified and modified 
(glycosylated) forms of the protein. I then investigated the cell type(s) 
synthesizing ABCA5 in the human skin and hair follicle and used several 
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methods of detection, and thoroughly characterized its expression pattern in both 
healthy and affected tissues. Moreover, I investigated whether the ABCA5 
expression pattern was conserved in mammals and using the same methods and 
approach in the analysis of mouse skin and hair follicles, observed strong 
expression in both epithelial and mesenchymal compartments in a pattern very 
similar to that of human hair follicles.  
ABCA5 was previously localized with several other candidate genes with 
CGHT based on its genomic position (SUN et al. 2009; FANTAUZZO et al. 2012) 
but no intragenic mutations were previously reported in the chr17q24.2-24.3 
candidate region or in any other genomic location. The identification of the 
ABCA5 c.4320+1G>C splice site mutation and expression in human skin and hair 
follicles was novel at the time of this report. Concurrent with our studies in the 
autosomal recessive CGHT case, we analyzed a sporadic CGHT case of distinct 
ethnic origin, yet whose excessive hair overgrowth phenotype closely resembled 
that of the autosomal recessive CGHT patient. Considering the rare, sporadic 
nature of CGHT and the previous identification of CNVs in the chr17q24.2-24.3 
region, we used a strategy very similar that described in Chapter II.2 in the 
sporadic XLH case to detect de novo structural variants with large pathogenic 
effects. 
In sporadic CGHT, we sought to identify structural variants using 
cytogenetic methods including G-banding of chromosomes, FISH using BAC 
clones, sub-telomeric FISH, and performed CNV analysis using whole-genome 
mapping (DESTEFANO et al. 2014). These studies led to the identification of a 
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translocation between chromosomes 3 and 17 that was not present in the 
parents of the proband, and our CNV analysis revealed a cryptic 1.3 Mb deletion 
at one of the translocation breakpoints on chromosome 17, which overlapped 
with the CGHT candidate region and spanned ABCA5. In previous analyses 
studying the genetic basis of autosomal CGHT, the Christiano lab identified 
CNVs that created position effects on the downstream gene, SOX9, an important 
regulator of hair follicle growth in humans and mice (discussed in Chapter I.5). 
However, the lab had not previously investigated ABCA5 as a candidate gene 
whose expression/function may be disrupted as a result of these CNVs.  
In Chapter III.2, I postulated that ABCA5 expression and/or function is 
compromised in the sporadic CGHT case, thus, I initially tested whether the 
second allele possessed an intragenic mutation in ACBA5. Using Sanger 
sequencing, I screened the exons and splice site junctions, as well as the 
promoter and regulatory sequences 2 Kb upstream of the gene, but did not 
identify mutations. I then tested the overall consequence of the 1.3 Mb deletion 
spanning ABCA5 on the mRNA and protein levels of the gene, using the same 
approach and methods of detection I used in the previous case. Importantly, 
ABCA5 expression was significantly reduced in patient hair follicles and the N-
glycosylated form of the protein was not detectable, similar to what I observed in 
the autosomal recessive CGHT case, suggesting a loss-of-function mutation. The 
significance of this finding and potential mechanisms of ABCA5 gene regulation 
are discussed in the following sections. 
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Upon the discovery of novel genes associated with a human disease 
phenotype, such as excessive hair overgrowth, the next step is to determine the 
functional consequences and mechanisms by which these genes act to control 
that trait. In Chapter III.2, I tested the consequence of ABCA5 loss-of-function in 
CGHT at the subcellular level based on what was previously known about this 
transporter (discussed in the following section). Studies in mouse models have 
demonstrated a role for Abca5 in lysosome integrity in autophagosome formation 
and cholesterol efflux (KUBO et al. 2005; YE et al. 2010). Therefore, I determined 
whether these processes were defective in autosomal recessive CGHT. I 
performed an initial examination of lysosome function in collaboration with the Di 
Paolo laboratory and used a well-established assay to measure autophagosome 
formation and degradation in control and CGHT keratinocytes (described in 
Chapter III.2) (DESTEFANO et al. 2014). In parallel to these studies, we tested the 
distribution of free cholesterol in CGHT patient and control cells using a filipin 
stain (described in Chapter III.2) to determine whether the overall content and 
localization pattern was affected. Remarkably, the results from both of these 
studies revealed reduced lysosome function, accumulation of autophagosomes 
and their cargo, as well as increased endolysosomal cholesterol in CGHT, further 
demonstrating a loss-of-function mutation in ABCA5. 
In Chapter III.2, I characterized the ABCA5 loss-of-function mutation in 
CGHT and observed subcellular defects in lysosome function and cholesterol 
transport. However, the precise mechanism by which ABCA5 acts to control hair 
growth in health and disease remains unknown. Several in vitro and in vivo 
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functional studies for ABCA5 and other ABC transporters have been performed 
and may provide insightful hints as to what allocrites, or transported substrates, 
are effluxed from the cell in an ABCA5-dependent manner (QUAZI AND MOLDAY 
2011).  In the following sections, I discuss what is currently known about ABC 
transporters in health and disease, the molecules they transport, the evidence for 
ABCA5 in the transport of key lipids and hormones, and how these molecules 
influence human hair growth. Moreover, I propose ongoing and future 
experiments to more thoroughly characterize the allocrite(s) of this transporter 
and the mechanisms by which ABCA5 contributes to the excessive hair 
overgrowth phenotype observed in CGHT. 
 
ABC transporters and their allocrites in human disease 
ABC transporters are key for the movement of a variety of molecules and 
substrates across membrane lipid bilayers, and they possess two 
transmembrane domains, coupling function to ATP hydrolysis via the ATP-
binding cassette motifs, Walker A, signature motif, and Walker B (QUAZI AND 
MOLDAY 2011). Functional studies of ABC transporters in the context of disease 
have demonstrated that the allocrite, or transported substrate, is the key 
determinant of the phenotype, as in some cases of human disease, the 
transporter itself is not expressed at the site of pathology (i.e. in the case of 
ABCC6 in pseudoxanthoma elasticum) (RINGPFEIL et al. 2000).  
Over the past decade, mutations in ABC transporters have been reported 
in several human syndromes (i.e. ABCA1 in Tangier disease, ABCA2 in 
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Alzheimer’s disease, ABCA4 in Stargadt disease, ABCC6 in pseudoxanthoma 
elasticum, ABCA12 in Harlequin ichthyosis, and ABCC9 in Cantu syndrome) 
(QUAZI AND MOLDAY 2011; TARLING et al. 2013), where several of these 
pathologies manifest skin and hair phenotypes and are discussed in Chapter 
III.2. The large majority of ABC transporters are known/thought to mediate the 
ATP-dependent translocation of sterols, lipids, hormones and other related 
compounds, which are crucial for the integrity of a wide variety of biological 
processes. Interestingly, ABCA5 is not well conserved among the ABCA family of 
transporters, possessing a maximal amino acid conservation of 42% among the 
chromosome 17q24 cluster (ABCA5, ABCA6, ABCA8, ABCA9, ABCA10), raising 
the question of whether these differences have biological impacts on protein 
localization and function.  
As previously mentioned, ABCA5 has never been associated with a 
human condition prior to the work presented in Chapter III.2, however, its 
upregulated expression has been observed in several tumors and is a reported 
biomarker for osteosarcoma, melanoma, undifferentiated colon and ovarian 
carcinomas (HEIMERL et al. 2007; OHTSUKI et al. 2007; SAINI et al. 2012). Notably, 
ABC transporters often confer resistance to drugs and chemotherapy/cancer-
related substrates including phospholipids and cholesterol, therefore, it is likely 
that in the context of tumor biology, ABCA5 upregulation may protect 
undifferentiated carcinoma cells from the intracellular accumulation of such toxic 
compounds.   
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Recently, a role for ABCA5 in cholesterol homeostasis was reported in 
neurons and in association with Alzheimer’s disease. ABCA5 stimulated 
cholesterol efflux in neurons and reduced Aβ production in vitro, where the 
process of Aβ formation is thought to be regulated by membrane cholesterol (FU 
et al. 2015). In vivo, ABCA5 expression was found to be elevated in the 
hippocampus of Alzheimer’s disease patient brains, suggesting a novel role for 
this transporter in a neurological human pathology and further supporting the 
hypothesis that ABCA5 mediates the efflux of cholesterol.  
Lipids, hormones and hair growth 
In humans, several inherited hair disorders, including alopecia, autosomal 
recessive woolly hair (ARWH) syndrome, and localized autosomal recessive 
hypotrichosis 2 (LAH2) can be attributed to, at least in part by, defects in 
cholesterol or lipid trafficking (SHIMOMURA et al. 2008; SHIMOMURA et al. 2009a; 
SHIMOMURA et al. 2009b; SHIMOMURA AND CHRISTIANO 2010). Mutations in the 
genes, P2RY5 and LIPH were initially identified from linkage and positional 
cloning studies in families with LAH2 and ARWH, yet at the time of their 
discovery, the precise mechanism by which these structural proteins acted to 
control human hair growth remained elusive. Thereafter, functional studies using 
biochemical assays, mouse models and in vitro cell culture systems 
demonstrated a role for lysophosphatidic acid (LPA) in keratinocyte differentiation 
and hair growth. P2RY5, or LPAR6, encodes a G protein-coupled receptor, which 
acts as a receptor for LPA, and lipase H (LIPH) encodes a phospholipase 
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enzyme that, through a cleavage event, produces LPA (SONODA et al. 2002; 
PASTERNACK et al. 2008). Mice null for Liph recapitulate pathological features of 
human WH syndrome (INOUE et al. 2011). Moreover, these functional studies 
elucidated the downstream effects of LPA signaling and convergent pathways, 
composed of the tumor necrosis factor converting enzyme (TACE), transforming 
growth factor (TGFα), and epidermal growth factor receptor (EGFR) pathways 
(INOUE et al. 2011). 
The peroxisome proliferator-activated receptor gamma (PPARγ) plays a 
crucial role in lipid homeostasis within the skin and hair follicle (DI-POI et al. 
2004), where it has multiple functions in epidermal differentiation, sebocyte 
differentiation and sebaceous gland formation, melanogenesis, dermal wound 
closure, as well as permeability barrier recovery (RAMOT et al. 2015). In mice, 
targeted ablation of PPARγ in the K15 lineage leads to severe defects in hair and 
skin biology, producing a phenotype reminiscent of the human lichen planopilaris 
(LPP) condition characterized by dystrophic hair follicles and follicular plugging, 
massive fibrosis and sebaceous gland atrophy (KARNIK et al. 2009).  
Beyond the context of lipids, hormone synthesis and signaling pathways 
have been described to influence human hair growth. Human patients with 
androgenetic alopecia (male-pattern baldness) progressively lose their hair on 
the front and top of their heads in response to increased androgen levels. 
Similarly, individuals with thyroid defects (both hypo- and hyperthyroidism) 
manifest skin and hair follicle abnormalities, including a thin epidermis and the 
development of alopecia. A recent study in mice examined the contribution of 
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thyroid hormone nuclear receptors TRα1 and TRα2 to hair follicle stem cell 
maintenance and found that mice deficient for these factors exhibit impaired 
epidermal proliferation, wound healing and hair growth, all of which were 
attributed to decreased stem cell activation in the hair follicle bulge (CONTRERAS-
JURADO et al. 2015). Intriguingly, there was an overall increase in the number of 
label retaining cells (LRCs) and this accumulation perturbed Smad/β-catenin 
signaling during stem cell proliferation and mobilization, leading to hair loss.  
There are many other examples of both humans and mice with 
dermatological defects resulting from increased/decreased hormone and lipid 
signaling. Intriguingly, all of the reported defects to date result in hair loss 
(alopecia), raising the question of what factors in these signaling pathways act as 
negative regulators in the hair follicle, such that their removal results in the 
production of more hairs. 
 
Determining the function of ABCA5 in hair growth 
Mouse Abca5 expression has been reported in the brain, lung, heart and thyroid 
gland, where this transporter was found to localize to lysosomes and 
endolysosomal like structures at the subcellular level (KUBO et al. 2005). 
Moreover, this localization pattern was observed for the human and rat 
orthologues, whose cDNAs have been reported to be expressed in the brain, 
lung and testis (PETRY et al. 2003; PETRY et al. 2006).  
Several years ago, Abca5 deficient mice were generated and reported to 
possess defects in lysosome integrity, where the mice developed symptoms of 
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lysosomal storage like disease in the heart and thyroid glands (KUBO et al. 2005).  
During morphogenesis, there were no observable defects, but by postnatal day 
30, symptoms of cardiomyopathy, exophthalmos and collapse of the thyroid 
gland were readily detectable, and the mice died shortly thereafter. Electron 
microscopy analysis of the affected tissues demonstrated an accumulation of 
autophasosome particles, highly suggestive of lysosome defect and consistent 
with the subcellular localization pattern of Abca5 (KUBO et al. 2005).  
Interestingly, exophthalmos is a symptom often observed in Graves’ 
disease in hyperthyroid patients, and Abca5 deficient thyroid glands exhibit this 
defect (BAHN AND HEUFELDER 1993; BAHN 2002). Quantification of thyroid 
hormone levels in the mice revealed that Abca5-/- mice possess markedly 
reduced levels compared to their wild type littermates, contradicting the 
pathological nature of Graves’ disease with increased thyroid levels and 
stimulated TSH receptor activity due to autoantibody production, and suggesting 
a distinct mechanism of action in Abca5-/- mice (BAHN AND HEUFELDER 1993; BAHN 
2002). Importantly, Abca5 localizes to lysosomes, its deficiency is associated 
with the collapse of the thyroid gland, and lysosomes are known to be 
responsible for the secretion of thyroid hormones (RICHARDSON et al. 1996). 
Taken together, this evidence strongly supports a role for ABCA5 in the efflux of 
thyroid hormones, but further functional studies will be required to definitively 
implicate this transporter in the efflux of these and other substrates. 
It currently remains unknown whether Abca5 deficient mice possess an 
excessive hair overgrowth phenotype because this was not directly tested. 
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Further detailed histological analyses in these mice along with additional 
experiments (discussed in Chapter III.2) will elucidate the contribution of Abca5 
to regulating hair growth. Upon a cursory examination of the Abca5-/- mice, it is 
clear that the mutant adult mice possess a full coat of hair, which is in contrast to 
the phenotype observed in human patients with hypo- or hyperthyroidism 
(discussed in the following section) (KUBO et al. 2005). This observation, in 
conjunction with the genetic association of human ABCA5 with CGHT, highlights 
the possibility that Abca5 loss-of-function in mice may promote hair growth rather 
than hair loss.  
In a separate study, the function of Abca5 was interrogated in the context 
of lipid signaling and cholesterol transport (YE et al. 2010), as several other 
members of the Abca family were previously implicated in the transport of 
cholesterol and other substrates and previous reports have demonstrated strong 
expression of Abca5 in the Leydig cells of the testis (a site of sterol hormone 
synthesis) (PETRY et al. 2006). Abca5 was found to function in resident 
macrophage cells of the liver, where its loss-of-function perturbed cholesterol 
efflux and led to the development of atherosclerosis following bone marrow 
transplantation of Abca5-/- macrophages into female irradiated LDLr-/- mice (YE et 
al. 2010). 
Collectively, the evidence based on Abca5 localization at the subcellular 
and tissue levels, as well as phenotypes observed in Abca5-/- mice strongly 
support a role for Abca5 in the endolysosomal system involved in the efflux of 
key sterols, hormones and/or lipids. We postulate that ABCA5 loss-of-function in 
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CGHT perturbs cholesterol and/or thyroid hormone transport during 
morphogenesis, disrupting key signaling pathways required for normal hair 
follicle patterning, morphogenesis and growth. 
 
Ongoing and future experiments 
Several in vitro and in vivo studies can be performed to test the role of ABCA5 in 
CGHT disease pathogenesis and identify the allocrite(s) whose perturbed 
transport mediates phenotypic effects. Using the Abca5-/- mouse model, the 
morphology, distribution and length of hairs can be measured using histological 
and morphometric analyses. Although a hair phenotype was not initially reported 
in these mice, hair phenotypes in mutant mice deficient for several factors can be 
subtle in the absence of detailed histological analyses. It is important to test all 
hair types (pelage hairs, vibrissae, tail hair), as they are distinct from one another 
in the context of morphology and genetic control (DUVERGER AND MORASSO 2009). 
Moreover, it is known that mouse models for human hair conditions do not 
always possess the same (or expected) phenotype. For example, FGF5 
mutations cause excessive hair overgrowth of mouse pelage hairs but only affect 
the eyelashes in humans. Likewise, the Koala mouse model has excessive hair 
overgrowth on the ears and muzzle, in contrast to the human Ambras syndrome 
patients. (FANTAUZZO et al. 2008; HIGGINS et al. 2014). Inducible overexpression 
of Abca5 during morphogenesis can be performed followed by phenotypic 
analysis to determine whether these mice exhibit features associated with 
136 
mutations in cholesterol and/or thyroid hormone transport-related proteins in 
mice, leading to hair loss. 
To determine the contribution of Abca5 to hair growth in one particular 
lineage (i.e. epithelial), conditional deletion of Abca5 can be performed in mice by 
crossing a floxed allele with a tissue-specific driver (i.e. K14 for epithelial cells of 
the skin and hair follicle). Testing the contribution of sterols in the skin during or 
following morphogenesis can be accomplished by topical administration of 
cyclodextrin, followed by histological analyses. Moreover, blocking ABCA 
transporter activity using glyburide treatment or other pharmacological inhibitors 
will elucidate whether the transporter positively or negatively regulates hair 
growth. Several biochemical assays and methods that have been previously 
used to identify the allocrites of other transporters include fluorescence 
anisotrophy using purified recombinant protein (measure binding affinity to 
transporter extracellular domain), in vitro transport assays using semi-
permeabilized cells, screening peptide libraries, and trapping transported 
peptides in the ER via glycosylation and ATP-independent binding assays 
(ANDROLEWICZ et al. 1993; HENDERSON et al. 1993; SUN et al. 1999; BISWAS-FISS 
et al. 2012). Given the evidence for ABCA5 in transporting cholesterol and 
thyroid hormones, these substrates can be directly tested and validated in  
Abca5-/- cells combined with competition assays. Additional functional studies 
using human patient materials can provide insight into the role of ABCA5 in 
thyroid hormone and cholesterol transport by measuring the overall levels of 
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these molecules and their subcellular localization patterns in ABCA5 loss-of-
function cells those rescued with the full-length coding sequence of ABCA5.  
A possibility to be considered in the pathogenesis of autosomal recessive 
CGHT is the contribution of other rare variants and their genetic interactions with 
ABCA5 to the overall disease phenotype. A plausible candidate that fits with this 
hypothesis is the DGKZ gene that encodes diacylglycerol (DAG) kinase zeta and 
whose protein phosphorylates phosphatidic acid, plays important roles in lipid 
signaling, and is implicated in neurological diseases (PACHECO AND JOPE 1996; 
VAN BLITTERSWIJK AND HOUSSA 2000). The missense mutation 
(c.1678C>T(p.P560S)) cosegregated with the CGHT disease phenotype in a 
homozygous recessive manner and in my initial expression analysis, I observed 
detectable levels of DGKZ transcripts in human skin and hair follicles. Of interest, 
the autosomal recessive CGHT patient also has epilepsy, and mice deficient for 
another DAG kinase gene (Dgke) exhibit features associated with epilepsy 
(RODRIGUEZ DE TURCO et al. 2001). This association, in conjunction with the 
recently reported role of ABCA5 function in the brain (FU et al. 2015), it is likely 
that the neurological phenotypes associated with CGHT in this patient are 
attributed to both ABCA5 and DGKZ loss-of-function mutations. This hypothesis 
can be tested in these mouse models, generating double mutants and compound 
heterozygotes, as well as by performing in vitro rescue experiments. 
In the context of gene regulation, we found in the sporadic CGHT case 
that ABCA5 levels were significantly reduced to those observed in the autosomal 
recessive CGHT case, suggesting the loss-of-function by haploinsufficiency. 
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Plausible mechanisms to explain this phenomenon are discussed in Chapter III.2 
and include monoallelic expression of this gene/locus, imprinting, trans regulatory 
interactions between homologous chromosomes, and dosage sensitivity. Testing 
monoallelic expression can be accomplished by overlaying SNP data with 
transcriptome sequencing (SKELLY et al. 2011), and in the context of imprinting, I 
examined the list of genes identified as being maternally imprinted from a screen 
performed in Dnmt3L mutant mice and did not identify ABCA5 as an imprinted 
gene (SCHULZ et al. 2010). Trans regulatory interactions can be identified using 
the Chromosome Conformation Capture (3C) technology with high-throughput 
sequencing, and differences in chromatin states between alleles can be 
determined using the Formaldehyde Assisted Isolation of Regulatory Elements 
(FAIRE) assay (SIMON et al. 2012), combining this ChIP-based approach with 
SNP genotyping to distinguish alleles.  
Lastly, dosage sensitivity of ABCA5 could be determined through the use 
of mouse models comparing the phenotypes between Abca5+/- to Abca5+/+ and 
Abca5-/- mice, and also by deleting the locus from one allele and assessing the 
downstream consequences. In sporadic CGHT, an analysis of lysosome function 
and cholesterol transport could provide insight as to whether deletion of one copy 
of ABCA5 is sufficient to produce a phenotype. However, unaffected related 
family members in the autosomal recessive CGHT case harbor one copy of the 
loss-of-function allele and do not have hypertrichosis, suggesting distinct 
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Chapter IV.1 Preface 
In the study of non-Mendelian, complex disorders, the methods and 
approaches used to identify pathogenic variants are distinct from those employed 
for Mendelian or monogenic diseases. Several reasons why common disorders 
are not amenable to conventional approaches include the lack of a clear 
inheritance pattern within families displaying the trait, the involvement of many 
variants that are more common within the general population and produce small 
effects, and the contribution of several environmental factors to the penetrance 
and severity of the disease. Therefore, the informative value of parametric 
linkage studies and genome-wide scans in family cohorts was limited because of 
the difficulty in identifying multiplex families in which the disease segregated. As 
a result, the most powerful approach to study these common conditions was to 
search for loci that are significantly associated across a population of unrelated 
patients (rather than shared within a family). 
Genome-Wide Association Studies (GWAS) were developed to identify 
common variants using a genotyping-based approach in case-control cohorts 
and identified new susceptibility loci. The success of a GWAS depends largely on 
the nature of the disease phenotype, variation, as well as sensitivity and 
specificity in the diagnosis. While the GWAS approach has been widely used for 
hundreds of complex diseases and traits, it operates under the assumption that 
these diseases are caused by many common variants with small effects and are 
present at a frequency of 5% or greater in the general population. As such, the 
proportion of heritability of a disease that has been accounted for by identified 
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variants identified in GWAS has been relatively small, highlighting the limitations 
of this method in detecting the rarer variants with larger effects, structural 
variants, and genetic interactions we now know contribute significantly to the 
“missing heritability.” Interestingly, the majority of susceptibility variants identified 
from GWAS reside within non-coding, intergenic DNA, suggesting that these 
variants predominantly exert pathogenic effects by disrupting regulatory regions 
and transcription factor binding sites.   
To circumvent the limitations of a GWAS, a robust and comprehensive 
approach must be used to detect the pathogenic variants in GWAS studies, and 
somehow incorporate this information into an understanding of the genetic 
architecture of the disease. A major challenge is how do we know what loci are 
biologically interesting and worth following up on? For genomic regions 
significantly associated with a trait, it is optimal to confirm these loci in an 
independent replication study, and subsequently, in a meta-GWAS analysis. 
Moreover, it is key to have some functional knowledge of the genes 
encompassed in the LD blocks and whether there is biological relevance to the 
disease phenotype. This information can be gathered from a variety of sources 
including prior knowledge of the gene(s) associated with the trait (family-based 
linkage studies, CNV analysis), mutations identified in similar Mendelian 
disorders (if applicable), pathological features of the disease that correlate with 
the dysregulation of certain genes and signaling pathways, eQTL analysis, and 
studies in mouse models for the disease. Based on this information, susceptibility 
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loci can then be prioritized for targeted deep resequencing to capture all the 
coding and non-coding variants in the candidate GWAS regions.  
The completion of the Human Genome Project and development of next-
generation sequencing methods have been instrumental in the recent 
implementation of the functional genomics approach to studying complex human 
disorders. Moreover, the ENCODE and Roadmap Epigenomics projects have 
greatly facilitated the identification of novel DNA regulatory elements, such that 
functional genomics studies can be used to test the consequences of disease-
associated variants in these regions (described in Chapter IV.4). Importantly, this 
approach has successfully been used for several complex genetic disorders to 
elucidate the mechanisms by which non-coding DNA can influence the regulation 
of gene expression levels (HUTCHINSON et al. 2014) (VERLAAN et al. 2009). 
In the work described in Chapter IV, we functionally decoded the genetic 
architecture of the ULBP3/6 locus in alopecia areata using targeted 
resequencing, identification of pathogenic variants, and determined their 
functional consequences. The Christiano lab previously performed the first 
GWAS in AA and identified eight regions of the genome that cluster into discrete 
LD blocks. As is observed for most autoimmune disorders, the HLA region was 
identified as the most significantly associated locus, but outside this region is a 
novel locus on chromosome 6q25.1 encoding the ULBP3/6 genes that is strongly 
associated with the disease. Importantly, the ULBP genes encode ligands for the 
cytotoxic T cell receptor, NKG2D that has previously been implicated in AA 
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pathogenesis, and these ligands possess strong upregulation in human AA 
lesional hair follicles.  
In Chapter IV.2, we replicated the findings from the initial GWAS study 
and identified new loci associated with the disease. We reported a replication 
study and meta-GWAS analysis conducted for AA that validated the previous 
associations, and moreover, identified two novel loci associated with AA. This 
work was performed in collaboration with Dr. Regina Betz and her research 
group at Bonn University (Germany) who provided the independent population 
cohorts (controls and patients) of European ancestry (author contributions 
described in Chapter IV.2). In the work described in Chapter IV.2, I characterized 
a new locus identified on chromosome 2q13, encoding the BCL2L11 (BIM) gene, 
that functions in apoptosis and the immune system. I first determined its 
expression levels in healthy human immune cells. To determine whether this 
gene was expressed in the hair follicle, I characterized the expression pattern of 
BIM in both human and mouse hair follicles using immunofluorescence staining, 
and performed immunohistochemical stains on the C3H/HeJ mouse model to 
detect BIM localization in AA lesional hair follicles. Based on my findings and the 
known role of this pro-apoptotic protein in the immune system, I postulated that 
dysregulation of BIM in affected individuals may contribute to the premature entry 
of AA hair follicles in dystrophic catagen that is characterized by massive 
apoptosis during active disease. 
In parallel with these studies, we also defined the immunological features 
underlying both human and mouse AA, based on the GWAS and meta-GWAS 
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findings implicating genes of both the adaptive and innate immune system. In 
Chapter IV.3, we collaborated with Dr. Raphael Clynes and members of his 
laboratory to investigate the role and contribution of the NKG2D-ULBP signaling 
pathway to AA disease pathogenesis. Initially, we used the mouse model to 
characterize the immunophenotype of the immune infiltrate in lesional hair 
follicles using immunofluorescence staining, FACS and cytotoxicity assays. 
Importantly, we utilized the grafting method in the C3H/HeJ mouse model to 
induce autoimmune hair loss, which allowed us to study disease prevention as 
well as reversal. To determine the functional requirement of CD8+NKG2D+ T 
cells, we performed subcutaneous injections of lymph node cells in unaffected 
and affected AA mice and determined that these cells were necessary and 
sufficient to induce disease pathogenesis. These experiments were performed by 
Drs. Zhenpeng Dai, Luzhou Xing and Ali Jabbari.  
In Chapter IV.3, I characterized the molecular profiles of human and 
mouse AA using microarray and RNA-seq technologies for transcriptional 
profiling on affected vs. unaffected skin. In this work, I analyzed the expression 
data from the mouse model and validated the dysregulation of key immune 
genes in these pathways using RT-PCR and immunofluorescence staining. We 
next used bioinformatics tools and statistical analyses to distinguish three 
primary gene expression signatures that included the interferon response genes, 
markers of cytotoxic T lymphocytes, and gamma chain cytokines, where Drs. 
Lynn Petukhova and Jane Cerise performed this work. Importantly, this 
transcriptional information correlated with genetic data from the GWAS, and 
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allowed us to define the signaling cascade involving the NKG2D-ULBP signaling 
pathway to identify the downstream genes and pathways as targets for 
therapeutic interventions. Using small molecule inhibitors (the FDA-approved 
drugs Tofacitinib and Ruxolitinib), we blocked the JAK/STAT signaling pathway in 
the mouse model to both prevent as well as reverse disease pathogenesis, and 
these experiments were conducted by Drs. Zhenpeng Dai, Luzhou Xing and Ali 
Jabbari. 
Considering the findings obtained from our functional studies in the mouse 
model, we next tested whether targeting the JAK/STAT pathway with these small 
molecule inhibitors could treat alopecia areata in human patients. Thus, we 
conducted a pilot clinical trial using Ruxolitinib and successfully treated three AA 
patients with Drs. Ali Jabbari and Julian Mackay-Wiggan obtained the patient 
samples for this study and performed the analyses. Importantly, our integrative 
approach to define the molecular pathology of AA was greatly informed from the 
initial GWAS findings, which implicated key genes and signaling pathways in 
disease pathogenesis. Furthermore, our expression analyses and genome-wide 
transcriptional profiling, together with our functional studies in the mouse model 
led to the identification of downstream targets as therapeutic interventions for 
both disease prevention and reversal in mouse and human AA.  
 In Chapter IV.4, I investigated the central question of what genes and 
mechanisms control spatiotemporal expression in the context of hair follicle 
immune privilege. Informed from the GWAS results and functional studies 
performed in mouse and human AA, I focused my studies on the ULBP3/6 locus 
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on chr.6q25 and sought to characterize the pathogenic variants and underlying 
mechanisms by which they contribute to dysregulation of the ULBP3/6 genes in 
AA lesional hair follicles. In Chapter IV.4, we performed targeted deep 
resequencing of this locus, and using functional genomics, identified common 
and rare variants that are enriched on the GWAS risk haplotypes. We annotated 
the non-coding variants using ENCODE and RegulomeDB to determine whether 
they interrupted TFBS and/or regulatory regions. These studies and analyses 
were conducted by Drs. Lynn Petukhova and Esther Drill. Given the emerging 
view that the genetic architecture underlying common disease is composed 
largely of non-coding variants, and that rare variants driving genetic associations 
produce larger effects than the common variants, I focused my subsequent 
studies on the rare, non-coding variants identified at the ULBP3/6 locus by 
targeted deep sequencing. 
In the work presented in Chapter IV.4, I aimed to characterize three rare 
and novel non-coding variants we identified that reside within CTCF binding sites 
downstream of ULBP6. I postulated that non-coding variants contribute to 
dysregulated transcription factor binding, regulatory activity, and/or long-range 
interactions at the ULBP3/6 locus. To test this hypothesis, I examined 
endogenous CTCF binding at the ULBP6 region in vivo using ChIP-PCR on 
healthy human scalp dermal fibroblasts, and thereafter characterized the 
regulatory activity of this region using luciferase reporter assays. I next tested the 
effects of the rare, non-coding variants on reporter activity, and investigated 
whether these variants can disrupt CTCF binding by overexpressing a tagged 
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form of CTCF and measuring reporter activity in vitro. To determine whether 
these variants created novel transcription factor binding sites, I performed an in 
silico analysis of the ULBP6 control and AA sequences.  
 In the context of alopecia areata and the loss of immune privilege in the 
hair follicle, I postulated that the ULBP3/6 locus may be spatiotemporally 
regulated and engages in CTCF-mediated long-range interactions. Consistent 
with my hypothesis, we found that there are several clustered sites of CTCF 
binding enrichment across the locus and that the non-coding variants overlap 
with interacting sequences from ENCODE CTCF-mediated Chromatin Interaction 
with Paired-End Tags (ChIA-PET) experiments. Future studies will test whether 
this candidate region is capable of engaging in long-range interactions in vitro, 
and identify CTCF-mediated long-range interactions at this locus that may be lost 
in human AA lesional hair follicles.  
Collectively, our strategy and approach to define the complex genetic 
architecture of alopecia areata was successful in identifying key genes and 
regulatory pathways that can be targeted to treat disease. Moreover, using 
functional genomics to study the ULBP3/6 locus allowed us to interrogate the 
effects of disease-associated rare, non-coding variants and identify the 




Chapter IV.2. Genome-wide meta-analysis in alopecia areata resolved HLA 
associations and reveals two new susceptibility loci (Manuscript #3). 
In this study, I characterized the expression of BIM, GARP, and LNK in human 
immune cell populations, including T cells, B cells, monocytes, NK cells, and 
PBMCs, as well as scalp hair follicles using RT-PCR. I then analyzed the 
expression pattern of BIM in human hair follicles as well as mouse hair follicles in 
anagen, catagen and telogen using immunofluorescence staining and confocal 
microscopy. Furthermore, I performed immunofluorescence staining for BIM on 
C3H/HeJ AA affected and unaffected hair follicles.  
 
Chapter IV.3. Genome-wide meta-analysis in alopecia areata resolved HLA 
associations and reveals two new susceptibility loci (Manuscript #4). 
In this work, I performed microarray expression profiling on total RNA isolated 
from C3H/HeJ affected and unaffected skin and analyzed the gene expression 
data. I validated dysregulated expression of key transcripts in immune signaling 
pathways using qRT-PCR as well as immunofluorescence staining on AA 
affected and unaffected skin.  
 
Chapter IV.4. Functional genomics at the ULBP6 locus identifies a role for 
CTCF variants in alopecia areata (Manuscript #5). 
In this study, I analyzed the function of the three rare variants we identified from 
targeted deep resequencing that reside within CTCF binding sites. I performed 
Sanger sequencing for these variants on patient DNA samples and cloned both 
control and AA sequences (250 bp region) into a reporter vector to characterize 
the regulatory activity of this region. I determined endogenous CTCF binding at 
the ULBP6 locus using ChIP-PCR on human dermal fibroblasts, and in these 
same cells, overexpressed a tagged form of CTCF in the presence of the AA rare 
variants to test changes in binding affinity. Moreover, I performed in silico 
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Genome-wide meta-analysis in alopecia areata
resolves HLA associations and reveals two new
susceptibility loci
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Alopecia areata (AA) is a prevalent autoimmune disease with 10 known susceptibility loci.
Here we perform the first meta-analysis of research on AA by combining data from two
genome-wide association studies (GWAS), and replication with supplemented ImmunoChip
data for a total of 3,253 cases and 7,543 controls. The strongest region of association is the
major histocompatibility complex, where we fine-map four independent effects, all implicating
human leukocyte antigen-DR as a key aetiologic driver. Outside the major histocompatibility
complex, we identify two novel loci that exceed the threshold of statistical significance,
containing ACOXL/BCL2L11(BIM) (2q13); GARP (LRRC32) (11q13.5), as well as a third nom-
inally significant region SH2B3(LNK)/ATXN2 (12q24.12). Candidate susceptibility gene
expression analysis in these regions demonstrates expression in relevant immune cells and the
hair follicle. We integrate our results with data from seven other autoimmune diseases and
provide insight into the alignment of AA within these disorders. Our findings uncover new
molecular pathways disrupted in AA, including autophagy/apoptosis, transforming growth
factor beta/Tregs and JAK kinase signalling, and support the causal role of aberrant immune
processes in AA.
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A
lopecia areata (AA) is one of the most prevalent
autoimmune diseases, with a lifetime risk of 1.7%
(ref. 1), and is the most common cause of hair loss in
children. In AA, aberrant immune destruction is targeted to the
hair follicle, resulting in non-scarring hair loss that typically begins
as patches, which can increase in size and coalesce and may
progress to cover the entire scalp (alopecia totalis), and body as
well (alopecia universalis). Disease prognosis is unpredictable and
highly variable. Its aetiologic basis has remained largely undefined,
creating barriers to the development of effective therapeutic
strategies and resulting in an enormous unmet medical need2,3.
Our first GWAS in AA identified associations in eight regions
of the genome, which were subsequently confirmed in indepen-
dent candidate gene studies4–7. Associated loci outside the human
leukocyte antigen (HLA) highlight particular immune response
pathways and also implicate genes expressed in the hair follicle.
For example, several regions contain genes with Treg functions,
including IL2RA, IL2/IL21, CTLA4 and Eos, whereas ULBP3/
ULBP6 implicate NKG2D-mediated cytotoxic T cells. Within the
hair follicle, expression of STX17 suggests a role for end-organ
autophagy, while PRDX5 implicates oxidative stress. A combined
analysis of this GWAS and a subsequent replication study led to
the identification of IL13/IL4 and KIAA0350/CLEC16A as new
gene loci5.
Here we perform a meta-analysis to expand our sample size,
and identify two new loci that exceed our threshold for
genome-wide significance and a third locus that is nominally
significant. We identify transcripts and/or protein for candidate
genes at all three loci in disease-relevant tissues. We perform
imputation and fine-mapping of the HLA, identifying four
independent associations that implicate HLA-DRb1. Finally, a
cross phenotype meta-analysis (CPMA) of our data with
published results from seven other autoimmune diseases identify
molecular pathways shared by AA and one or more other
disorders.
Results
In this study, we have increased our cohort size and performed a
combined analysis of two GWAS using Illumina Human660W-
and Omni1-Quad BeadChips, analysing a total of 2,489 cases
and 5,287 controls ascertained in the US and Central Europe
(Supplementary Table 1). Association analyses are performed
with logistic regression. In a meta-analysis of these data, nine of
the previously implicated regions exceeded statistical significance
(Po5 10 8), with STX17 achieving nominal significance
(rs10124366; P¼ 1.09 10 5) (Fig. 1; Supplementary Data 1).
First, to resolve the major histocompatibility complex (MHC)
association signal (P¼ 4.91 10 58 for the best single-nucleo-
tide polymorphism (SNP), rs9275516), we used a published
imputation and analysis protocol to perform fine-mapping
(Supplementary Data 2)8. Conditional analysis revealed four
independent variants located at the classical HLA-DRA and HLA-
DRB1 genes. The most significant variant was amino-acid
position 37 in HLA-DRb1 (omnibus P value¼ 4.99 10 73).
Of the five possible amino acids at this position, Leu (odds ratio
(OR)¼ 1.56), Tyr (OR¼ 1.54) and Phe (OR¼ 1.19) conferred a
higher risk of AA, whereas the other residues conferred lower risk
(OR for Asn¼ 0.42; OR for Ser¼ 0.74). Adjusting for the effects
of HLA-DRb1 amino-acid position 37, we found an independent
association due to an intronic SNP of HLA-DRA, rs9268657
(OR¼ 0.63, P value¼ 4.48E 41). Functional annotation of this
SNP and its close proxies (R240.9) reveal that they influence
expression levels of HLA-DRB1 (ref. 9). Adjusting for
both HLA-DRb1 amino-acid position 37 and rs9268657,
we identified another independent association for the classical
allele HLA-DRB1*04:01 (OR¼ 1.64, P value¼ 1.76 10 12),
confirming previous associations in candidate gene studies10,11.
Finally, adjusting for HLA-DRb1 amino-acid position 37,
rs9268657 and HLA-DRB1*04:01, amino-acid position 13 in
HLA-DRb1 was also significant (P value¼ 4.57 10 16). Of the
six possible alleles at this position, three increased risk (Tyr,
OR¼ 1.41; Ser, OR¼ 1.35; Phe, OR¼ 1.09), two are protective
(His, OR¼ 0.57; Gly, OR¼ 0.50) and one demonstrated no effect
(Arg, OR¼ 0.98) (Supplementary Table 2). Further rounds of
conditional analyses yielded no additional significant results
(P42.11 10 6).
Collectively, these four independent associations in the MHC
implicate HLA-DR as the primary risk factor in AA, presumably
through antigen presentation, similar to other immune-mediated
diseases12. For example, HLA-DRb1 amino-acid positions 13 and
37 contribute to P4 and P9 peptide-binding pockets, respectively;
the disease associations of HLA-DRB1*04:01 are thought to be
driven by the shared epitope (amino-acid residues 70–74)12,
which also occur within the peptide-binding cleft (Fig. 2).
Polymorphic residues within peptide-binding pockets of
HLA-DR influence binding affinities of peptides, and thus may
shape the repertoire of autoantigens capable of triggering or
perpetuating disease.
Next, we performed replication of SNPs in functionally
relevant loci that achieved suggestive evidence for association
in the meta-analysis (5 10 84P41 10 5), utilizing an
independent cohort of Central European ancestry. The
Immunochip was used to genotype 318 cases and 1,688 controls
and a Sequenom assay was used to genotype 85 SNPs not
included on the Immunochip in a cohort of 764 cases and
568 controls. This analysis identified statistically significant
associations in two novel genomic regions: chromosome 2q13
containing ACOXL and BCL2L11 (rs3789129, P¼ 1.51 10 8,
ORA¼ 1.3), and chromosome 11q13.5 containing C11orf30
and LRCC32 (rs2155219, P¼ 1.25 10 8, ORT¼ 1.2) (Table 1;
Supplementary Data 3).
The association signal at chromosome 2q13 is located within
an intron of ACOXL, and the region of association extends to
include BCL2L11 (Fig. 3). This region has been implicated in
GWAS for two other autoimmune diseases: immunoglobulin-A
nephropathy and primary sclerosing cholangitis13. ACOXL
belongs to the acyl-coenzyme A oxidase gene family. While
other family members play well-studied roles in peroxisomal
beta-oxidation, very little is known about the function of this
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Figure 1 | Manhattan plot for genome-wide tests of association in
meta-analysis. To conduct a meta-analysis across two GWAS, genotypes
were imputed for each data set yielding 1.2 million SNPs. Standard
association analysis with logistic regression including PC covariates was
performed within each cohort and results were combined with s.e. weighted
meta-analysis.
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gene. BCL-2-like 11, also known as BIM, is a member of the
BCL-2 protein family and contains a Bcl-2 homology domain 3
(BH3) that interacts with other members to act as a pro-apoptotic
factor. BIM has been widely studied in the context of apoptosis of
immune cells, and has also been implicated in apoptosis of
melanocytes14. More recently, data have emerged that implicate
BIM in the destruction of some end-organs in autoimmune
diseases, such as pancreatic beta cells in type 1 diabetes15.
Furthermore, BIM has also been shown to regulate autophagy16,
adding to growing evidence for the importance of this process in
AA as recently shown by functional studies of STX17 (refs 17,18).
BIM is widely expressed in multiple cell types, including
immune-related, epithelial and hair follicle cells19. We first
performed reverse transcription (RT)–PCR analysis of BIM
expression in immune cells and scalp hair follicles (SHFs). We
detected BIM transcript in whole-peripheral blood mononuclear
cells (PBMCs), including T, natural killer and B cells, and
monocytes (MCs) (Fig. 4a). In plucked human SHFs, we observed
expression of an alternative splice isoform, BIM-S, the most
pro-apoptotic variant (Fig. 4a)20,21. To characterize protein
localization within hair follicles, we performed immuno-
fluorescence staining on both human and mouse hair follicles.
In the human hair follicle, BIM is highly expressed in the bulb of
the hair follicle, especially within the matrix cells, in a pattern
strikingly restricted to early catagen, but not anagen or telogen
(Fig. 4b). The hair bulb matrix is the principal location of
differentiated, pigment-producing melanocytes, which are
postulated to undergo apoptosis during catagen22. In mouse
hair follicles, BIM localized to the apoptosing strand and lower
portion of the catagen hair follicle, consistent with its expression
in human hairs. Remarkably, BIM expression was restricted to
catagen hair follicles, where immunofluorescence staining
performed on anagen or telogen hairs produced no signal
(Fig. 4c, upper panel). Finally, to investigate a possible role of
BIM in AA pathogenesis, we used a mouse model that
recapitulates genetic and molecular profiles of human AA23.
C3H/HeJ spontaneously develops AA, and we performed
immunofluorescence staining on affected and unaffected skin.
We observed a striking and widespread increase in BIM
expression throughout affected skin and hair follicles, which
was not restricted to catagen hair follicles and appeared further
upregulated in lesional skin (Fig. 4c, lower panel). The regression
stage of a normal cycling hair follicle, catagen, is characterized by
apoptosis and cell death. We postulate that dysregulation of BIM
in hair-matrix keratinocytes and/or hair follicle melanocytes
contributes to the early entry into dystrophic catagen in AA hair
follicles in active disease.
The second novel region that exceeded statistical significance at
chromosome 11q13.5 (rs2155219, P¼ 1.25 10 8) contains three
gene transcripts, including C11orf30, GUCY2E and GARP
(LRRC32). GWAS have implicated this region in several
autoimmune and inflammatory diseases (www.genome.gov/gwas-
tudies). GARP is expressed on activated Tregs and binds and
augments transforming growth factor beta bioavailability23–26,
functioning to induce FOXP3 expression and Treg differentiation.
Expression of GARP on activated human Treg cells correlates with
Table 1 | Candidate genes in AA GWAS regions.
Locus Genes of interest SNP Chr BP A1A2 P OR
6p21.32 HLA-DQB1 rs9275524 6 32,783,087 TC 1.8E60 0.52
10p15.1 IL15RA,IL2RA rs3118470 10 6,141,719 TC 7.7E 21 0.71
2q33.2 CD28,CTLA4,ICOS rs231775 2 204,440,959 AG 2.2E 20 0.72
6q25.1 RAET1L,ULBP3 rs12183587 6 150,396,301 TG 5.9E24 1.48
11q13 PRDX5 rs574087 11 63,859,524 AG 8.7E 14 1.32
12q13 IKZF4 (Eos),ERBB3 rs2292239 12 54,768,447 TG 4.4E09 1.25
4q27 IL21,IL2 rs7682481 4 123,743,476 CG 4.8E09 1.23
5q31.1 IL13,1L4 rs848 5 132,024,399 AC 4.8E09 1.27
2q13 ACOXL,BCL2L11(BIM) rs3789129 2 111,414,511 AC 1.5E08 1.31
11q13.5 GARP(LRRC32) rs2155219 11 75,976,842 TG 4.1E08 1.21
1p13.2 PTPN22 rs2476601 1 114,179,091 AG 8.9E08 1.34
12q24.12 SH2B3(LNK),ATXN2 rs653178 12 110,492,139 TC 1.6E07 0.84
16p13.13 CIITA,CLEC16A,SOCS1 rs3862469 16 11101581 TC 1.7E07 0.82
9q31.1 STX17, NR4A3 rs10124366 9 101,727,524 AG 1.1E05 0.83
GWAS, genome-wide association studies; OR, odds ratio; SNP, single-nucleotide polymorphism.
Fourteen regions in the genome have demonstrated association with AA by GWAS and replication. For each region, genes of interested are listed, along with the most significant SNP, its location in the
genome, P value and OR obtained with logistic regression from the combined analysis (N¼ 10,796). P values and effect estimates from each analytic stage are in Supplementary Table 3.
P-values in bold exceed the threshold for genome-wide statistical significance.
Tyrβ37
Residues 70–74 (shared epitope
of HLA-DRβ1*0401)
Hisβ13
Figure 2 | Positions of amino-acid residues demonstrating independent
association with alopecia areata. Structure of disease-associated HLA-
DRB1*04:01 allele and polymorphic residues involved in susceptibility to
AA. The peptide-binding cleft of an HLA-DR molecule is shown in cartoon
representation with the a-chain coloured in blue and b-chain in green. The
MHC-bound peptide is shown in cartoon representation and coloured
yellow. Residues His13b and Tyr37b corresponding to amino-acid positions
with independent disease association are shown in a stick model along with
the shared epitope (residues 70–74). Crystal structure of HLA-DR4 bound
to melanocytes lineage-specific antigen gp120 was used (PDB 4IS6).
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their increased suppressive activity, and GARP knockdown
reduces their suppressive activity24,27. Not surprisingly, we found
that GARP is highly expressed in whole PBMCs, consistent with
previous reports. Unexpectedly, we also detected a strong signal for
GARP in plucked control SHFs, a site not previously described and
perhaps atypical for the expression of a Treg protein (Fig. 4). This
suggests a potential role for GARP in hair biology and implicates
significance of its disruption in AA at the site of pathology for the
phenotype.
A third novel region on chromosome 12q24.12 that achieved
suggestive evidence for association (P¼ 1.3 10 7) is of interest,
because several genes harboured within the region functionally
align with other associated genes. This region has demonstrated
associations with multiple autoimmune diseases, and contains
10 genes including SH2B adaptor protein 3 (SH2B3) and aldehyde
dehydrogenase 2 family (ALDH2). SH2B3, also known as LNK, is
a key negative regulator of cytokine signalling via receptor tyrosine
kinases and JAK signalling. Two missense variants that confer
increased cytokine production and enhanced signalling have been
reported in the literature (rs3184504 and rs72650673)28,29.
We genotyped these two functional polymorphisms in a sample
of 96 chromosomes from AA patients carrying the AA-associated
risk allele (rs653178*G), and found that 93 chromosomes also
carried the rs3184504*T risk allele (f¼ 0.97). This increase in
allele frequency over what would be expected among a sample of
European Americans (f¼ 0.51 in Exome Variant Server ESP6500)
indicates that there is strong linkage disequilibrium (LD) between
the AA-associated risk variant and this functional polymorphism,
and suggests that R262W could be contributing to AA
pathogenesis. The rs72650673*A allele was not found in our
sample, consistent with its low allele frequency among
European Americans (f¼ 0.002 in Exome Variant Server
ESP6500). We found by RT–PCR analysis that LNK is highly
expressed in whole PBMCs, as well as T cells, natural killer, B cells
and MCs, but did not detect expression in plucked SHFs (Fig. 4).
ALDH2 has been identified as a citrullinated antigen in
rheumatoid arthritis patients30. This gene has been studied in
the skin, with expression localizing to epidermis, sebaceous glands
and hair follicles, where it is hypothesized to reduce the
accumulation of oxidative stress-induced aldehydes31.
The strong association with HLA class II in AA points
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Figure 3 | Detailed map of associated SNPs and gene locations for newly identified loci. Two regions in the genome exceeded statistical significance
when the replication data were combined with the meta-analysis results (N¼ 10,796) and analysed with logistic regression. (a Chromosome 2q13 includes
ACOXL and BCL2L11 (BIM). (b) Chromosome 12q24.12 included C11orf30 and LRCC32 (GARP).
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The importance of this T-cell subset is supported by the presence
of perifollicular CD4þ T cells in addition to intrabulbar CD8þ
T cells in human AA. Finally, we analysed these data in the
context of other autoimmune diseases by performing CPMA
using the 107 SNPs used in the original description of the analysis
and data from seven other autoimmune diseases32. We found 50
SNPs that are associated at or near significance across two or
more diseases, and clustering of these according to their
association with disease identified five groups (Fig. 5a,b).
Protein–protein interaction graphs of each SNP cluster
demonstrate that for several of the groups, the proteins coded
from these regions interact either directly or via an intermediary
to a significant degree (Fig. 5c). Integration of AA into the CPMA
demonstrates mechanistic alignment with coeliac disease, type 1
diabetes, rheumatoid arthritis, multiple sclerosis and Crohn’s
disease, with most of the overlap coming from the first cluster of
genes.
Collectively, this meta-analysis for the first time resolves HLA
associations and demonstrates the pivotal aetiological role of
HLA-DR. Furthermore, the identification of specific residues in
HLA-DRb1 that are over-represented among AA patients will
allow us to better model peptide class II MHC interactions and
thus predict autoantigens in AA. Associations outside HLA
provide new evidence for the importance of Treg maintenance
and immune response pathways in AA. Furthermore, autophagy
and apoptosis are emerging as processes of aetiologic importance
in AA. These insights will allow us to better understand the
molecular taxonomy of autoimmune diseases and the alignment
of AA within this class of disorders. Importantly, as GWAS help
to resolve disease mechanisms and identify pathogenic pathways
perturbed in AA and autoimmunity in general, these approaches
advance the field towards precision medicine in autoimmunity.
Methods
Patient population. All participating studies were reviewed and approved by the
Institutional Review Boards and ethics committees at Columbia University; MD
Anderson Cancer Center; University of Minnesota, Minneapolis; University of
Colorado, Denver; University of California, San Francisco; and the Universities of
Bonn, Düsseldorf, Münster, Berlin, Hamburg and Munich, Germany; and
Antwerp, Belgium, and were conducted in accordance with the Declaration of
Helsinki Principles. All study subjects provided written informed consent.
For the previously published GWAS and the ImmunoChip samples, cases were



















































Figure 4 | Characterization BIM, GARP and LNK expression. (a) BIM, GARP and LNK expression in human immune cells and hair follicles. RT–PCR
was performed on BIM, GARP and LNK to determine gene expression in T cells, natural killer cells (NK), B cells, monocytes (MC), peripheral blood
mononuclear cells (PBMCs) and scalp hair follicles (SHF). b2M PCR was used as a loading control for each complementary DNA. Two splice variants are
observed for BIM expression: BIM-S (192 bp) and BIM-L (372 bp). Expected amplicon sizes: BIM (372 bp and 192 bp), GARP (226 bp) and LNK (409 bp).
(b) Immunofluorescence staining in human hair follicles reveals that BIM is highly expressed in matrix cells of the catagen hair bulb. (c) In healthy hair
follicles from the C67BL6 mouse strain, BIM is strongly expressed in the apoptosing strand of mouse catagen hair follicles and is absent from anagen
and telogen hair follicles. Immunofluorescence staining on affected and unaffected skin from the AA mouse model strain, C3H/HeJ, reveals that BIM
expression levels and the localization pattern are aberrant in affected hair follicles compared with unaffected C3H/HeJ and C57BL6 hair follicles.
DAPI, 40,6-diamidino-2-phenylindole.
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the US through five clinical sites and confirms diagnosis. Control data for these
samples were obtained from publically available data. There were two sources of
control data for the GWAS4. First, a data set was obtained from subjects enrolled in
the New York Cancer Project33 and genotyped as part of previous studies34. Second,
a data set was obtained from the Cancer Genetic Markers of Susceptibility (CGEMS)
breast35 and prostate36 cancer studies (http://cgems.cancer.gov/data/). The
ImmunoChip control data were obtained from the NIDDK inflammatory bowel
disease genetics consortium (http://medicine.yale.edu/intmed/ibdgc/index.aspx). The
cases and controls for the previously unreported GWAS were ascertained from
outpatient clinics, private dermatology practices and via AA self-support groups in
Belgium and Germany. Inclusion criteria followed published guidelines37, and
additionally included diagnosis by a trained and experienced clinician. European
GWAS controls included population-based controls established within the National
Genome Research Network for use as universal controls (PopGen38, KORA39), and
the Heinz Nixdorf Recall Study40 and an additional population-based cohort from
the Heinz Nixdorf Recall40 study. Sample counts by ascertainment location and
genotyping platform are summarized in Supplementary Table 1.
Genotyping. DNA was extracted from peripheral blood leukocytes by salting out
with saturated NaCl solution according to standard methods, or by using a
Chemagic Magnetic Separation Module I (Chemagen, Baesweiler, Germany), in
accordance with the manufacturer’s instructions. Whole-genome genotyping for the
meta-analayis was performed on either Illumina HumanHap550 BeadChip or the
Illumina Omni express, as detailed in Supplementary Table 1. The replication cohort
was genotyped with the Illumina Immunochip. In addition, SNPs selected for
replication, which were not present on the Immunochip, were genotyped on the
MassArray system using a Sequenom Compact MALDI-TOF device and iPLEX Gold
reagents (Sequenom, San Diego, CA) in multiplex reactions. Primer sequences and
standard assay conditions are available upon request. Standard quality-control (QC)
metrics were employed, removing data for SNPs and samples with call rates less than
90. Additional genotyping was performed by standard PCR-based techniques.
Discovery QC and imputation. Technical QC was performed with QC conducted
on each data set separately using a common approach. The following QC para-
meters were applied: (i) missing rate per SNP o0.05 (before sample removal
below), (ii) missing rate per individual o0.02, (iii) heterozygosity per individual
±0.2 (Fhet, statistic, standardized values in plink), (iv) missing rate per SNP
o0.02 (after sample removal above), (iv) missing rate per SNP difference in cases
and controls o0.02, (vi) Hardy–Weinberg equilibrium (in controls) Po10 6, (vii)
Hardy–Weinberg equilibrium (in cases) Po10 10. Study sample sizes varied
between 1,200 and 3,000 individuals. The number of SNPs per study after QC
varied between 420,000 and 640,000. On average, the QC processes excluded 44
individuals per study (with a range of
13–107 individuals) and 13,000 SNPs per study (with a range of 3,000–20,000
SNPs). After QC, the GWAS data sets together comprised 2,489 cases and 5,287
controls and, for the next steps of the ‘genetic QC’ analysis, a set of 221,784 SNPs
common to all platforms and successfully genotyped in each GWAS sample was
extracted. These SNPs were then further pruned to remove LD (leaving no pairs
with r240.05) and lower-frequency SNPs (minor allele frequency o0.05), leaving
64,099 SNPs suitable for robust relatedness testing and population structure ana-
lysis (see below). Imputation of untyped SNPs was performed within each study in
batches of 300 individuals. These batches were randomly drawn to keep the same
case-control ratio as in the total sample from that study. We used Beagle 3.13.
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rs7709212 (5q33.3; IL12B, UBLCP1)
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Figure 5 | Cross-phenotype meta-analysis revealing functional clusters of genes and proteins indicating patterns of shared disease mechanisms
across autoimmune diseases. (a) Fifty SNPs with evidence of association to more than one autoimmune disease (Pcpmao0.01) are clustered by
association with disease. (b) For each cluster and disease pair, a cumulative association statistic was calculated using Fisher’s omnibus test to combine
P values. The varying pattern of disease association for each cluster suggests each group represents a distinct co-morbid mechanism. (c) Proteins
coded within a 100-Mb window centred on each SNP within each cluster are depicted in protein–protein interaction maps. Three of the five clusters have
significant protein inter-connectivity (permuted Po0.05).
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NCBI 36) using a chunk size of 10 Mb with 410 phased haplotypes comprising
1,233,578 SNPs, using default parameters. Lambda-GC was carefully monitored
before and after imputation.
Genetic QC included relatedness testing and principal component analyses
based on 64,099 LD-independent SNPs, present on all platforms in this study.
Relatedness testing was done with PLINK41, reporting pairs with genome identity
(pi-hat) 40.9 as ‘identical samples’ and with pi-hat40.2 as being closely related.
After random shuffling, one individual from each related pair was excluded from
downstream analysis. From groups with multiple related pairs (for example, a
family), only one individual was kept.
Discovery principal component analysis. Principal component estimation was
done with the same collection of SNPs on the non-related subset of individuals.
We estimated the first 20 principal components and tested each of them for
phenotype association (using logistic regression with study indicator variables
included as covariates) and evaluated their impact on the genome-wide test sta-
tistics using Lamda-GC (the genomic control inflation factor based on the median
w2) after genome-wide association of the specified principal component. On the
basis of this, we decided to include principal components 1, 2, 3, 4, 5 and 6 for
downstream analysis as associated covariates.
Association analysis. The primary scan had a total of 2,332 QCþ cases and
5,233 QCþ controls. Association testing was carried out in PLINK41, using the
dosage data from the imputation and using the first six principal components as
covariates, chosen as described above from the first 20 principal components. The
four data sets had Lamda-GC values of 1.025, 1.041, 1.040 and 1.042.
A fixed-effect meta-analysis was performed using ORs and s.e. The final meta-
analysis had a Lambda-GC of 1.076.
MHC imputation and association analysis. Starting from the genotyped SNPs, we
imputed classical HLA alleles and corresponding polymorphic amino acids within
classical HLA proteins, following a recently described protocol8. In total, 8,271 variants
including SNPs, amino acids and classical HLA alleles at 2- and 4-digit resolution were
tested for association in the MHC region. Logistic regression was applied for testing for
association, including the six first principal components and a dummy variable for the
cohort identification of each sample. Single-test association was performed for all types
of variants, as well as omnibus tests for the amino acids. The conditional analyses were
performed using the initial principal component analysis covariates, the dummy
variable for the cohort, and adjusting for the top and conditional hits.
Analysis of immunochip data. To identify the sample ethnicities in the case
cohort, we calculated the principal components (PC) 1 and 2 using Hapmap 3, and
mapped the case samples to the principal components. Samples that do not cluster
with the Hapmap3 European samples were discarded. The NIDDK control cohort
has been cleaned for sample ethnicity and is thus not necessary to undergo such
procedure. For both case and control cohort, we then removed samples that have
missing genotype rate 42% and variants that have missing genotype rate 42% for
each cohort. For the control cohort, we additionally removed variants that fail the
Hardy–Weinberg equilibrium test (P value o1 10 5). The case and the control
cohorts were then merged, and we removed variants that have different missing-
ness in cases and in controls (P value o1 10 5) and samples that have high
heterozygosity (43 s.d.). We used PLINK to infer the genetic relationships
between the remaining samples and we randomly removed one of the samples for
each related sample pair (PI_HAT40.5)41. The final cleaned data set has 318 cases
and 1,688 controls. We tested the association between the genetic variants and AA
using PLINK with the principal components 1–5 as covariates.
RT–PCR and immunofluorescence staining. RT–PCR was performed on total
RNA extracted from plucked human SHFs and T cells, natural killer cells, B cells,
MCs, PBMCs that were isolated by FACS from whole blood. The primer sequences
of the BIM, GARP, LNK and b2M genes are as follows: BIM F: 50-TAAGTTC
TGAGTGTGACCGAGA-30, R: 30-CCATTGCACTGAGATAGTGGTTG-50 ;
GARP F: 50-CGCTCCCGAGACTCATCTAC-30 , R: 50-AGGTGCTCAAGAAAG
CTGTCG-30 ; LNK F: 50-GTGGGGAATACGTGCTCACTT-30 , R: 50-TGTCCA
CGACCGAGGGAAA-30 ; b2M F: 50-GAGGCTATCCAGCGTACTCCA-30 ,
R: 50-CGGCAGGCATACTCATCTTTT-30 . Full blots are provided as a
Supplementary Figure 1.
Immunofluorescence staining was performed on human and mouse samples.
Human skin and hair follicle sections were obtained from control occipital scalp
biopsies discarded during surgery and considered to be non-human subject
research under 45 CFR Part 46 (Institutional Review Board exempted). Mouse
anagen skin (day 30), catagen skin (day 42) and telogen skin (day 50) was collected
from the dorsal region and embedded in optimal cutting temperature for
sectioning (10mm). Slides were fixed with 50% MeOH/50% acetone for 10 min
at 220 mC, washed with 1 phosphate-buffered saline and then blocked with
2% fish skin gelatin (Sigma Aldrich, MO, USA). The a-BIM antibody (Rabbit)
(Biorbyt, orb10190) was used at a concentration of 1:200 for both mouse and
human studies. Slides were washed, incubated with the Alexa Fluor 488 donkey
anti-rabbit IgG (Molecular Probes, Invitrogen) secondary antibody (1:800 in
1 phosphate-buffered saline), mounted with VECTASHIELD mounting medium
with DAPI (Vector Laboratories, Burlingame, CA, USA) and imaged using a LSM 5
laser-scanning Axio Observer Z1 confocal microscope (Carl Zeiss).
Cross-phenotype meta-analysis. The protocol for this analysis was adopted from
previously described work on cross-phenotype meta-analysis32. Using Dataset S1
from the Supplementary Data of the original analysis, we added in AA association
P values for the 107 SNPs originally investigated. For SNPs with no P value, we
used Broad Institutes SNAP to find a proxy SNP with r240.9 (http://
www.broadinstitute.org/mpg/snap/). The CPMA statistic was then recalculated for
all 107 SNPs using a code (found here: http://coruscant.itmat.upenn.edu/
software.html) implementing the original description. All SNPs meeting a
significance threshold of o0.01 were included in clustering analysis. Clustering was
done by first binning P values into four groups based on magnitude and clustered
using the Cluster package. Cumulative association statistics were calculated in R
using Fisher’s omnibus test. Protein–protein interaction analysis was performed
using DAPPLE, a publicly available web application (http://
www.broadinstitute.org/mpg/dapple). Settings for DAPPLE included the 1000
genome assembly, 5,000 permutations and 50-kb regulatory region upstream and
downstream. All statistical analyses were performed in R version 3.0.1.
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Alopecia areata (AA) is a common autoimmune disease 
resulting from damage of the hair follicle by T cells. The 
immune pathways required for autoreactive T cell activation  
in AA are not defined limiting clinical development of  
rational targeted therapies1. Genome-wide association studies 
(GWAS)2 implicated ligands for the NKG2D receptor  
(product of the KLRK1 gene) in disease pathogenesis.  
Here, we show that cytotoxic CD8+NKG2D+ T cells are both 
necessary and sufficient for the induction of AA in mouse 
models of disease. Global transcriptional profiling of mouse 
and human AA skin revealed gene expression signatures 
indicative of cytotoxic T cell infiltration, an interferon-g  
(IFN-g) response and upregulation of several g-chain (gc) 
cytokines known to promote the activation and survival  
of IFN-g–producing CD8+NKG2D+ effector T cells. 
Therapeutically, antibody-mediated blockade of IFN-g, 
interleukin-2 (IL-2) or interleukin-15 receptor b (IL-15Rb) 
prevented disease development, reducing the accumulation 
of CD8+NKG2D+ T cells in the skin and the dermal IFN 
response in a mouse model of AA. Systemically administered 
pharmacological inhibitors of Janus kinase (JAK) family protein 
tyrosine kinases, downstream effectors of the IFN-g and gc 
cytokine receptors, eliminated the IFN signature and prevented 
the development of AA, while topical administration promoted 
hair regrowth and reversed established disease. Notably, three 
patients treated with oral ruxolitinib, an inhibitor of JAK1 and 
JAK2, achieved near-complete hair regrowth within 5 months 
of treatment, suggesting the potential clinical utility of JAK 
inhibition in human AA.
Alopecia areata is a T cell–mediated autoimmune disease charac-
terized phenotypically by hair loss and, histologically, by infiltrating 
T cells surrounding the hair follicle bulb (reviewed in ref. 1). Previous 
studies have shown that transfer of total T cells (but not B cells or 
sera) can cause the disease in human xenograft models3, as well as 
in C3H/HeJ mice4, a mouse strain that develops spontaneous AA 
with considerable similarity to human AA. Broad-acting intralesional 
steroids are the most commonly used therapy for AA, with varying 
success. Progress in developing effective, rationally targeted therapies 
has been limited by our lack of mechanistic understanding of the 
underlying key T cell inflammatory pathways in AA.
We2 and others5 have previously identified a cytotoxic subset of 
CD8+NKG2D+ T cells within the infiltrate surrounding human AA 
hair follicles, as well as concomitant upregulation in the follicle itself 
of the ‘danger signals’ ULBP3 (ref. 2) and MICA5, two NKG2D ligands 
(NKG2DLs) whose importance in disease pathogenesis has also been 
suggested by genome-wide association studies2.
To determine the contribution of CD8+NKG2D+ T cells to AA 
pathogenesis, we used the C3H/HeJ mouse model6, which sponta-
neously develops alopecia and recapitulates many pathologic fea-
tures of human AA7. In lesional skin biopsies from alopecic mice, 
CD8+NKG2D+ T cells infiltrate the epithelial layers of the hair fol-
licle, which overexpress the NKG2DLs, H60 and Rae-1, analogous to 
what has been observed in skin biopsies of human AA2 (Fig. 1a,b and 
Supplementary Fig. 1a,b). Flow cytometric analysis of the CD45+ 
leukocyte population in the skin revealed a marked increased number 
of CD8+NKG2D+ T cells in the skin of diseased C3H/HeJ mice, in 
conjunction with cutaneous lymphadenopathy and increased total 
cellularity, as compared with disease-free C3H/HeJ mice (Fig. 1c,d). 
Other cell types, including CD4+ T cells4 and mast cells8, were 
present in much smaller numbers (Supplementary Fig. 1c and data 
not shown).
The immunophenotype of the skin-infiltrating CD8+ T cells in 
mice with AA was similar to that of the CD8+NKG2D+ population 
found in the cutaneous lymph nodes: CD8αβ+ effector memory 
T cells (TEM, CD8hiCD44hiCD62LlowCD103+) bearing several natural 
killer (NK) immunoreceptors, including CD49b and NKG2A, NKG2C 
and NKG2E (Fig. 1e and Supplementary Fig. 1d). These CD8+ TEM 
cells expressed high levels of IFN-γ and exhibited NKG2D-dependent 
cytotoxicity against ex vivo–expanded syngeneic dermal sheath tar-
get cells (Fig. 1f). Gene expression analysis of the CD8+NKG2D+ 
T cells isolated from alopecic C3H/HeJ lymph node cells using 
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RNA-seq demonstrated a transcriptional profile characteristic of 
effector cytotoxic T lymphocytes (CTLs)9,10 and identified several 
additional NK-specific transcripts (Supplementary  Table  1 and 
Supplementary Fig. 2).
We next evaluated the requirement of these CD8+ TEM cells in dis-
ease pathogenesis. Transfer of cytotoxic CD8+NKG2D+ cells or total 
lymph node cells from diseased mice induced AA in all five healthy 
C3H/HeJ recipients by 14 weeks after transfer, whereas lymph node 
cell populations depleted of NKG2D+ cells were unable to transfer 
disease (Fig.  1g). Thus, CD8+NKG2D+ T cells are the dominant 
cell type in the dermal infiltrate and are necessary and sufficient for 
T cell–mediated transfer of AA.
To characterize the transcriptional profile of AA lesional skin 
from C3H/HeJ mice as well as human AA, we performed Affymetrix 
microarray analyses to identify differentially expressed genes in skin 
between individuals with AA and skin from control individuals 
without disease (Supplementary Fig. 3 and Supplementary Tables 
2 and 3) Three gene expression signatures were identified in lesional 
skin: IFN response genes, such as those encoding the IFN-inducible 
chemokines CXCL-9, CXCL-10 and CXCL-11 (Supplementary 
Figs. 3 and 4), several key CTL-specific transcripts, such as those 
encoding CD8A and granzymes A and B, and γc cytokines and their 
receptors, such as the transcripts for interleukin-2 (IL-2) and IL-15, 
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Figure 1 CD8+NKG2D+ cytotoxic T lymphocytes accumulate in the skin and are necessary and sufficient to induce disease in AA mice.  
(a) Immunofluorescence staining of NKG2D ligand (H60) in the hair follicle inner root sheath (marked by K71). Scale bar, 100 µm. (b) CD8+NKG2D+ 
cells in hair follicles of C57BL/6, healthy C3H/HeJ and C3H/HeJ AA mice. Top scale bar, 100 µm; bottom scale bar, 50 µm. (c) Cutaneous 
lymphadenopathy and hypercellularity in C3H/HeJ AA mice. (d) Frequency (number shown above boxed area) of CD8+NKG2D+ T cells in the skin and 
skin-draining lymph nodes in alopecic mice versus ungrafted mice. (e) Immunophenotype of CD8+NKG2D+ T cells in cutaneous lymph nodes of C3H/HeJ 
alopecic mice. (f) Left, Rae-1t–expressing dermal sheath cells grown from C3H/HeJ hair follicles. Right, dose-dependent specific cell lysis induced by 
CD8+NKG2D+ T cells isolated from AA mice cutaneous lymph nodes in the presence of blocking anti-NKG2D antibody or isotype control. Effector to 
target ratio given as indicated. Data are expressed as means ± s.d. (g) Hair loss in C3H/HeJ mice injected subcutaneously with total lymph node (LN) 
cells, CD8+NKG2D+ T cells alone, CD8+NKG2D− T cells or lymph node cells depleted of NKG2D+ (5 mice per group). Mice are representative of two 
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to be expressed on infiltrating lymphocytes surrounding human AA 
hair follicles11, we performed immunofluorescence analysis for both 
IL-15 and its chaperone receptor IL-15Rα to identify the source 
of IL-15 in the skin. We detected a marked upregulation of both 
components in AA hair follicles in both human and mouse AA and 
found IL-15Rβ expressed on infiltrating CD8+ T cells in humans 
(Supplementary Figs. 5 and 6).
IL-2 and IL-15 are well-known drivers of cytotoxic activity by 
IFN-γ–producing CD8+ effector T cells and NK cells12,13 and have 
been implicated in the induction and/or maintenance of autoreactive 
a Control Anti–IFN-γ
Control Anti–IL-2d
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Figure 2 Prevention of AA by blocking antibodies to IFN-γ, IL-2 or IL-15Rβ. C3H/HeJ grafted mice were treated systemically from the time of grafting.  
(a–h) AA development in C3H/HeJ grafted mice treated systemically from the time of grafting with antibodies to IFN-γ (a,b), IL-2 (d,e) and IL-15Rβ (g,h). 
Frequency (number shown above boxed area) of CD8+NKG2D+ T cells in the skin of mice treated with antibodies to IFN-γ (b), IL-2 (e) and IL-15Rβ (h) 
compared to PBS-treated mice. (*P < 0.05, **P < 0.01, ***P < 0.001, statistical methods described in the Supplementary Methods. Immunohistochemical 
staining of skin biopsies showing CD8 and MHC class I and II expression in skin of mice treated with isotype control antibody or with antibodies to  
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CD8+ T cells14–16. To test the efficacy of IFN-γ– and γc-targeted 
therapies in vivo, we used the well-established graft model of AA, in 
which skin grafts from mice with spontaneous AA are transferred 
onto the backs of unaffected 10-week-old recipient C3H/HeJ mice. 
In this model, AA develops reliably in 95-100% of grafted recipients 
within 6–10 weeks7, allowing us to test interventions aimed at either 
preventing or reversing disease.
The role of IFN-γ in AA was previously investigated using both 
knockout studies and administration of IFN-γ, where IFN-γ–deficient 
mice were resistant and exogenous IFN-γ precipitated disease17,18. 
Administration of neutralizing antibodies to IFN-γ at the time of 
grafting prevented AA development in grafted recipients and abro-
gated major histocompatibility complex (MHC) upregulation and 
CD8+NKG2D+ infiltration in the skin (Fig. 2a–c). Likewise, a role 
for IL-2 in AA pathogenesis was previously established using genetic 
experiments in which IL-2 haploinsufficiency on the C3H/HeJ back-
ground conferred resistance to disease by about 50% using the graft 
model19, and this role is supported by our genome-wide associa-
tion studies in humans2. Systemically administered blocking anti-
bodies to either IL-2 (Fig. 2d–f) or IL-15Rβ (Fig. 2g–i) prevented 
AA in grafted mice, blocked the accumulation of CD8+NKG2D+ 
T cells in the skin and abrogated MHC upregulation. However, 
IL-21 blockade failed to prevent the development of AA in grafted 
C3H/HeJ mice (Supplementary  Fig.  7). Notably, none of these 
blocking antibodies given alone was able to reverse established AA 
(data not shown).
We next asked whether we could recapitulate the effects of type I 
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Figure 3 Systemic JAK1/2 or JAK3 inhibition prevents the onset of AA in grafted C3H/HeJ mice. (a–j) AA development in C3H/HeJ grafted mice treated 
systemically from the time of grafting with ruxolitinib (JAK1/2i) (a,b) or tofacitinib (JAK3i) (f,g) (**P < 0.01). Frequency (number shown above boxed 
area) of CD8+NKG2D+ T cells in skin and cutaneous lymph nodes of mice treated with PBS or with JAK1/2i (c) or JAK3i (h) (***P < 0.001, statistical 
methods described in Supplementary Methods). Immunohistochemical staining of skin biopsies showing CD8 and MHC class I and II expression in skin 
of mice treated with PBS or with JAK1/2i (d) or JAK3i (i). ALADIN score of transcriptional analysis from mice treated with PBS or with JAK1/2i (e) or 
JAK3i (j), given as log2 mean expression Z-scores as indicated in the Supplementary Methods. Hair regrowth after an additional 12 weeks after treatment 
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inhibitors of JAK kinases, which signal downstream of a wide range 
of cell surface receptors. In particular, IFN-γ receptors and γc fam-
ily receptors signal through JAK1/2 and JAK1/3, respectively20. 
JAK activation was shown by the presence of phosphorylated signal 
transducer and activator of transcription (STAT) proteins (pSTAT1, 
pSTAT3 and to a lesser extent pSTAT5) in human and mouse alopecic 
hair follicles, but not in normal hair follicles (Supplementary Fig. 8). 
In in vitro–cultured dermal sheath cells from C3H/HeJ mice,  exog-
enous IFN-γ increased STAT1 activation, whereas IFN-γ plus TNF-
α increased surface IL-15 expression (Supplementary  Fig.  9a,b). 
Ruxolitinib, a US Food and Drug Administration (FDA)–approved 
small-molecule inhibitor of the JAK1/2 kinases (JAK selectivity is 
JAK1 = JAK2>Tyk2>>>JAK3)21 critical for IFN-γR signaling inhibited 
these responses (Supplementary Fig. 9a,b). In cultured CTL effec-
tors from C3H/HeJ mice, the FDA-approved small-molecule JAK3 
inhibitor tofacitinib (JAK3>JAK1>>JAK2 selectivity)22 blocked IL-
15–triggered pSTAT5 activation (Supplementary Fig. 9c). Tofacitinib 
also blocked killing of dermal sheath cells (Supplementary Fig. 9d) 
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Figure 4 Reversal of established AA with topical small-molecule inhibitors  
of the downstream effector kinases JAK1/2 or JAK3, and clinical results  
of patients with AA. (a) Three mice per group with long-standing AA  
(at least 12 weeks after grafting) treated topically on the dorsal back  
with 0.5% JAK1/2i (center), 0.5% JAK3i (bottom) or vehicle alone  
(Aquaphor, top) by daily application for 12 weeks. This experiment  
was repeated three times. Hair regrowth at an additional 8 weeks after  
treatment withdrawal is also shown. (b) Time course of hair regrowth  
index shown as weeks after treatment. (c) The frequency (number shown  
above boxed area) of CD8+NKG2D+ T cells in the skin of mice treated with  
JAK1/2i or JAK3i compared to vehicle control mice (mean ± s.e.m., n = 3  
per group, *P < 0.05, **P < 0.01, statistical methods described in the Supplementary Methods). NS, not significant. (d) The ALADIN score  
shows treatment-related loss of CTL and IFN signatures, given as log2 mean expression Z-scores as indicated in the Supplementary Methods.  
(e) Immunohistochemical staining of mouse skin biopsies shows treatment-related loss of expression of CD8 and MHC class I and II markers.  
Scale bar, 100 µm. (f) Treatment of patient 3 with AA, who had hair loss involving >80% of his scalp at baseline, with ruxolitinib and hair regrowth after 
12 weeks of oral treatment. (g) Clinical correlative studies of biopsies obtained before treatment (baseline) and after 12 weeks of treatment of patient 2,  
including immunostains for CD4, CD8 and human leukocyte antigen (HLA) class I (A, B, C) and class II (DP, DQ, DR). Scale bar, 200 µm. (h,i) RNA 
microarray analysis from treated patients 1 and 2 with AA (before treatment versus after treatment versus 3 normal subjects) presented as a heatmap (h)  
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To test whether inhibition of these signaling pathways would 
be therapeutically effective in vivo, we systemically administered 
 ruxolitinib (Fig.  3a–c) and tofacitinib (Fig.  3f–h) at the time of 
grafting and found that they prevented the development of AA and 
the expansion of CD8+NKG2D+ T cells in all grafted recipients. 
The skin of mice treated with either drug showed no histological 
signs of inflammation (Fig. 3d,i). Global transcriptional analysis of 
whole-skin biopsies showed that both drugs also blocked the dermal 
inflammatory signature, as measured by Alopecia Areata Disease 
Activity Index (ALADIN, Fig. 3e,j), and Gene Expression Dynamic 
Index (GEDI) analysis (Supplementary Fig. 10)23.
We next asked whether systemic tofacitinib treatment could reverse 
established disease by initiating therapy 7 weeks after grafting, a time 
point at which all mice had developed extensive AA. Systemic therapy 
resulted in substantial hair regrowth all over the body, reduced the 
frequency of CD8+NKG2D+ T cells and reversed histological markers 
of disease (Supplementary Fig. 11), all of which persisted 2–3 months 
after the cessation of treatment.
Next, to test a more clinically relevant route of delivery, we asked 
whether topical administration of protein tyrosine kinase inhibitors 
could reverse established AA in mice with kinetics similar to those of 
systemic delivery. In established disease, we found that topical rux-
olitinib and topical tofacitinib were both highly effective in reversing 
disease in treated lesions (applied to back skin). A full coat of hair 
emerged in the ruxolitinib- or tofacitinib-treated mice by 7 weeks of 
treatment (data not shown), and we observed complete hair regrowth 
within 12 weeks following topical therapy (Fig. 4a,b). Topical therapy 
was associated with a markedly reduced proportion of CD8+NKG2D+ 
T cells in the treated skin and lymph node (Fig. 4c), normalization 
of the ALADIN transcriptional signature (Fig. 4d), reversal of histo-
logical markers of disease (Fig. 4e) and correction of the GEDI in all 
treated mice (Supplementary Fig. 12). Notably, untreated areas on 
the abdomen remained alopecic (Fig. 4a and Supplementary Fig. 13), 
demonstrating that topical therapy acted locally and that the observed 
therapeutic effects were not the result of systemic absorption. These 
effects were visible as early as 2–4 weeks after the onset of treatment 
(Supplementary Fig. 14) and persisted 2–3 months after the cessation 
of treatment (Fig. 4a).
To test the efficacy of JAK inhibitors in human subjects with AA, 
we treated three patients with moderate to severe disease orally with 
 ruxolitinib, 20 mg twice daily. Ruxolitinib is currently FDA-approved 
for the treatment of myelofibrosis24,25, a disease driven by wild-type 
and mutant JAK2 signaling downstream of hematopoietic growth fac-
tor receptors. In addition, small clinical studies using topical ruxolitinib 
in psoriasis26 have demonstrated anti-inflammatory activity that may 
be due to interruption of the IL-17 signaling axis. All three ruxolitinib-
treated patients exhibited near-complete hair regrowth within 3 to 
5 months of oral treatment (Fig. 4f and Supplementary Figs. 15 and 
16). Comparison of biopsies obtained at baseline and after 12 weeks 
of treatment demonstrated reduced perifollicular T cell infiltration, 
reduced follicular expression of human leukocyte antigen class I and 
class II expression (Fig. 4g) and normalization of the ALADIN inflam-
matory and hair keratin signatures following treatment (Fig. 4h,i).
Taken together, our data suggest CD8+NKG2D+ T cells promote 
AA pathogenesis, acting as cytolytic effectors responsible for autoim-
mune attack of the hair follicle (Supplementary Fig. 17). We postulate 
that IFN-γ produced by CD8 T cells leads to the collapse of immune 
privilege in the hair follicle27, inducing further production of IL-15 
(ref. 28) (Supplementary  Figs.  5  and  6) and a feed-forward loop 
that promotes type I cellular autoimmunity. The clinical response 
of a small number of patients with AA to treatment with the JAK1/2 
inhibitor ruxolitinib suggests future clinical evaluation of this com-
pound or other JAK protein tyrosine kinase inhibitors currently in 
clinical development is warranted in AA29.
MeTHoDS
Methods and any associated references are available in the online 
version of the paper.
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Mice. 7- to 10-week-old female C57BL/6 and C3H/HeJ mice (Jackson 
Laboratories, Bar Harbor, ME) were used and maintained under specific 
pathogen–free conditions. Experiments were performed in compliance with 
institutional guidelines as approved by the Institutional Animal Care and Use 
Committee of Columbia University Medical Center.
Transfer of alopecia areata using grafted C3H/HeJ skin. Normal-haired 
C3H/HeJ mice were grafted at 8 weeks of age (during the second telogen) with 
skin from a C3H/HeJ mouse that developed AA spontaneously, as described 
previously7. In brief, mice spontaneously affected with AA were euthanized, 
and full thickness skin grafts of approximately 2 cm in diameter were removed 
and grafted to normal-haired C3H/HeJ mice. All experiments included 10 
grafted mice (5 treated and 5 untreated) and 3 sham grafted mice (mice grafted 
with autologous grafts). Hair loss typically began at around 4–6 weeks after 
grafting. No sham grafted mouse developed hair loss.
Flow cytometric analysis of skin and cutaneous lymph nodes. To make a 
single-cell suspension of mouse skin, fat was removed from the overlying 
skin in cold PBS and then incubated in collagenase type I (2 mg/ml in PBS) 
at 32 °C for 75 min. After digestion, the skin was minced in RPMI/10% FBS, 
filtered through a 70-µM cell strainer and centrifuged at 1100g for 5 min. 
The pellet was resuspended in RPMI/10% FBS, filtered through a 40-µM cell 
strainer and spun at 400g for 5 min. The pellet was resuspended in FACS buffer 
(PBS/5% BSA), DAPI to gate on live cells and staining antibodies (listed in 
Supplementary Methods). Cutaneous lymph nodes were pooled, minced in 
RPMI, filtered through a 40-µM cell strainer, centrifuged at 400g for 5 min, 
stained and analyzed on a BD LSR II flow cytometer.
Transfer  of  T  cell  populations  into  recipient  C3H/HeJ  mice. For posi-
tive selection of T cell populations, lymph node cells were obtained from 5 
C3H/HeJ alopecic mice, stained with anti-CD4, anti-CD8 and anti-NKG2D 
antibodies) and then sorted (BD Influx) to obtain two fractions: CD8+NKG2D+ 
T cells and CD8+NKG2D− T cells. Antibody dilutions are given in the 
Supplementary Methods. Three to five 7-week-old C3H/HeJ mice per group 
were injected subcutaneously with two million sorted cells of each population. 
For negatively selected populations, NKG2D+ cells were depleted by incubat-
ing total lymph node cells from 3 alopecic C3H/HeJ mice with biotinylated 
anti-NKG2D (CX5) and then with streptavidin-conjugated beads (Miltenyi) 
before removal on a Miltenyi magnetic column. Five million cells (either 
CD8/NKG2D-depleted or total lymph node cells) were suspended in 100 ul 
PBS and transferred into each of 5 mice by subcutaneous injection.
Prevention and treatment studies in mice. For prevention studies, mice were 
treated beginning on the day of grafting (n = 5–10 mice per group). For anti-
IFN-γ experiments, i.p. injections of hamster isotype control IgG or hamster 
polyclonal anti-IFN-γ IgG (BioXCell) 300 µg in 100µl PBS were administered 
ten times weekly for 12 weeks. For anti–IL-2 experiments, i.p. injections of 
control rat isotype control IgG or simultaneous administration of two anti-
IL-2 rat monoclonal antibodies (BioXCell) (250 µg clone S4B6 and 250 µg 
JES6-1 together in 100 µl PBS) were administered three times weekly for 
12 weeks. For anti–IL-15-Rβ experiments, i.p. injections of rat isotype control 
IgG or anti-IL-15Rβ antibody (Biolegend, clone TM-β1) (200 µg in 100 µl 
PBS) were administered two times weekly for 12 weeks. For JAK1/2i experi-
ments, mice were administered vehicle (0.5% methylcellulose; Sigma-Aldrich) 
or vehicle-containing 50 mg/kg of JAK1/2i ruxolitinib (ChemieTek) daily by 
oral gavage for 12 weeks. For JAK3i experiments, mice were implanted sub-
cutaneously with Alzet osmotic mini-pumps (pumps, model 2004, Durect 
Corporation) on the back of each mouse to deliver vehicle (poly(ethylene 
glycol) (PEG)300) or vehicle containing the JAK3i tofacitinib (Abmole) at 
15 mg/kg/day for 12 weeks.
For topical treatment studies, grafted mice with long-standing AA (more 
than 8 weeks) were treated once daily for 12 weeks to affected skin on the dorsal 
back with vehicle (10% DMSO in Aquaphor) or vehicle containing JAK inhibi-
tors, initially dissolved in DMSO and then diluted 1:10 in Aquaphor, to achieve 
0.5% JAKi ointment). Full-thickness skin biopsies were excised from the dorsal 
surface of each mouse at interim time points, and skin samples were either 
snap frozen in liquid nitrogen for RNA extraction or snap frozen in OCT for 
immunostaining. Hair status was examined twice weekly.
Human clinical studies. We initiated a single center, proof-of-concept clini-
cal trial in the Clinical Trials Unit in the Department of Dermatology at the 
Columbia University Medical Center entitled “An Open-Label Pilot Study to 
Evaluate the Efficacy of ruxolitinib in Moderate to Severe Alopecia Areata,” 
ClinicalTrials.gov identifier NCT01950780. The protocol for this interven-
tion trial was reviewed and approved by the Institutional Review Board at 
Columbia University and conducted under the Declaration of Helsinki prin-
ciples. Informed consent was received before inclusion in the study. Eligibility 
criteria included >30% hair loss for at least 3 months in duration with no 
evidence for hair regrowth at the time of enrollment. The first three treated 
patients are described here. The ruxolitinib dose was 20 mg orally twice daily 
for 3–6 months. Skin punch biopsies were obtained at baseline and after 
12 weeks of treatment. Consent for photography was obtained for the patients 
shown in Figure 4 and in the Supplementary Figures 15 and 16.
Immunohistochemistry  and  immunofluorescence. 8 µM acetone-fixed 
frozen mouse skin or human skin sections were air-dried and stained 
overnight with anti-mouse or anti-human antibodies (see Supplementary 
Methods) at 4 °C in a moist chamber. Human hair follicles were microdis-
sected and embedded in OCT compound before sectioning and staining 
(see Supplementary Methods).
Primary  dermal  sheath  and  lymphokine-activated  killer  (LAK)  cell 
culture. Dermal sheath (DS) cells were isolated from microdissected mouse 
vibrissa follicles and cultured in 20% FBS DMEM with 5 ng/ml murine FGF 
(Pepro Tech). LAK cells were generated from bulk splenocytes plated at 
4 × 106 in 6-well plates with 50 ng/ml murine IL-15 (Pepro Tech), 50 nM JAK3i 
(tofacitinib) or 50 ng/ml murine IL-15 plus 50 nM JAK3i and incubated at 
37 °C in a 5% CO2 incubator for 96 h.
In vitro cytotoxicity assays. Determination of specific killing of target cells 
was performed using CFSE-labeled DS cells as targets mixed with different 
ratios of effector cells incubated for 5 h at 37 °C 5% CO2 with or without 
neutralizing rat anti-mouse NKG2D antibody (20 ug/ml) (Biolegend, CX5). 
Specific lysis of DS cells was determined flow cytometrically by measuring cell 
death of CFSE + DS cells using Annexin V/7-AAD.
Gene expression sample preparation in human and mouse skin and T cells.  
Total RNA was isolated using the miRNeasy Mini Kit (Qiagen Inc., Valencia, 
CA, USA) with on-column DNA digestion using the RNase-free DNase 
set (Qiagen, Inc.). For RNA-seq analysis CD3+CD8+CD44+NKG2D+ and 
CD3+CD8+CD44+NKG2D− cells were flow-sorted from lymph nodes 
of alopecic C3H/HeJ mice. RNA was extracted as above and prepared for 
RNA-seq using the TruSeq RNA Sample Prep Kit v2. Samples were sequenced 
on the HiSeq 2000 sequencer (Illumina, San Diego, CA) for 50 cycles. 
RNA-seq files were demultiplexed by the Rockefeller University Genomics 
Core Facility.
For global transcriptional profiling in mouse skin, total extracted RNA was 
processed using the 3′ IVT Express Kit from Affymetrix. Resulting biotinylated 
cDNA samples were hybridized to the Mouse Genome 430 2.0 gene chips and 
subsequently washed, stained with streptavidin-phycoerythrin and scanned on 
an HP GeneArray Scanner (Hewlett-Packard Company, Palo Alto, CA). For gene 
expression studies, mice grafted with autologous healthy skin were included as 
sham-operated controls.
For human AA samples, perilesional punch biopsies from 5 patients with 
patchy alopecia areata who were not undergoing local or systemic treat-
ments were collected and compared to scalp biopsies from 5 unrelated unaf-
fected individuals. All procedures were performed under Institutional Review 
Board–approved protocols at Columbia University and conducted under the 
Declaration of Helsinki principles. Informed consent was received before inclu-
sion in the study. Extracted total RNA was reverse transcribed and amplified 




























San Carlos, CA). Amplified cDNA was biotinylated with the Encore Biotin Module 
(NuGEN Technologies) and then hybridized to the U133 Plus 2.0 gene chips. 
RT-PCR confirmations done as described in the Supplementary  Methods. 
Primer sequences are given in Supplementary Tables 4 and 5.
Statistical  analyses. Statistical methods for each figure are given in the 
Supplementary Methods. No statistical method was used to predetermine 
sample size. The investigators were not blinded to allocation during experi-
ments and outcome assessment. The experiments were not randomized.
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C3H/HeJ mouse strain (Jackson Laboratories, Bar Harbor, ME) was used for all 
animal studies.  Only female mice were used.  Mouse recipients of alopecic skin grafts 
were aged 7-10 weeks at the time of grafting. For prevention experiments, drug 
administration began the day after grafting.  For systemic treatment studies, drug 
administration was initiated approximately 3 months after mice lost their hair.  For 
topical treatment studies, drug administration was initiated 20 weeks following grafting. 
All animal procedures were done according to protocols approved by the Columbia 
University Medical Center Institutional Animal Care and Use Committee. 
Human studies 
All human studies have been approved by the Columbia University Medical 
Center Institutional Review Board and were conducted under the Declaration of Helsinki 
principles.  Informed written consent was received from participants before inclusion in 
the study. 
Clinical Evaluation of Oral Ruxolitinib in Alopecia Areata 
We initiated a single center, proof-of-concept clinical trial in the Clinical Trials 
Unit in the Department of Dermatology at the Columbia University Medical Center 
entitled “An Open-Label Pilot Study to Evaluate the Efficacy of RUXOLITINIB in 




The primary efficacy endpoint of this initial pilot study is the proportion of 
responders achieving 50% or greater regrowth at the end of treatment compared to 
baseline.  Secondary endpoints include the changes in hair growth both during and after 
treatment measured as a continuous variable; patient global assessments; quality of life 
assessments; and durability of response following treatment cessation.   
Inclusion criteria included 30 to 95% hair loss due to alopecia areata (AA) as 
measured by SALT score30; hair loss duration of at least 3 months; stable hair loss 
without active evidence of regrowth; subject age 18-75 years.  
Exclusion criteria included active scalp disease other than AA; medical history 
that might increase the risks related to ruxolitinib e.g. hematologic, infectious, immune 
related diseases or malignancies; current treatment with any modality that might affect 
AA response; medications known to interact with ruxolitinib; pregnancy; etc.  
Subjects on study are treated with oral ruxolitinib 20mg BID for at least 3 months. 
The patients in this manuscript have achieved over 90% regrowth. Skin punch biopsies 
(4mm) were obtained at baseline and after 12 weeks of treatment. 
Antibodies used for mice treatment, flow cytometry, immunostaining and western 
blot analysis 
All antibodies used in these studies are listed in table form below. 
Flow cytometric analysis used the following anti-mouse antibodies: CD3 (17A2, 
Ebioscience), CD4 (GK1.5, BD), CD8α (53-6.7, BD), CD8β (YTS156.7.7, Biolegend), 
NKG2D (CX5, Ebioscience), NKG2A/C/E (clone 20d5, Ebioscience), CD44 (IM7, BD), 




CD103 (2E7, eBioscience), IFNγ (XMG1.2, Ebioscience), Granzyme B (NGZB, 
eBioscience), Rae-1 (186107, R&D). 
For immunohistochemical studies of mouse skin, 8 µM methanol-fixed frozen 
skin sections were stained with primary rat antibodies (Biolegend) including: anti-CD8 
(clone 53-6.7), Biotin anti-MHC class I (clone 36-7.5), anti-MHC class II (clone 
M5/114.15.2). Biotinylated goat anti-rat IgG (Life Technologies) was used as secondary 
antibody.  For immunofluorescence studies anti-H60 (R&D, clone 205326), anti-Pan 
Rae-1(R&D, clone 186107), anti-NKG2D (R&D clone 191004), anti-IL-15 (SCBT, H-
114), anti-IL-15 RA (SCBT, N-19), anti-K71 (Abcam), primary antibody were used in 
immunofluorescence. Alexa Fluor 488 or Alexa Fluor 594-conjugated goat anti-Rat, 
donkey anti-Rabbit or donkey anti-Goat antibody was used as secondary antibody (Life 
Technologies).  
For immunohistochemical studies of human skin, 5µM formalin fixed and paraffin 
skin section were used. After heat antigen retrieval, skin sections were stained with 
primary anti-human antibodies including: anti-CD8(Abcam ab4055), anti-CD4(,Leica 
clone 1-F6), HLA Class 1 ABC(Abcam clone EMR8-5), HLA-DR/DP/DQ(SCBT clone 
CR3/43). ImmPRESS HRP Anti-Rabbit Ig or Mouse Ig (Peroxidase) Polymer (Vector 
Lab) were used as secondary antibody. 
Human hair follicles were microdissected and embedded in OCT compound prior 
to sectioning and staining.  8 µM methanol-fixed frozen sections were stained with anti-
IL-15 (SCBT, H-114) and anti-IL-15 RA (SCBT, N-19) or anti-IL-15 RB (SCBT, C-20) 




594-conjugated secondary antibody (Life Technologies).  All images were captured with 
an SDRC Zeiss Exciter Confocal Microscope.  
For western blotting, samples with treatment were resolved by 4-12% SDS-
PAGE (Life Technologies) and then transferred to Westran PVDF membranes (GE 
Healthcare life Sciences). Blots were probed with the following Abs (All from Cell 
Signaling Technology): anti-phospho-STAT1 (Tyr701), anti-phospho-STAT5 (Tyr694), 
anti-STAT1 and anti-STAT5.  
Antibodies for in vivo treatment  
Mouse antibody  Company Clone  Cat No. 
Anti-IL15 Rβ Biolegend TM-β1 123204 
IL-2 BioXcel S4B6-1 BE0043-1 
IL-2 BioXcel JES6-1A12 BE0043 
IFN-γ BioXcel H22 BE0254 
IL-21 Ebioscience FFA21 16-7211-85 
 
Antibodies for flow cytometry (1/100 dilution) 
Mouse 
antibody  Company Clone  Cat No. 
CD3 Ebioscience 17A2 17-0032 
CD4 BD GK1.5 560181 
CD8a BD 53-6.7 560469 
CD8b Biolegend YTS156.7.7 126610 
NKG2D Ebioscience CX5 12-5882 
NKG2A/C/E Ebioscience 20d5 13-5896 
CD44 BD IM7 553133 
CD45 BD 30-F11 552848 
D49b BD Dx5 553857 
Cd62L BD MEL-14 553152 
CD69 BD H1.2F3 557392 
CD103 Ebioscience 2E7 17-1031 




Pan Rae-1 R&D systems 186107 MAB17582 
Granzyme B Ebioscience NGZB 11-8898 
 
Antibodies for immunostaining and western blot (1/100 dilution unless otherwise noted) 
Human antibody  Company Clone  Cat No. 
CD3 Abcam PS1 Ab699 
CD8 SCBT C8/144B Sc-53212 
CD4 Leica 1-F6 CD4-1F6-L-CE 
HLA Class I ABC Abcam EMR8-5 ab70328 
HLA-DR/DP/DQ SCBT CR3/43 sc-53302 
 
Mouse antibody  Company Clone  Cat No. 
CD8 Biolegend 53-6.7 100702 
MHC-class I Biolegend 36-7.5 114903 
MHC-class II Biolegend M5/114.15.2 107602 
H60 R&D systems 205326 MAB1155 
Pan Rae-1 R&D systems 186107 MAB17582 
NKG2D R&D systems 191004 MAB1547 
 
Mouse/Human antibody  Company Clone  Cat No. IF/IHC Dilution 
IL-15 SCBT polyclonal H-114 sc-7889  
IL-15RA SCBT polyclonal N-19 sc-1524  
Phospho-Stat1 (Tyr701) Cell signaling D4A7 7649  
Phospho-Stat3 (Tyr705) Cell signaling D3A7 9145 1/200 
Phospho-Stat5 (Tyr694) Cell signaling C11C5 9359 1/400 
Stat1 Cell signaling polyclonal 9172  
Stat5 Cell signaling polyclonal 9363  
K71 Abcam polyclonal Ab133817  
STAT1, STAT5, pSTAT1 and pSTAT5 ab’s were diluted 1/1000 for western blots. 
IL-15 and IL-15RA staining blocking reagents 
Blocking reagent  Company Cat No. 
IL-15 Peprotech AF-200-15 






Samples were sequenced on the HiSeq 2000 sequencer (Illumina, San Diego, 
CA) for 50 cycles.  RNA-Seq files were demultiplexed by the Rockefeller University 
Genomics Core Facility.  Quality control of the sample fastq files was performed using 
fastqc31.  TopHat32 was used to map transcripts to the UCSC mm9 reference genome 
from iGenome.  The RefSeq gene annotation packaged with this iGenome version of 
the UCSC mm9 were used.  The htseq-count utility from the HTSeq package was used 
to convert TopHat bam files to counts that could be used as input for downstream 
analysis of differential expression with edgeR33.  Absent genes were removed and a 
pseudocount of 1 was added in order to avoid division by zero in downstream analysis.  
EdgeR was used to identify differentially expressed genes using a matched pairs design 
with three biological replicates. 
Microarray Analysis 
Quality Control, Preprocessing  
For the mouse cDNA samples were hybridized to the Mouse Genome 430 2.0 
gene chips and subsequently washed, stained with streptavidin-phycoerythrin, and 
scanned on an HP GeneArray Scanner (Hewlett-Packard Company, Palo Alto, CA).  
For the human, amplified cDNA was hybridized to the Human Genome U133 Plus 2.0 
gene chips.   
Microarray quality control and preprocessing were performed using BioConductor 




mice, 2) prevention mice with three treatments vs. placebo and sham-operated mice, 
and 3) treatment mice for two treatments vs. placebo were performed separately using 
the same pipeline.  
Quality control was performed using the affyanalysisQC package from 
http://arrayanalysis.org/. AffyanalysisQC uses the R/BioConductor packages: affy, 
affycomp, affypdnn, affyPLM, affyQCReport, ArrayTools, bioDistm biomaRt, simpleaffy, 
and yaqcaffy to perform QC within a single script.  RMA normalization34 was performed 
on each experimental group separately.  Batch effect correction using ComBat was 
required for the prevention experiments.   Batches, treatments and time points were 
modeled treating each treatment group effect as constant over time, and grouping the 
PBS controls in groups reflecting both treatment and time.  
In addition to the preprocessing that was done for the mouse skin samples, 
Harshlight was used to correct for image defects for the human skin samples.  
 
Data Deposition 
Microarray and RNA-seq data was deposited in Gene Expression Omnibus, accession 
numbers GSE45657, GSE45512, GSE45513, GSE45514, GSE45551, and GSE58573. 
Identification of Gene Signatures 




Initial analysis of differential gene expression was performed on the spontaneous 
mouse 3x3 and the human 5x5 data sets using limma35.  A threshold of 1.5 fold change 
and unadjusted p-value of 0.05.  
Unsupervised analysis 
Hierarchical clustering was performed using Cluster36 on the 363 genes from the 
human 5x5 and 583 genes from the spontaneous mouse 3x3 that met the threshold 
abs(logFC) > 1, unadjusted p-value <= 0.05. Genes were median centered and 
normalized.  Spearman rank correlation was used as the similarity measure and 
average linkage was used to perform row (genes) and column (sample) clustering. 
Visualization of the hierarchical clusters was performed with java TreeView37. Gene 
Expression Dynamic Index (GEDI) analysis was used to visualize how “metagenes” 
identified with a self organizing map algorithm vary across samples38.  Metagenes are 
clusters of genes that show similar expression patterns across samples and that are 
assigned to a single pixel in a two dimensional grid.  Neighboring pixels demonstrate 
similar expression patterns to one another. 
 
RT-PCR Validation  
Predicted differentially expressed genes in human and mouse were confirmed 
using RT-PCR.  First-strand cDNA was synthesized using a ratio of 2:1 random primers: 
Oligo (dT) primer and SuperScript III RT (Invitrogen) according to the manufacturer's 
instructions. qRT-PCR was performed on an ABI 7300 machine and analyzed with ABI 
Relative Quantification Study software (Applied Biosystems, Foster City, CA, USA). 




using Power SYBR Green PCR Master Mix (Applied Biosystems), 250 nM primers 
(Invitrogen) and 20 ng cDNA in a 20µL reaction volume. Primer sequences are provided 
in Supplementary Tables 4 and 5.  The following PCR protocol was used: step 1: 50°C 
for 2 min; step 2: 95°C for 10 min; step 3: 95°C for 15 s; step 4: 60°C for 1 min; repeat 
steps 3 and 4 for 40 cycles. All samples were run in quadruplicate for three independent 
runs and normalized against an endogenous internal control as indicated. 
ALADIN scores 
 The IFN and CTL signatures were used to develop a bivariate score statistic. 
Individual signature IFN and CTL scores were determined following procedures used in 
human SLE39,40. The sets of genes selected to comprise our IFN and CTL signatures 
were CD8A, GZMB, and ICOS for the CTL signature, and CXCL9, CXCL10, CXCL11, 
STAT1, and MX1 for the IFN signature.  The scores for the prevention mice were 
calculated in relation to the sham mice; whereas, the scores for the topical treatment 
experiments were calculated relative to all the samples at week zero.  Based on our 
human studies (unpublished), ALADIN was further extended to include a hair keratin 
(KER) signature.  The set of genes selected to comprise the KER signature are DSG4, 
HOXC31, KRT31, KRT32, KT33B, KRT82, PKP1, and PKP2.  The ALADIN scores for 
the baseline and 12 week skin biopsies obtained from subjects enrolled in the oral 
Ruxolitinib clinical trial were calculated relative to the healthy controls at baseline. 
 
Power analysis 
For the analysis of response to treatment, we performed a two-sample 




treated and placebo mice for the case when the true proportion in population 1 (the 
treatment group) expected to respond to treatment is 0.95 and the true proportion in 
population 2 (the placebo group) expected to respond is 0.20.  At a significance level of 
alpha = 0.05, using Barnard’s exact test we calculated a power of 0.803 for a one-sided 
test to detect a difference of proportions when the proportions for the two populations 
are 0.95 and 0.20 with group sample sizes equal to five each.  In some cases in which 
fewer than 5 animals per group were present per experiment, multiple experiments were 
collapsed in order to ensure statistical power. 
Statistical Analysis of Treatment Effects 
Mice were expected to exhibit alopecia 4-12 weeks after grafting of alopecic skin.  
Experiments in which control mice failed to demonstrate hair loss by 8 weeks were 
aborted.  For the prevention experiments, a time-to-event survival analysis for interval 
censored data was performed.  The survival and interval packages in R were used to 
perform log-rank tests. Hair growth index was calculated as described11. 
For the treatment experiments (Figure 4b), the R package nparLD was used to 
test the hypothesis that there exists a treatment by time interaction.  Analyses were 
performed using the hair growth index from three replicate experiments containing three 
mice from each treatment and placebo group for a total of nine mice from each 
group.   A F1-LD-F1 design was employed.  For the JAK1/2i treatment vs. placebo, the 
hypothesis of no interaction, i.e., parallel time profiles, is rejected at the 5% level using 
both the Wald-Type Statistic and the ANOVA-Type Statistic with the p-values of 4.40e-
21 and 3.35e-18, respectively.  For the JAK3i Treatment vs Placebo, the hypothesis of 




Type Statistic and the ANOVA-Type Statistic with the p-values of 1.45e-30 and 2.42e-
21, respectively. 
All mice were included in survival (time-to-event) analysis statistics.  For lymph node 
and skin cell analysis, biopsy was harvested at the indicated time points following 
treatment in parallel with control mice.  In the IFN-γ- and IL-2- neutralization 
experiments one out of five control mice that did not exhibit hair loss was not included in 
the photographs (Figures 2b, 2e).  These mice were not sacrificed in order to continue 
to monitor for hair loss, but for statistical purposes for skin cell analysis (Figure 2b, 2e), 
these unanalyzed samples were assigned a cell count value of 0% CD8+NKG2D+ cells 
to allow for a rigorous and conservative statistical comparison with treated mice. 
No randomization was used and the investigators were not blinded to the group 
allocation during the experiments or when assessing the outcomes. 
Unpaired parametric two-sided t-tests were used to test for differences in means and 
frequencies between treated and untreated groups.  For statistical purposes, we 
assume all variances to be the same for each group. 
Interval censored log-rank tests were used to perform all time to event survival 
analysis.  This test properly accounts for data where the exact event time is not known 
but the event is known to fall within some interval. 
Nonparametric longitudinal data analysis was used to test for response x time 






Sample sizes, number of replicates, and statistical tests among experiments 
 
Figure n_control n_exp experiment statistic p-value 
1c 3+3+3+3 6+6+6+6 C3HAA/C3H cell counts t < 0.0001 
1d 2+2+2 5+5+4 C3HAA/C3H skin t < 0.0001 
1d 3+3+2 4+4+4 C3HAA/C3H lymph node t < 0.0001 
1f 3 3 primary cell culture N/A  NA 
2b 5 5 α-IFNg, mice with hair loss log-rank 0.047 
2b 5 5 α-IFNg Skin cell counts t 0.0228 
2e 5 5 α-IL2, mice with hair loss log-rank 0.048 
2e 5 5 α-IL2 Skin cell counts t 0.0091 
2h 5+4+3 5+4+3 α-IL15Rb, mice with hair loss log-rank 1.11E-05 
2h 2+2+1 2+2+2 α-IL15Rb Skin cell counts t < 0.0001 
3b 4+6 4+6 JAK1/2i, mice with hair loss log-rank 0.00041 
3c 2+3 3+3 JAK1/2i Skin cell counts t 0.0003 
3c 2+3 4+5 JAK1/2i lymph node cell counts t < 0.0001 
3g 7 5 JAK3i, mice with hair loss log-rank 0.0025 
3h 2+2 2+3 JAK3i Skin cell counts t 0.0002 
3h 2+2 2+3 JAK3i lymph node cell counts t 0.0049 
4b 3+3+3 3+3+3 JAK1/2i / JAK3i / Vehicle nonparLD 
Jak1/2i 4.4e-21, 
Jak3i 1.5e-30 
4c 3 3 JAK1/2i / JAK3i / Vehicle Skin t 
Jak1/2i 0.017, 
Jak3 0.015 
4c 3 3 





For in vivo studies data are provided as cumulative data.  The number of replicates are 
provided as shown above; For example “3+3+3+3” refers to four separate experiments each 
including three experimental mice. For in vitro studies (Figures 1f, 3d, and 3e), experiments 














Supplementary Figure 1.  NKG2D-NKG2DL expression in mouse AA  
a, Rae-1 is upregulated in the AA HF. Immunostaining of lesional using a pan-Rae-1 
antibody in C3H/HeJ alopecic mice, unaffected C3H/HeJ mice and C57Bl.6 mice. b, 
H60 and Rae-1 are overexpressed in AA.  NKG2DL expression in alopecic lesional skin 
from C3H/HeJ mice compared with non-lesional skin from unaffected C3H/HeJ mice. 
RT-PCR data from cDNA from 3 mice are shown and represented as relative to 
GAPDH. c, CD4 T cells are infrequent in AA lesional skin: Flow cytometric evaluation of 
lesional alopecic skin. Quantitation of CD4 and CD8 T cells as a percentage of total 
gated CD3+ or CD45+ cells.  d, Effector memory immunophenotype of CD8+NKG2D+ T 
cells are similar in lesional skin and in the cutaneous draining lymph node.  Gated 
CD8alpha+NKG2D+ T cells are displayed for CD8beta, NKG2D, NKG2A/C/E, CD44, 
CD103 and CD62L expression. 
  
a b
C57BL/6 C3H C3H AA
Rae-1Rae-1 Rae-1
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Venn Diagram Group Gene overlap 
Group I (NKG2D+CD8+ 
T cell and NK cell 
(Bezman)) 
Arsb, Gem, Itga2, Klf12, Klrd1, Spry2, Styk1, Sytl3, 
4831426l19Rik, A930038C07Rik 
Group II (CD8+NKG2D+ T 
cell and CD8+ cell (Best)) 
Anxa1, Atp2b4, Bhlhe40, Casp1, Ccl3, Ccl4, 
Ccr2, Crybg3, Ctla2a, Cx3cr1, Cyfip1, 
Dennd5a, Dkkl1, Dock5, Ern1, F2rl2, Fam129a, 
Fasl, Fcgr2b, Gadd45b, Gna15, Gzmk, Id2, 
Ifng, Irf4, Itga1, Itgax, Kcnk5 Klrc1, L1cam, 
Lgals1, Ncald, Ptprj, Rnf216, Rora, S100a4, 
S100a6 Soat2, Ttc39c, Zdhhc2, Zeb2 
Group III (CD8+NKG2D+ T 
cell and CD8+ cell (Best) 
and NK cell (Bezman)) 
Car5b, Ccl5, Fbxl2, Gm11435, Gzma, Gzmb, Il12rb2, 
Klrc2, Klrc3, Klre1, Klrk1, Osbpl3, S1pr5, Slc25a24  
 






Top and bottom left panels,  List of genes and Venn diagram showing overlap of our 
CTL gene expression with those in the literature41,42  Bottom right panel,  Network Map 
of differentially expressed upregulated genes in CD3+ CD8+NKG2D+ LN cells vs. 
CD8+NKG2D- cells.  String.db was used to create a biological interaction score matrix 
with the differentially expressed genes.  The network map was created using cytoscape; 
only biological interactions >0.75 were used.  Nodes represent genes, and edges 
represent biological interactions as derived from string.db.  Node size is proportional to 






Signature Human Mouse 
CTL GZMA(3.65x), CD8A(3.04x), GZMB(2.75x), 
GZMK(2.68x), PRF1(2.30x), LCP2(2.29x), 
CD2(2.22x), IL7(2.20x), THEMIS(2.14x) 
Gzma(56.37x), Cd8a(9.05x), Gzmb(21.74x), 
Gzmk(2.61x), Prf1(1.62x), Lcp2(2.32x), Cd2(3.32x), 
Il7(1.99x), Themis(1.84x) 
IFN CXCL10(12.37x), CXCL9(9.53x), 
MMP12(4.04x), IFI44(3.03x), SPP1(2.69x), 
IRF8(2.64x), PTPRC(2.63x), CCL2(2.54x), 
RSAD2(2.49x), CCL5(2.36x), IFIT2(2.28x), 
C1S(2.28x), TLR3(2.25x), IFIT3(2.19x), 
OAS2(2.12x), GBP1(2.11x), XCL1(2.05x), 
CCR2(2.04x), CXCL11(1.86x), IFNG(1.57x), 
STAT1(1.53x), JAK1(0.85x) 
Cxcl10(37.58x), Cxcl9(42.30x), Mmp12(10.18x), 
Ifi44(20.58x), Spp1(10.61x), Irf8(4.44x), Ptprc(2.11x), 
Ccl2(6.12x), Rsad2(3.20x), Ccl5(27.95x), Ifit2(2.39x), 
C1s(2.49x), Tlr3(2.34x), Ifit3(4.75x), Oas2(3.97x), 
Gbp1(17.81x), Xcl1(2.88x), Ccr2(4.66x), 
Cxcl11(53.33x), Ifng(4.71x), Stat1(14.48x), Jak1(1.40x) 
γc IL15(2.24x), JAK3(2.10x), IL2RG(2.08x), 
IL2RB(1.98x), IL15RA(1.60x), IL21R(1.84x), 
IL2RA(1.12x), IL7(2.20x), IL7R(1.61x) 
Il15(0.80x), Jak3(1.39x), Il2rg(2.94x), Il2rb(3.14x), 
Il15ra(1.40x), Il21r(1.69x), Il2ra(1.57x), Il7(1.99x), 
Il7r(2.39x) 





St8sia4(1.86x), Gpr65(3.25x), Glipr1(2.33x), 
Ikzf1(2.34x), Cd274(8.41x), Samd9l(4.37x), 
Lcp1(2.25x), Sash3(2.76x), Atp8b4(3.44x) 
 
Supplementary Figure 3. Validation of mouse RNA expression studies.  
 
To determine the expression signature of C3H/HeJ mouse skin affected with alopecia areata, 
lesional skin was isolated from three affected female mice and three unaffected aged-matched 
controls. Total and small RNAs were isolated from whole skin and biotin-labeled cRNA was 





















































2.0 Genechip. Data analysis was done as outlined in the Methods. Top panel, Representative 
list of differentially expressed genes among human AA and C3H/HeJ AA reveals shared 
inflammatory pathways, in particular IFNγ pathway genes, genes representative of CD8 
effectors, and a striking γc pathway signature. Middle panel, Heatmap depicting the significantly 
and differentially expressed genes between C3H/HeJ affected and unaffected skin. Bottom 
panel, Validation by qRT-PCR of several selected immune-related genes from this list whose 
expression levels are significantly upregulated in AA lesional skin compared to unaffected skin, 
where each bar represents the average fold change of three independent experiments. UA = 







Supplementary Figure 4.  Validation of human 
mRNA expression studies.   
Validation by qRT-PCR of several selected immune-
related genes whose expression levels were 
significantly upregulated by transcriptional profiling in 
human AA lesional skin (n=5) compared to unaffected 






Supplementary Figure 5.  IL-15 Staining of Human AA hair follicles.  
IL-15 and IL-15RA expression are upregulated in the outer root sheath of human AA 
(compared with normal controls, NC). a, Human hair follicles stained for IL-15, IL-15Rα, 
and merged image. b, Frozen 5µM human hair follicle sections from two patients with 
AA, stained with isotype control, anti-IL-15 and anti-IL-15RA without and with blocking 
reagents as indicated above. c, Hair follicle infiltrates contain CD8+ T cells that co-
expressed CD122 (IL-15Rβ). d, As a positive control, human lesional skin from a patient 














































staining of IL-15 and IL-15Rα, while normal foreskin does not. Isotype control: normal 
rabbit IgG control for rabbit anti-IL15 antibody, or normal goat IgG for goat anti-IL15RA 
antibody. Blocking:  IL-15 protein plus anti-IL15 antibody, or IL-15RA peptide plus anti-
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Supplementary Figure 6.  IL-15 Staining of mouse AA hair follicles.  
a, IL-15 and IL-15Rα expression are upregulated in the outer root sheath of mouse AA 
(compared with non-alopecic controls, C3H). b, The positive staining of IL-15/IL-15Rα in 
alopecia mouse cutaneous lymph nodes is inhibited by blocking reagents. Isotype 
control: normal rabbit IgG control for rabbit anti-IL15 antibody, or normal goat IgG for 
goat anti-IL15RA antibody. Blocking:  IL-15 protein plus anti-IL15 antibody, or IL-15RA 
peptide plus anti-IL15Rα antibody.  c, IL-15 and IL-15Rα expression is induced after 








control or 1000ng IFNγ and 250ngTNFα in 100ul PBS, and were sacrificed 72 hours 









Supplementary Figure 7. IL-21 blockade fails to prevent the onset of Alopecia 
Areata in C3H/HeJ mice.  
 
C3H/HeJ grafted mice were treated from the time of grafting with 300 mg anti-IL-21 
antibody (Ebioscience, Clone FFA21) injected intraperitoneally three times a week for 
14 weeks. (a) The onset of alopecia is not inhibited by anti-IL-21 treatment in grafted 
C3H/HeJ mice. (b)Time course of the onset of hair loss in control mice and anti-IL-21 
treated mice was shown as weeks after grafting. (c) The frequency of CD8+NKG2D+ T 


















































































































Supplementary Figure 8.  STAT expression in human and mouse hair follicles.  
Skin sections from human normal controls (top/left panels) or human AA hair follicles 
(bottom/left), were costained for CD3 and a phosphorylated STAT molecule as indicated 
above.  Mouse skin sections from unaffected C3H/HeJ mice (top right) or alopecic 
C3H/HeJ mice (bottom right) were costained for CD8 and a phosphorylated STAT 









Supplemental Figure 9.  JAK inhibitors diminish responses to IFN-γ  and IL-15. 
a, JAK1/2i (ruxolitinib) inhibits IFNγ-induced Stat1 activation and b, IL-15 production in 
dermal sheath cells. c, JAK3i (tofacitinib) inhibits IL-15-induced Stat5 activation in T 
cells. d, JAK3i inhibits IL-15-induced LAK cell cytotoxic function. e, JAK3i inhibits IL-15-
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Supplementary Figure 10.  GEDI analysis from prevention studies.  
GEDI analysis was performed on gene profiles from JAK1/2i- or JAK3i- treated mice.  A 
subjectively identified region of metagenes (white outline) that correlated with either the 




















Supplementary Figure 11.  Systemic treatment of AA mice with JAK3 inhibitor.   
C3H/HeJ mice with long-standing alopecia areata were treated with tofacitinib with Alzet 
osmotic mini-pumps (pumps, model 2004, Durect Corporation) implanted 
subcutaneously on the back of each mouse to deliver vehicle (poly(ethylene glycol) 
(PEG)300) or vehicle containing JAK3i tofacitinib (Abmole) at 15 mg/kg/day for 12 wks. 
a, Alopecia areata reversal was complete on both the back and belly, although the rate 
of hair regrowth was slower than with topical administration. b, Flow cytometric analysis 
of skin and cutaneous lymph node populations shows elimination of the CD8+NKG2D+ T 
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treated with tofacitinib or placebo demonstrates elimination of CD8 infiltration and MHC 








Supplementary Figure 12.  GEDI of topical treatments.   
GEDI analysis was performed on C3H/HeJ mice before treatment (left 3 rows of 
panels), after 6 weeks of treatment (middle 3 rows of panels), or after 12 weeks of 
treatment (right 3 rows of panels.  Treatments included topical formulations of ruxolitinib 


























Supplementary Figure 13. Immunofluorescence staining of untreated abdominal 
skin.   
Ventral skin sections from mice treated with topical formulations of vehicle control (top 
row), ruxolitinib/JAK1/2i (middle row), or tofacitinib/JAK3i (bottom row) on their dorsal 
surfaces were stained with CD8 (left column), MHC Class I (middle column), or MHC 








Supplementary Figure 14.  Immunofluorescence staining of skin at early 
timepoints during topical treatment.  
Skin sections from mice treated with topical formulations of vehicle control (left columns) 
or ruxolitinib/JAK1/2i (right columns) were stained with CD8, MHC Class I, or MHC 
Class II as indicated.  Skin sections were stained prior to starting treatment (top row), or 
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Supplemental Figure 15. Patient #1 response to ruxolitinib.   
 
Patient #1 at baseline (A) and after 12 weeks (B) and 20 weeks (C) of treatment.  Near 
complete hair re-growth is seen by 20 weeks.  Patient #2, data not shown, also 










Supplemental Figure 16. Patient #3 response to ruxolitinib.  
 
Patient #3 at baseline (a), after 12 weeks (b) and after 16 weeks (c) of treatment.  
Patients enrolled in this pilot study are anticipated to be treated until maximal response 
or up to 6 months of treatment, followed by observation off drug for an additional 3 
months to assess response durability. 
  
A. Baseline B. 12 weeks C. 16 weeks 
Nature Medicine: doi:10.1038/nm.3645
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Supplementary Figure 17.  Schematic representation of our model of the IL-
15/IFNγ  axis in alopecia areata and its targeting using JAKis.   
Interferon gamma and IL-15/IL-15Ra cooperate to induce a Type I cytotoxic response. 
CD8 T cells produce IFNγ which breaks the immunological privilege of the hair follicle, 
upregulating antigen presentation (MHC I and II), inducing inflammatory chemokines 
(CXCL9-11), induction of NKG2DLs and upregulation of IL-15/IL-15Ra by the hair 
follicle.  In turn, this leads to the further recruitment and activation of effector 
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Abstract 
Alopecia areata (AA) is among the most highly prevalent human autoimmune diseases, 
characterized by disfiguring hair loss due to the collapse of immune privilege in the hair 
follicle. To determine the genetic architecture of AA, the Christiano lab recently 
performed a Genome-Wide Association Study (GWAS) and identified the ULBP3/6 
locus on chr.6q25.1 (p = 5.9 x 10-24) as the most significantly associated locus outside 
the HLA region. The ULBP genes reside within a 180 Kb MHC class I-related cluster 
and encode ligands for the NKG2D cytotoxic T cell receptor. Importantly, these ligands 
possess striking upregulation in both human and mouse AA hair follicles, and we 
showed that CD8+NKG2D+ cells are both necessary and sufficient to induce disease in 
the AA mouse model, establishing a definitive role for the ULBP-NKG2D signaling axis 
in disease pathogenesis. To identify genetic variants in the ULBP3/6 locus that are 
associated with AA, we performed targeted deep resequencing on 124 AA patients and 
uncovered a number of rare, non-coding variants enriched on GWAS risk haplotypes. 
Interestingly, we identified three novel variants that reside within ULBP6 regulatory 
elements that coincide with CTCF ChIP-seq binding sites. These variants fall within 
paired-end tags from an ENCODE CTCF-mediated Chromatin Interaction with Paired-
End Tags (ChIA-PET) experiments, suggesting this region engages in long-range 
interactions. In vitro, ULBP6 AA rare variants decreased reporter activity and abrogated 
CTCF-mediated ULBP6 repression, and in vivo, we observed CTCF binding enrichment 
at ULBP6 by ChIP-PCR on human scalp dermal fibroblasts. Our findings identify a role 
for CTCF variants at the ULBP3/6 locus in association with AA, suggesting that long-
range regulatory interactions may control gene expression in the hair follicle.
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Introduction 
Alopecia areata (AA) is an autoimmune disease characterized by disfiguring hair loss 
that affects approximately 5.3 million people. An underlying genetic basis for AA is 
supported by the observed heritability in first-degree relatives (10-fold increased risk), 
twin studies (42-55% concordance in monozygotic twins) and family-based linkage 
studies (VAN DER STEEN et al. 1992; MCDONAGH AND TAZI-AHNINI 2002) (JACKOW et al. 
1998; MARTINEZ-MIR et al. 2003), though the key pathogenic risk variants underlying this 
complex disease remained elusive.  
The Christiano lab conducted an initial Genome-Wide Association Study 
(GWAS), identifying eight regions that clustered into discrete linkage disequilibrium (LD) 
blocks and surpassed genome-wide statistical significance, including the HLA 
(MICA/MICB), ULBP3/6, CTLA4, IL2RA, IL2/IL21, IKZF4 (Eos), STX17 and PRDX5 loci 
(PETUKHOVA et al. 2010). To expand gene discovery, we recently conducted a meta-
analysis GWAS and replication expanding our cohort up to 3,253 cases and 7,543 
controls, which identified two novel loci and increased the genome-wide significance of 
our previous findings (BETZ et al. 2015). Remarkably, our GWAS/meta-GWAS results 
pointed to the ULBP3/6 region on chr.6q25.1 (p = 5.9 x 10-24) as the most significantly 
associated locus outside the HLA region.  
The ULBP (cytomegalovirus UL16-binding protein) genes reside in a 180-
kilobase MHC class I-related cluster on human chromosome 6q25.1, and encode 
multiple ligands for the activating cytotoxic T cell receptor, NKG2D (CAO AND HE 2004). 
Our GWAS and subsequent replication are the first to implicate the ULBP gene cluster 
in any human disease, although allelic variants and polymorphisms in other NKG2DLs 
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(MICA/MICB) have been previously associated with AA (BARAHMANI et al. 2006; ITO et 
al. 2008). 
The NKG2D receptor is expressed on CD8+ cytotoxic T cells and NK cells, and 
becomes activated in the presence of a stressed cell upregulating ULBP ligand 
expression as a “danger signal” (CAILLAT-ZUCMAN 2006). NKG2D-medated cytotoxicity 
has been well described in the context of viral infection, autoimmunity as well as cancer 
(GONZALEZ et al. 2006).  The Christiano lab previously demonstrated a marked 
upregulation of the NKG2D ligands, ULBP3 and MICA on human AA lesional hair 
follicles, and showed that NKG2D+CD8+ T cells infiltrate the base of the hair follicle 
during active disease. In the alopecia areata mouse model (C3H/HeJ strain) that 
recapitulates many pathological features of adult AA in humans, we observed an 
upregulation of the NKG2D ligands, H60 and Rae-1 (analogous to human MICA and 
ULBP), and demonstrated that cytotoxic CD8+NKG2D+ T cells are both necessary and 
sufficient for the induction of hair loss and disease pathogenesis (PETUKHOVA et al. 
2010; XING et al. 2014) (BARAHMANI et al. 2006; ITO et al. 2008). These immunological 
findings and the strong genetic association of ULBP3/6 with human AA provide a 
definitive role for the ULBP-NKG2D signaling axis, yet the precise pathogenic NKG2DL 
variants contributing to autoimmunity in the hair follicle remain unknown. 
There are several well-characterized immune-related loci that are 
transcriptionally regulated in a spatiotemporal manner by long-range chromosomal 
interactions (JHUNJHUNWALA et al. 2009; SEKIMATA et al. 2009; MAJUMDER AND BOSS 
2010; WILLIAMS et al. 2013; SHARAF et al. 2014), including IFNG, class II cytokine 
receptor (CIICR) genes, Th2 genes including IL4, IL5, and IL13, and the HLA region 
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encoding the Major Histocompatability Complex (MHC) molecules that are 
transcriptionally regulated in a spatiotemporal manner by long-range chromosomal 
interactions (JHUNJHUNWALA et al. 2009; SEKIMATA et al. 2009; MAJUMDER AND BOSS 
2010; WILLIAMS et al. 2013; SHARAF et al. 2014). Many of these genes reside within 
clusters, which imply genetic structures governed by long-range interactions. The 
chromatin remodeling insulator protein CTCF has been described in several contexts to 
facilitate these interactions during lineage commitment, the generation of antigen 
diversity, as well during an immune response (JHUNJHUNWALA et al. 2009; SEKIMATA et 
al. 2009; MAJUMDER AND BOSS 2010; WILLIAMS et al. 2013; SHARAF et al. 2014). 
Considering the strong association of ULBP3/6 with AA and predominantly intergenic 
location of GWAS SNPs, we postulated that non-coding Single Nucleotide Variants 
(SNVs) contribute to dysregulated transcription factor binding, ULBP regulatory activity, 
and/or long-range interactions disrupting ULBP3/6 repression in the AA hair follicle. 
Here, we identified and characterized novel and rare susceptibility variants by 
performing targeted deep resequencing the ULBP3/6 locus. Using a robust functional 
genomics approach combined with in vivo and in vitro analyses, we identified the 
ULBP6 candidate region as a site for CTCF binding enrichment in human scalp dermal 
fibroblasts, and demonstrated that AA rare susceptibility variants not only disrupt 
regulatory activity, but also abrogate CTCF-mediated repressive effects on the ULBP6 
sequence. Moreover, the novel, rare variants are predicted to create new TFBS for 
activating proteins in immune signaling pathways. Our findings point to a novel role for 
CTCF and long-range interactions in the pathology of AA, providing insight into the 
mechanisms contributing to dysregulated ULBP3/6 expression in the AA hair follicle. 
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Results 
Targeted deep re-sequencing of the ULBP3/6 locus and functional genomics 
studies reveal novel rare, non-coding variants in CTCF binding sites 
The initial GWAS revealed eight genomic regions that are significantly associated with 
AA and cluster into discrete linkage disequilibrium blocks (PETUKHOVA et al. 2010). 
Since GWAS tag SNPs are intended to capture the majority of common genetic 
variation at a particular region, they usually represent a very small portion of the 
variants and provide very little insight about rare variants.  Therefore, it is necessary to 
perform targeted deep resequencing to identify both rare and common variants that are 
driving the genetic association of the tagSNPs. We prioritized these regions for targeted 
enrichment based on our GWAS LD peaks and our functional studies in the C3H/HeJ 
mouse model demonstrating a crucial role for the NKG2D signaling pathway in AA 
pathology (XING et al. 2014). 
To define the candidate region at the ULBP3/6 locus to be resequenced, we 
initially performed conditional analysis and determined that the 13 tag SNPs identified 
from the initial GWAS formed two statistically independent risk haplotypes (color coded 
blue and yellow in Figure 1A), encompassed within a 72 Kb region including both 
ULBP3 and ULBP6. We next designed a RainDance primer library to identify variants 
carried on these GWAS defined risk haplotypes and deep sequenced the entire 72 Kb 
region in 122 AA GWAS cases (Figure 1A). We identified 7 exonic variants, 48 intronic 
variants, and 364 intergenic variants. To identify rare variants potentially enriched in our 
cohort of AA patients, we selected all variants new or reported to be rare in public 
databases (f<0.01; n=129) that are found in 3 or more patients (n=29), which yielded a 
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total of 189 potentially causal variants (29 rare variants enriched on GWAS haplotypes 
and 160 common variants associated with risk haplotypes). We next performed 
functional annotations of the non-coding variants using Encyclopedia of DNA elements 
(ENCODE) and RegulomeDB to prioritize variants that may disrupt transcription factor 
binding sites (TFBS) and regulatory function in human keratinocytes and dermal 
fibroblasts, which are the target cells under autoimmune attack in AA.
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We identified 21 rare variants that fall within ENCODE defined regulatory regions 
and areas of chromatin accessibility (overlapping with DNAse I hypersensitive sites and 
H3K27Ac peaks), and 37 rare variants in known TFBS based on ChIP-seq data in 
human keratinocytes and fibroblasts (Figure 1B). We discovered a region with potential 
regulatory function at the ULBP6 locus harboring a cluster of rare and novel variants 
(not yet reported in public databases) (Figure 1B). Interestingly, three variants (G!C 
[chr6:150,336,528], G!T [chr6:150,336,541], and T!C [chr6:150,336,614]) reside 
within intergenic CTCF binding sites ~5 Kb downstream from the 3’ end of ULBP6 with 
ChIP-seq evidence for CTCF binding (Figure 1D). At least one of these novel variants 
was present in 9 independent samples in our cohort of 119 samples, generating a 
collapsed allele frequency of 3.8%. In addition, at a site ~1.1 Kb downstream of the 
CTCF variants, we found an enrichment of a rare variant (rs113050885) that also falls 
within a SUZ12 binding site and is located 28 bp downstream of a highly significant AA 
GWAS SNP rs9479403 (p-value, 4.4 x 10-18) and 54 bp upstream of GWAS SNP 
rs4242284 (p-value 2.1 x 10-08). Because the two GWAS SNPs are less than 100 bp 
away from each other, we were able to directly interrogate the Raindance sequence 
reads and confirmed that in every case, the rare variant rs113050885 lies on a 
haplotype in phase with the two common risk variants, suggesting that the rare variant 
is contributing to the association evidence.  
CTCF is endogenously bound and enriched at the ULBP6 candidate region in 
human scalp dermal fibroblasts 
CTCF is a well-characterized repressive insulator best known for its ability to block 
promoter-enhancer interactions by forming repressive chromatin loops (PHILLIPS AND 
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CORCES 2009), and previous studies have demonstrated that the genes encoding 
NKG2D ligands are actively repressed in healthy tissues (CAILLAT-ZUCMAN 2006). Our 
functional genomic studies at the ULBP3/6 locus revealed areas of chromatin 
accessibility (marked by DNAse I hypersensitivity sites), a feature of insulator sites, and 
CTCF binding by ChIP-seq (ENCODE).
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To determine whether CTCF is endogenously bound in healthy human hair 
follicles, we performed Chromatin Immunoprecipitation (ChIP) on two independent 
dermal fibroblast cell lines derived from the human scalp (Figure 2). Sanger sequencing 
the ULBP3/6 candidate region on both cell lines demonstrated that neither carries the 
AA risk haplotypes in ULBP3/6 (data not shown). We then determined enrichment for 
CTCF by immunoblotting using two validated antibodies as well as a FLAG-tagged form 
of CTCF to demonstrate CTCF antibody recognition (Figure 2A). CTCF 
immunoprecipitation on dermal fibroblasts overexpressing or lacking the FLAG-CTCF 
construct, followed by immunoblotting for CTCF and FLAG revealed a ~130 KDa band 
identical between transfected samples that were probed for α-CTCF and α-FLAG, with 
no α-FLAG reactivity in the untransfected samples (Figure 2A). Importantly, 
immunoprecipitation for CTCF using two distinct antibodies produced an intense and 
identical band on immunoblots that was absent in α-IgG pull downs, demonstrating 
strong CTCF enrichment (Figure 2B, C).  
To validate the efficiency of the ChIP assay on human scalp dermal fibroblasts, 
we then performed qPCR on the reverse-crosslinked fragmented gDNA for GAPDH and 
the H19 imprinting control region (ICR), which serve as positive controls for α-Pol II and 
CTCF occupancy, respectively. We observed enrichment for Pol II at the GAPDH 
promoter (~45% of input) as expected, and CTCF at the H19 ICR (35-45%), consistent 
with previous reports (Figure 2D). We next tested for CTCF enrichment specifically at 
the ULBP6 candidate region using qPCR, and observed a strong signal (50-70% of 
input) compared to that of the H19 ICR, which is only bound by CTCF on the maternal 
allele (PHILLIPS AND CORCES 2009) (Figure 2D, E). Furthermore, we obtained the same 
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results using a second set of primers specific to the ULBP6 candidate region (data not 
shown), and amplification of a site completely devoid of CTCF occupancy as a negative 
control (chr1q31.3) yielded no signal (Figure 2E). Taken together, these results clearly 
demonstrate that CTCF binding is enriched at this locus in healthy human dermal 
fibroblasts.  
Regulatory activity of the ULBP6 candidate region is reduced in the presence of 
AA rare, non-coding variants 
To gain insight as to the potential regulatory function(s) of the ULBP6 candidate region 
harboring the three rare variants, we first cloned a 250 bp fragment spanning the 
candidate region from control and AA genomic DNA samples into the pGF-mCMV 
vector (System Biosciences) upstream of a minimal CMV promoter (Figure 3A). We 
observed a significant increase in reporter activity by ~3 fold (p < 0.001) compared to 
the empty vector, scrambled sequence and a sequence containing no CTCF site 
(Figure 3B). We next tested the effects of the three rare, non-coding variants on reporter 
activity in vitro using the same approach, where a sequence containing all three variants 
in the CTCF sites was compared to the wild-type sequence and that containing no 
CTCF sites (Figure 3B). In the presence of the three AA variants, reporter activity was 
reduced by ~30% (p < 0.01), demonstrating differences in regulatory and trans factor 
binding properties (Figure 3B). To assess whether the decreased signal was attributable 
to one or more variant and considering that most AA patients with either risk haplotype 
harbor one rare variant, we cloned the ULBP6 candidate region harboring the individual 
rare variants and observed a significant decrease in activity in constructs containing 
rare variants 2 (G!T) and 3 (T!C), whereas the construct containing rare variant 1 
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(G!C) displayed activity similar to that of the control sequence (Figure 3C). The levels 
of rare variants 2 and 3-induced reporter activity were equivalent to the sequence 
containing all rare variants (Figure 3C), suggesting that these SNVs are producing the 
greatest effect.   
AA rare variants alter CTCF-mediated repressive activity at the ULBP6 intergenic 
region  
Our previous observations (Figure 3B and C) demonstrate that the AA rare variants 
reduce the reporter activity compared to that of the control sequence. Given the 
observation that these variants reside within CTCF binding sites, we next tested the 
effects of exogenous CTCF on these sequences. Using the pGF-mCMV reporter to test 
the effects of trans binding factors on the ULBP6 sequence, we first validated the 
efficiency of the system by cloning in the sequence for the cAMP response element 
binding protein (CREB), which drives strong reporter activity alone, and is further 
activated by PMA (phorbol 12-myristate 13-acetate), an activator of Protein Kinase C 
(PKC) (Figure S2) (MAO et al. 2007). We observed a marked increase in luciferase and 
GFP activity with CREB alone (2500-fold increase) and a nearly three-fold increase 
upon the addition of PMA to transfected cells (p<0.05) (Figure S1). To determine the 
effects of exogenous CTCF on the control ULBP6 region, we transfected human dermal 
fibroblasts with a FLAG-tagged form of CTCF in conjunction with the ULBP6-luciferase 
reporter, and observed a strong repressive effect (65-70% reduction; p<0.001) 
compared to a sequence containing no CTCF binding sites as well as the empty vector 
(Figure 3D). This finding is consistent with the known role of CTCF as an insulator and 
repressor, as well as with previous studies demonstrating its repressive effects in long-
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range reporter assays (NATIVIO et al. 2009). We next tested the consequence of the AA 
rare variants on CTCF-mediated repressive activity, and observed near abolishment of 
the repressive effect of CTCF on ULBP6 reporter activity (Figure 3D). These results 
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Figure 3. AA rare, non-coding variants disrupt ULBP6 regulatory activity and abrogate CTCF binding 
A. View of the ULBP6 250 bp region cloned into the pGreenFire reporter vector containing a minimal CMV 
promoter. B. Luciferase assay of the ULBP6 control (wild-type) and AA rare variants sequences compared 
to a sequencing containing no CTCF site, and normalized to the empty vector. The pCMV-GFP vector 
containing the full CMV promoter was included as a positive control for the assay. C. Luciferase activity of 
the individual AA rare variants 1-3 compared to the control and AA sequences containing all variants (ULBP 
AA). D. The effects of CTCF overexpression on luciferase activity; NC = negative control sequence 
containing no CTCF site, PC = positive control region containing multiple CTCF sites.  
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Novel TFBS created by rare variants point to increased activation of ULBP6 in AA 
In our initial analysis of the rare non-coding variants at the ULBP3/6 locus, we used 
RegulomeDB to test whether these variants are predicted to abolish TFBS motifs or 
other regulatory elements in the region. However, this analysis did not provide insight 
into whether the AA variants are predicted to create novel TFBS. We next performed an 
in silico analysis of the control and AA sequences using the software program TFBIND 
that searches for TFBS as well as TATA, GC, and CCAAT boxes. We identified two 
additional TFBS generated by two rare variants that were not found in the control 
sequence, specifically ELK1 and EGR3. ELK1 (ETS domain containing protein 1) is a 
transcriptional activator downstream of the ERK1/2 signaling pathway, reported to 
preferentially bind to the IL10 risk allele in systemic lupus erythematosus (SLE) and 
become activated by ULBPs to mediate natural killer cell responses (SUTHERLAND et al. 
2002; SAKURAI et al. 2013). EGR3 (Early growth response protein 3) is an NFAT target 
gene and inducer of NFKB during inflammation and antigen-induced proliferation of B 
and T cells (WIELAND et al. 2005; LI et al. 2012). Considering the known functions of 
these activating TFs in the immune system, we postulate that an increased binding 
affinity for ELK1 and EGR3 at the ULBP6 regulatory region could also contribute to the 
sustained activation of ULBP3/6 gene expression in AA.  
CTCF-mediated long-range interactions at the ULBP3/6 locus  
Several immune-related genes are transcriptionally regulated in a spatiotemporally 
coordinated manner during lineage commitment, immune responses as well as other 
processes. These loci have been reported to engage in long-range interactions 
associated with changes in chromatin architecture to promote a more transcriptionally 
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active environment. This phenomenon has been demonstrated at the HLA locus, the 
Th2 locus, as well as several others, where the CTCF chromatin insulator/remodeling 
protein mediates chromatin-looping events to block or promote enhancer-promoter 
interactions, depending on the context (MAJUMDER et al. 2008; MAJUMDER AND BOSS 
2010; GILLEN AND HARRIS 2011). Moreover, recent studies have demonstrated the 
presence of super enhancers (SEs) at well-characterized immune loci that serve as 
large clusters of lineage-specific transcriptional enhancers, where SEs are defined by 
p300 binding occupancy and H3K27Ac enrichment and CTCF demarcates these 
boundaries (HNISZ et al. 2013; FARH et al. 2015; VAHEDI et al. 2015). To determine 
whether the ULBP3/6 locus possesses SE activity, we performed in silico analysis of the 
region using ENCODE data (Figure 4). We did not observe enrichment for p300 or 
H3K27Ac, however, we did identify clusters of CTCF binding in chromatin-accessible 
regions (DNAse 1 hypersensitive sites and ENCODE FAIRE-seq) (Figure 4).  
In the context of alopecia areata and the loss of immune privilege in the hair 
follicle, the ULBP genes are strongly upregulated in the lesional hair follicle, raising the 
possibility that this locus participates in long-range interactions associated with gene 
repression in the healthy hair follicle. In our in silico analysis of the ULBP3/6 locus, we 
observed several clustered sites of CTCF binding enrichment in multiple cell types, and 
observed overlap with ENCODE CTCF-mediated Chromatin Interaction with Paired-End 
Tags (ChIA-PET) experimental data that identified CTCF-mediated long-range 
interactions at this locus (Figure 4). Two of the rare variants lie directly within a paired-
end tag (representing an interacting sequence) (rare variant cluster indicated by the 
blue vertical line), while the other paired-end tag is situated ~100 Kb downstream of 
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ULBP6 (Figure 4, gray bars). 
This finding together, with those from our reporter assays (Figure 3), provides evidence 
to support the hypothesis that the rare, non-coding variants may disrupt regulatory 
activity and/or long-range interactions at the ULBP3/6 locus in AA. Future functional 
studies utilizing long-range reporter assays and chromatin conformation capture (3C) 
with high throughput sequencing in human dermal fibroblasts will elucidate whether the 
ULBP6 candidate region participates in long-range interactions, what the interacting 
sequences are, and whether the AA rare variants alter such interactions. 
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Discussion 
For decades, the genetic architecture underlying alopecia areata has remained elusive, 
and our understanding of disease pathogenesis was limited to the knowledge of its 
autoimmune basis and the immunopathological findings in the skin characteristic of 
active disease. Recently, family-based studies at both the candidate and genome-wide 
levels have uncovered novel genes and loci associated with AA (MARTINEZ-MIR et al. 
2007), but given its polygenic inheritance pattern, a more comprehensive approach was 
warranted to decode the complex genetic architecture.  
The Christiano lab recently conducted the first GWAS for AA and identified eight 
regions of the genome that were significantly associated with the disease, where the 
highest signal outside the HLA emanated from the ULBP3/6 locus, a region not 
previously associated with AA or any other autoimmune disorder. The ULBP genes 
encode ligands for the cytotoxic T cell receptor NKG2D whose signaling axis had 
previously been implicated in AA disease pathogenesis from candidate gene 
association studies (MICA/B ligands) (BARAHMANI et al. 2006). Moreover, the 
overrepresentation of allelic variants in other NKG2D ligands (MICA, MICB) had also 
been reported in other autoimmune diseases, including rheumatoid arthritis (RA), type 1 
diabetes (T1D), celiac disease (CeD), and many of our GWAS regions of association 
were shared with these diseases (PETUKHOVA 2010).  
Given the common dysregulation of NKG2D signaling but unique association of 
ULBP3/6 with AA, the statistical associations at this locus were biologically validated by 
the presence of CD8+NKG2D+ T cells within the immune infiltrate and a strong 
upregulation of the ULBP3/6 ligands on lesional hair follicles (PETUKHOVA 2010). 
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Importantly, this finding was consistent with a previous report of the upregulation of 
another NKG2D ligand, MICA, on human lesional hair follicles, and collectively, these 
data placed the ULBP-NKG2D signaling axis squarely at the center of disease 
pathogenesis in AA. Importantly, our recent replication study in an independent cohort 
and meta-GWAS analysis not only validated but also increased the significance of the 
association signal for the ULBP3/6 locus in AA (BETZ et al. 2015).  Moreover, we 
recently demonstrated that CD8+NKG2D+ cells are both necessary and sufficient for 
disease pathogenesis in the C3H/HeJ mouse model for AA (XING et al. 2014). In this 
study, we determined the underlying pathogenic variants at the ULBP3/6 locus driving 
the association with human AA. 
Here, we performed targeted deep resequencing of the ULBP3/6 locus in 124 AA 
patients and tested the hypothesis that rare, non-coding variants contribute to 
dysregulated transcription factor binding and regulatory activity of this locus. In the 
study of common diseases, the emerging picture of the genetic architecture is 
highlighting the contribution of rare variants to the “missing heritability,” therefore, we 
focused our studies on rare variants that are enriched on GWAS risk haplotypes. 
Importantly, our robust functional genomics approach enabled us to interrogate the 
functional consequences of these variants in the context of regulatory activity and 
transcription factor binding, and identified novel variants that reside within CTCF binding 
sites. We discovered that these variants alter the overall molecular properties of the 
ULBP6 downstream sequence, since they decreased the reporter activity in vitro. 
Interestingly, we observed a stronger effect for variants 2 and 3 on decreasing reporter 
activity than the three variants combined, suggesting the presence of different trans-
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binding factors and/or complexes, and that these variants are producing the strongest 
effect. We found that these variants created new TFBS in silico for stress-induced 
activating proteins with known roles in the immune system, and that the repressive 
effects of CTCF binding to this sequence are abrogated in the presence of the AA rare 
variants.  
Functional genomics studies have been performed in other complex genetic 
disorders following deep resequencing of candidate regions to characterize the effects 
of susceptibility variants on regulatory activity and/or transcription factor binding 
(VERLAAN et al. 2009; HUTCHINSON et al. 2014; KAPOOR et al. 2014). Interestingly, a 
recent functional genomics study reported the association of non-coding variants that 
were identified from GWAS in several common autoimmune diseases (Celiac disease, 
IBD, Crohn’s disease) and by SNP genotyping followed by genome-wide bisulfite 
sequencing, reported allele-specific methylation patterns associated with the variants 
(HUTCHINSON et al. 2014). Moreover, a functional genomics study at the 
ZPBP2/GSDMB/ORMDL3 locus associated with asthma and several autoimmune 
disorders reported allele-specific chromatin remodeling, perturbed CTCF binding and 
altered nucleosome occupancy associated with non-coding variants (VERLAAN et al. 
2009). Collectively, these studies highlight the functional and regulatory mechanisms by 
which non-coding variants may contribute to disease pathogenesis. 
Several immune-related loci including the MHC cluster, the Th2 region (IL4, IL5, 
IL13), and IL-1/IL-36/IL-37 gene cluster have been reported to engage in long-range 
chromatin interactions that govern the spatiotemporal regulation of these genes 
(JHUNJHUNWALA et al. 2009; SEKIMATA et al. 2009; MAJUMDER AND BOSS 2010; WILLIAMS 
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et al. 2013; SHARAF et al. 2014). Additionally, reorganization of the nuclear architecture 
and the formation of active chromatin hubs has been observed for some of these loci 
that engage in intra- and interchromosomal looping interactions upon differentiation or 
cytokine stimulation (JHUNJHUNWALA et al. 2009; MAJUMDER AND BOSS 2010). Many 
immune-related genes are monoallelically expressed and tightly coordinated regulation 
of gene expression in the immune system is key for many biological processes including 
V(D)J recombination in the generation of antigen diversity, as well as T cell lineage 
commitment (JHUNJHUNWALA et al. 2009). 
Recent studies have demonstrated that lineage-specific super-enhancers (SEs), 
defined as large clusters of transcriptional enhancers for genes controlling cellular 
identity, are present at several well-characterized immune loci, and are detected by 
lineage-specific p300 binding occupancy and H3K27Ac enrichment (HNISZ et al. 2013; 
FARH et al. 2015; VAHEDI et al. 2015). A large-scale fine mapping study of GWAS 
variants conducted across many autoimmune diseases revealed that ~90% of causal 
variants are non-coding, and moreover, that ~60% of those variants reside within 
immune-cell enhancers and/or TFBS for master regulators of immune cell differentiation 
and activation (FARH et al. 2015). Most recently, T cell maps of SEs were generated and 
pointed to cytokine and cytokine receptor genes as the predominant source of SE 
architecture (VAHEDI et al. 2015). In the context of disease, T cell SEs were enriched at 
autoimmune disease-associated SNPs, where treatment of T cells with an inhibitor of 
the JAK/STAT pathway, tofacitinib, disproportionately affected the expression of SE-
localized risk genes associated with rheumatoid arthritis (VAHEDI et al. 2015). 
Importantly, these studies identified key regulatory nodes in immune pathways and 
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have also defined a role for the insulator protein, CTCF in demarcating the boundaries 
of SEs across immune-related loci. Considering these findings, we utilized ENCODE 
data in both immune cells and keratinocytes and fibroblasts to examine the ULBP3/6 
locus for SE activity. While we observed clusters of CTCF binding enriched at sites of 
open chromatin (ENCODE FAIRE-seq and DNAse1 hypersensitive sites), we did not 
detect enrichment for p300 or H3K27Ac binding at these sites (Figure 4), suggesting 
that this region may not possess SE activity. 
CTCF has several reported roles in the immune system, engaging in 
chromosome loops that bring immune enhancer elements in close proximity to 
promoters (facilitating gene expression), or physically creating barriers that separate 
genes from distal regulatory elements (promoting a repressive state) (PHILLIPS AND 
CORCES 2009). CTCF is a protein that homodimerizes with itself and heterodimerizes 
with the cohesin complex, components of the polycomb repressive complex, as well as 
many other factors (LI et al. 2008; RUBIO et al. 2008). The many functions of CTCF have 
been characterized in various cell types and systems, and several studies have 
demonstrated a clear inverse correlation between CTCF binding occupancy and the 
CpG methylation status, particularly at the H19/IGF2 imprinting control region (ICR) 
(PHILLIPS AND CORCES 2009). 
In the context of long-range interactions, we postulate that the ULBP3/6 gene 
cluster is spatiotemporally controlled and chromosomally configured in a repressive 
state, such that these genes remain repressed in healthy cells. It remains to be 
determined whether these genes exhibit monoallelic expression and/or distinct 
chromatin configurations. Future studies to elucidate these questions will include 
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overlaying SNP genotyping and transcriptome-based data, as well as performing the 
Formaldehyde Assisted Isolation of Regulatory Elements (FAIRE) assay that detects 
regulatory regions devoid of nucleosomes. In conjunction with ChIP-PCR for CTCF, this 
method can be used to determine allele-specific chromatin effects at the ULBP6 region 
that may be perturbed in the presence of the AA rare, non-coding variants (SIMON et al. 
2012).  
To determine whether CTCF-mediated long-range interactions are present at the 
ULBP6 locus, we analyzed ENCODE data from ChIA-PET experiments to capture 
CTCF-mediated interactions, and identified several interactions present at this locus in 
distinct cell types. Remarkably, we found that the AA rare non-coding variants lie 
precisely within three paired-end tags from CTCF ChIA-PET experiments, where the 
other paired-end tag lies ~100 Kb downstream of ULBP6, providing strong evidence for 
potential CTCF-mediated long-range interactions at this locus. Based on our findings, 
we suggest these interactions may be disrupted in the context of disease pathogenesis. 
Future experiments to test this hypothesis will include long-range reporter assays to 
determine whether the ULBP6 candidate region can function as an insulator element in 
the presence of CTCF, ChIA-PET assays on healthy hair follicle fibroblasts to identify 
cell type-specific CTCF-mediated interacting sequences at this locus, and Hi-C 
(Chomosome Conformation Capture with high-throughput sequencing) to identify all 
intra- and interchromosomal interactions in both healthy and AA patient fibroblasts.  
Although we provide evidence to support the hypothesis that AA variants disrupt 
CTCF-mediated long-range interactions at this locus, it is likely there are several 
additional binding proteins involved in these interactions. As previously mentioned, 
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CTCF has been reported to bind the cohesin complex, which is composed of four 
subunits (SSC1, SSC3, SMC1, SMC3) and is known to regulate the separation of sister 
chromatids during cell division (RUBIO et al. 2008). An in silico analysis of predicted 
TFBS motifs within the ULBP6 region demonstrated SMC1 and SMC3 binding sites in 
close proximity to the CTCF sites. Moreover, CTCF is known to interact with 
components of the polycomb repressive complex 2 (LI et al. 2008) and we also 
identified predicted SUZ12 and EZH2 binding sites in silico, where one of the non-
coding variants identified from our deep sequencing study lies within a predicted SUZ12 
motif. Taken together, we postulate that these proteins together with CTCF orchestrate 
long-range interactions contributing to the spatiotemporal ULBP3/6 gene expression. 
In this study, we successfully utilized the functional genomics approach to 
uncover genetic susceptibility variants at the ULBP3/6 locus, which we identified as a 
critical node of the NKG2D signaling axis in disease pathogenesis. We identified and 
characterized three rare and novel non-coding variants enriched on GWAS risk 
haplotypes, and found that they alter the molecular properties of the sequence, disrupt 
CTCF binding sites and create novel TFBS. In the context of the complex and dynamic 
regulation of immune-related genes and their association with SEs, we postulate that 
similar mechanisms employing long-range interactions control the ULBP3/6 locus to 
ensuring proper spatiotemporal expression. Moreover, based on the findings from our 
functional experiments, we provide evidence that the rare and novel, non-coding 
variants identified in this study disrupt the regulatory activity and transcription factor 
binding properties in this region, further underscoring the biological significance of this 
locus in AA disease pathogenesis.
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Materials and Methods 
Ethics Statement 
Informed consent was obtained from all subjects and approval for this study was 
provided by the Institutional Review Board of Columbia University in accordance with 
the Declaration of Helsinki Principles. 
Patient information and materials 
Patients from the previously published GWAS were ascertained through the National 
Alopecia Areata Registry (NAAR) and guidelines for enrollment as well as control cases 
used are described in (PETUKHOVA et al. 2010). GWAS samples were selected for 
targeted resequencing based on disease severity, family history of AA and enrichment 
of risk haplotypes.  Genomic DNA samples isolated from whole blood were previously 
obtained from the GWAS cases, and subject DNA samples containing one or more rare 
variant enriched on GWAS haplotypes were selected for functional studies. Human 
dermal scalp fibroblasts were isolated from occipital scalp biopsies taken from healthy 
controls that are considered IRB-exempted  (45 CFR Part 6) non-human materials. The 
human hTERT DP cell line used in ChIP assays was purchased through Applied 
Biological Materials (Cat. #T0501). 
Targeted deep resequencing of the ULBP3/6 locus 
We designed a Raindance primer library to deep sequence 72 Kb of the ULBP3/6 
encompassing the 13 typed SNPs and 47 imputed SNPs from the GWAS. Targeted 
deep resequencing of the ULBP3/6 locus was performed in 124 AA patients on the 
Roche 454 FLX platform, and the data were analyzed using the GATK pipeline (Broad 
Institute, Germany). Identification of rare variants was based on the novelty or rare 
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frequency of identified variants in public databases, and enrichment was defined as 
being prevalent in three or more AA cases. Functional annotations using ENCODE and 
RegulomeDB databases were performed to identify the non-coding rare variants with 
predicted regulatory function and/or in TFBS motifs. 
Cloning and reporter assays 
For all reporter assays, the pGF-mCMV vector (System Biosciences) harboring a 
minimal CMV promoter was used. The ULBP6 region was amplified using a nested 
PCR: F1: 5’- TTCCCTCCTTCATCCTCGCGGGGAC-3’; R1: 5’- GCAATGAGGAAAGA 
GTCCTAATTC-3’; F2: 5- CTCTCAGTCTCCTGCTCTCTGCCTTGT-3’; R2: 
TGGGGTCGCGGTCCAACCGGCGTTTAG-3’. A region containing no CTCF sites was 
amplified using the following primers: F: 5’- GACACTGAGCCTTGTTATTCGTACATAC-
3’; R: 5’- ATAAGCAGACCTAAGACCTCACAGAGC-3’. For the positive control of CTCF 
binding, an oligonucleotide sequence containing tandem CTCF sites was synthesized 
through Integrated DNA Technologies (IDT). The CREB sequence used for reporter 
assays is as follows: CATGGTGACGTCACTTGGTGACGTCACCTGGTGACGTC 
ACGTGGTGACGTCACATGGTGACGTCA. PMA (phorbol 12-myristate 13-acetate) was 
purchased through Sigma Aldrich. 
 Human dermal fibroblasts were nucleofected using the Amaxa Nucleofector and 
Basic Mammalian Fibroblasts reagents (Lonza) with 2ug of each DNA construct for the 
pmCMV-GFP vector, the CTCF-FLAG construct, as well as a control Renilla luciferase 
reporter. Luciferase activity was measured using the Promega Dual Luciferase assay kit 
on a 96-well plate reader. Firefly/Renilla luciferase ratios were calculated and samples 
were normalized to the empty vector.  
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Chromatin Immunoprecipitation (ChIP) and Immunoblotting 
ChIP was performed using the EZ-ChIP kit reagents and protocol with the following 
modifications. Human dermal fibroblast cells isolated from scalp and the human hTERT 
DP cell line (Applied Biological Materials, cat. #T0501) were grown to confluency on 15 
cm dishes (each containing 1.0-2.0 x 107 cells), cross-linked using formaldehyde (final 
concentration 1.1%), and then centrifuged for subsequent nuclei purification and 
sonication.  Following cell lysis, cells were resuspended in sonication buffer, sonicated 
for 30-45 minutes (30” on/off cycles) using the Bioruptor bath sonicator (Diagenode). 
Fifty micro liters of nuclear lysate was saved for each sample as Input Chromatin (1/20 
of the ChIP reaction).  For antibody binding, 2ug was used for CTCF clone 2.24.3.10.1.4 
from EMD Millipore (monoclonal antibody 1) and CTCF clone 1.2.1.5.4 from EMD 
Millipore (monoclonal antibody 2); 1ug antibody was used for RNA polymerase II clone 
CTD4H8 from EMD Millipore and normal mouse IgG (EMD Millipore cat. # 12-371B). 
Following the elution of protein/DNA complexes, crosslinks were reversed overnight at 
65°C and protein was isolated prior to DNA purification for immunoblotting.  
 Immunoblotting for CTCF was performed using the protocol described in 
(DESTEFANO et al. 2014) to determine enrichment prior to proceeding with the PCR. As 
a positive control for CTCF detection, protein isolated from human dermal fibroblasts 
that were transfected with a FLAG-tagged form of CTCF (NM_006565 cDNA ORF 
clone, OriGene RC202416L2) was run on an SDS-PAGE gel and blotted for CTCF 
(monoclonal antibody 1) and FLAG (monoclonal antibody, OriGene clone 4Ca).  The 
CTCF and FLAG antibodies were used at a concentration of 1:2000 and 1:000, 
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respectively, and the goat anti-mouse-HRP light chain-specific secondary antibody was 
used at a concentration of 1:2,500. 
qPCR on ChIP DNA 
Following ChIP for CTCF, qPCR was performed using standard methods and the 
protocol described in (DESTEFANO et al. 2014) to determine CTCF binding enrichment at 
the ULBP6 region. Relative quantification was used (ddCt method) to normalize IP 
samples to Input Chromatin, where Ct values were adjusted for the Input Chromatin 
dilution by subtracting 4.322 (Log2 20, dilution factor), and percent total input was 




REV: 5'-TCGAACAGGAGGAGCAGAGAGCGA-3'  
H19 ICR 
FOR: 5’-CCCATCTTGCTGACCTCAC -3’ 
REV: 5’-AGACCTGGGACGTTTCTGTG-3’ 
ULBP6 CTCF region 
FOR: 5’- GTGGACCAAGCTGACTAAGAATGA G-3’ 




A Student T test was used to calculate statistical significance (p < 0.05) in all reporter 




Figure S1. Scheme of the pGF-mCMV reporter construct and positive control for 
activity. The CREB sequence was cloned upstream of the mimimal CMV promoter and 
becomes activated upon the addition of PMA. Luciferase assay in dermal fibroblasts 













Chapter IV.5 Discussion 
The search for causal genetic variants underlying complex, polygenic traits has 
proven to be a challenging task, due to the non-Mendelian patterns of inheritance and 
the contribution of many genetic and environmental factors. Therefore, GWAS became 
the popular approach to study these complex traits in populations rather than family-
based cohorts, and this method has been performed for many well-defined traits, 
including diabetes, cancer, height, and several autoimmune disorders that display great 
heterogeneity across the population. While the GWAS has its limitations (detection 
threshold, cohort size required to see an effect, etc.), we now possess improved tools 
and technologies for next-generation sequencing that have already been utilized in 
several complex diseases and provided key insights into the distribution and 
contribution of variants (rare vs. common, coding vs. non-coding) to disease heritability 
(GOLDSTEIN 2009; ZHU et al. 2011).  
Depending on the nature of the condition, GWAS studies conducted with larger 
cohorts may be fruitful in identifying novel susceptibility variants, but for most cases, this 
is not the case. Instead, GWAS performed for traits like height and type 2 diabetes have 
uncovered numerous variants associated with each trait, but that collectively only 
account for a small proportion of disease heritability. In light of these findings, the 
‘common-disease-common-variant’ hypothesis posits that these polygenic disorders are 
composed of relatively frequent variants in the population that have low penetrances, or 
effect sizes, and thus require large cohorts. However, if we assume that for a given trait, 
nearly all the variants of large effect have been uncovered by GWAS, we would expect 
to see that upon increasing the cohort size, there is a “diminishing return” on effect size 
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distributions. In other words, it would take a lot of variants to account for the full 
heritability. Recent estimations of the number of common variants required to explain all 
the variance were calculated (GOLDSTEIN 2009), highlighting the implausibility of this 
model and its ability to identify the genetic component of a disorder.  
On the opposite end of the spectrum, the ‘common-disease-rare-variant’ 
hypothesis posits that there are many rare variants with large effect sizes that account 
for a large percent of disease heritability. Based on the observations that common 
variants account for a small proportion of heritability for complex traits, low-frequency 
variants are more abundant in the human genome than common variants, and GWAS 
experiments cannot detect rare variants, the current view holds that the “missing 
heritability” can be accounted for by several rare variants with moderate effects, 
structural variants (i.e. CNVs), and genetic as well as gene-environment interactions 
(MANOLIO et al. 2009).  
Importantly, next-generation sequencing approaches have afforded us the ability 
to detect the rare variants with larger effects and determine their contribution to disease 
pathogenesis. However, the most robust strategy to identify the missing heritability is to 
study both family-based and population-based cohorts for linkage analysis, whole-
exome and genome sequencing, GWAS and subsequent replication(s)/meta-GWAS 
analysis, targeted deep resequencing of candidate regions, and CNV analysis to detect 
structural variants that would otherwise be missed. When prioritizing candidate regions 
for further investigation, it is of tremendous value to perform gene-expression based 
analyses (microarrays, RNA-seq) that can be correlated with the genetics, functional 
genomics studies to determine the consequences of intergenic variants on regulatory 
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function and transcription factor binding, as well as functional studies on mouse models 
that recapitulate genetic and/or pathological features of the human disease.  
These approaches (discussed in Chapter IV.2-IV.4) enabled us to maximize our 
identification of susceptibility variants in alopecia areata. In the context of studying 
complex diseases, AA serves as a useful model and system, particularly in the context 
of autoimmune disorders, since there is strong evidence in support of a genetic basis 
and we have direct access to the pathological tissue as well as a mouse model that 
recapitulates the human pathology. Unlike other autoimmune disorders, the end organ 
(the hair follicle) is not destroyed, allowing us to perform detailed molecular and 
functional studies. 
The immunopathological basis of AA is defined as the loss-of-immune privilege in 
the hair follicle leading to disfiguring hair loss, characterized by the infiltration of T 
lymphocytes at the base of the hair follicle. Interestingly, only growing, pigmented hair 
follicles are targeted, thus it is thought that AA is an antigen-driven disease, and that 
genetic dysregulation at both the level of the target (hair follicle) and effector cell (T cell) 
contributes to the pathology. Thus, we expect to identify genetic susceptibility variants in 
hair follicle-related genes and/or genes uniquely associated with AA, as has been 
observed from the GWAS and subsequent meta-GWAS analysis described in Chapter 
IV.2. 
In the initial GWAS, eight regions of the genome were identified to be associated 
with AA, where several of these loci overlapped with type 1 diabetes, rheumatoid 
arthritis, and Celiac disease (PETUKHOVA et al. 2010). In these autoimmune conditions, 
the NKG2D pathway plays an important role in disease pathogenesis, thus the genetic 
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overlap at several immune-related loci further supported a role for the involvement of 
this pathway in AA pathogenesis. The Christiano lab uncovered two novel loci, STX17 
and ULBP3/6 that are uniquely associated with AA. STX17 is a SNARE tethering 
protein involved in autophagy in melanocytes that is expressed in the hair follicle and 
has been shown to be associated with the grey hair phenotype in horses (SUNDSTROM et 
al. 2012; REISSMANN AND LUDWIG 2013; TEIXEIRA et al. 2013). The genetic association of 
STX17 with human AA is biologically intriguing in the context of genes dysregulated in 
the end organ, as AA preferentially attacks the growing, pigmented hair follicle during 
active disease.  In both the GWAS and meta-GWAS studies, the strongest association 
signal observed outside the HLA region came from the ULBP3/6 locus, a novel region 
whose association is unique to AA. Given the known role of these genes in the NKG2D 
pathway and their upregulated expression in lesional hair follicles, we further 
investigated their role in AA and characterize the susceptibility variants driving the 
genetic association. 
In Chapter IV.2-IV.4, we applied a robust strategy to define the genetic 
architecture and biological pathways that are disrupted in AA. Informed by the initial 
genetic studies, we identified the key mediators of cytotoxicity, defined their contribution 
to disease pathogenesis using functional studies in the C3H/HeJ mouse model, and 
then targeted them for therapeutic intervention in both mice and humans. In Chapter 
IV.2, we identified novel genes association with AA and replicated the previous findings 
in an independent cohort followed by a meta-GWAS analysis. We resolved the major 
histocompatibility complex (MHC) signal, and defined the independent risk variants 
located at the HLA-DRA and HLA-DRB1 genes. Moreover, we uncovered two novel loci 
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associated with AA on chr2q13 and chr11q13.5, both of which have been previously 
associated with autoimmune disorders (BETZ et al. 2015). I characterized the novel 
BCL2L11 (BIM) gene on chr2q13 in association with AA. This gene encodes a pro-
apoptotic factor that functions in immune cells as well as melanocytes, and is widely 
expressed in multiple cell types including epithelial and hair follicle cells (O'REILLY et al. 
2000; LUO AND RUBINSZTEIN 2013). Moreover, since the regression stage of a normal 
cycling hair follicle, catagen, is characterized by apoptosis and cell death, and in AA, the 
hair follicle enters catagen prematurely due to autoimmune attack, BIM emerged as an 
interesting candidate gene to investigate in the contexts of both effector and target cell 
dysregulation.  
In the work described in Chapter IV.2, I performed detailed molecular analyses of 
BIM and characterized its expression pattern in human immune cell populations, hair 
follicles, as well as within the mouse hair follicle. Consistent with its role in melanocyte 
apoptosis, BIM was expressed in keratinocytes and melanocytes in the human hair 
follicle bulb. Intriguingly, when I tested its expression pattern in mouse anagen, catagen, 
and telogen skin, BIM expression was restricted to catagen hair follicles, and in the 
context of disease pathogenesis using the C3H/HeJ mouse model, was more 
widespread and diffuse (BETZ et al. 2015). These data further support the hypothesis 
that BIM dysregulation may contribute to early entry into dystrophic catagen in AA hair 
follicles during active disease. To further implicate BIM in disease pathogenesis, the 
next steps following this study could include detailed functional analyses using mouse 
models, targeted deep resequencing of this locus to identify susceptibility variants in 
237 
human AA, and functional genomics studies to determine the consequences and effects 
of these variants in disease pathogenesis. 
Considering our findings thus far and the implications of several important 
immune and hair follicle-related genes in AA disease pathogenesis, I next characterized 
the transcriptional profile of human and mouse lesional skin using an unbiased 
approach. The overarching goals of the work presented in Chapter IV.3 were to define 
the requirement for NKG2D+CD8+ T cells in disease pathogenesis and identify the key 
signaling molecules that drive cytotoxicity and can be targeted in the context of 
therapeutic treatment. In this study, I identified the genes with dysregulated expression 
using microarray analysis and transcriptome sequencing. Importantly, these studies 
identified three primary gene expression signatures that strongly implicated the NKG2D-
ULBP signaling pathway and the role of cytokine genes and their receptors in immune 
cell activation during natural killer cell-mediated attack. The immunological findings and 
immunohistochemical analyses complemented the genetic studies in humans that 
revealed a strong association with these loci, and using bioinformatics tools to analyze 
gene expression data, we successfully identified key drivers of cytotoxicity, including 
IL15 and IL2, in interferon gamma-producing CD8+ T cells.  
In the context of the bidirectional signaling and crosstalk events that occur 
between the target and effector cells to initiate destruction, it remains unknown in AA 
which comes first—the dysregulation at the end organ (the “chicken”) or within the T 
cells (the “egg”). Given the association of the NKG2D-ULBP signaling pathway in AA 
disease pathogenesis, and the presence of CD8+NKG2D+ T cells in the immune 
infiltrate, we tested the requirement for these cells in disease using the mouse model. 
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We first showed ex vivo in syngeneic dermal sheath cells that the T cells bearing the 
NKG2D receptor are in fact the cells mediating cytotoxicity during the autoimmune 
attack in AA. Using subcutaneous injections of total lymph node cells, NKG2D- cells, 
FAC sorted CD8+NKG2D+ T cells, and CD8+NKG2D- T cells, we demonstrated that 
CD8+NKG2D+ T cells are both necessary and sufficient to induce disease (XING et al. 
2014).  
Because these cells produce the cytokines and drivers of toxicity that are 
associated with the autoimmune response, we next targeted several type I cytokines 
(i.e. IL5 and IL2) in the mouse model using blocking antibodies. Although these 
antibodies alone did not reverse established disease, we learned that these cytokines 
signal through the JAK/STAT pathway, and thus, intervened downstream using FDA-
approved small molecule inhibitors (Ruxolitinib and Tofacitinib) of JAKs 1-3. Importantly, 
this approach was successful in preventing and reversing the disease in the mouse 
model, and more recently, in treating human patients to fully restore hair growth (XING et 
al. 2014).  
Collectively, these findings reinforced my interest in studying the human genetic 
variants in the NKG2D-ULBP pathway, thus, the goal of my work in Chapter IV.4 was to 
understand the mechanisms by which susceptibility variants at the ULBP3/6 locus act to 
control the dysregulated expression of these genes in the human AA hair follicle. The 
GWAS revealed a strong association between the ULBP3/6 locus and AA, where 
perhaps not surprisingly, the highest signal of association resided within an intergenic 
region of non-coding DNA. The emerging picture of the genetic architecture underlying 
complex disease highlights a role of rare and non-coding variants, and thus, I identified 
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and characterized the effects of the susceptibility variants at ULBP3/6 associated with 
human AA. To accomplish this, we performed targeted deep resequencing of this locus, 
and identified rare and common variants that were enriched on GWAS risk haplotypes. 
In Chapter IV.4, we performed a detailed functional genomics study, characterizing the 
functions of three novel rare and non-coding variants identified from our targeted deep 
sequencing, and using publically available ENCODE data, determined that these 
variants resided within a presumptive regulatory region. Moreover, we crosschecked the 
variants against RegulomeDB and found that they were predicted to disrupt CTCF 
TFBS. In vivo, I used ChIP-PCR to detect endogenous CTCF binding at this locus, and 
in vitro, I found that CTCF exerts repressive effects on the ULBP6 sequence, consistent 
with its known role as an insulator and repressor. The presence of the AA variants 
markedly reduced reporter activity and abolished CTCF-mediated repression, 
suggesting that these variants exhibit decreased affinity for CTCF binding at this locus.  
In the AA patients harboring these rare variants, the associated risk haplotypes 
also possess common variants at this locus, whose effects I did not test in this study. 
Although the rare variants are likely to produce larger effects than common variants, it is 
possible that the common variants (in conjunction with the rare variants) produce an 
effect and contribute to the altered molecular properties of this sequence. Importantly, 
the data and findings from this study do not exclude the contribution of additional factors 
involved in the regulation of this locus. As discussed in Chapter IV.4, we postulated a 
role for other trans binding factors including the cohesin and PRC2 protein complexes in 
facilitating ULBP3/6 long-range regulatory interactions. 
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Functional genomics studies performed in other autoimmune diseases have 
begun to uncover the mechanisms by which non-coding variants exert their effect and 
act at a given locus, and have implicated a role for heterozygous SNVs in allele-specific 
methylation and chromatin remodeling (discussed in Chapter IV.4) (HUTCHINSON et al. 
2014) (VERLAAN et al. 2009). We uncovered a novel role for long-range interactions at 
the ULBP3/6 locus, and CTCF as a candidate for mediating these interactions. This is 
further supported by the observation of CTCF ChIA-PET data from ENCODE 
experiments. It remains an open question as to whether the chromatin architecture of 
one ULBP3/6 allele is distinct from the other, and whether this difference somehow 
influences how the homologous allele is regulated. Further functional studies examining 
the chromosomal architecture of this region will elucidate this phenomenon and are 
discussed in Chapter IV.4.  
In the context of an immune response, several immune-related loci engage in 
CTCF-mediated long-range regulatory interactions, some of which have been shown to 
possess super-enhancers whose boundaries are demarcated by CTCF binding (HNISZ 
et al. 2013; FARH et al. 2015; VAHEDI et al. 2015). Although the ULBP gene cluster was 
not identified in previous studies that reported these super-enhancers, and this region is 
not enriched for p300 loading (a characteristic feature of SEs) in keratinocytes or 
fibroblasts (data not shown), we identified large peaks of H3K27Ac (mark of active 
regulatory elements) demarcated by CTCF ChIP-seq binding, as well as clusters of 
DNAse I hypersensitivity sites. Therefore, it remains possible that this region possesses 
SE-like structures that contribute to the upregulation of these ligands during an immune 
response or targeted autoimmune attack.  
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The HLA genes and regulatory mechanisms controlling their spatiotemporal 
expression have been well characterized and are known to involve complex 
intrachromosomal interactions resulting in conformational changes in chromatin 
architecture (MAJUMDER et al. 2006; MAJUMDER et al. 2008; MAJUMDER AND BOSS 2011). 
Considering what is known about the genomic mechanisms regulating these and 
several other immune-related genes (JHUNJHUNWALA et al. 2009; SEKIMATA et al. 2009; 
MAJUMDER AND BOSS 2010; WILLIAMS et al. 2013; SHARAF et al. 2014), I postulate that 
the ULBP3/6 locus may be under similar control and in a tightly coordinated fashion to 
ensure that these genes remain off in healthy cells (i.e. the hair follicle). Interestingly, 
the ULBP gene cluster resides on the opposite arm of chromosome 6 relative to the 
HLA locus, raising the question of whether conformational changes in chromatin 
structure and movement at one arm constrain or in some way affect the overall 
configuration of the opposite arm. In other terms, could the conformational changes at 
the HLA locus influence the configuration of the ULBP locus? Time-lapsed in vivo 
imaging of fluorescently tagged chromosomes, FISH analysis of these regions, and 
chromosome conformation capture-based methods (discussed in Chapter IV.4) 
following cytokine stimulation may provide some insight into this phenomenon.  
Considering the nature of immune privilege in the hair follicle that is in part 
characterized by the active repression of MHC and other immune-related genes (i.e. 
ULBPs), it invites the question of whether these genes are regulated by similar 
mechanisms, and perhaps by the same factors. Based on the collective findings from 
our comprehensive study interrogating the genetic, molecular and immunopathological 
bases of AA, I postulate that long-range interactions at the ULBP3/6 locus may serve as 
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a genomic mechanism regulating the spatiotemporal expression of these genes 
(maintaining active repression in healthy tissues), and that in the context of disease, 
non-coding susceptibility variants identified in AA patients abrogate the regulatory and 
transcription factor binding properties, resulting in perturbed intrachromosomal 
interactions. 
 In conclusion, the studies described in Chapter IV of this thesis and the 
approaches we used in this work demonstrate innovative strategies to dissect the 
genetic architecture underlying complex genetic disease. The pursuit of this study 
effectively began over 15 years ago, where after completing the first GWAS for AA, the 
Christiano lab was immediately faced with a daunting list of associated SNPs and 
genomic regions whose biological relevance and contribution to disease pathogenesis 
was unknown. Combining the GWAS data with functional studies in the mouse model, 
next-generation sequencing methods and functional genomics tools provided us with 















Chapter V. General Discussion 
The genetic underpinnings of human hair growth are complex, invoking several 
mechanisms to regulate gene expression. As such, hair follicle morphogenesis and 
growth are tightly regulated processes, where perturbations lead to abnormalities in the 
size, pattern, structure, and number of hair follicles. Thus, we can study genetic 
conditions affecting hair growth as models to interrogate the molecular basis of the 
pathology, and obtain novel insight into mechanisms and pathways required for normal 
hair growth. The hair follicle is a miniorgan with a highly complex and dynamic structure, 
providing an excellent system to study genetics because of its readily accessible nature 
and continuous cycling through the lifetime of the animal. Moreover, the key 
developmental pathways and diverse range of cell types in the hair follicle are well 
characterized, and the spatiotemporal regulation of gene expression has been widely 
studied. 
 When studying genetic conditions affecting hair growth, the approaches and tools 
we use depend largely on the prevalence of the trait in the general population and the 
observed inheritance pattern. We can readily predict the transmission of traits that are 
inherited in a Mendelian fashion and use the classic genetic approach to identify the 
genes involved. However, there are the rare, extreme traits we don’t see too often in the 
general population (such as excessive hair overgrowth all over the body), and these 
sporadic conditions have historically been difficult to study using positional and 
functional cloning approaches. On the opposite end of the spectrum, many genes plus 
environmental factors control common, complex polygenic traits like male-pattern 
baldness and alopecia areata, and so these traits have been difficult to study because 
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they do not follow a classic Mendelian inheritance pattern.  
 The completion of the human genome sequence in 2003 has revolutionized the 
field of genetics and genomics, providing a transformative tool in medicine that has 
greatly facilitated the identification of disease-associated genes. With the advent of 
GWAS studies a little over a decade ago, large-scale population-based studies to 
identify regions of association became the preferred choice in tackling the complex 
genetic architecture of non-Mendelian diseases. Moreover, next-generation sequencing 
methods and technologies have become standard practice over the past eight years, far 
surpassing the prediction of a two-fold improvement in the speed and cost of genome 
sequencing per year (MOORE 1965; MARDIS 2008). These novel and sophisticated 
approaches have greatly facilitated the identification of pathogenic variants in 
monogenic, Mendelian disorders and complex genetic diseases alike. In the former, 
these tools have enabled us to perform whole-genome/exome and targeted deep 
sequencing in the extreme cases of rare, sporadic traits whose genetic lesions 
remained elusive. And in the latter, these tools have enabled the capture of all genetic 
variation residing within GWAS regions of association. By targeted deep resequencing, 
we can now identify the rare variants that were previously undetected by GWAS, and 
perform further functional studies to determine their contribution to disease 
pathogenesis. 
The goal of my thesis research was to identify and characterize the genetic 
mechanisms controlling human hair growth. To accomplish this, I studied three inherited 
conditions affecting human hair growth, from the rarest syndromes of excessive hair 
overgrowth, to a very common autoimmune disease of hair loss, alopecia areata, and 
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the approaches I used to detect the underlying variants in these conditions were 
contingent upon the inheritance patterns and overall prevalence within the population. In 
the first part of my thesis, I identified structural and genomic effects on human hair 
growth in a rare, sporadic Mendelian disorder using a combination of CNV analysis and 
next-generation sequencing methods (Chapter II). In the second part, I characterized 
single-gene effects on human hair growth in a rare, familial condition using whole-
exome sequencing (Chapter III). Lastly, I performed a functional analysis of rare, non-
coding variants in a complex polygenic autoimmune disease utilizing functional 
genomics (Chapter IV). It is important to note that throughout the work described in this 
thesis, our understanding of the genetic mechanisms perturbed in human disease were 
not only facilitated by, but also dependent upon, the availability of a comprehensive, 
detailed map of the human genome, as well as several novel and sophisticated 
technologies in next-generation sequencing.  
 
Rare Structural Variants Controlling Human Hair Growth 
Rare Mendelian diseases are defined as affecting fewer than 200,000 people in the 
population (in the United States) and the number of rare diseases recorded in OMIM is 
currently estimated to be between 6,000-7,000 (BOYCOTT et al. 2013). The rate of an 
intragenic mutation per gene (for an average gene length of 1,500 bp coding sequence), 
copy, and generation is approximately 5.6 x 10-6 for silent mutations, 1.28 x 10-7 for 
missense mutations, and 1.7 x 10-6 for disruptive mutations (ZUK et al. 2014). In 
contrast, the estimated incidence of inherited hypertrichosis syndromes is far lower, 
highlighting the presence of unusual genetic mechanisms underlying this rare sporadic 
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condition. Consistent with this observation, the Christiano lab and other groups have 
previously identified de novo, complex structural variants in the autosomal dominant 
and sporadic forms of hypertrichosis whose genetic basis have not previously been 
identified. Thus, it has been suggested that these syndromes are genomic disorders, 
characterized by structural and numerical chromosome anomalies (ZHU et al. 2011a).  
 In Chapter II, I identified the effects of structural and genomic defects on human 
hair growth in a large Mexican family with X-linked hypertrichosis in which the Christiano 
lab had previously reported linkage to chromosome Xq24-27 (FIGUERA et al. 1995; 
TADIN-STRAPPS et al. 2003).  Using a combination of cytogenetic methods and next-
generation sequencing technologies to detect structural variants, we identified a large 
interchromosomal insertion at a palindromic site that completed cosegregated with the 
disease phenotype (DESTEFANO et al. 2013), and was consistent with findings in two 
unrelated XLH families that possess interchromosomal insertions at the same 
palindrome site on Xq27.1 (ZHU et al. 2011a).  However, the sequence content and 
sizes of the insertions are distinct across the three families. Given the rarity of these 
syndromes and the severity of the phenotypes, the probability of identifying three 
independent events characterized by such unusual genetic mechanisms is extremely 
small. Thus, this observation raised the question, how do these interchromosomal 
insertions exert their pathogenic effects and cause excessive hair overgrowth?  
 Several plausible mechanisms by which the insertions can disrupt hair growth 
include the disruption of a gene in the region, the introduction of novel regulatory 
elements or dosage-sensitive genes, separation of the nearby genes from their 
regulatory elements and altering expression levels, and disruption of the chromosomal 
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architecture and inter/intrachromosomal interactions. I deduced that the latter two 
mechanisms were most likely given that the insertions reside within a gene desert, do 
not contain full open reading frames for protein-coding genes or any genes involved in 
hair follicle development, and the size and content of the insertions is different among 
the three families.   
 Therefore, I tested the hypothesis that the interchromosomal insertion we 
identified altered the expression levels of the genes in the surrounding region, and that 
the candidate gene(s) would be expressed in the human hair follicle. Using qRT-PCR 
and RNA-seq, I determined the expression levels of the genes in the surrounding region 
and observed a significant and selective decrease in FGF13, a gene not previously 
implicated in human hair growth. I characterized its expression pattern in both human 
and mouse hair follicles, as well as in the context of XLH pathology (DESTEFANO et al. 
2013). My interest in FGF13 as a potential candidate emerged from the observation that 
FGFs play very important roles in hair follicle morphogenesis and cycling, one key 
example being FGF5, whose mutations increase the duration of anagen and cause the 
angora excessive hair overgrowth phenotype in mice and many other organisms 
(HEBERT et al. 1994). However, it is very likely that the interchromosomal insertion 
mediates pathogenic effects through a variety of mechanisms, including the disruption 
of important inter- and intrachromosomal interactions, and future studies examining 
genome-wide chromosomal interactions (i.e. using Hi-C, discussed in Chapter II) will 
provide insight into perturbed or ectopic interactions in XLH.  
 The overall incidence of X-linked disorders in the population is estimated to be 
between 1:10,000-1:30,000, thus, if the interchromosomal insertions identified in the 
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three X-linked hypertrichosis families exerted their pathogenic effects on a single gene 
(such as FGF13), one would expect to find intragenic mutations within the population at 
the same frequency as the predicted mutation rate for that gene, concurrent with the 
excessive hair overgrowth phenotype. Moreover, the affected family members of two of 
the X-linked hypertrichosis families possess additional congenital anomalies, including 
scoliosis and spina bifida (Chinese family, 125 Kb insertion) (ZHU et al. 2011a), and 
deafness, dental, as well as palate anomalies (Mexican family from our study, 389 Kb 
insertion), suggesting the dysregulation of several genes. Given the rarity of these 
syndromes and the identification of de novo structural variants, I postulate that the 
interchromosomal insertions exert several downstream effects and disrupt the 
spatiotemporal regulation of genes required for hair follicle patterning and 
morphogenesis.  
 
The Human Hair Follicle and Developmental Patterning 
During hair follicle morphogenesis in humans, the lanugo hairs, which are uniformly 
long, fine and unpigmented, and first appear on the scalp and forehead.  Prior to the 
time when these hairs are shed in utero, the developing fetus appears to be covered in 
hair, where the same follicles on the scalp are also present on the forehead and face—a 
feature not observed in adult humans. These hair follicles are then shed in a 
synchronous manner and replaced by vellus hairs on the body and terminal hairs on the 
scalp, where every subsequent hair cycle is asynchronous. In the context of 
hypertrichosis, the excessive hair overgrowth phenotype is present at birth (congenital), 
and the hairs that cover the body are typically of the terminal type. Importantly, this 
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observation suggests that the genetic mechanisms underlying these syndromes perturb 
early events during hair follicle patterning and morphogenesis. I postulate that the 
signaling pathways that regulate the formation of a vellus versus a terminal hair and the 
boundaries demarcating these regions are altered by the genetic defect(s), and lead to 
a transformation in the type of hair produced. Although the precise mechanism(s) by 
which genetic mutations cause an excessive hair overgrowth phenotype in 
hypertrichosis are not clear, I postulate a role for the classical developmental signaling 
pathways (such as Wnt, Shh, and Bmp) whose roles in patterning have been well-
characterized and widely studied in model organisms.  
 Given the well-defined and conserved role of the Wnt signaling pathway in 
developmental patterning, it has been suggested that the master regulators of human 
hair follicle patterning are Wnt-related genes, since gain-of-function mutations lead to 
excessive hair overgrowth (overexpression of stabilized β-catenin in the epithelium 
induces extra hair follicles in mice), and loss-of-function mutations block hair follicle 
induction (β-catenin ablation or overexpression of the Wnt inhibitor, Dkk1, in mice 
abrogates hair follicle morphogenesis) (HELD 2010) (ANDL et al. 2002). Interestingly, the 
key regulator of moustache and eyebrow growth in dogs is the R-spondin 2 (RSPO2) 
gene (CADIEU et al. 2009), a regulator of Wnt signaling. In humans, mutations in the 
WNT10A gene cause sparse hair across the body, scalp, eyebrows and eyelashes 
(ADAIMY et al. 2007). While there is strong evidence for the involvement of Wnt signaling 
in hair follicle patterning, genetic studies in humans and mice have demonstrated that 
there are many additional genes required for hair follicle patterning and morphogenesis 
that do not reside within the Wnt pathway. I postulate that the underlying genetic 
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defect(s) in human hypertrichosis syndromes disrupts several important signaling 
pathways required for proper hair follicle patterning, leading to an excessive hair 
overgrowth phenotype. 
 From flies to mice, studies in model organisms have elucidated the key genes 
and signaling pathways whose disruption or ectopic expression causes severe 
patterning defects and homeotic transformations. Genetic studies performed decades 
ago have demonstrated that many well-conserved key developmental processes and 
biological traits are controlled by discrete loci that encompass the necessary genes and 
regulatory elements for proper spatiotemporal control of gene expression. In the fly, the 
Achaete-Scute Complex (AS-C) is a well-studied locus that controls bristle patterning, 
and the expression of the achaete and scute genes is spatiotemporally regulated by 
nearby cis-enhancers (GOMEZ-SKARMETA et al. 1995). Similarly, the well-conserved Hox 
genes in metazoans that control anterior-posterior patterning during embryogenesis are 
clustered into paralogous groups, exhibiting spatiotemporal regulation and the unique 
property of colinearity, where their chromosomal arrangement correlates with their 
expression domains and the order of the structures they form along the body (MALLO et 
al. 2010) (DUBOULE 1998).  
 In the context of the human hair follicle, it has been speculated that the genes 
controlling hair patterning and the boundaries separating different hair types might be 
spatially arranged or clustered at a genomic locus that operates as a “Hair 
Headquarters,” similar to the AS-C locus in the fly (HELD 2010). In humans, this 
phenomenon is observed in the control of epidermal differentiation, where the genes 
comprising the Epidermal Differentiation Complex (EDC) on chromosome 1 are 
252 
coordinated in a spatiotemporal manner (OH et al. 2014). Similarly, the type I and type II 
keratin intermediate filament genes are arranged in a cluster on human chromosomes 
17q12-21 and 12q13, respectively, whose coordinated activation is required for 
keratinization within the differentiating cells of the hair follicle (POWELL et al. 1991; 
POWELL AND ROGERS 1997; DUNN et al. 1998). While the Christiano lab and other groups 
have identified several genes that control hair follicle growth (SHIMOMURA AND 
CHRISTIANO 2010), these genes are not linked or clustered within a single locus. Given 
the observation that hair follicle morphogenesis and cycling are tightly coordinated 
processes controlled by well-defined signaling pathways, I postulate that several hair 
patterning-related genes are co-regulated in a spatiotemporal manner, perhaps 
facilitated by the same transcription factors, regulatory elements and/or long-range 
chromosomal interactions.  
 
Evolutionary Atavisms and Hair Growth 
Inherited hypertrichosis syndromes have long fascinated evolutionary geneticists 
because they are considered recurrences of an ancestral phenotype, or atavisms, which 
are quite extraordinary. Despite their rarity, they have been observed in several species 
and included the presence of a tail on a newborn human, extra toes in extant horses, 
hind limbs in whales, and a reptile-like coronary circulation and myocardial architecture 
in humans (HALL 1984; CANTU AND RUIZ 1985; HALL 1995; HALL 2010). The occurrence 
of these ancient traits suggests that the genetic potential to create these structures has 
been retained throughout evolution, and further highlights the presence of unusual 
mechanisms that are invoked to reactivate these genes. 
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 Humans have lost a significant amount of their hair compared to non-human 
primates; thus, it has been postulated that the genes promoting a fuller coat were 
silenced during evolution (i.e. not under purifying selection). To date, no hair-related 
genes have been reported among the loci within the selective sweeps (regions 
positively selected for) of the human genome. However, there are several reports on the 
existence on pseudogenes in the type I keratin gene family locus on chromosome 
17q21.2 that have not been identified in rodents (HESSE et al. 2004; ROGERS et al. 
2004), but it remains unclear whether they are present in non-human primates who are 
evolutionarily closer to humans. Importantly, studying the inherited forms of 
hypertrichosis has provided us with important clues as to the genes and loci that may 
have contributed to a fuller coat of hair in non-human primates. 
 To gain insight into atavistic genes at the Xq27.1 locus in XLH, I performed 
comparative genomic analyses of DNA sequences, but this did not reveal the presence 
of non-human primate-specific genes or human-specific pseudogenes. It remains to be 
tested whether the presence of the insertion alters the conformational structure of the X 
chromosome and causes ectopic non-homologous chromosomal interactions with 
sequences that encode important patterning genes during hair follicle morphogenesis. 
One interesting candidate to examine would be the Glypican-3 (GPC3) gene at Xq26, 
residing nearly 6 Mb away from the interchromosomal insertion, that encodes a cell 
surface heparan sulfate proteoglycan and regulates the IGF and WNT signaling 
pathways. Gpc3 loss-of-function mutations in the mouse leads to cellular and tissue 
overgrowth via inhibition of the non-canonical Wnt pathway and by increasing the 
signaling activity of the canonical pathway (CHIAO et al. 2002) (SONG et al. 2005). GPC3 
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mutations in humans cause Simpson-Golabi-Behmel syndrome, characterized by tissue 
overgrowth and several congenital defects and demonstrating phenotypic similarity to 
Beckwith-Wiedemann syndrome (PILIA et al. 1996; LI et al. 2001; JAKUBOVIC AND JOTHY 
2007). Simpson-Golabi-Behmel patients do not display an observable hair defect, but it 
would be interesting to determine whether perturbations in GPC3 spatiotemporal 
expression (rather than function) during morphogenesis can alter the Wnt signaling 
pathway, and perhaps lead to defects in hair follicle patterning. 
  
Identifying Single-Gene Effects on Human Hair Growth 
The mutations underlying rare, sporadic conditions affecting hair growth are often not 
intragenic, but rather, variants in chromosome number or structure that are complex and 
likely produce several downstream effects. Thus, it is often difficult to identify the 
precise mechanism(s) by which these variants act to produce the phenotype. The study 
of rare, Mendelian disorders affecting hair growth overcomes this limitation, since the 
genetic architecture is mostly composed of intragenic variants (exonic, splice site) with 
large effect sizes. By examining families with conditions affecting hair growth, the 
Christiano lab and others have successfully identified the pathogenic mutations that 
cosegregated with the disease phenotype providing novel insight into the genes and 
mechanisms involved.  
 In families with a rare autosomal dominant condition of hair loss called hereditary 
hypotrichosis simplex (HHS, characterized by hair follicle miniaturization), the Christiano 
lab performed genetic linkage analysis to map the disease locus, and identified a point 
mutation in the APCDD1 gene encoding a membrane-bound glycoprotein. Remarkably, 
255 
the same point mutation was identified in three distinct families (two Pakistani, one 
Italian), providing strong evidence for the involvement of this gene in HHS pathogenesis 
(SHIMOMURA et al. 2010). Moreover, high APCDD1 expression was observed in both 
mesenchymal and epithelial compartments of the hair follicle, consistent with a role for 
this gene in hair follicle miniaturization, and APCDD1 was identified as a novel inhibitor 
of the Wnt signaling pathway. These findings thus provided key insight into the 
underlying mechanisms and pathways involved in hair follicle miniaturization, a process 
by which thick, terminal hairs are progressively transformed into fine, vellus hairs. 
Collectively, our lab has studied inherited conditions of both hair loss and excessive hair 
growth, which afforded us the ability to identify the mechanisms controlling human hair 
growth. 
 In Chapter III of my thesis, I characterized the genetic defect underlying a rare, 
familial condition affecting hair growth by studying a small consanguineous family with 
congenital generalized hypertrichosis terminalis (CGHT). Using whole-exome 
sequencing, we identified a novel splice site mutation in the ABC transporter gene, 
ABCA5 that cosegregated with the disease phenotype in a homozygous recessive 
manner, and subsequently demonstrated that the mutation leads to the complete loss-
of-function (DESTEFANO et al. 2014). Importantly, the defining aspect of our filtering 
strategy that pointed to ABCA5 as the candidate gene was its genomic position, where 
CNVs in chromosome 17q23-24 encompassing ABCA5 were previously associated with 
CGHT (SUN et al. 2009; FANTAUZZO et al. 2012). Using several methods of detection, I 
found that ABCA5 is highly expressed in both epithelial and mesenchymal 
compartments of the human hair follicle, and that its expression is conserved within 
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mouse anagen hair follicles. Moreover, ABCA5 expression and localization was 
markedly reduced in CGHT patient hair follicles, the site of pathology for the phenotype, 
providing strong evidence for a complete loss-of-function (DESTEFANO et al. 2014). 
 Upon the discovery of novel genes associated with a human disease phenotype 
like excessive hair overgrowth, the next question in understanding the functional 
consequences is, what are the mechanisms by which these genes act? To answer this, 
I tested ABCA5 function in the context of lysosome function and cholesterol transport, 
since previous reports in Abca5-/- mice have demonstrated a role for this transporter in 
these processes (KUBO et al. 2005; YE et al. 2010). Remarkably, we found that ABCA5 
loss-of-function leads to reduced lysosome function, an accumulation of 
autophagosomes, autophagosomal cargos and increased endolysosomal cholesterol in 
CGHT keratinocytes (DESTEFANO et al. 2014). These data highlight a role for ABCA5 in 
controlling the fate of lipoprotein-derived cholesterol in humans, and are consistent with 
observations in mouse models.  
In conjunction with my studies in Chapter III defining the genetic basis of 
autosomal recessive CGHT, I also analyzed an unrelated sporadic CGHT case from 
Mexico whose excessive hair overgrowth phenotype closely resembled that of the 
autosomal recessive CGHT case. Using cytogenetic methods and CNV analysis to 
detect structural variants, we identified a de novo t3;17 translocation that led to a cryptic 
1.3 Mb deletion of chr17q24.2-24.3 encompassing ABCA5. Thus, I postulated that 
ABCA5 expression and/or function is compromised in the sporadic CGHT case, and 
using detailed molecular and functional analyses, showed that ABCA5 expression and 
protein localization was significantly reduced in patient hair follicles (DESTEFANO et al. 
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2014). Collectively, the findings from our study point to a prominent and evolutionarily 
conserved role for this gene in regulating hair growth. 
Based on my findings together with previous reports in the literature, I postulate 
that ABCA5 possesses multiple functions in the hair follicle and plays an integral role in 
both lipid transport and hormone signaling pathways. Similar to the expression of the 
P2RY5 and LIPH genes that regulate lipid transport in the hair follicle, ABCA5 is 
strongly expressed in the IRS of the human and mouse hair follicle. Moreover, its dual 
expression in epithelial and mesenchymal lineages of the hair follicle (similar to that of 
APCDD1) suggest a role for this transporter in regulating the transformation of vellus to 
terminal hairs (where APCDD1 loss-of-function causes hair follicle miniaturization).  
Studies examining ABC transporters in human disease have shed light onto the 
significance of the allocrite as the key determinant of the phenotype. It remains an open 
question as to what specific molecule(s) are being transported by ABCA5 in the human 
hair follicle, as there is collective evidence for the involvement of both cholesterol and 
thyroid related hormones as substrates based on functional studies in mice. It may be 
that ABCA5 functions differently in the skin and hair follicle, compared to its functions in 
the heart and thyroid gland, where the latter two organs progressively deteriorate and 
eventually collapse in the knockout mouse. In contrast, the hair follicles appear to be 
intact and based on photos from the publication, the mice clearly possess a full coat of 
hair, though it currently remains unknown whether Abca5 deficient mice possess an 
excessive hair overgrowth phenotype because this was not directly tested. 
In the context of CGHT, we examined ABCA5 expression and function only 
within the skin and hair follicle, as we did not have access to other cell types. Thus, it 
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would be interesting to determine whether tissues that do not express ABCA5 possess 
any pathological defect, as well as whether the subcellular defects in the endolysosomal 
pathway observed in CGHT keratinocytes are also present within other cell types. In 
light of our observations, I postulate that the accumulation and sequestration of free 
cholesterol inside lysosomes may exert consequences at the subcellular level, perhaps 
by altering the physical and/or signaling properties of cytosolic and membrane-bound 
proteins that require cholesterol as a covalent modification to function. It is interesting to 
speculate that the activity of such proteins functioning in hair follicle morphogenesis 
may be altered due to scarce levels of free cholesterol at the cell periphery or within the 
cytosol. Further functional studies would be required to directly test this hypothesis. 
Histological analysis of CGHT patient hair follicles from the forearm region 
revealed large pigmented hairs in anagen, where control hair follicles isolated from this 
same site were exclusively in catagen and telogen (DESTEFANO et al. 2014). 
Importantly, quantification of the lengths of the hair shafts revealed a significant 
increase in CGHT hair length, suggesting that CGHT hair follicles may possess an 
increased duration of anagen. Interestingly, I noticed that the ORS cells of the CGHT 
hair follicles appeared enlarged compared to controls—an effect I also observed in 
cultured CGHT keratinocytes (data not shown), and by hematoxylin and eosin staining, 
the cytoplasmic region of the outer most cellular layer of the ORS is white (instead of 
pink). This effect is consistent with the well-characterized observation that growing ORS 
cells and the stem cells in the bulge region are rich in glycogen particles (ORR et al. 
1977; VSEVOLODOV et al. 1983; IMCKE et al. 1987; YAMAUCHI AND KUROSAKA 2010). 
Interestingly, humans with glycogen storage disease type II (Pompe disease, autosomal 
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recessive) possess an accumulation of glycogen particles in the lysosomes resulting 
from mutations in the lysosomal acid alpha-glucosidase enzyme (KO et al. 1999; 
FERNANDEZ-HOJAS et al. 2002; MANGANELLI AND RUGGIERO 2013). Since ABCA5 is 
essential for the integrity of lysosomes, I postulate that this transporter may participate 
in the efflux of glycogen in hair follicle keratinocytes, and functional studies in the CGHT 
patient cells as well as the Abca5-/- mouse model will provide further insights.  
In the autosomal recessive CGHT case, the family we studied is 
consanguineous, and thus, the proband is homozygous recessive for several variants in 
regions of the genome that are identical-by-descent (IBD). In some autosomal recessive 
rare Mendelian conditions resulting from consanguinity, whole-exome sequencing 
studies have revealed the involvement of more than one pathogenic variant, especially 
in cases where an atypical phenotype is produced that resembles two separate 
monogenic disorders (i.e. patients with oculocutaneous albinism and neutropenia) 
(CULLINANE et al. 2011). Thus, it remains an open question as to whether the phenotype 
of excessive hair overgrowth, gingival hyperplasia and epilepsy observed in the 
autosomal recessive CGHT case is caused by more than one pathogenic variant and/or 
genetic interactions. An interesting candidate to test is the DKGZ gene that encodes a 
diacyglycerol kinase important for lipid signaling in the brain and in T cells (MEHTA et al. 
2002; LUO et al. 2004; GHARBI et al. 2011; RINCON et al. 2012) (SCHMIDT et al. 2013). 
Based on studies in knockout mouse models, it is likely that the DKGZ substitution 
mutation in autosomal recessive CGHT is causal to the patient’s seizures.  
Interestingly, DKGZ phosphorylates DAG to phosphatidic acid, which is the 
substrate used to produce 2-acyl lysophosphatidic acid (LPA) by the LIPH enzyme. 
260 
Importantly, signaling pathways that regulate lipid metabolism are involved in the 
regulation of hair growth, evidenced by mutations in the P2RY5 and LIPH genes 
associated with the LAH and autosomal recessive woolly hair phenotypes in humans 
and mice (SONODA et al. 2002; PASTERNACK et al. 2008) (INOUE et al. 2011) (KAZANTSEVA 
et al. 2006; SHIMOMURA et al. 2008; SHIMOMURA et al. 2009). Although neither Dkgz-/- 
mice nor human patients with DGKZ or DGKE mutations displays an obvious hair 
phenotype (LEMAIRE et al. 2013) (OZALTIN et al. 2013), it is possible that a genetic 
interaction between the DKGZ and ABCA5 genes produces the phenotype observed in 
autosomal recessive CGHT. Epistasis experiments using mouse models and functional 
studies in CGHT patient cells will clarify the contributions of each of these genes to 
disease pathogenesis. 
 
Characterizing Polygenic Effects on Human Hair Growth 
In the first two parts of my thesis, I examined the genetic basis of rare inherited 
conditions affecting hair growth, and using cytogenetic methods and next-generation 
sequencing, identified structural and intragenic variants underlying the sporadic and 
familial forms, respectively. In these disorders, the pathogenic variants are present at a 
very low frequency in the population (or de novo) and exert large effects, such that their 
causality to disease pathogenesis can often be clearly defined using the appropriate 
methods of detection and functional studies. However, the conditions affecting hair 
growth that are more common in the general population are typically composed of many 
genetic variants (polygenic) with small effects, whose contributions to disease 
pathogenesis are more difficult to characterize.  
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 In Chapter IV of my thesis, I investigated the genetic architecture of a common, 
polygenic autoimmune disease of disfiguring hair loss, alopecia areata, and using a 
functional genomics approach, characterized the role of rare genetic variants at the 
ULBP3/6 locus that is strongly implicated in disease pathogenesis. This locus encoding 
the NKG2D ligands was previously identified as the strongest association signal outside 
the HLA in the first GWAS for AA and demonstrated a strong upregulation of ULBP3 in 
human lesional hair follicles (PETUKHOVA et al. 2010). In Chapter IV.2, we performed a 
replication study and meta-GWAS analysis to expand gene discovery and identify true 
positive associations, which increased the genome-wide significance for the ULBP3/6 
locus association and also identified the BCL2L11 (BIM) gene as a novel locus 
associated with AA. Using several methods of detection, I characterized its expression 
in both human immune cells and hair follicles, and observed dysregulated Bim 
localization in mouse AA lesional hair follicles, implicating a role for this gene in disease 
pathogenesis. Based on the known functions of BIM as an apoptotic factor in immune 
cells and melanocytes, I postulate that BIM dysregulation in the AA hair follicle may 
contribute to the early entry into dystrophic catagen in AA hair follicles during active 
disease. Future follow-up studies will require functional analyses in mouse models, the 
identification of BIM susceptibility variants in human AA by targeted deep sequencing, 
and functional genomics to determine their consequences and contributions to disease 
pathogenesis. 
 In Chapter IV.3, I focused on the question, what are the genes that are 
dysregulated in alopecia areata? I characterized the transcriptional profile of human and 
mouse lesional skin and in collaboration with several lab members, uncovered three 
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primary gene expression signatures characteristic of immune cell activation and natural 
killer cell-mediated attack, further underscoring the NKG2D-ULBP signaling pathway. 
Furthermore, we demonstrated that T cells bearing the NKG2D receptor are both 
necessary and sufficient for disease pathogenesis (XING et al. 2014).  Because these 
cells produce the cytokines and drivers of toxicity that are associated with the 
autoimmune response, we then targeted the downstream pathways of type I cytokines 
that signal through the JAK/STAT pathway using FDA-approved small molecule 
inhibitors (Ruxolitinib and Tofacitinib), and successfully prevented and reversed the 
disease in the mouse model. Subsequently, these findings led us to test the 
effectiveness of these small molecule inhibitors in human AA, and in a small pilot clinical 
trial, we successfully treated the disease and observed complete hair regrowth in the 
patients. 
 Collectively, our findings highlight the genetic and molecular basis of the collapse 
of immune privilege in the hair follicle that is characteristic of active disease in AA. Our 
genetic studies in human patients demonstrated strong associations with genes in both 
immune-related pathways (acting at the level of the effector T cells), and genes that are 
expressed in the target cells of the hair follicle. In lesional hair follicles, upregulated 
expression of NKG2D ligands in the dermal sheath cells is consistent with the 
observations that NKG2D+CD8T cells infiltrate the base of the hair follicle, and 
highlights the crosstalk between the target and effector cells in close proximity to one 
another, ultimately leading to cellular destruction. Importantly, these findings have 
defined the molecular basis of AA pathogenesis and shed light onto the previously 
uncharacterized cascade of signaling events during active disease in both humans and 
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mice. The requirement for NKG2D+CD8+ T cells for active disease, in conjunction with 
the genetic association of the NKG2D ligands with human AA, place the NKG2D-ULBP 
signaling axis squarely at the center of disease pathogenesis and invite the question of 
what genetic variants contribute to dysregulation of the ULBP3/6 locus in human AA.   
 
Functional Genomics Studies at the ULBP6 Locus in AA 
The quest to identify the pathogenic variants associated with complex human genetic 
disorders requires a robust and comprehensive approach integrating genetic, genomic, 
expression, and functional data. The functional genomics revolution was created to 
accomplish just this task, and designed to address the questions of what can we make 
of this information and how do we find the causal variants that disrupt regulatory and/or 
gene function. The genome-wide and high throughput integration of massive datasets 
allows us to tell a comprehensive biological story about the genetic, genomic, and 
functional information in a complex disease. Importantly, the ENCODE and Roadmap 
Epigenomics projects have greatly facilitated the process of interpreting mapped 
sequencing data through the systematic identification of functional regulatory elements 
including promoters, enhancers, and insulators. Notably, this approach, combined with 
CNV analysis, expression-based data and functional studies in mouse models is well 
powered to capture a large portion of the missing heritability in complex genetic 
disease. 
 In Chapter IV.4, the goal of my work was to identify and characterize the 
susceptibility variants at the ULBP3/6 locus in AA that confer a degree of genetic risk in 
human AA. To accomplish this, we performed targeted deep resequencing of this locus 
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using the Raindance technology, and since the emerging picture of the genetic 
architecture underlying complex disease highlights a role of rare and non-coding 
variants, I focused my functional studies on a cluster of rare, novel variants at ULBP6 
that are enriched on the AA GWAS risk haplotypes. Using ENCODE and RegulomeDB, 
we found that these variants reside within regulatory regions, are predicted to disrupt 
CTCF sites downstream of ULBP6, and fall within paired-end tags from ENCODE ChIA-
PET data on CTCF-mediated long-range chromatin interactions. Importantly, I 
demonstrated that CTCF is endogenously bound to the ULBP6 candidate region in 
human dermal fibroblasts, and that the AA variants disrupt regulatory activity and CTCF 
binding in vitro. Using in silico analysis, I found that two of these variants create novel 
transcription factor binding sites for the activating proteins, ELK1 and EGR3, both of 
which have important roles in the immune system. Collectively, these findings support a 
role for rare, non-coding variants in disrupting the spatiotemporal regulation of the 
ULBP3/6 locus in AA, and we postulate that these variants perturb long-range 
interactions that are otherwise required for ULBP repression in healthy tissues.  
 The findings from this study are exciting and novel, perfectly complementing the 
genetic studies in humans, immunopathological findings, and functional studies in the 
mouse model. In my analysis of the ULBP3/6 locus, I exclusively tested the contribution 
of rare variants enriched on GWAS haplotypes under the assumption that they would 
produce larger effects than the common variants, however, I postulate that the 
combination of both rare and common variants on susceptibility haplotypes produce the 
maximal effects at this locus during active disease. In addition to CTCF, we identified 
other transcription factor binding site motifs in the ULBP6 region with which the rare, 
265 
non-coding variants overlap (i.e. proteins of the cohesin and SUZ12 complexes), and I 
postulate that these factors also engage in long-range interactions that are potentially 
disrupted at this locus.  
 Until recently, the process of identifying and characterizing susceptibility variants 
in complex genetic diseases was very challenging. With thousands of SNPs to sift 
through (mostly in non-coding regions) for the hundreds of GWAS performed for 
common disorders, the primary limitation and bottleneck resided in the ability to identify 
the true positive associations and genomic regions harboring susceptibility variants that 
are actually pathogenic. Because the common-variant-common-disease assumption is 
intrinsic to the design of a GWAS, the success of uncovering variants that account for a 
significance portion of the heritability was limited, since we now know that rare variants 
and copy number variants (not detected by GWAS) significantly contribute to this 
“missing heritability” (GOLDSTEIN 2009; ZHU et al. 2011b). The identification of rare 
variants and their frequencies in complex genetic diseases will prove a challenging task, 
requiring the sequencing of many thousands of cases and controls, as rare variants are 
often not in LD with the common variants on risk haplotypes and may be population 
specific (ZUK et al. 2014). Since rare variants are likely to be deleterious and kept at a 
lower frequency by purifying selection, association tests to determine enrichment for 
individual rare variants may not be feasible, but rather, will require the aggregation of 
variants to be analyzed.  
 The large majority of the significant associations identified from GWAS studies 
reside within non-coding stretches of DNA several kilobases away from genes, 
highlighting that there is still much to be discovered in correlating genotype with 
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phenotype. However, several recent studies in complex traits have successfully 
implemented the functional genomics approach to characterize the function of non-
coding variants and determine their impact on gene expression (i.e. expression 
quantitative trait loci (eQTL)). In the post-GWAS area, the correlation between 
sequence variation and mRNA expression was initially used to identify an eQTL, but 
more recent studies have examined variants in the context of TF binding, DNA 
methylation, chromatin accessibility, alternative splicing, lincRNAs, RNA editing, and 
mRNA degradation (ALBERT AND KRUGLYAK 2015).  
 Overlaying GWAS data for a given complex trait with eQTL mapping data in 
several tissues has proven a useful strategy to maximize the likelihood of finding 
GWAS-eQTL pairs, where this approach successfully detected a novel causal 
regulatory variant at the NOS1AP locus that modulates a heart-specific enhancer 
previously missed in eQTL studies performed on other tissues (KAPOOR et al. 2014). 
Similarly, GWAS variants in eQTLs have been shown to act in a long-range manner, as 
in the case of a common variant associated with myocardial infarction that resides 
within a 3’ UTR but creates a novel TF binding site that upregulates the SORT1 gene 
~40 Kb away specifically in the liver. Remarkably, further functional studies in mouse 
demonstrated that SORT1 influences the levels of low-density lipoprotein cholesterol, a 
major risk factor for myocardial infarction (MUSUNURU et al. 2010). Moreover, in the 
context of hair-related complex genetic traits, a recent functional genomics study 
defined the molecular basis for classic blond hair in Europeans, elegantly demonstrating 
the mechanism by which a common SNP in the KITLG gene regulatory region 
influences hair follicle pigmentation in both humans and mice (GUENTHER et al. 2014). 
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 Collectively, these findings demonstrate the applicability and success of the 
functional genomics approach to the study complex genetic diseases. In our human AA 
studies, we utilized a powerful and integrative functional genomics approach to decode 
the genetic variation at the ULBP3/6 locus, and identified a cluster of rare, non-coding 
variants that disrupt the regulatory activity and transcription factor binding properties of 
this region, strongly supporting a role for these variants in disease pathogenesis. 
 
Conclusion 
In my thesis work, I have used three genetic conditions affecting hair growth as models 
to interrogate the molecular basis of the pathology and obtain novel insight into 
mechanisms and pathways required for normal hair growth. Importantly, the approaches 
I used to decode the genetic architecture of rare, sporadic and familial Mendelian, as 
well as common, polygenic conditions were instrumental in my success identifying 
complex structural variants, a splice site mutation in a novel gene associated with 
human hair growth, and rare, non-coding variants at the ULBP3/6 locus in human 
disease. Thus, the work in this thesis has demonstrated that a combinatorial strategy 
employing the classical genetic approach, CNV analysis, targeted and genome-wide 
next-generation sequencing, as well as functional genomics studies proves the most 
successful for identifying disease-associated genes and novel genetic mechanisms that 
control our traits.  
 
Perspectives 
The completion of the human genome sequence greatly facilitated the development of 
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advanced technologies for whole-genome and targeted genome sequencing 
approaches, revolutionizing the field of genomics. In the context of health, reproductive 
fitness and personalized medicine, it is important to understand the underlying 
mechanisms and genes controlling our traits as well as the impacts of the surrounding 
environment. Over the past decade, we gained profound insight into the natural person-
to-person variation and genetic heterogeneity at the DNA level that was previously 
unrecognized. Comparing the genomes of healthy individuals from distinct geographic 
regions shed light onto such sequence variation and the many changes that were 
tolerated, from SNPs to large insertions or deletions, raising an interesting question 
about what we consider pathogenic versus benign when searching for causal mutations 
in genetic diseases. Moreover, we learned that the coding portion of our DNA, or the 
exome, comprises a mere ~1% (30 Mb) of our genome, but its contribution to biological 
function is profound, evidenced by the large number of genetic diseases caused by 
mutations in single genes.  
 To date, mutations have been identified for approximately 50% of the 7,000 rare 
monogenic diseases reported in the OMIM database, and it is estimated that the 
remaining 50% will be identified by the year 2020.  Recently, the Human Phenome 
Project has been launched to promote a collective integration of genetic and phenotypic 
data internationally that will facilitate the identification of novel disease genes and 
improve the definition and characterization of phenotypes. By interconnecting multiple 
databases and resources, cohorts can be combined to increase the statistical power for 
detection of novel variants and functionally decode the genotypes associated with the 
many human phenotypes. 
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 In the context of common disease, deep sequencing technologies have afforded 
us a more comprehensive and detailed overview of the genetic variation within the 
regions of association identified by GWAS. Upon the targeted resequencing of GWAS 
cases, the focus in the field shifted from the common-variant-common-disease 
hypothesis to the current perspective, which supports a role for common variants with 
small effects, rare and structural variants with moderate effects, gene-gene interactions 
and gene-environment interactions. Although many studies and technological advances 
thereafter have greatly facilitated gene discovery in both rare and common disorders, 
there are still many unannotated genes and transcripts whose functions and 
contributions to disease pathogenesis remain unclear. Moreover, the massive amount 
of sequencing data generated from high-throughput experiments posed new challenges 
on how to process, analyze, and interpret this information. Over the past few years, 
there has been a surge in the development of novel bioinformatics tools and strategies 
aimed at accomplishing this task, and in the study of both rare and common diseases, a 
robust strategy integrating genotype and phenotype data with functional studies will 
undoubtedly provide deeper insights into the complexities of our genomic landscape, 
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